File,Alias,Question,Answer,Confidence
sample_nocs/0000000243.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000000243.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000243.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000000243.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000243.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000243.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000000243.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000243.PDF,product_name,What is the Product name?,VELCADE,98
sample_nocs/0000000243.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000000243.PDF,species,What is the species?,Multiple myeloma,55
sample_nocs/0000000243.PDF,noc_date,What is the date of the document?,NA,NA
sample_nocs/0000000243.PDF,medicinal_ingredients,What are the medicinal ingredients?,"VELCADE, VELCADE, proteasome inhibitor",42
sample_nocs/0000000285.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000000285.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000285.PDF,noc_reason,What was the reason for the submission?,Approval of VELCADE was based on analyses of response rates.,28
sample_nocs/0000000285.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000285.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000285.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000000285.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000285.PDF,product_name,What is the Product name?,VELCADE,73
sample_nocs/0000000285.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000000285.PDF,species,What is the species?,NA,NA
sample_nocs/0000000285.PDF,noc_date,What is the date of the document?,"December 17, 2004",95
sample_nocs/0000000285.PDF,medicinal_ingredients,What are the medicinal ingredients?,bortezomib mannitol boronic ester,54.000003814697266
sample_nocs/0000000301.PDF,canadian_reference_product,What is the Canadian Reference Product?,FEMARA* 2.5 mg,58.999996185302734
sample_nocs/0000000301.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000301.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000000301.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000301.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000301.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000000301.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000301.PDF,product_name,What is the Product name?,FEMARA,54.000003814697266
sample_nocs/0000000301.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",FEMARA* 2.5 mg,65
sample_nocs/0000000301.PDF,species,What is the species?,NA,NA
sample_nocs/0000000301.PDF,noc_date,What is the date of the document?,NA,NA
sample_nocs/0000000301.PDF,medicinal_ingredients,What are the medicinal ingredients?,"FEMARA, active substance letrozole",58
sample_nocs/0000000354.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEMPLAR,66
sample_nocs/0000000354.PDF,directorate,What is the directorate that approved the submission?,Direction générale des produits de santé et des aliments,45
sample_nocs/0000000354.PDF,noc_reason,What was the reason for the submission?,ZEMPLAR,58.999996185302734
sample_nocs/0000000354.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000354.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000354.PDF,submission_no,What is the Submission Number?,087818,93
sample_nocs/0000000354.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000354.PDF,product_name,What is the Product name?,ZEMPLAR,82
sample_nocs/0000000354.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",ZEMPLAR,35
sample_nocs/0000000354.PDF,species,What is the species?,ZEMPLAR,96
sample_nocs/0000000354.PDF,noc_date,What is the date of the document?,2005/11/18,99
sample_nocs/0000000354.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Paricalcitol, 5 mcg/mL, solution",81
sample_nocs/0000000357.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEMPLAR,91
sample_nocs/0000000357.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000357.PDF,noc_reason,What was the reason for the submission?,drug sponsor,46
sample_nocs/0000000357.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000357.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000357.PDF,submission_no,What is the Submission Number?,087818,99
sample_nocs/0000000357.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000357.PDF,product_name,What is the Product name?,ZEMPLAR*,57
sample_nocs/0000000357.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",ZEMPLAR*,33
sample_nocs/0000000357.PDF,species,What is the species?,NA,NA
sample_nocs/0000000357.PDF,noc_date,What is the date of the document?,"March 31, 2005",94
sample_nocs/0000000357.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Paricalcitol, ZEMPLAR",24
sample_nocs/0000000644.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000000644.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000644.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000000644.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000644.PDF,dossier_id,What is the Dossier Id?,088659,94
sample_nocs/0000000644.PDF,submission_no,What is the Submission Number?,088659,97
sample_nocs/0000000644.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000644.PDF,product_name,What is the Product name?,XYREMMD,98
sample_nocs/0000000644.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000000644.PDF,species,What is the species?,NA,NA
sample_nocs/0000000644.PDF,noc_date,What is the date of the document?,5 août 2005,73
sample_nocs/0000000644.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Oxybate de sodium 500 mg/mL, solution orale",43
sample_nocs/0000000722.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000000722.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000722.PDF,noc_reason,What was the reason for the submission?,submitted data from quality (chemistry and manufacturing) studies,35
sample_nocs/0000000722.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000722.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000722.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000000722.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000722.PDF,product_name,What is the Product name?,PFOSRENOL,31
sample_nocs/0000000722.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","250 mg, 500 mg, 750 mg, 1000 mg",27.000001907348633
sample_nocs/0000000722.PDF,species,What is the species?,NA,NA
sample_nocs/0000000722.PDF,noc_date,What is the date of the document?,"February 19, 2007",97
sample_nocs/0000000722.PDF,medicinal_ingredients,What are the medicinal ingredients?,"lanthanum carbonate hydrate, lanthanum carbonate hydrate",21
sample_nocs/0000000821.PDF,canadian_reference_product,What is the Canadian Reference Product?,SATIVEX,33
sample_nocs/0000000821.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000821.PDF,noc_reason,What was the reason for the submission?,supplément a la présentation de drogue nouvelle,38
sample_nocs/0000000821.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000821.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000821.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000000821.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000000821.PDF,product_name,What is the Product name?,SATIVEX®,33
sample_nocs/0000000821.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000000821.PDF,species,What is the species?,Cannabis,56
sample_nocs/0000000821.PDF,noc_date,What is the date of the document?,7 juin 2007,64
sample_nocs/0000000821.PDF,medicinal_ingredients,What are the medicinal ingredients?,"delta-9-tétrahydrocannabinol, cannabidiol",15.000000953674316
sample_nocs/0000000867.PDF,canadian_reference_product,What is the Canadian Reference Product?,LYRICA,73
sample_nocs/0000000867.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000867.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000000867.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000867.PDF,dossier_id,What is the Dossier Id?,088400,97
sample_nocs/0000000867.PDF,submission_no,What is the Submission Number?,088400,99
sample_nocs/0000000867.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,49
sample_nocs/0000000867.PDF,product_name,What is the Product name?,LYRICA,88
sample_nocs/0000000867.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",988462,6
sample_nocs/0000000867.PDF,species,What is the species?,NA,NA
sample_nocs/0000000867.PDF,noc_date,What is the date of the document?,3 juin 2005,48
sample_nocs/0000000867.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Prégabaline, 25 mg de prégabaline, capsules",9
sample_nocs/0000000969.PDF,canadian_reference_product,What is the Canadian Reference Product?,Merck Frosst Canada Ltd.,36
sample_nocs/0000000969.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000000969.PDF,noc_reason,What was the reason for the submission?,drug sponsor,91
sample_nocs/0000000969.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000000969.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000000969.PDF,submission_no,What is the Submission Number?,108483,94
sample_nocs/0000000969.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Frosst Canada Ltd.,58.999996185302734
sample_nocs/0000000969.PDF,product_name,What is the Product name?,PrEMENDTM,38
sample_nocs/0000000969.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","80 mg and 125 mg, capsules",90
sample_nocs/0000000969.PDF,species,What is the species?,NA,NA
sample_nocs/0000000969.PDF,noc_date,What is the date of the document?,"August 20, 2007",91
sample_nocs/0000000969.PDF,medicinal_ingredients,What are the medicinal ingredients?,"PrEMEND,  Aprepitant, 80 mg and 125 mg, capsules",17
sample_nocs/0000001034.PDF,canadian_reference_product,What is the Canadian Reference Product?,VECTIBIXMc,72
sample_nocs/0000001034.PDF,directorate,What is the directorate that approved the submission?,Health Canada,41
sample_nocs/0000001034.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001034.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000001034.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001034.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000001034.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000001034.PDF,product_name,What is the Product name?,VECTIBIXMc,77
sample_nocs/0000001034.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",20 mg/mL,37
sample_nocs/0000001034.PDF,species,What is the species?,panitumumab,90
sample_nocs/0000001034.PDF,noc_date,What is the date of the document?,Juin 2008,26
sample_nocs/0000001034.PDF,medicinal_ingredients,What are the medicinal ingredients?,"fluoropyrimidine, l'oxaliplatine et l'irinotécan",16
sample_nocs/0000001050.PDF,canadian_reference_product,What is the Canadian Reference Product?,Pfizer Canada Inc.,46
sample_nocs/0000001050.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000001050.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001050.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000001050.PDF,dossier_id,What is the Dossier Id?,078188,71
sample_nocs/0000001050.PDF,submission_no,What is the Submission Number?,078188,97
sample_nocs/0000001050.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,61
sample_nocs/0000001050.PDF,product_name,What is the Product name?,Przeldox,58
sample_nocs/0000001050.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000001050.PDF,species,What is the species?,NA,NA
sample_nocs/0000001050.PDF,noc_date,What is the date of the document?,27 août 2007,78
sample_nocs/0000001050.PDF,medicinal_ingredients,What are the medicinal ingredients?,Przeldox* chlorhydrate de ziprasidone monohydraté,25
sample_nocs/0000001260.PDF,canadian_reference_product,What is the Canadian Reference Product?,OLMETEC,39
sample_nocs/0000001260.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000001260.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001260.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000001260.PDF,dossier_id,What is the Dossier Id?,115991,81
sample_nocs/0000001260.PDF,submission_no,What is the Submission Number?,115991,97
sample_nocs/0000001260.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000001260.PDF,product_name,What is the Product name?,Prolmetec,62
sample_nocs/0000001260.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","5, 20  and 40 mg",34
sample_nocs/0000001260.PDF,species,What is the species?,NA,NA
sample_nocs/0000001260.PDF,noc_date,What is the date of the document?,28 octade 2008,2
sample_nocs/0000001260.PDF,medicinal_ingredients,What are the medicinal ingredients?,olmésartan médoxomil,48
sample_nocs/0000001281.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000001281.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,62
sample_nocs/0000001281.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001281.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",82
sample_nocs/0000001281.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001281.PDF,submission_no,What is the Submission Number?,110853,97
sample_nocs/0000001281.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Galderma Canada Inc.,82
sample_nocs/0000001281.PDF,product_name,What is the Product name?,METVIX,98
sample_nocs/0000001281.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02323273, Topical, Cream, 168mg/g",81
sample_nocs/0000001281.PDF,species,What is the species?,NA,NA
sample_nocs/0000001281.PDF,noc_date,What is the date of the document?,FES 26 2009,40
sample_nocs/0000001281.PDF,medicinal_ingredients,What are the medicinal ingredients?,methyl aminolevulinate (supplied as methyl aminolevulinate hydrochloride),66
sample_nocs/0000001316.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Clavamox Tablets, Pfizer Canada Inc., Animal Health Group, Canada",75
sample_nocs/0000001316.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000001316.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001316.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"D. lan Alexander, DVM, PhD",22
sample_nocs/0000001316.PDF,dossier_id,What is the Dossier Id?,"9460-N0766-520, -521, -522, -523",84
sample_nocs/0000001316.PDF,submission_no,What is the Submission Number?,"111532, 111530, 111529, 111533",77
sample_nocs/0000001316.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000001316.PDF,product_name,What is the Product name?,Noroclav,97
sample_nocs/0000001316.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02323850, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 50 mg/tab, Clavulanic acid (as clavulanate potassium) 12.5 mg/tab",62
sample_nocs/0000001316.PDF,species,What is the species?,"Cats (62.5 mg only), dogs (62.5 mg, 125 mg, 250 mg, 375 mg)",52
sample_nocs/0000001316.PDF,noc_date,What is the date of the document?,"March 13, 2009",94
sample_nocs/0000001316.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin (as amoxicillin trihydrate) Clavulanic acid (as clavulanate potassium),85
sample_nocs/0000001517.PDF,canadian_reference_product,What is the Canadian Reference Product?,LOCACORTEN VIOFORM EARDROPS,88
sample_nocs/0000001517.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000001517.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change.,52.999996185302734
sample_nocs/0000001517.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,85
sample_nocs/0000001517.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001517.PDF,submission_no,What is the Submission Number?,130072,99
sample_nocs/0000001517.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Paladin Labs Inc.,75
sample_nocs/0000001517.PDF,product_name,What is the Product name?,LOCACORTEN VIOFORM EARDROPS,94
sample_nocs/0000001517.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00074454,35
sample_nocs/0000001517.PDF,species,What is the species?,NA,NA
sample_nocs/0000001517.PDF,noc_date,What is the date of the document?,JUN 03 2009,88
sample_nocs/0000001517.PDF,medicinal_ingredients,What are the medicinal ingredients?,Flumethasone Pivalate / Clioquinol,96
sample_nocs/0000001527.PDF,canadian_reference_product,What is the Canadian Reference Product?,Vyvanse c,87
sample_nocs/0000001527.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000001527.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001527.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000001527.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001527.PDF,submission_no,What is the Submission Number?,120534,77
sample_nocs/0000001527.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Shire Canada Inc.,45
sample_nocs/0000001527.PDF,product_name,What is the Product name?,Vyvanse c,74
sample_nocs/0000001527.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",30 mg et 50 mg,69
sample_nocs/0000001527.PDF,species,What is the species?,NA,NA
sample_nocs/0000001527.PDF,noc_date,What is the date of the document?,18 mars 2009,89
sample_nocs/0000001527.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Dimésylate de lisdexamfétamine, promédicament de la dextroamphétamine",5
sample_nocs/0000001624.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000001624.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000001624.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,91
sample_nocs/0000001624.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,91
sample_nocs/0000001624.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001624.PDF,submission_no,What is the Submission Number?,129658,98
sample_nocs/0000001624.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,93
sample_nocs/0000001624.PDF,product_name,What is the Product name?,MYLAN-BECLO AQ,96
sample_nocs/0000001624.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02172712,48
sample_nocs/0000001624.PDF,species,What is the species?,NA,NA
sample_nocs/0000001624.PDF,noc_date,What is the date of the document?,JUN 29 2009,73
sample_nocs/0000001624.PDF,medicinal_ingredients,What are the medicinal ingredients?,Beclomethasone Dipropionate,97
sample_nocs/0000001663.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Didronel, Procter & Gamble Pharmaceuticals Canada Inc.",46
sample_nocs/0000001663.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000001663.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,95
sample_nocs/0000001663.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",62
sample_nocs/0000001663.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001663.PDF,submission_no,What is the Submission Number?,130811,98
sample_nocs/0000001663.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,90
sample_nocs/0000001663.PDF,product_name,What is the Product name?,MYLAN-ETIDRONATE,90
sample_nocs/0000001663.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02245330 (ORL, TAB, 200 mg)",68
sample_nocs/0000001663.PDF,species,What is the species?,NA,NA
sample_nocs/0000001663.PDF,noc_date,What is the date of the document?,JUL 08 2009,48
sample_nocs/0000001663.PDF,medicinal_ingredients,What are the medicinal ingredients?,Etidronate Disodium,98
sample_nocs/0000001689.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Norvasc, Pfizer Canada Inc., Canada",47
sample_nocs/0000001689.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,52.999996185302734
sample_nocs/0000001689.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000001689.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",65
sample_nocs/0000001689.PDF,dossier_id,What is the Dossier Id?,0201D,93
sample_nocs/0000001689.PDF,submission_no,What is the Submission Number?,089371,98
sample_nocs/0000001689.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ratiopharm inc.,63
sample_nocs/0000001689.PDF,product_name,What is the Product name?,RATIO-AMLODIPINE,95
sample_nocs/0000001689.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02259605 ORL, TAB, 5mg",69
sample_nocs/0000001689.PDF,species,What is the species?,NA,NA
sample_nocs/0000001689.PDF,noc_date,What is the date of the document?,JUL 09 2009,89
sample_nocs/0000001689.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amlodipine( supplied as amlodipine besylate ) Amlodipine ( supplied under la forme de bésylate d'amlodipine,6
sample_nocs/0000001694.PDF,canadian_reference_product,What is the Canadian Reference Product?,KOGENATE® FS,52
sample_nocs/0000001694.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,51
sample_nocs/0000001694.PDF,noc_reason,What was the reason for the submission?,Revision to Product Monograph / Révision to la Monographie de produit,48
sample_nocs/0000001694.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Elwyn Griffith,83
sample_nocs/0000001694.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001694.PDF,submission_no,What is the Submission Number?,124448,98
sample_nocs/0000001694.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Inc.,60.000003814697266
sample_nocs/0000001694.PDF,product_name,What is the Product name?,KOGENATE® FS,75
sample_nocs/0000001694.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Lyophilized Powder for Injection, 250 IU/vial",89
sample_nocs/0000001694.PDF,species,What is the species?,NA,NA
sample_nocs/0000001694.PDF,noc_date,What is the date of the document?,JUL 7 2009,21
sample_nocs/0000001694.PDF,medicinal_ingredients,What are the medicinal ingredients?,Antihemophilic Factor (Recombinant)/ Facteur antlhémophilique (Recombinant),20
sample_nocs/0000001957.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Clavulin, SmithKline Beecham Pharma, Division of SmithKline",25
sample_nocs/0000001957.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000001957.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,90
sample_nocs/0000001957.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",55
sample_nocs/0000001957.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000001957.PDF,submission_no,What is the Submission Number?,129774,98
sample_nocs/0000001957.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000001957.PDF,product_name,What is the Product name?,AMOXI-CLAV,86
sample_nocs/0000001957.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02326507 (ORL, TAB, Amoxicillin 250mg / Clavulanic Acid 125 mg)",23
sample_nocs/0000001957.PDF,species,What is the species?,NA,NA
sample_nocs/0000001957.PDF,noc_date,What is the date of the document?,SEP 22 2009,51
sample_nocs/0000001957.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin supplied as Amoxicillin Trihydrate / Clavulanic Acid supplied as Potassium Clavulanate,93
sample_nocs/0000002012.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000002012.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000002012.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000002012.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,85
sample_nocs/0000002012.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002012.PDF,submission_no,What is the Submission Number?,132613,98
sample_nocs/0000002012.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,MM Therapeutics Inc.,94
sample_nocs/0000002012.PDF,product_name,What is the Product name?,AVENTYL,94
sample_nocs/0000002012.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00015229 (ORL,CAP, 10 mg)",66
sample_nocs/0000002012.PDF,species,What is the species?,NA,NA
sample_nocs/0000002012.PDF,noc_date,What is the date of the document?,OCT 5 2009,94
sample_nocs/0000002012.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nortriptyline supplied as Nortriptyline Hydrochloride,97
sample_nocs/0000002087.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Ciprobay, Bayer AG, Germany",77
sample_nocs/0000002087.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000002087.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000002087.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",65
sample_nocs/0000002087.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002087.PDF,submission_no,What is the Submission Number?,133073,98
sample_nocs/0000002087.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,82
sample_nocs/0000002087.PDF,product_name,What is the Product name?,CIPROFLOXACIN,71
sample_nocs/0000002087.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02335352 (ORL, TAB, 250 mg)",72
sample_nocs/0000002087.PDF,species,What is the species?,NA,NA
sample_nocs/0000002087.PDF,noc_date,What is the date of the document?,OCT 21 2009,82
sample_nocs/0000002087.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride,89
sample_nocs/0000002092.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Norvasc, Pfizer Canada Inc.",41
sample_nocs/0000002092.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000002092.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,91
sample_nocs/0000002092.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",72
sample_nocs/0000002092.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002092.PDF,submission_no,What is the Submission Number?,131627,98
sample_nocs/0000002092.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,90
sample_nocs/0000002092.PDF,product_name,What is the Product name?,JAMP-AMLODIPINE,91
sample_nocs/0000002092.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02331071 (ORL, 5 mg)",88
sample_nocs/0000002092.PDF,species,What is the species?,NA,NA
sample_nocs/0000002092.PDF,noc_date,What is the date of the document?,21 SEP. 2009,58
sample_nocs/0000002092.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amlodipine supplied as Amlodipine Besylate,95
sample_nocs/0000002133.PDF,canadian_reference_product,What is the Canadian Reference Product?,KIDROLASE,78
sample_nocs/0000002133.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,61
sample_nocs/0000002133.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change / Changement dan le nom d'un fabricant,48
sample_nocs/0000002133.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Elwyn Griffiths,91
sample_nocs/0000002133.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002133.PDF,submission_no,What is the Submission Number?,120402,99
sample_nocs/0000002133.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,EUSA Pharma SAS,88
sample_nocs/0000002133.PDF,product_name,What is the Product name?,KIDROLASE,98
sample_nocs/0000002133.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",01926438,52.999996185302734
sample_nocs/0000002133.PDF,species,What is the species?,NA,NA
sample_nocs/0000002133.PDF,noc_date,What is the date of the document?,APR 17 2008,90
sample_nocs/0000002133.PDF,medicinal_ingredients,What are the medicinal ingredients?,Asparaginase,99
sample_nocs/0000002162.PDF,canadian_reference_product,What is the Canadian Reference Product?,NOVO-BENZYDAMINE,94
sample_nocs/0000002162.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,79
sample_nocs/0000002162.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,89
sample_nocs/0000002162.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,88
sample_nocs/0000002162.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002162.PDF,submission_no,What is the Submission Number?,121722,98
sample_nocs/0000002162.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novopharm Ltd.,51
sample_nocs/0000002162.PDF,product_name,What is the Product name?,NOVO-BENZYDAMINE,95
sample_nocs/0000002162.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02310422,49
sample_nocs/0000002162.PDF,species,What is the species?,NA,NA
sample_nocs/0000002162.PDF,noc_date,What is the date of the document?,JUN 0 3 2008,52.999996185302734
sample_nocs/0000002162.PDF,medicinal_ingredients,What are the medicinal ingredients?,Benzydamine Hydrochloride,92
sample_nocs/0000002296.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Biaxin BID, Abbott Laboratories, Canada",73
sample_nocs/0000002296.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000002296.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name Nouveau nom du fabricant et du produit,42
sample_nocs/0000002296.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",68
sample_nocs/0000002296.PDF,dossier_id,What is the Dossier Id?,BID,71
sample_nocs/0000002296.PDF,submission_no,What is the Submission Number?,105585,98
sample_nocs/0000002296.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,68
sample_nocs/0000002296.PDF,product_name,What is the Product name?,SANDOZ CLARITHROMYCIN,69
sample_nocs/0000002296.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02266539 (ORL, TAB, 250mg)",79
sample_nocs/0000002296.PDF,species,What is the species?,NA,NA
sample_nocs/0000002296.PDF,noc_date,What is the date of the document?,JUN 6 2008,58
sample_nocs/0000002296.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Clarithromycin, Clarithromycine",72
sample_nocs/0000002390.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000002390.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,60.000003814697266
sample_nocs/0000002390.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000002390.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",75
sample_nocs/0000002390.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002390.PDF,submission_no,What is the Submission Number?,114887,98
sample_nocs/0000002390.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Boehringer Ingelheim (Canada) Ltd.,76
sample_nocs/0000002390.PDF,product_name,What is the Product name?,Pradax,98
sample_nocs/0000002390.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02312433, Oral, Capsule, 75 mg",82
sample_nocs/0000002390.PDF,species,What is the species?,NA,NA
sample_nocs/0000002390.PDF,noc_date,What is the date of the document?,"June 10, 2008",92
sample_nocs/0000002390.PDF,medicinal_ingredients,What are the medicinal ingredients?,dabigatran etexilate,62
sample_nocs/0000002430.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Coreg, Smithkline Beecham Pharma, Division of SmithKline",46
sample_nocs/0000002430.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000002430.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,91
sample_nocs/0000002430.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",60.000003814697266
sample_nocs/0000002430.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002430.PDF,submission_no,What is the Submission Number?,134393,98
sample_nocs/0000002430.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Zymcan Pharmaceuticals Inc.,82
sample_nocs/0000002430.PDF,product_name,What is the Product name?,ZYM-CARVEDILOL,88
sample_nocs/0000002430.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02338068 (ORL,TAB, 3.125 mg)",80
sample_nocs/0000002430.PDF,species,What is the species?,NA,NA
sample_nocs/0000002430.PDF,noc_date,What is the date of the document?,NOV 26 2009,73
sample_nocs/0000002430.PDF,medicinal_ingredients,What are the medicinal ingredients?,Carvedilol,99
sample_nocs/0000002563.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000002563.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000002563.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000002563.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,89
sample_nocs/0000002563.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002563.PDF,submission_no,What is the Submission Number?,135612,98
sample_nocs/0000002563.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,UCB Canada Inc.,90
sample_nocs/0000002563.PDF,product_name,What is the Product name?,KEPPRA,96
sample_nocs/0000002563.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02247027 (ORL,TAB, 250 mg)",78
sample_nocs/0000002563.PDF,species,What is the species?,NA,NA
sample_nocs/0000002563.PDF,noc_date,What is the date of the document?,JAN 132010,91
sample_nocs/0000002563.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levetiracetam,98
sample_nocs/0000002679.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Seroquel, AstraZeneca Canada Inc., Canada",50
sample_nocs/0000002679.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000002679.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000002679.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",68
sample_nocs/0000002679.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002679.PDF,submission_no,What is the Submission Number?,135988,98
sample_nocs/0000002679.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Cobalt Pharmaceuticals Inc.,97
sample_nocs/0000002679.PDF,product_name,What is the Product name?,QUETIAPINE,73
sample_nocs/0000002679.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02342596 (ORL, TAB, 25 mg)",82
sample_nocs/0000002679.PDF,species,What is the species?,NA,NA
sample_nocs/0000002679.PDF,noc_date,What is the date of the document?,JAN 2.9 2010,83
sample_nocs/0000002679.PDF,medicinal_ingredients,What are the medicinal ingredients?,Quetiapine supplied as Quetiapine Fumarate,95
sample_nocs/0000002690.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Glumetza, Biovail Pharmaceuticals Canada, Division of Biovail Canada",25
sample_nocs/0000002690.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,51
sample_nocs/0000002690.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000002690.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",82
sample_nocs/0000002690.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002690.PDF,submission_no,What is the Submission Number?,112952,98
sample_nocs/0000002690.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Incorporated,94
sample_nocs/0000002690.PDF,product_name,What is the Product name?,APO-METFORMIN ER,95
sample_nocs/0000002690.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02305062, Oral, Tablet (Extended-Release) 500 mg",68
sample_nocs/0000002690.PDF,species,What is the species?,NA,NA
sample_nocs/0000002690.PDF,noc_date,What is the date of the document?,NA,NA
sample_nocs/0000002690.PDF,medicinal_ingredients,What are the medicinal ingredients?,Metformin Hydrochloride,97
sample_nocs/0000002746.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zithromax, Pfizer Canada Inc., Canada",45
sample_nocs/0000002746.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000002746.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000002746.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",65
sample_nocs/0000002746.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002746.PDF,submission_no,What is the Submission Number?,136268,97
sample_nocs/0000002746.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Cobalt Pharmaceuticals Inc.,98
sample_nocs/0000002746.PDF,product_name,What is the Product name?,AZITHROMYCIN,77
sample_nocs/0000002746.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02343347 (ORL, TAB, 250 mg)",84
sample_nocs/0000002746.PDF,species,What is the species?,NA,NA
sample_nocs/0000002746.PDF,noc_date,What is the date of the document?,FES 15 2010,31
sample_nocs/0000002746.PDF,medicinal_ingredients,What are the medicinal ingredients?,Azithromycin supplied as Azithromycin Monohydrate,92
sample_nocs/0000002754.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Norvasc, Pfizer Canada Inc.",44
sample_nocs/0000002754.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000002754.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000002754.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",66
sample_nocs/0000002754.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002754.PDF,submission_no,What is the Submission Number?,136274,98
sample_nocs/0000002754.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,85
sample_nocs/0000002754.PDF,product_name,What is the Product name?,APX-AMLODIPINE,88
sample_nocs/0000002754.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02343274 (ORL, TAB, 5 mg)",85
sample_nocs/0000002754.PDF,species,What is the species?,NA,NA
sample_nocs/0000002754.PDF,noc_date,What is the date of the document?,FES 15 2010,41
sample_nocs/0000002754.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amlodipine supplied as Amlodipine Besylate,96
sample_nocs/0000002851.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pariet, Janssen-Ortho Inc., Canada",58.999996185302734
sample_nocs/0000002851.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,60.000003814697266
sample_nocs/0000002851.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000002851.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",69
sample_nocs/0000002851.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002851.PDF,submission_no,What is the Submission Number?,119609,98
sample_nocs/0000002851.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,91
sample_nocs/0000002851.PDF,product_name,What is the Product name?,APO-RABEPRAZOLE,95
sample_nocs/0000002851.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02345579, Oral, Tablet (Enteric Coated), 10 mg",83
sample_nocs/0000002851.PDF,species,What is the species?,NA,NA
sample_nocs/0000002851.PDF,noc_date,What is the date of the document?,MAR 162010,84
sample_nocs/0000002851.PDF,medicinal_ingredients,What are the medicinal ingredients?,rabeprazole sodium,76
sample_nocs/0000002918.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000002918.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000002918.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,97
sample_nocs/0000002918.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,87
sample_nocs/0000002918.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000002918.PDF,submission_no,What is the Submission Number?,137183,99
sample_nocs/0000002918.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alkopharma,99
sample_nocs/0000002918.PDF,product_name,What is the Product name?,SANOREX,80
sample_nocs/0000002918.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00432407 (ORL, TAB, 1 mg)",90
sample_nocs/0000002918.PDF,species,What is the species?,NA,NA
sample_nocs/0000002918.PDF,noc_date,What is the date of the document?,MAR 26 2010,94
sample_nocs/0000002918.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mazindol,98
sample_nocs/0000003115.PDF,canadian_reference_product,What is the Canadian Reference Product?,RITUXAN,43
sample_nocs/0000003115.PDF,directorate,What is the directorate that approved the submission?,Health  and the Food Branch,5
sample_nocs/0000003115.PDF,noc_reason,What was the reason for the submission?,Addition to the indication for Chronic Lymphocytic Leukemia (CLL):,51
sample_nocs/0000003115.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000003115.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003115.PDF,submission_no,What is the Submission Number?,129956,98
sample_nocs/0000003115.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,98
sample_nocs/0000003115.PDF,product_name,What is the Product name?,Rituxan,66
sample_nocs/0000003115.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000003115.PDF,species,What is the species?,NA,NA
sample_nocs/0000003115.PDF,noc_date,What is the date of the document?,MAY 05 2010,41
sample_nocs/0000003115.PDF,medicinal_ingredients,What are the medicinal ingredients?,"rituximab, rituximab",45
sample_nocs/0000003216.PDF,canadian_reference_product,What is the Canadian Reference Product?,DOXYCYCLINE TABLETS DOXYCYCLINE CAPSULES,76
sample_nocs/0000003216.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000003216.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,89
sample_nocs/0000003216.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,87
sample_nocs/0000003216.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003216.PDF,submission_no,What is the Submission Number?,138009,98
sample_nocs/0000003216.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,49
sample_nocs/0000003216.PDF,product_name,What is the Product name?,DOXYCYCLINE TABLETS DOXYCYCLINE CAPSULES,86
sample_nocs/0000003216.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02351242 (ORL,TAB, 100 mg) Doxycycline Tablets",58.999996185302734
sample_nocs/0000003216.PDF,species,What is the species?,NA,NA
sample_nocs/0000003216.PDF,noc_date,What is the date of the document?,MAY 25 2010,99
sample_nocs/0000003216.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxycycline supplied as Doxycycline Hyclate,95
sample_nocs/0000003219.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003219.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000003219.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,90
sample_nocs/0000003219.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,89
sample_nocs/0000003219.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003219.PDF,submission_no,What is the Submission Number?,138224,100
sample_nocs/0000003219.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,55
sample_nocs/0000003219.PDF,product_name,What is the Product name?,Furosemide,49
sample_nocs/0000003219.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02351420 (ORL,TAB, 20 mg)",83
sample_nocs/0000003219.PDF,species,What is the species?,NA,NA
sample_nocs/0000003219.PDF,noc_date,What is the date of the document?,MAY 26 2010,99
sample_nocs/0000003219.PDF,medicinal_ingredients,What are the medicinal ingredients?,Furosemide,97
sample_nocs/0000003225.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Amatine, Shire Canada Inc., Canada",51
sample_nocs/0000003225.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000003225.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,95
sample_nocs/0000003225.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",58
sample_nocs/0000003225.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003225.PDF,submission_no,What is the Submission Number?,138681,97
sample_nocs/0000003225.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Incorporated,90
sample_nocs/0000003225.PDF,product_name,What is the Product name?,MIDODRINE,97
sample_nocs/0000003225.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02278677 (ORL, TAB, 2.5 mg)",75
sample_nocs/0000003225.PDF,species,What is the species?,NA,NA
sample_nocs/0000003225.PDF,noc_date,What is the date of the document?,MAY 27 2010,71
sample_nocs/0000003225.PDF,medicinal_ingredients,What are the medicinal ingredients?,Midodrine Hydrochloride,98
sample_nocs/0000003229.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Adalat XL, Bayer Inc., Canada",68
sample_nocs/0000003229.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000003229.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000003229.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",71
sample_nocs/0000003229.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003229.PDF,submission_no,What is the Submission Number?,138544,98
sample_nocs/0000003229.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,94
sample_nocs/0000003229.PDF,product_name,What is the Product name?,NIFEDIPINE EXTENDED RELEASE,84
sample_nocs/0000003229.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02351587 (ORL, TER, 30 mg)",80
sample_nocs/0000003229.PDF,species,What is the species?,NA,NA
sample_nocs/0000003229.PDF,noc_date,What is the date of the document?,MAY 26 2010,99
sample_nocs/0000003229.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nifedipine,79
sample_nocs/0000003245.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003245.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000003245.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,97
sample_nocs/0000003245.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,87
sample_nocs/0000003245.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003245.PDF,submission_no,What is the Submission Number?,138152,99
sample_nocs/0000003245.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GlaxoSmithKline Inc.,93
sample_nocs/0000003245.PDF,product_name,What is the Product name?,CLINDOXYL GEL,94
sample_nocs/0000003245.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02243158,57
sample_nocs/0000003245.PDF,species,What is the species?,NA,NA
sample_nocs/0000003245.PDF,noc_date,What is the date of the document?,MAY 7 2010,99
sample_nocs/0000003245.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clindamycin supplied as Clindamycin Phosphate Benzoyl Peroxide,92
sample_nocs/0000003294.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003294.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000003294.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000003294.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",76
sample_nocs/0000003294.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003294.PDF,submission_no,What is the Submission Number?,126931,98
sample_nocs/0000003294.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hospira Healthcare Corporation,98
sample_nocs/0000003294.PDF,product_name,What is the Product name?,Precedex,98
sample_nocs/0000003294.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02339366, Intravenous, Solution, 100mcg/ml",73
sample_nocs/0000003294.PDF,species,What is the species?,NA,NA
sample_nocs/0000003294.PDF,noc_date,What is the date of the document?,"December 09, 2009",89
sample_nocs/0000003294.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dexmedetomidine(supplied as Dexmedetomidine Hydrochloride),35
sample_nocs/0000003350.PDF,canadian_reference_product,What is the Canadian Reference Product?,Cefa-Dri®,52
sample_nocs/0000003350.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000003350.PDF,noc_reason,What was the reason for the submission?,Change in ownership,99
sample_nocs/0000003350.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,98
sample_nocs/0000003350.PDF,dossier_id,What is the Dossier Id?,OF15-21-B1716-106,85
sample_nocs/0000003350.PDF,submission_no,What is the Submission Number?,138278,97
sample_nocs/0000003350.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000003350.PDF,product_name,What is the Product name?,Cefa-Dri®,81
sample_nocs/0000003350.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02173255, Intramammary, Gel, 300 mg/10mL",52.999996185302734
sample_nocs/0000003350.PDF,species,What is the species?,Dry cows,96
sample_nocs/0000003350.PDF,noc_date,What is the date of the document?,JUN 16 2010,74
sample_nocs/0000003350.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cephapirin (as cephapirin benzathine),69
sample_nocs/0000003362.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Chlorhydrate de saxagliptine, 5 mg, comprimés",48
sample_nocs/0000003362.PDF,directorate,What is the directorate that approved the submission?,Direction générale des produits de santé et desaliments,47
sample_nocs/0000003362.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000003362.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000003362.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003362.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000003362.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000003362.PDF,product_name,What is the Product name?,"Chlorhydrate de saxagliptine, 5 mg, comprimés",43
sample_nocs/0000003362.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",5 mg,80
sample_nocs/0000003362.PDF,species,What is the species?,NA,NA
sample_nocs/0000003362.PDF,noc_date,What is the date of the document?,2010/06/10,98
sample_nocs/0000003362.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Chlorhydrate de saxagliptine, 5 mg, comprimés",80
sample_nocs/0000003472.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Neurontin, Parke-Davis, division of Warner Lambert Canada Inc., Canada",33
sample_nocs/0000003472.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,81
sample_nocs/0000003472.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,89
sample_nocs/0000003472.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",52.999996185302734
sample_nocs/0000003472.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003472.PDF,submission_no,What is the Submission Number?,117730,98
sample_nocs/0000003472.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Zymcan Pharmaceuticals Inc.,72
sample_nocs/0000003472.PDF,product_name,What is the Product name?,ZYM-GABAPENTIN,89
sample_nocs/0000003472.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02304775 (ORL, CAP, 100mg)",66
sample_nocs/0000003472.PDF,species,What is the species?,NA,NA
sample_nocs/0000003472.PDF,noc_date,What is the date of the document?,JUL 9 2008,25
sample_nocs/0000003472.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gabapentin,97
sample_nocs/0000003510.PDF,canadian_reference_product,What is the Canadian Reference Product?,Zevalin,71
sample_nocs/0000003510.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,54.000003814697266
sample_nocs/0000003510.PDF,noc_reason,What was the reason for the submission?,change in manufacturing new facility / nouvel emplacement de fabrication,36
sample_nocs/0000003510.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Elwyn Griffiths,73
sample_nocs/0000003510.PDF,dossier_id,What is the Dossier Id?,CPID,14
sample_nocs/0000003510.PDF,submission_no,What is the Submission Number?,120306,98
sample_nocs/0000003510.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Inc.,58.999996185302734
sample_nocs/0000003510.PDF,product_name,What is the Product name?,Zevalin,86
sample_nocs/0000003510.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, LIQ, 3.2 mg/2mL",84
sample_nocs/0000003510.PDF,species,What is the species?,NA,NA
sample_nocs/0000003510.PDF,noc_date,What is the date of the document?,OCT 14 2008,83
sample_nocs/0000003510.PDF,medicinal_ingredients,What are the medicinal ingredients?,ibritumomab tiuxetan,93
sample_nocs/0000003573.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003573.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000003573.PDF,noc_reason,What was the reason for the submission?,Addition of alternate manufacturing site for the finished product,96
sample_nocs/0000003573.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",83
sample_nocs/0000003573.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003573.PDF,submission_no,What is the Submission Number?,120347,98
sample_nocs/0000003573.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hospira Healthcare Corporation,99
sample_nocs/0000003573.PDF,product_name,What is the Product name?,0.4% Lidocaine Hydrochloride and 5% Dextrose Injection USP,91
sample_nocs/0000003573.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, Lidocaine Hydrochloride, 4 mg/mL",82
sample_nocs/0000003573.PDF,species,What is the species?,NA,NA
sample_nocs/0000003573.PDF,noc_date,What is the date of the document?,"October 14, 2008",94
sample_nocs/0000003573.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lidocaine Hydrochloride and Dextrose,96
sample_nocs/0000003594.PDF,canadian_reference_product,What is the Canadian Reference Product?,Bovatec,100
sample_nocs/0000003594.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000003594.PDF,noc_reason,What was the reason for the submission?,Addition of Federated Co-operatives Ltd. for the manufacturing of Co-op Bovatec Pasture Cattle Mineral,92
sample_nocs/0000003594.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Louis Boulay,97
sample_nocs/0000003594.PDF,dossier_id,What is the Dossier Id?,9460-A0189-508,96
sample_nocs/0000003594.PDF,submission_no,What is the Submission Number?,114441,98
sample_nocs/0000003594.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000003594.PDF,product_name,What is the Product name?,Bovatec,98
sample_nocs/0000003594.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02242923, Oral, Drug premix, 150 g/kg",64
sample_nocs/0000003594.PDF,species,What is the species?,"Cattle, lambs",93
sample_nocs/0000003594.PDF,noc_date,What is the date of the document?,MAR 25 2008,96
sample_nocs/0000003594.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lasalocid sodium,98
sample_nocs/0000003660.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003660.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,58.999996185302734
sample_nocs/0000003660.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000003660.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",74
sample_nocs/0000003660.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003660.PDF,submission_no,What is the Submission Number?,114004,98
sample_nocs/0000003660.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alcon Canada Incorporated,97
sample_nocs/0000003660.PDF,product_name,What is the Product name?,NEVANAC OPHTHALMIC SUSPENSION,63
sample_nocs/0000003660.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02308983, Ophthalmic, Suspension, 0.1%",74
sample_nocs/0000003660.PDF,species,What is the species?,NA,NA
sample_nocs/0000003660.PDF,noc_date,What is the date of the document?,APR 7 2008,87
sample_nocs/0000003660.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nepafenac,97
sample_nocs/0000003740.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pantoloc, Solvay Pharma Inc., Canada/Altana Pharma AG,",31
sample_nocs/0000003740.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,58
sample_nocs/0000003740.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000003740.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",58.999996185302734
sample_nocs/0000003740.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003740.PDF,submission_no,What is the Submission Number?,101031,99
sample_nocs/0000003740.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,90
sample_nocs/0000003740.PDF,product_name,What is the Product name?,APO-PANTOPRAZOLE,94
sample_nocs/0000003740.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02292912, Oral, Tablet ( Delayed-Release ), 20 mg",41
sample_nocs/0000003740.PDF,species,What is the species?,NA,NA
sample_nocs/0000003740.PDF,noc_date,What is the date of the document?,"March 12, 2008",96
sample_nocs/0000003740.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pantoprazole(suppled as Pantoprazole Sodium )/ Pantoprazole ( comme Pantoprazole Sodique,16
sample_nocs/0000003920.PDF,canadian_reference_product,What is the Canadian Reference Product?,COMBIVIR,81
sample_nocs/0000003920.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,72
sample_nocs/0000003920.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,97
sample_nocs/0000003920.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,90
sample_nocs/0000003920.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003920.PDF,submission_no,What is the Submission Number?,140577,98
sample_nocs/0000003920.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ViiV Healthcare Shire Canada,84
sample_nocs/0000003920.PDF,product_name,What is the Product name?,COMBIVIR,99
sample_nocs/0000003920.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02239213,55
sample_nocs/0000003920.PDF,species,What is the species?,NA,NA
sample_nocs/0000003920.PDF,noc_date,What is the date of the document?,AUG 8 2010,74
sample_nocs/0000003920.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lamivudine / Zidovudine,96
sample_nocs/0000003990.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000003990.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000003990.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000003990.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,85
sample_nocs/0000003990.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000003990.PDF,submission_no,What is the Submission Number?,140827,98
sample_nocs/0000003990.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,95
sample_nocs/0000003990.PDF,product_name,What is the Product name?,Ranitidine,55
sample_nocs/0000003990.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02286106 (ORL, TAB, 150 mg)",87
sample_nocs/0000003990.PDF,species,What is the species?,NA,NA
sample_nocs/0000003990.PDF,noc_date,What is the date of the document?,AUG 25 2010,83
sample_nocs/0000003990.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ranitidine supplied as Ranitidine Hydrochloride,96
sample_nocs/0000004008.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000004008.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000004008.PDF,noc_reason,What was the reason for the submission?,"Update to the Product Monograph: Warnings and Precautions, Adverse Reactions, Action and Clinical Pharmacology, Clinical Trials.",68
sample_nocs/0000004008.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",69
sample_nocs/0000004008.PDF,dossier_id,What is the Dossier Id?,9427-B0456-43,51
sample_nocs/0000004008.PDF,submission_no,What is the Submission Number?,111362,98
sample_nocs/0000004008.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Inc.,63
sample_nocs/0000004008.PDF,product_name,What is the Product name?,GLUCOBAY,99
sample_nocs/0000004008.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 50 mg",88
sample_nocs/0000004008.PDF,species,What is the species?,NA,NA
sample_nocs/0000004008.PDF,noc_date,What is the date of the document?,DEC 11 2007,80
sample_nocs/0000004008.PDF,medicinal_ingredients,What are the medicinal ingredients?,Acarbose,97
sample_nocs/0000004124.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Proscar, Merck Frosst Canada Ltd., Canada",43
sample_nocs/0000004124.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000004124.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,89
sample_nocs/0000004124.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",78
sample_nocs/0000004124.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004124.PDF,submission_no,What is the Submission Number?,141486,98
sample_nocs/0000004124.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000004124.PDF,product_name,What is the Product name?,JAMP-FINASTERIDE,47
sample_nocs/0000004124.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02357224 (ORL,TAB, 5 mg)",72
sample_nocs/0000004124.PDF,species,What is the species?,NA,NA
sample_nocs/0000004124.PDF,noc_date,What is the date of the document?,SEP 29 2010,98
sample_nocs/0000004124.PDF,medicinal_ingredients,What are the medicinal ingredients?,Finasteride,97
sample_nocs/0000004195.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cefzil, Bristol-Myers Squibb Canada Inc.",27.000001907348633
sample_nocs/0000004195.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000004195.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000004195.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",80
sample_nocs/0000004195.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004195.PDF,submission_no,What is the Submission Number?,104754,99
sample_nocs/0000004195.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,94
sample_nocs/0000004195.PDF,product_name,What is the Product name?,Sandoz Cefprozil,96
sample_nocs/0000004195.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02302179, Oral, Tablet, 250mg",95
sample_nocs/0000004195.PDF,species,What is the species?,NA,NA
sample_nocs/0000004195.PDF,noc_date,What is the date of the document?,NOV 21 2007,80
sample_nocs/0000004195.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cefprozil,97
sample_nocs/0000004303.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000004303.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000004303.PDF,noc_reason,What was the reason for the submission?,New Indication: Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant,64
sample_nocs/0000004303.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",77
sample_nocs/0000004303.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004303.PDF,submission_no,What is the Submission Number?,104227,99
sample_nocs/0000004303.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,REVISED,94
sample_nocs/0000004303.PDF,product_name,What is the Product name?,CUBICIN,94
sample_nocs/0000004303.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 500 mg/Vial",86
sample_nocs/0000004303.PDF,species,What is the species?,Staphylococcus aureus,60.000003814697266
sample_nocs/0000004303.PDF,noc_date,What is the date of the document?,MAR 14 2008,92
sample_nocs/0000004303.PDF,medicinal_ingredients,What are the medicinal ingredients?,Daptomycin,98
sample_nocs/0000004313.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000004313.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000004313.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000004313.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,85
sample_nocs/0000004313.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004313.PDF,submission_no,What is the Submission Number?,114625,98
sample_nocs/0000004313.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,87
sample_nocs/0000004313.PDF,product_name,What is the Product name?,CARDURA,99
sample_nocs/0000004313.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","01958100 (ORL,TAB, 1mg)",92
sample_nocs/0000004313.PDF,species,What is the species?,NA,NA
sample_nocs/0000004313.PDF,noc_date,What is the date of the document?,JUN 21 2007,79
sample_nocs/0000004313.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxazosin supplied as Doxazosin Mesylate,96
sample_nocs/0000004332.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000004332.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000004332.PDF,noc_reason,What was the reason for the submission?,Revisions to the Product Monograph. Removal of chronic indication and safety updates.,71
sample_nocs/0000004332.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",66
sample_nocs/0000004332.PDF,dossier_id,What is the Dossier Id?,9427-N1065-23,54.000003814697266
sample_nocs/0000004332.PDF,submission_no,What is the Submission Number?,105050,99
sample_nocs/0000004332.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Novartis Ophthalmics, Novartis Pharmaceuticals Canada Inc.",91
sample_nocs/0000004332.PDF,product_name,What is the Product name?,VOLTAREN OPHTHA,98
sample_nocs/0000004332.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Ophthalmic, Solution, 1 mg/ml",89
sample_nocs/0000004332.PDF,species,What is the species?,NA,NA
sample_nocs/0000004332.PDF,noc_date,What is the date of the document?,mARS 04 2007,23
sample_nocs/0000004332.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diclofenac Sodium 0.1%,97
sample_nocs/0000004483.PDF,canadian_reference_product,What is the Canadian Reference Product?,Prilium 150 mg (Imidapril Hydrochloride),71
sample_nocs/0000004483.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000004483.PDF,noc_reason,What was the reason for the submission?,previously 2001034N,40
sample_nocs/0000004483.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Siddika Mithani,51
sample_nocs/0000004483.PDF,dossier_id,What is the Dossier Id?,9460-V0135-514,97
sample_nocs/0000004483.PDF,submission_no,What is the Submission Number?,"110450, previously 2001034N",69
sample_nocs/0000004483.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000004483.PDF,product_name,What is the Product name?,Prilium 150 mg (Imidapril Hydrochloride),49
sample_nocs/0000004483.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02297280, oral, powder for solution, 0.150 g/vial",71
sample_nocs/0000004483.PDF,species,What is the species?,dogs,93
sample_nocs/0000004483.PDF,noc_date,What is the date of the document?,12 2007,58.999996185302734
sample_nocs/0000004483.PDF,medicinal_ingredients,What are the medicinal ingredients?,Imidapril hydrochloride,73
sample_nocs/0000004487.PDF,canadian_reference_product,What is the Canadian Reference Product?,Apo-Ibuprofen,91
sample_nocs/0000004487.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,63
sample_nocs/0000004487.PDF,noc_reason,What was the reason for the submission?,New dosage form,92
sample_nocs/0000004487.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",80
sample_nocs/0000004487.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004487.PDF,submission_no,What is the Submission Number?,102963,98
sample_nocs/0000004487.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,78
sample_nocs/0000004487.PDF,product_name,What is the Product name?,Apo-Ibuprofen,95
sample_nocs/0000004487.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02295970 -ORAL SUSPENSION, 100 mg/5ml",51
sample_nocs/0000004487.PDF,species,What is the species?,NA,NA
sample_nocs/0000004487.PDF,noc_date,What is the date of the document?,JUN 30 2007,34
sample_nocs/0000004487.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ibuprofen,96
sample_nocs/0000004514.PDF,canadian_reference_product,What is the Canadian Reference Product?,SUDAFED SINUS ADVANCE,94
sample_nocs/0000004514.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000004514.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,95
sample_nocs/0000004514.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,84
sample_nocs/0000004514.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004514.PDF,submission_no,What is the Submission Number?,111170,98
sample_nocs/0000004514.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,McNeil Consumer Healthcare,98
sample_nocs/0000004514.PDF,product_name,What is the Product name?,SUDAFED SINUS ADVANCE,91
sample_nocs/0000004514.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02242217,57
sample_nocs/0000004514.PDF,species,What is the species?,NA,NA
sample_nocs/0000004514.PDF,noc_date,What is the date of the document?,JAN 23 2007,87
sample_nocs/0000004514.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ibuprofen / Pseudoephedrine Hydrochloride,88
sample_nocs/0000004545.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Prinivil, Merck Frosst Canada & Co, Canada",32
sample_nocs/0000004545.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,66
sample_nocs/0000004545.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000004545.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",64
sample_nocs/0000004545.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004545.PDF,submission_no,What is the Submission Number?,099076,98
sample_nocs/0000004545.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,90
sample_nocs/0000004545.PDF,product_name,What is the Product name?,SANDOZ LISINOPRIL,85
sample_nocs/0000004545.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02289199, Oral, Tablet, 5mg",95
sample_nocs/0000004545.PDF,species,What is the species?,NA,NA
sample_nocs/0000004545.PDF,noc_date,What is the date of the document?,OCT 17 2007,90
sample_nocs/0000004545.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lisinopril supplied as Lisinopril Dihydrate,89
sample_nocs/0000004634.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000004634.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Product Directorate,50
sample_nocs/0000004634.PDF,noc_reason,What was the reason for the submission?,"for its use in ""adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's type""",52.999996185302734
sample_nocs/0000004634.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000004634.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004634.PDF,submission_no,What is the Submission Number?,134197,97
sample_nocs/0000004634.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000004634.PDF,product_name,What is the Product name?,Therapeutic Product Directorate,96
sample_nocs/0000004634.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000004634.PDF,species,What is the species?,Alzheimer's type,21
sample_nocs/0000004634.PDF,noc_date,What is the date of the document?,NA,NA
sample_nocs/0000004634.PDF,medicinal_ingredients,What are the medicinal ingredients?,Memantine Hydrochloride,78
sample_nocs/0000004804.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zyprexa, Eli Lilly Canada Inc.",23
sample_nocs/0000004804.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,79
sample_nocs/0000004804.PDF,noc_reason,What was the reason for the submission?,Revisions to the Product Monograph,96
sample_nocs/0000004804.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",61
sample_nocs/0000004804.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004804.PDF,submission_no,What is the Submission Number?,110485,99
sample_nocs/0000004804.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novopharm Limited,93
sample_nocs/0000004804.PDF,product_name,What is the Product name?,NOVO-OLANZAPINE,94
sample_nocs/0000004804.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 2.5mg",88
sample_nocs/0000004804.PDF,species,What is the species?,NA,NA
sample_nocs/0000004804.PDF,noc_date,What is the date of the document?,JUN 0 6 2007,58
sample_nocs/0000004804.PDF,medicinal_ingredients,What are the medicinal ingredients?,Olanzapine,92
sample_nocs/0000004805.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zofran, GlaxoSmithKline Inc., Canada",52
sample_nocs/0000004805.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000004805.PDF,noc_reason,What was the reason for the submission?,Product Name Change from Apo-Ondansetron,94
sample_nocs/0000004805.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,83
sample_nocs/0000004805.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000004805.PDF,submission_no,What is the Submission Number?,114394,98
sample_nocs/0000004805.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc,95
sample_nocs/0000004805.PDF,product_name,What is the Product name?,Ondansetron InJECTION USP,50
sample_nocs/0000004805.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02291703 (IV,SOL, 2 mg/mL)",70
sample_nocs/0000004805.PDF,species,What is the species?,NA,NA
sample_nocs/0000004805.PDF,noc_date,What is the date of the document?,JUN 0 1 2007,25
sample_nocs/0000004805.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ondansetron supplied as Ondansetron Hydrochloride Dihydrate,93
sample_nocs/0000005025.PDF,canadian_reference_product,What is the Canadian Reference Product?,HUMIRA,94
sample_nocs/0000005025.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000005025.PDF,noc_reason,What was the reason for the submission?,Alternate drug delivery system HUMIRA® pen Système d'administration alternatif de médicaments HUMIRA® stylo,49
sample_nocs/0000005025.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Pierre J. Charest,77
sample_nocs/0000005025.PDF,dossier_id,What is the Dossier Id?,m27,5
sample_nocs/0000005025.PDF,submission_no,What is the Submission Number?,105273,98
sample_nocs/0000005025.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Abbott Laboratories, Limited",97
sample_nocs/0000005025.PDF,product_name,What is the Product name?,HUMIRA,85
sample_nocs/0000005025.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, Sol, 40 mg/0.8 mL",75
sample_nocs/0000005025.PDF,species,What is the species?,NA,NA
sample_nocs/0000005025.PDF,noc_date,What is the date of the document?,DEC 1 2006,71
sample_nocs/0000005025.PDF,medicinal_ingredients,What are the medicinal ingredients?,adalimumab,90
sample_nocs/0000005127.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Rocephin, Hoffman-LaRoche Limited",38
sample_nocs/0000005127.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000005127.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000005127.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,48
sample_nocs/0000005127.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005127.PDF,submission_no,What is the Submission Number?,099798,98
sample_nocs/0000005127.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmaceutical Partners of Canada,62
sample_nocs/0000005127.PDF,product_name,What is the Product name?,"CEFTRIAXONE FOR INJECTION, USP",82
sample_nocs/0000005127.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02289679,51
sample_nocs/0000005127.PDF,species,What is the species?,NA,NA
sample_nocs/0000005127.PDF,noc_date,What is the date of the document?,DEC 15 2006,85
sample_nocs/0000005127.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ceftriaxone (as Ceftriaxone sodium),76
sample_nocs/0000005189.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Antirobe Capsules 75 mg, Pharmacia Animal Health, Canada",45
sample_nocs/0000005189.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000005189.PDF,noc_reason,What was the reason for the submission?,to correct a clerical error,84
sample_nocs/0000005189.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Siddika Mithani, Ph.D.",31
sample_nocs/0000005189.PDF,dossier_id,What is the Dossier Id?,9460-C1411-504,91
sample_nocs/0000005189.PDF,submission_no,What is the Submission Number?,2004147A,97
sample_nocs/0000005189.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000005189.PDF,product_name,What is the Product name?,Clinacin Tablets 75 mg,89
sample_nocs/0000005189.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02277727, oral, tablets, 75 mg/tab",82
sample_nocs/0000005189.PDF,species,What is the species?,dogs,99
sample_nocs/0000005189.PDF,noc_date,What is the date of the document?,"March 6, 2006",93
sample_nocs/0000005189.PDF,medicinal_ingredients,What are the medicinal ingredients?,clindamycin (as clindamycin hydrochloride),71
sample_nocs/0000005202.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000005202.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000005202.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,87
sample_nocs/0000005202.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,50
sample_nocs/0000005202.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005202.PDF,submission_no,What is the Submission Number?,110390,98
sample_nocs/0000005202.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmel Inc.,76
sample_nocs/0000005202.PDF,product_name,What is the Product name?,PHL-DOXYCYCLINE,94
sample_nocs/0000005202.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02289458 (ORL, TAB, 100mg)",64
sample_nocs/0000005202.PDF,species,What is the species?,NA,NA
sample_nocs/0000005202.PDF,noc_date,What is the date of the document?,DEC. 2 2006,89
sample_nocs/0000005202.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxycycline supplied as Doxycycline Hyclate,95
sample_nocs/0000005257.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000005257.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,69
sample_nocs/0000005257.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000005257.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",58.999996185302734
sample_nocs/0000005257.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005257.PDF,submission_no,What is the Submission Number?,094663,98
sample_nocs/0000005257.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,91
sample_nocs/0000005257.PDF,product_name,What is the Product name?,Pediatric Digoxin Injection C.S.D.,72
sample_nocs/0000005257.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02048272, Intramuscular, Intravenous, Liquid, 0.05 mg/mL",63
sample_nocs/0000005257.PDF,species,What is the species?,NA,NA
sample_nocs/0000005257.PDF,noc_date,What is the date of the document?,"February 2, 2006",96
sample_nocs/0000005257.PDF,medicinal_ingredients,What are the medicinal ingredients?,Digoxin,99
sample_nocs/0000005420.PDF,canadian_reference_product,What is the Canadian Reference Product?,INFERGEN,62
sample_nocs/0000005420.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,33
sample_nocs/0000005420.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,94
sample_nocs/0000005420.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Pierre J. Charest,72
sample_nocs/0000005420.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005420.PDF,submission_no,What is the Submission Number?,104824,99
sample_nocs/0000005420.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Valeant Canada limitée/Limited,34
sample_nocs/0000005420.PDF,product_name,What is the Product name?,INFERGEN,95
sample_nocs/0000005420.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02239832 (SC,SOL, 0.03mg/mL)",39
sample_nocs/0000005420.PDF,species,What is the species?,NA,NA
sample_nocs/0000005420.PDF,noc_date,What is the date of the document?,MAY 9 2006,98
sample_nocs/0000005420.PDF,medicinal_ingredients,What are the medicinal ingredients?,Interferon Alfacon-1,94
sample_nocs/0000005431.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Combivent, Boehringer Ingelheim (Canada) Ltd, Canada",71
sample_nocs/0000005431.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000005431.PDF,noc_reason,What was the reason for the submission?,Product name change,98
sample_nocs/0000005431.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,88
sample_nocs/0000005431.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005431.PDF,submission_no,What is the Submission Number?,104235,99
sample_nocs/0000005431.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Cobalt Pharmaceuticals Inc.,95
sample_nocs/0000005431.PDF,product_name,What is the Product name?,CO SALBUT-IPRAT INHALATION SOLUTION,92
sample_nocs/0000005431.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02276348, INH, SOL, 0.5mg/2.5ml Ipratropium Bromide",67
sample_nocs/0000005431.PDF,species,What is the species?,NA,NA
sample_nocs/0000005431.PDF,noc_date,What is the date of the document?,MAR 29 2006,94
sample_nocs/0000005431.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ipratropium Bromide(supplied as Ipratropium Bromide Monohydrate) and Salbutamol (supplied as Salbutamol Sulfate),30.000001907348633
sample_nocs/0000005475.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000005475.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000005475.PDF,noc_reason,What was the reason for the submission?,changes to manufacturing facility / changes to l'emplacement de fabrication,37
sample_nocs/0000005475.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Pierre J. Charest,76
sample_nocs/0000005475.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005475.PDF,submission_no,What is the Submission Number?,096436,99
sample_nocs/0000005475.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Genzyme Canada Inc.,80
sample_nocs/0000005475.PDF,product_name,What is the Product name?,ALDURAZYME,88
sample_nocs/0000005475.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 0.58 mg/mL",85
sample_nocs/0000005475.PDF,species,What is the species?,NA,NA
sample_nocs/0000005475.PDF,noc_date,What is the date of the document?,FEB 17 2006,95
sample_nocs/0000005475.PDF,medicinal_ingredients,What are the medicinal ingredients?,laronidase,99
sample_nocs/0000005479.PDF,canadian_reference_product,What is the Canadian Reference Product?,MUSTARGEN,91
sample_nocs/0000005479.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000005479.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,95
sample_nocs/0000005479.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,55
sample_nocs/0000005479.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005479.PDF,submission_no,What is the Submission Number?,110438,99
sample_nocs/0000005479.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ovation Pharmaceuticals Inc.,67
sample_nocs/0000005479.PDF,product_name,What is the Product name?,MUSTARGEN,99
sample_nocs/0000005479.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00016063 (IP,IPC,IPL,IV, PWSO, 10mg/Vial)",49
sample_nocs/0000005479.PDF,species,What is the species?,NA,NA
sample_nocs/0000005479.PDF,noc_date,What is the date of the document?,DEC. 22 2006,75
sample_nocs/0000005479.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mechlorethamine supplied as Mechlorethamine Hydrochloride,96
sample_nocs/0000005546.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cosopt, Merck Frosst Canada Ltd., Canada",42
sample_nocs/0000005546.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000005546.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,95
sample_nocs/0000005546.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",55
sample_nocs/0000005546.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005546.PDF,submission_no,What is the Submission Number?,143236,98
sample_nocs/0000005546.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,84
sample_nocs/0000005546.PDF,product_name,What is the Product name?,TEVA-DORZOTIMOL,94
sample_nocs/0000005546.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02320525,43
sample_nocs/0000005546.PDF,species,What is the species?,NA,NA
sample_nocs/0000005546.PDF,noc_date,What is the date of the document?,DEC 08 2010,51
sample_nocs/0000005546.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dorzolamide supplied as Dorzolamide Hydrochloride / Timolol Supplied as Timolol Maleate,84
sample_nocs/0000005756.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000005756.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000005756.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000005756.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,90
sample_nocs/0000005756.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005756.PDF,submission_no,What is the Submission Number?,144613,98
sample_nocs/0000005756.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Valeant Canada LP/Valeant Canada S.E.C,48
sample_nocs/0000005756.PDF,product_name,What is the Product name?,ZYBAN,93
sample_nocs/0000005756.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02238441 (ORL, TER, 150 mg)",73
sample_nocs/0000005756.PDF,species,What is the species?,NA,NA
sample_nocs/0000005756.PDF,noc_date,What is the date of the document?,FEB 11 2011,48
sample_nocs/0000005756.PDF,medicinal_ingredients,What are the medicinal ingredients?,Bupropion Hydrochloride,97
sample_nocs/0000005848.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zofran, Glaxo Wellcome GmbH & Co., Germany",65
sample_nocs/0000005848.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000005848.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,91
sample_nocs/0000005848.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",83
sample_nocs/0000005848.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005848.PDF,submission_no,What is the Submission Number?,144802,98
sample_nocs/0000005848.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Avanstra Inc.,55
sample_nocs/0000005848.PDF,product_name,What is the Product name?,AVA-ONDANSETRON,93
sample_nocs/0000005848.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02362910 (oral, tablet, 8 mg)",51
sample_nocs/0000005848.PDF,species,What is the species?,NA,NA
sample_nocs/0000005848.PDF,noc_date,What is the date of the document?,FEB 25 2011,82
sample_nocs/0000005848.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ondansetron supplied as Ondansetron Hydrochloride Dihydrate,96
sample_nocs/0000005885.PDF,canadian_reference_product,What is the Canadian Reference Product?,COLGATE TOTAL ADVANCED HEALTH GUM DEFENSE,55
sample_nocs/0000005885.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,69
sample_nocs/0000005885.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000005885.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",70
sample_nocs/0000005885.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005885.PDF,submission_no,What is the Submission Number?,144026,98
sample_nocs/0000005885.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Colgate-Palmolive Canada Inc.,79
sample_nocs/0000005885.PDF,product_name,What is the Product name?,COLGATE TOTAL ADVANCED HEALTH GUM DEFENSE,91
sample_nocs/0000005885.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02364786, Dental, Toothpaste, 0.243% / W/W / 0.300% / W/W",63
sample_nocs/0000005885.PDF,species,What is the species?,NA,NA
sample_nocs/0000005885.PDF,noc_date,What is the date of the document?,MAR 08 2011,97
sample_nocs/0000005885.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium Fluoride / Triclosan,84
sample_nocs/0000005944.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000005944.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000005944.PDF,noc_reason,What was the reason for the submission?,Additional Product Name,99
sample_nocs/0000005944.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,88
sample_nocs/0000005944.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000005944.PDF,submission_no,What is the Submission Number?,107691,98
sample_nocs/0000005944.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Genpharm Inc.,56
sample_nocs/0000005944.PDF,product_name,What is the Product name?,METFORMIN,49
sample_nocs/0000005944.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02284782 (ORL, TAB, 500mg)",55
sample_nocs/0000005944.PDF,species,What is the species?,NA,NA
sample_nocs/0000005944.PDF,noc_date,What is the date of the document?,AOUT AUG 172006,34
sample_nocs/0000005944.PDF,medicinal_ingredients,What are the medicinal ingredients?,Metformin Hydrochloride,97
sample_nocs/0000006014.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000006014.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000006014.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000006014.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,83
sample_nocs/0000006014.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006014.PDF,submission_no,What is the Submission Number?,145173,98
sample_nocs/0000006014.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,69
sample_nocs/0000006014.PDF,product_name,What is the Product name?,K-DUR,93
sample_nocs/0000006014.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00713376 (ORAL,EXTENDED-RELEASE TABLET, 1.5 g)",33
sample_nocs/0000006014.PDF,species,What is the species?,NA,NA
sample_nocs/0000006014.PDF,noc_date,What is the date of the document?,MAR 21 2011,93
sample_nocs/0000006014.PDF,medicinal_ingredients,What are the medicinal ingredients?,Potassium Chloride,99
sample_nocs/0000006016.PDF,canadian_reference_product,What is the Canadian Reference Product?,ELOCOM,83
sample_nocs/0000006016.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000006016.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000006016.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Supriya Sharma MD MPH FRCPC,84
sample_nocs/0000006016.PDF,dossier_id,What is the Dossier Id?,00851736,52
sample_nocs/0000006016.PDF,submission_no,What is the Submission Number?,145174,100
sample_nocs/0000006016.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,65
sample_nocs/0000006016.PDF,product_name,What is the Product name?,ELOCOM,95
sample_nocs/0000006016.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00871095 (TOPICAL, LOTION, 1 mg/g)",78
sample_nocs/0000006016.PDF,species,What is the species?,NA,NA
sample_nocs/0000006016.PDF,noc_date,What is the date of the document?,MAR 21 2011,93
sample_nocs/0000006016.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mometasone Furoate,99
sample_nocs/0000006203.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zocor, Merck Frosst Canada & Co., Canada",40
sample_nocs/0000006203.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000006203.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name,89
sample_nocs/0000006203.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,55
sample_nocs/0000006203.PDF,dossier_id,What is the Dossier Id?,9427-D1287-133,87
sample_nocs/0000006203.PDF,submission_no,What is the Submission Number?,106396,98
sample_nocs/0000006203.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Dominion Pharmacal,97
sample_nocs/0000006203.PDF,product_name,What is the Product name?,DOM-SIMVASTATIN,97
sample_nocs/0000006203.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02281619 (ORL, TAB, 5mg)",65
sample_nocs/0000006203.PDF,species,What is the species?,NA,NA
sample_nocs/0000006203.PDF,noc_date,What is the date of the document?,JUN 20 2006,74
sample_nocs/0000006203.PDF,medicinal_ingredients,What are the medicinal ingredients?,Simvastatin,98
sample_nocs/0000006215.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000006215.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000006215.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000006215.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,58
sample_nocs/0000006215.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006215.PDF,submission_no,What is the Submission Number?,105773,98
sample_nocs/0000006215.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,50
sample_nocs/0000006215.PDF,product_name,What is the Product name?,FLUOTIC,94
sample_nocs/0000006215.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02099225 (ORL,ECT, 20mg)",74
sample_nocs/0000006215.PDF,species,What is the species?,NA,NA
sample_nocs/0000006215.PDF,noc_date,What is the date of the document?,MAY 16 2006,54.000003814697266
sample_nocs/0000006215.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium Fluoride,84
sample_nocs/0000006255.PDF,canadian_reference_product,What is the Canadian Reference Product?,RHO-TRIAMCINOLONE AQ,92
sample_nocs/0000006255.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000006255.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000006255.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Omer Boudreau,54.000003814697266
sample_nocs/0000006255.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006255.PDF,submission_no,What is the Submission Number?,108014,99
sample_nocs/0000006255.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,51
sample_nocs/0000006255.PDF,product_name,What is the Product name?,RHO-TRIAMCINOLONE AQ,94
sample_nocs/0000006255.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02236568 (NAS,SPRAY, 55ug/DOSE)",68
sample_nocs/0000006255.PDF,species,What is the species?,NA,NA
sample_nocs/0000006255.PDF,noc_date,What is the date of the document?,SEP 0 5 2006,89
sample_nocs/0000006255.PDF,medicinal_ingredients,What are the medicinal ingredients?,Triamcinolone Acetonide,95
sample_nocs/0000006493.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000006493.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000006493.PDF,noc_reason,What was the reason for the submission?,"Addition of Clinical Trial Data from HIV Infected Pregnant Women Updates to the Post-Market Data, and the Antiretroviral Pregnancy Registry",91
sample_nocs/0000006493.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",54.000003814697266
sample_nocs/0000006493.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006493.PDF,submission_no,What is the Submission Number?,142308,98
sample_nocs/0000006493.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bristol-Myers Squibb Canada,84
sample_nocs/0000006493.PDF,product_name,What is the Product name?,REYATAZ,98
sample_nocs/0000006493.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule, 100 mg",84
sample_nocs/0000006493.PDF,species,What is the species?,NA,NA
sample_nocs/0000006493.PDF,noc_date,What is the date of the document?,MAY 0 5 2011,76
sample_nocs/0000006493.PDF,medicinal_ingredients,What are the medicinal ingredients?,Atazanavir (supplied as atazanavir sulfate),67
sample_nocs/0000006688.PDF,canadian_reference_product,What is the Canadian Reference Product?,BOOSTRIX® POLIO,90
sample_nocs/0000006688.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,33
sample_nocs/0000006688.PDF,noc_reason,What was the reason for the submission?,product monograph revised/Monographie du produit révisée,38
sample_nocs/0000006688.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Elwyn Griffiths,84
sample_nocs/0000006688.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006688.PDF,submission_no,What is the Submission Number?,140874,98
sample_nocs/0000006688.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GlaxoSmithKline Inc.,83
sample_nocs/0000006688.PDF,product_name,What is the Product name?,BOOSTRIX® POLIO,93
sample_nocs/0000006688.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","NA, IM, SUS, 0.5 mL/single dose",89
sample_nocs/0000006688.PDF,species,What is the species?,diphtheria toxoid,76
sample_nocs/0000006688.PDF,noc_date,What is the date of the document?,JUL 11 2011,44
sample_nocs/0000006688.PDF,medicinal_ingredients,What are the medicinal ingredients?,"diphtheria toxoid, tetanus toxoid, filamentous hemagglutinin, pertactin, inactivated polio virus type 1, inactivated polio virus type 2, Inactivated polio virus type 3",52
sample_nocs/0000006728.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000006728.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,60.000003814697266
sample_nocs/0000006728.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000006728.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",68
sample_nocs/0000006728.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006728.PDF,submission_no,What is the Submission Number?,138343,98
sample_nocs/0000006728.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc.,58.999996185302734
sample_nocs/0000006728.PDF,product_name,What is the Product name?,ZYTIGA,92
sample_nocs/0000006728.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02371065, Oral, Tablet, 250 mg",90
sample_nocs/0000006728.PDF,species,What is the species?,NA,NA
sample_nocs/0000006728.PDF,noc_date,What is the date of the document?,JUL 27 2011,83
sample_nocs/0000006728.PDF,medicinal_ingredients,What are the medicinal ingredients?,Abiraterone acetate,52
sample_nocs/0000006760.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Risperdal, Janssen-Ortho Inc., Canada",30.000001907348633
sample_nocs/0000006760.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000006760.PDF,noc_reason,What was the reason for the submission?,New Manufacturer and Product Name / Nouveau nom de fabricant et du produit,72
sample_nocs/0000006760.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",67
sample_nocs/0000006760.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006760.PDF,submission_no,What is the Submission Number?,147760,100
sample_nocs/0000006760.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Angita Pharma Inc.,76
sample_nocs/0000006760.PDF,product_name,What is the Product name?,AG-RISPERIDONE,97
sample_nocs/0000006760.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02369079 (ORAL, TABLET, 0.25 mg)",77
sample_nocs/0000006760.PDF,species,What is the species?,NA,NA
sample_nocs/0000006760.PDF,noc_date,What is the date of the document?,AUG 22 2011,66
sample_nocs/0000006760.PDF,medicinal_ingredients,What are the medicinal ingredients?,Risperidone,97
sample_nocs/0000006856.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000006856.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000006856.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000006856.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Supriya Sharma, MD MPH FRCPC",82
sample_nocs/0000006856.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000006856.PDF,submission_no,What is the Submission Number?,142198,100
sample_nocs/0000006856.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Colgate-Palmolive Canada Inc.,96
sample_nocs/0000006856.PDF,product_name,What is the Product name?,COLGATE TOTAL ADVANCED HEALTH SENSITIVE,90
sample_nocs/0000006856.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02373254, Dental, Toothpaste, 0.243% / W/W / 0.3% / W/W",58
sample_nocs/0000006856.PDF,species,What is the species?,NA,NA
sample_nocs/0000006856.PDF,noc_date,What is the date of the document?,SEP 20 2011,98
sample_nocs/0000006856.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium Floride / Triclosan / Silicon Dioxide,84
sample_nocs/0000006945.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Ketaset (Pfizer Canada Inc., Animal Health Group) DIN# 02173239",23
sample_nocs/0000006945.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000006945.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000006945.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Change,83
sample_nocs/0000006945.PDF,dossier_id,What is the Dossier Id?,OF15-21-V0135-128-141465,60.000003814697266
sample_nocs/0000006945.PDF,submission_no,What is the Submission Number?,141465,98
sample_nocs/0000006945.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000006945.PDF,product_name,What is the Product name?,Narketan,89
sample_nocs/0000006945.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02374994, Intramuscular, Solution, 100mg/mL",78
sample_nocs/0000006945.PDF,species,What is the species?,Cats,99
sample_nocs/0000006945.PDF,noc_date,What is the date of the document?,OCT 8 2011,81
sample_nocs/0000006945.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ketamine (as Ketamine HCI),85
sample_nocs/0000007041.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zocor, Merck Frosst Canada Ltd., Canada",23
sample_nocs/0000007041.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,72
sample_nocs/0000007041.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,68
sample_nocs/0000007041.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000007041.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007041.PDF,submission_no,What is the Submission Number?,150514,98
sample_nocs/0000007041.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Marcan Pharmaceuticals Inc.,95
sample_nocs/0000007041.PDF,product_name,What is the Product name?,MAR-SIMVASTATIN,98
sample_nocs/0000007041.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02375036 (oral, tablet, 5 mg)",80
sample_nocs/0000007041.PDF,species,What is the species?,NA,NA
sample_nocs/0000007041.PDF,noc_date,What is the date of the document?,NOV 16 2011,84
sample_nocs/0000007041.PDF,medicinal_ingredients,What are the medicinal ingredients?,Simvastatin,99
sample_nocs/0000007062.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000007062.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007062.PDF,noc_reason,What was the reason for the submission?,Change in ownership,99
sample_nocs/0000007062.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,97
sample_nocs/0000007062.PDF,dossier_id,What is the Dossier Id?,OF15-21-L0857-103-148483,51
sample_nocs/0000007062.PDF,submission_no,What is the Submission Number?,148483,98
sample_nocs/0000007062.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000007062.PDF,product_name,What is the Product name?,Anased,87
sample_nocs/0000007062.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00682233, Intramuscular, intravenous, Solution, 100 mg/mL",49
sample_nocs/0000007062.PDF,species,What is the species?,Horses,100
sample_nocs/0000007062.PDF,noc_date,What is the date of the document?,NOV 2 & 2011,76
sample_nocs/0000007062.PDF,medicinal_ingredients,What are the medicinal ingredients?,Xylazine (as xylazine hydrochloride),80
sample_nocs/0000007102.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cellcept, Hoffmann-La Roche Ltd., Canada",50
sample_nocs/0000007102.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,49
sample_nocs/0000007102.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000007102.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,96
sample_nocs/0000007102.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007102.PDF,submission_no,What is the Submission Number?,128639,98
sample_nocs/0000007102.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,91
sample_nocs/0000007102.PDF,product_name,What is the Product name?,APO-MYCOPHENOLATE,96
sample_nocs/0000007102.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02352559, Oral, Capsule, 250 mg",90
sample_nocs/0000007102.PDF,species,What is the species?,NA,NA
sample_nocs/0000007102.PDF,noc_date,What is the date of the document?,NOV 30 2011,81
sample_nocs/0000007102.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mycophenolate Mofetil,98
sample_nocs/0000007132.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Plavix, Sanofi-Synthelabo Canada Inc., Canada",50
sample_nocs/0000007132.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007132.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000007132.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000007132.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007132.PDF,submission_no,What is the Submission Number?,093486,98
sample_nocs/0000007132.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Cabada Limited,83
sample_nocs/0000007132.PDF,product_name,What is the Product name?,Teva-Clopidogrel,93
sample_nocs/0000007132.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02293161, Oral, Tablet, 75 mg",88
sample_nocs/0000007132.PDF,species,What is the species?,NA,NA
sample_nocs/0000007132.PDF,noc_date,What is the date of the document?,DEC 14 2011,91
sample_nocs/0000007132.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel (supplied as Clopidogrel Bisulfate),51
sample_nocs/0000007232.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Amerge, GlaxoSmithKline Inc., Canada",49
sample_nocs/0000007232.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000007232.PDF,noc_reason,What was the reason for the submission?,Manufacturer and product name change / Changement du nom du fabricant et du produit,56
sample_nocs/0000007232.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,96
sample_nocs/0000007232.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007232.PDF,submission_no,What is the Submission Number?,151834,98
sample_nocs/0000007232.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,87
sample_nocs/0000007232.PDF,product_name,What is the Product name?,TEVA-NARATRIPTAN,97
sample_nocs/0000007232.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02314290 (oral, tablet, 1 mg)",87
sample_nocs/0000007232.PDF,species,What is the species?,NA,NA
sample_nocs/0000007232.PDF,noc_date,What is the date of the document?,JAN 13 2012,81
sample_nocs/0000007232.PDF,medicinal_ingredients,What are the medicinal ingredients?,Naratriptan supplied as Naratriptan Hydrochloride,97
sample_nocs/0000007267.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Singulair, Merck Frosst Canada Ltd.",45
sample_nocs/0000007267.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000007267.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,72
sample_nocs/0000007267.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000007267.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007267.PDF,submission_no,What is the Submission Number?,151641,98
sample_nocs/0000007267.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NT Pharma Canada Ltd.,62
sample_nocs/0000007267.PDF,product_name,What is the Product name?,NTP-MONTELUKAST,90
sample_nocs/0000007267.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02376822 (oral, chewable tablet, 4 mg)",46
sample_nocs/0000007267.PDF,species,What is the species?,NA,NA
sample_nocs/0000007267.PDF,noc_date,What is the date of the document?,JAN 18 2012,78
sample_nocs/0000007267.PDF,medicinal_ingredients,What are the medicinal ingredients?,Montelukast supplied as Montelukast Sodium,94
sample_nocs/0000007285.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Paxil, SmithKline Beecham Pharma, Canada",78
sample_nocs/0000007285.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000007285.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,65
sample_nocs/0000007285.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000007285.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007285.PDF,submission_no,What is the Submission Number?,145370,99
sample_nocs/0000007285.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Avanstra Inc.,48
sample_nocs/0000007285.PDF,product_name,What is the Product name?,AVA-PAROXETINE,91
sample_nocs/0000007285.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02365103 (oral, tablet, 10 mg)",74
sample_nocs/0000007285.PDF,species,What is the species?,NA,NA
sample_nocs/0000007285.PDF,noc_date,What is the date of the document?,JAN 30 2012,43
sample_nocs/0000007285.PDF,medicinal_ingredients,What are the medicinal ingredients?,Paroxetine supplied as Paroxetine Hydrochloride,95
sample_nocs/0000007357.PDF,canadian_reference_product,What is the Canadian Reference Product?,Loratadine SOFT GEL CAPSULE,81
sample_nocs/0000007357.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007357.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000007357.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,96
sample_nocs/0000007357.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007357.PDF,submission_no,What is the Submission Number?,148332,98
sample_nocs/0000007357.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,88
sample_nocs/0000007357.PDF,product_name,What is the Product name?,Loratadine SOFT GEL CAPSULE,89
sample_nocs/0000007357.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02379481, Oral, Capsule, 10mg",84
sample_nocs/0000007357.PDF,species,What is the species?,NA,NA
sample_nocs/0000007357.PDF,noc_date,What is the date of the document?,FEB 102012,94
sample_nocs/0000007357.PDF,medicinal_ingredients,What are the medicinal ingredients?,Loratadine,99
sample_nocs/0000007379.PDF,canadian_reference_product,What is the Canadian Reference Product?,Metacam Oral Suspension for Cats,97
sample_nocs/0000007379.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007379.PDF,noc_reason,What was the reason for the submission?,Additional claim,99
sample_nocs/0000007379.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,98
sample_nocs/0000007379.PDF,dossier_id,What is the Dossier Id?,OF15-21-B1716-100-146261,72
sample_nocs/0000007379.PDF,submission_no,What is the Submission Number?,146261,98
sample_nocs/0000007379.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000007379.PDF,product_name,What is the Product name?,Metacam Oral Suspension for Cats,97
sample_nocs/0000007379.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02360489, Oral, Suspension, 0.5 mg/mL",84
sample_nocs/0000007379.PDF,species,What is the species?,Cats,99
sample_nocs/0000007379.PDF,noc_date,What is the date of the document?,FEB 21 2012,87
sample_nocs/0000007379.PDF,medicinal_ingredients,What are the medicinal ingredients?,Meloxicam,94
sample_nocs/0000007588.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000007588.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007588.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000007588.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000007588.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007588.PDF,submission_no,What is the Submission Number?,153002,99
sample_nocs/0000007588.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Insight Pharmaceuticals LLC,98
sample_nocs/0000007588.PDF,product_name,What is the Product name?,MONICURE COMBO,99
sample_nocs/0000007588.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02382628, Oral/Topical, Capsule/Cream/Kit, 150 MG / 2%",54.000003814697266
sample_nocs/0000007588.PDF,species,What is the species?,NA,NA
sample_nocs/0000007588.PDF,noc_date,What is the date of the document?,APR 0 5 2012,54.000003814697266
sample_nocs/0000007588.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluconazole / Miconazole Nitrate,96
sample_nocs/0000007934.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Ocuflux, Allergan Inc., Canada",35
sample_nocs/0000007934.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000007934.PDF,noc_reason,What was the reason for the submission?,Manufacturer and product name change / Changement du nom du fabricant et du produit,56
sample_nocs/0000007934.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,90
sample_nocs/0000007934.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007934.PDF,submission_no,What is the Submission Number?,155891,98
sample_nocs/0000007934.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,86
sample_nocs/0000007934.PDF,product_name,What is the Product name?,SANDOZ OFLOXACIN,81
sample_nocs/0000007934.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02247189,44
sample_nocs/0000007934.PDF,species,What is the species?,NA,NA
sample_nocs/0000007934.PDF,noc_date,What is the date of the document?,JUN 21 2012,79
sample_nocs/0000007934.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ofloxacin,92
sample_nocs/0000007952.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000007952.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000007952.PDF,noc_reason,What was the reason for the submission?,"Addition of an alternate manufacturing, packaging and testing site.",83
sample_nocs/0000007952.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,96
sample_nocs/0000007952.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000007952.PDF,submission_no,What is the Submission Number?,152290,99
sample_nocs/0000007952.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc.,72
sample_nocs/0000007952.PDF,product_name,What is the Product name?,VELCADE,61
sample_nocs/0000007952.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 3.5 mg/vial",85
sample_nocs/0000007952.PDF,species,What is the species?,NA,NA
sample_nocs/0000007952.PDF,noc_date,What is the date of the document?,JUN 27 2012,79
sample_nocs/0000007952.PDF,medicinal_ingredients,What are the medicinal ingredients?,bortezomib (supplied as bortezomib mannitol boronic ester),46
sample_nocs/0000008053.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Temodal, Schering-Plough, Belgium",50
sample_nocs/0000008053.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000008053.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000008053.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000008053.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008053.PDF,submission_no,What is the Submission Number?,143070,98
sample_nocs/0000008053.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accord Healthcare Inc.,52.999996185302734
sample_nocs/0000008053.PDF,product_name,What is the Product name?,AHI-TEMOZOLOMIDE CAPSULES,86
sample_nocs/0000008053.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02389819, Oral, Capsule, 20 mg",87
sample_nocs/0000008053.PDF,species,What is the species?,NA,NA
sample_nocs/0000008053.PDF,noc_date,What is the date of the document?,JUL 24 2012,83
sample_nocs/0000008053.PDF,medicinal_ingredients,What are the medicinal ingredients?,Temozolomide,99
sample_nocs/0000008156.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000008156.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,79
sample_nocs/0000008156.PDF,noc_reason,What was the reason for the submission?,"New Indication: As add-on combination therapy with premixed or long/intermediate acting insulin (with or without metformin) in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when diet and exercise, and therapy",36
sample_nocs/0000008156.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008156.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008156.PDF,submission_no,What is the Submission Number?,150121,99
sample_nocs/0000008156.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,79
sample_nocs/0000008156.PDF,product_name,What is the Product name?,JANUVIA,98
sample_nocs/0000008156.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 100 mg",85
sample_nocs/0000008156.PDF,species,What is the species?,NA,NA
sample_nocs/0000008156.PDF,noc_date,What is the date of the document?,AUG 7 2012,77
sample_nocs/0000008156.PDF,medicinal_ingredients,What are the medicinal ingredients?,sitagliptin (supplied as sitagliptin phosphate monohydrate),49
sample_nocs/0000008266.PDF,canadian_reference_product,What is the Canadian Reference Product?,GD-SILDENAFIL R,50
sample_nocs/0000008266.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,70
sample_nocs/0000008266.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,69
sample_nocs/0000008266.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,94
sample_nocs/0000008266.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008266.PDF,submission_no,What is the Submission Number?,157200,99
sample_nocs/0000008266.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GenMed,56
sample_nocs/0000008266.PDF,product_name,What is the Product name?,GD-SILDENAFIL R,96
sample_nocs/0000008266.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02392682,46
sample_nocs/0000008266.PDF,species,What is the species?,NA,NA
sample_nocs/0000008266.PDF,noc_date,What is the date of the document?,SEP 06 2012,99
sample_nocs/0000008266.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sildenafil supplied as sildenafil citrate,91
sample_nocs/0000008395.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000008395.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000008395.PDF,noc_reason,What was the reason for the submission?,Modification of specification and testing method before packaging.,72
sample_nocs/0000008395.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008395.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008395.PDF,submission_no,What is the Submission Number?,146260,99
sample_nocs/0000008395.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,88
sample_nocs/0000008395.PDF,product_name,What is the Product name?,Champix,99
sample_nocs/0000008395.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 1 mg",85
sample_nocs/0000008395.PDF,species,What is the species?,NA,NA
sample_nocs/0000008395.PDF,noc_date,What is the date of the document?,OCT 04 2012,93
sample_nocs/0000008395.PDF,medicinal_ingredients,What are the medicinal ingredients?,Varenicline (supplied as varenicline tartrate),74
sample_nocs/0000008440.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000008440.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000008440.PDF,noc_reason,What was the reason for the submission?,"New Indication: In combination with pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, plus pioglitazone do not provide adequate glycemic control.",40
sample_nocs/0000008440.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008440.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008440.PDF,submission_no,What is the Submission Number?,150966,98
sample_nocs/0000008440.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,61
sample_nocs/0000008440.PDF,product_name,What is the Product name?,JANUVIA,99
sample_nocs/0000008440.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 25 mg",87
sample_nocs/0000008440.PDF,species,What is the species?,NA,NA
sample_nocs/0000008440.PDF,noc_date,What is the date of the document?,OCT 1 0 2012,35
sample_nocs/0000008440.PDF,medicinal_ingredients,What are the medicinal ingredients?,sitagliptin (supplied as sitagliptin phosphate monohydrate),52
sample_nocs/0000008514.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Arimidex, Astra Zeneca Canada Inc., Canada",33
sample_nocs/0000008514.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,64
sample_nocs/0000008514.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000008514.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,96
sample_nocs/0000008514.PDF,dossier_id,What is the Dossier Id?,OSIP-BPPI,50
sample_nocs/0000008514.PDF,submission_no,What is the Submission Number?,116634,97
sample_nocs/0000008514.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc.,41
sample_nocs/0000008514.PDF,product_name,What is the Product name?,pms-ANASTROZOLE,88
sample_nocs/0000008514.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02320738, Oral, Tablet, 1 mg",83
sample_nocs/0000008514.PDF,species,What is the species?,NA,NA
sample_nocs/0000008514.PDF,noc_date,What is the date of the document?,OCT 25 2012,70
sample_nocs/0000008514.PDF,medicinal_ingredients,What are the medicinal ingredients?,Anastrozole,96
sample_nocs/0000008604.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000008604.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,48
sample_nocs/0000008604.PDF,noc_reason,What was the reason for the submission?,New intermediate seed lots and working seed lot/Nouveau lot de semence intermédiaire et nouveau lot de travail,41
sample_nocs/0000008604.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,72
sample_nocs/0000008604.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008604.PDF,submission_no,What is the Submission Number?,154201,99
sample_nocs/0000008604.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi Pasteur Limited,97
sample_nocs/0000008604.PDF,product_name,What is the Product name?,Vivaxim,76
sample_nocs/0000008604.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","NA, IM, Salmonella typhi VI capsular polysaccharide vaccine",90
sample_nocs/0000008604.PDF,species,What is the species?,Salmonella typhi,42
sample_nocs/0000008604.PDF,noc_date,What is the date of the document?,NOV 1 2012,75
sample_nocs/0000008604.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Salmonella typhi VI capsular polysaccharide vaccine/Vaccin polysaccharide capsulaire Vi purified contre Salmonella typhi, Inactivated hepatitis A virus/ vaccin anti-hépatitique A inactivé",21
sample_nocs/0000008622.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000008622.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000008622.PDF,noc_reason,What was the reason for the submission?,Manufacturer name change / Changement du nom du fabricant,28
sample_nocs/0000008622.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000008622.PDF,dossier_id,What is the Dossier Id?,OSIP-BPPI,60.000003814697266
sample_nocs/0000008622.PDF,submission_no,What is the Submission Number?,158348,98
sample_nocs/0000008622.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AbbVie Corporation,90
sample_nocs/0000008622.PDF,product_name,What is the Product name?,NIMBEX,91
sample_nocs/0000008622.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02229422,55
sample_nocs/0000008622.PDF,species,What is the species?,NA,NA
sample_nocs/0000008622.PDF,noc_date,What is the date of the document?,NOV. 1 2012,70
sample_nocs/0000008622.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cisatracurium supplied as Cisatracurium Besylate,85
sample_nocs/0000008687.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lipitor, Pfizer Canada Inc.",38
sample_nocs/0000008687.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,74
sample_nocs/0000008687.PDF,noc_reason,What was the reason for the submission?,Additional product name / Nom du produit additionnel,45
sample_nocs/0000008687.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008687.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008687.PDF,submission_no,What is the Submission Number?,159558,98
sample_nocs/0000008687.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,82
sample_nocs/0000008687.PDF,product_name,What is the Product name?,ATORVASTATIN,55
sample_nocs/0000008687.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02396424 (oral, tablet, 10 mg)",81
sample_nocs/0000008687.PDF,species,What is the species?,NA,NA
sample_nocs/0000008687.PDF,noc_date,What is the date of the document?,NOV 9 2012,85
sample_nocs/0000008687.PDF,medicinal_ingredients,What are the medicinal ingredients?,Atorvastatin supplied as atorvastatin calcium propylene glycol solvate,65
sample_nocs/0000008875.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lipidil Supra, Fournier Pharma Inc., Canada",62
sample_nocs/0000008875.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000008875.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000008875.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008875.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008875.PDF,submission_no,What is the Submission Number?,149115,100
sample_nocs/0000008875.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ranbaxy Pharmaceuticals Canada Inc.,86
sample_nocs/0000008875.PDF,product_name,What is the Product name?,Ran-Fenofibrate S,93
sample_nocs/0000008875.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02391309, Oral, Tablet, 100 mg",92
sample_nocs/0000008875.PDF,species,What is the species?,NA,NA
sample_nocs/0000008875.PDF,noc_date,What is the date of the document?,DEC 17 2012,93
sample_nocs/0000008875.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fenofibrate,96
sample_nocs/0000008944.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zestril, AstraZeneca Canada Inc., Canada",18
sample_nocs/0000008944.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,73
sample_nocs/0000008944.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,72
sample_nocs/0000008944.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008944.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008944.PDF,submission_no,What is the Submission Number?,159530,99
sample_nocs/0000008944.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GenMed,56
sample_nocs/0000008944.PDF,product_name,What is the Product name?,GD-LISINOPRIL,98
sample_nocs/0000008944.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02398907 (oral, tablet, 5 mg)",82
sample_nocs/0000008944.PDF,species,What is the species?,NA,NA
sample_nocs/0000008944.PDF,noc_date,What is the date of the document?,JAN 8 2013,92
sample_nocs/0000008944.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lisinopril supplied as Lisinopril Dihydrate,94
sample_nocs/0000008966.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Norvasc, Pfizer Canada Inc.",40
sample_nocs/0000008966.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000008966.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,73
sample_nocs/0000008966.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000008966.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000008966.PDF,submission_no,What is the Submission Number?,160684,98
sample_nocs/0000008966.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accel Pharma Inc.,58.999996185302734
sample_nocs/0000008966.PDF,product_name,What is the Product name?,ACCEL-AMLODIPINE,97
sample_nocs/0000008966.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02398788 (oral, tablet, 2.5 mg)",47
sample_nocs/0000008966.PDF,species,What is the species?,NA,NA
sample_nocs/0000008966.PDF,noc_date,What is the date of the document?,JAN 7 2013,94
sample_nocs/0000008966.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amlodipine supplied as Amlodipine Besylate,96
sample_nocs/0000009016.PDF,canadian_reference_product,What is the Canadian Reference Product?,Gamunex ®,54.000003814697266
sample_nocs/0000009016.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,42
sample_nocs/0000009016.PDF,noc_reason,What was the reason for the submission?,New Indication for Guillain-Barre Syndrome (GBS) / Nouvelle indication for the Syndrome de Guillain-Barré,24
sample_nocs/0000009016.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,74
sample_nocs/0000009016.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009016.PDF,submission_no,What is the Submission Number?,148326,98
sample_nocs/0000009016.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Grifols Therapeutics Inc.,86
sample_nocs/0000009016.PDF,product_name,What is the Product name?,Gamunex ®,83
sample_nocs/0000009016.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV / SC, SOL, 10 g/100 mL",75
sample_nocs/0000009016.PDF,species,What is the species?,NA,NA
sample_nocs/0000009016.PDF,noc_date,What is the date of the document?,JAN 29 2013,88
sample_nocs/0000009016.PDF,medicinal_ingredients,What are the medicinal ingredients?,Immune Globulin (Human) / Immunoglobuline (Humaine),74
sample_nocs/0000009140.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000009140.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000009140.PDF,noc_reason,What was the reason for the submission?,Manufacturer name change / Changement du nom du fabricant,52
sample_nocs/0000009140.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,87
sample_nocs/0000009140.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009140.PDF,submission_no,What is the Submission Number?,160897,98
sample_nocs/0000009140.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Correvio (UK) Ltd.,75
sample_nocs/0000009140.PDF,product_name,What is the Product name?,AGGRASTAT,93
sample_nocs/0000009140.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02240705 (intravenous, liquid, 0.25 mg/mL)",40
sample_nocs/0000009140.PDF,species,What is the species?,NA,NA
sample_nocs/0000009140.PDF,noc_date,What is the date of the document?,FEB 0 5 2013,81
sample_nocs/0000009140.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tirofiban supplied as tirofiban hydrochloride,95
sample_nocs/0000009223.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000009223.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000009223.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000009223.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,94
sample_nocs/0000009223.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009223.PDF,submission_no,What is the Submission Number?,153557,98
sample_nocs/0000009223.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ferring Inc,60.000003814697266
sample_nocs/0000009223.PDF,product_name,What is the Product name?,LYSTEDA,99
sample_nocs/0000009223.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02401959, Oral, Tablet, 650 mg",65
sample_nocs/0000009223.PDF,species,What is the species?,NA,NA
sample_nocs/0000009223.PDF,noc_date,What is the date of the document?,FEB 13 2013,89
sample_nocs/0000009223.PDF,medicinal_ingredients,What are the medicinal ingredients?,tranexamic acid,76
sample_nocs/0000009258.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cipro, Bayer Inc., Canada",30.000001907348633
sample_nocs/0000009258.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000009258.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,73
sample_nocs/0000009258.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000009258.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009258.PDF,submission_no,What is the Submission Number?,161591,98
sample_nocs/0000009258.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accord Healthcare Inc,52
sample_nocs/0000009258.PDF,product_name,What is the Product name?,CIPROFLOXACIN TABLETS,71
sample_nocs/0000009258.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02400766 (oral, tablet, 250 mg)",85
sample_nocs/0000009258.PDF,species,What is the species?,NA,NA
sample_nocs/0000009258.PDF,noc_date,What is the date of the document?,FEB 14 2013,92
sample_nocs/0000009258.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride,89
sample_nocs/0000009282.PDF,canadian_reference_product,What is the Canadian Reference Product?,Fabrazyme,81
sample_nocs/0000009282.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,33
sample_nocs/0000009282.PDF,noc_reason,What was the reason for the submission?,New manufacturing facility/ Nouvel emplacement de fabrication,69
sample_nocs/0000009282.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,88
sample_nocs/0000009282.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009282.PDF,submission_no,What is the Submission Number?,157668,97
sample_nocs/0000009282.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Genzyme Canada Inc.,80
sample_nocs/0000009282.PDF,product_name,What is the Product name?,Fabrazyme,99
sample_nocs/0000009282.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, PWSO, 5 mg/vial",89
sample_nocs/0000009282.PDF,species,What is the species?,NA,NA
sample_nocs/0000009282.PDF,noc_date,What is the date of the document?,FEB 22 2013,92
sample_nocs/0000009282.PDF,medicinal_ingredients,What are the medicinal ingredients?,agalsidase beta,75
sample_nocs/0000009285.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Neurontin, Pfizer Canada Inc., Canada",44
sample_nocs/0000009285.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000009285.PDF,noc_reason,What was the reason for the submission?,New manufacturer and product name / Nouveau nom du fabricant et du produit,73
sample_nocs/0000009285.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000009285.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009285.PDF,submission_no,What is the Submission Number?,162179,98
sample_nocs/0000009285.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000009285.PDF,product_name,What is the Product name?,JAMP-GABAPENTIN TABLETS,70
sample_nocs/0000009285.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02402289 (oral, tablet, 600 mg)",58.999996185302734
sample_nocs/0000009285.PDF,species,What is the species?,NA,NA
sample_nocs/0000009285.PDF,noc_date,What is the date of the document?,FEB 22 2013,79
sample_nocs/0000009285.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gabapentin,96
sample_nocs/0000009414.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000009414.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,75
sample_nocs/0000009414.PDF,noc_reason,What was the reason for the submission?,"Updates to the Warnings & Precautions, and the Dosage & Administration sections of the Product Monograph",87
sample_nocs/0000009414.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000009414.PDF,dossier_id,What is the Dossier Id?,9427-J0921-108,87
sample_nocs/0000009414.PDF,submission_no,What is the Submission Number?,155655,98
sample_nocs/0000009414.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc.,52
sample_nocs/0000009414.PDF,product_name,What is the Product name?,DORIBAX,97
sample_nocs/0000009414.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for solution, 500 mg / Vial",82
sample_nocs/0000009414.PDF,species,What is the species?,NA,NA
sample_nocs/0000009414.PDF,noc_date,What is the date of the document?,MAR 5 2013,45
sample_nocs/0000009414.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doripenem supplied as Doripenem Monohydrate,96
sample_nocs/0000009620.PDF,canadian_reference_product,What is the Canadian Reference Product?,Advantage Multi 100 (Imidacloprid + Moxidectin),42
sample_nocs/0000009620.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000009620.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000009620.PDF,approving_dg,What is the name of the Director General that signed this NOC?,D.C. Kirkpatrick,65
sample_nocs/0000009620.PDF,dossier_id,What is the Dossier Id?,9460-B0456-546,95
sample_nocs/0000009620.PDF,submission_no,What is the Submission Number?,2002069N,91
sample_nocs/0000009620.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000009620.PDF,product_name,What is the Product name?,Advantage Multi 100 (Imidacloprid + Moxidectin) (Topical Parasiticide for Dogs),57
sample_nocs/0000009620.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02263564,60.000003814697266
sample_nocs/0000009620.PDF,species,What is the species?,Dogs,99
sample_nocs/0000009620.PDF,noc_date,What is the date of the document?,JAN 17 2005,81
sample_nocs/0000009620.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Imidacloprid, Moxidectin",90
sample_nocs/0000009718.PDF,canadian_reference_product,What is the Canadian Reference Product?,ALTI-AMOXI CLAV-125F,74
sample_nocs/0000009718.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000009718.PDF,noc_reason,What was the reason for the submission?,New Strengths,92
sample_nocs/0000009718.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",26
sample_nocs/0000009718.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000009718.PDF,submission_no,What is the Submission Number?,073239,99
sample_nocs/0000009718.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000009718.PDF,product_name,What is the Product name?,ALTI-AMOXI CLAV-125F,61
sample_nocs/0000009718.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02244646,52.999996185302734
sample_nocs/0000009718.PDF,species,What is the species?,NA,NA
sample_nocs/0000009718.PDF,noc_date,What is the date of the document?,oct 09 2001,51
sample_nocs/0000009718.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin as Amoxicillin Trihydrate Clavulanic Acid as Clavulanate Potassium,84
sample_nocs/0000009985.PDF,canadian_reference_product,What is the Canadian Reference Product?,Urispas Pharmascience Inc.,67
sample_nocs/0000009985.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000009985.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000009985.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000009985.PDF,dossier_id,What is the Dossier Id?,9427-A1114-316,90
sample_nocs/0000009985.PDF,submission_no,What is the Submission Number?,065818,98
sample_nocs/0000009985.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000009985.PDF,product_name,What is the Product name?,APO-FLAVOXATE Tablet 200mg,95
sample_nocs/0000009985.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02244842 200mg,92
sample_nocs/0000009985.PDF,species,What is the species?,NA,NA
sample_nocs/0000009985.PDF,noc_date,What is the date of the document?,NOV. 09 2001,44
sample_nocs/0000009985.PDF,medicinal_ingredients,What are the medicinal ingredients?,Flavoxate Hydrochloride,96
sample_nocs/0000010027.PDF,canadian_reference_product,What is the Canadian Reference Product?,PANACUR PASTE 10%,96
sample_nocs/0000010027.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010027.PDF,noc_reason,What was the reason for the submission?,Treatment of equine larval cyathostomosis induced by encysted larvae (third and fourth stage) of cyathostomes.,85
sample_nocs/0000010027.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000010027.PDF,dossier_id,What is the Dossier Id?,9460-J0471-532,98
sample_nocs/0000010027.PDF,submission_no,What is the Submission Number?,2000125S,77
sample_nocs/0000010027.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010027.PDF,product_name,What is the Product name?,PANACUR PASTE 10%,96
sample_nocs/0000010027.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02113163,98
sample_nocs/0000010027.PDF,species,What is the species?,Horses,100
sample_nocs/0000010027.PDF,noc_date,What is the date of the document?,MAR 27 2001,97
sample_nocs/0000010027.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fenbendazole 100 mg/g,90
sample_nocs/0000010045.PDF,canadian_reference_product,What is the Canadian Reference Product?,Neurontin,97
sample_nocs/0000010045.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010045.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000010045.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,44
sample_nocs/0000010045.PDF,dossier_id,What is the Dossier Id?,9427-N0454-432,52.999996185302734
sample_nocs/0000010045.PDF,submission_no,What is the Submission Number?,064762,98
sample_nocs/0000010045.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010045.PDF,product_name,What is the Product name?,NOVO-GABAPENTIN Capsules,96
sample_nocs/0000010045.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02244513 100mg,96
sample_nocs/0000010045.PDF,species,What is the species?,NA,NA
sample_nocs/0000010045.PDF,noc_date,What is the date of the document?,SEP. 21 2001,94
sample_nocs/0000010045.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gabapentin,97
sample_nocs/0000010117.PDF,canadian_reference_product,What is the Canadian Reference Product?,Claritin,97
sample_nocs/0000010117.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010117.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000010117.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,45
sample_nocs/0000010117.PDF,dossier_id,What is the Dossier Id?,9427-A1114-194,87
sample_nocs/0000010117.PDF,submission_no,What is the Submission Number?,061071,98
sample_nocs/0000010117.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010117.PDF,product_name,What is the Product name?,APO-LORATADINE Tablet,95
sample_nocs/0000010117.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02243880-10mg,58.999996185302734
sample_nocs/0000010117.PDF,species,What is the species?,NA,NA
sample_nocs/0000010117.PDF,noc_date,What is the date of the document?,JUN 112001,86
sample_nocs/0000010117.PDF,medicinal_ingredients,What are the medicinal ingredients?,Loratadine,99
sample_nocs/0000010354.PDF,canadian_reference_product,What is the Canadian Reference Product?,FORTOVASE ROCHE,80
sample_nocs/0000010354.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010354.PDF,noc_reason,What was the reason for the submission?,Product Name Change from Fortovase,98
sample_nocs/0000010354.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,43
sample_nocs/0000010354.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000010354.PDF,submission_no,What is the Submission Number?,070158,98
sample_nocs/0000010354.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,60.000003814697266
sample_nocs/0000010354.PDF,product_name,What is the Product name?,FORTOVASE ROCHE,79
sample_nocs/0000010354.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02239083 (CAP,ORL, 200mg)",35
sample_nocs/0000010354.PDF,species,What is the species?,NA,NA
sample_nocs/0000010354.PDF,noc_date,What is the date of the document?,FEB 13 2001,87
sample_nocs/0000010354.PDF,medicinal_ingredients,What are the medicinal ingredients?,Saquinavir,92
sample_nocs/0000010411.PDF,canadian_reference_product,What is the Canadian Reference Product?,PARNATE,98
sample_nocs/0000010411.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,68
sample_nocs/0000010411.PDF,noc_reason,What was the reason for the submission?,Change in Manufacturer Name,98
sample_nocs/0000010411.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",22
sample_nocs/0000010411.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000010411.PDF,submission_no,What is the Submission Number?,072559,98
sample_nocs/0000010411.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010411.PDF,product_name,What is the Product name?,PARNATE,98
sample_nocs/0000010411.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","01919598 (TAB,ORL, 10mg)",90
sample_nocs/0000010411.PDF,species,What is the species?,NA,NA
sample_nocs/0000010411.PDF,noc_date,What is the date of the document?,AUT 15 2001,65
sample_nocs/0000010411.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tranylcypromine as Tranylcypromine Sulfate,87
sample_nocs/0000010452.PDF,canadian_reference_product,What is the Canadian Reference Product?,Cordarone Intravenous Wyeth-Ayerst Canada Inc.,72
sample_nocs/0000010452.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010452.PDF,noc_reason,What was the reason for the submission?,New Dosage Form,95
sample_nocs/0000010452.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,45
sample_nocs/0000010452.PDF,dossier_id,What is the Dossier Id?,9427-P1489-243,72
sample_nocs/0000010452.PDF,submission_no,What is the Submission Number?,064196,98
sample_nocs/0000010452.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010452.PDF,product_name,What is the Product name?,PMS-AMIODARONE for Injection BP,95
sample_nocs/0000010452.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",50 mg/ml,50
sample_nocs/0000010452.PDF,species,What is the species?,NA,NA
sample_nocs/0000010452.PDF,noc_date,What is the date of the document?,MAR 11 2002,92
sample_nocs/0000010452.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amiodarone hydrochloride,98
sample_nocs/0000010489.PDF,canadian_reference_product,What is the Canadian Reference Product?,ISOJEX SYRINGES I 125,83
sample_nocs/0000010489.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,41
sample_nocs/0000010489.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,95
sample_nocs/0000010489.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Julia Hill,98
sample_nocs/0000010489.PDF,dossier_id,What is the Dossier Id?,BGTD,84
sample_nocs/0000010489.PDF,submission_no,What is the Submission Number?,079683,98
sample_nocs/0000010489.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010489.PDF,product_name,What is the Product name?,ISOJEX SYRINGES I 125,90
sample_nocs/0000010489.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",N/A,95
sample_nocs/0000010489.PDF,species,What is the species?,NA,NA
sample_nocs/0000010489.PDF,noc_date,What is the date of the document?,6 SEP 2002,99
sample_nocs/0000010489.PDF,medicinal_ingredients,What are the medicinal ingredients?,Albumin Radioiodated I 125,94
sample_nocs/0000010492.PDF,canadian_reference_product,What is the Canadian Reference Product?,RATIO-ACYCLOVIR,77
sample_nocs/0000010492.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,60.000003814697266
sample_nocs/0000010492.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,95
sample_nocs/0000010492.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,46
sample_nocs/0000010492.PDF,dossier_id,What is the Dossier Id?,9427-R0798-85,87
sample_nocs/0000010492.PDF,submission_no,What is the Submission Number?,080356,98
sample_nocs/0000010492.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010492.PDF,product_name,What is the Product name?,RATIO-ACYCLOVIR,97
sample_nocs/0000010492.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02078627 (TAB,ORL, 200mg)",75
sample_nocs/0000010492.PDF,species,What is the species?,NA,NA
sample_nocs/0000010492.PDF,noc_date,What is the date of the document?,OCT 24 2002,88
sample_nocs/0000010492.PDF,medicinal_ingredients,What are the medicinal ingredients?,Acyclovir,95
sample_nocs/0000010526.PDF,canadian_reference_product,What is the Canadian Reference Product?,TORBUTROL TABLETS 1 MG,67
sample_nocs/0000010526.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010526.PDF,noc_reason,What was the reason for the submission?,Alternate source of active ingredient,98
sample_nocs/0000010526.PDF,approving_dg,What is the name of the Director General that signed this NOC?,D.C. Kirkpatrick,61
sample_nocs/0000010526.PDF,dossier_id,What is the Dossier Id?,9460-A1408-565,94
sample_nocs/0000010526.PDF,submission_no,What is the Submission Number?,2001010S,95
sample_nocs/0000010526.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010526.PDF,product_name,What is the Product name?,TORBUTROL TABLETS 1 MG,70
sample_nocs/0000010526.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00844977,98
sample_nocs/0000010526.PDF,species,What is the species?,Dogs,99
sample_nocs/0000010526.PDF,noc_date,What is the date of the document?,APR 17 2002,77
sample_nocs/0000010526.PDF,medicinal_ingredients,What are the medicinal ingredients?,Butorphanol (as butorphanol tartrate) 1 mg/tab,68
sample_nocs/0000010603.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Taxotere, Concentrate for Injection",37
sample_nocs/0000010603.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,55
sample_nocs/0000010603.PDF,noc_reason,What was the reason for the submission?,New Indication: Monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotheraphy regimen.,79
sample_nocs/0000010603.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",20
sample_nocs/0000010603.PDF,dossier_id,What is the Dossier Id?,9427-A1563-58,94
sample_nocs/0000010603.PDF,submission_no,What is the Submission Number?,069551,98
sample_nocs/0000010603.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010603.PDF,product_name,What is the Product name?,"Taxotere, Concentrate for Injection",55
sample_nocs/0000010603.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",N/A,94
sample_nocs/0000010603.PDF,species,What is the species?,NA,NA
sample_nocs/0000010603.PDF,noc_date,What is the date of the document?,FEEV 19 2002,74
sample_nocs/0000010603.PDF,medicinal_ingredients,What are the medicinal ingredients?,docetaxel,99
sample_nocs/0000010610.PDF,canadian_reference_product,What is the Canadian Reference Product?,RATIO-DOXYCYCLINE,52
sample_nocs/0000010610.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,57
sample_nocs/0000010610.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,95
sample_nocs/0000010610.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000010610.PDF,dossier_id,What is the Dossier Id?,9427-R0798-54,87
sample_nocs/0000010610.PDF,submission_no,What is the Submission Number?,077371,98
sample_nocs/0000010610.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010610.PDF,product_name,What is the Product name?,RATIO-DOXYCYCLINE,95
sample_nocs/0000010610.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02091232 (TAB,ORL, 100mg)",56
sample_nocs/0000010610.PDF,species,What is the species?,NA,NA
sample_nocs/0000010610.PDF,noc_date,What is the date of the document?,MAY 08 2002,99
sample_nocs/0000010610.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxycycline as Doxycycline Hyclate,94
sample_nocs/0000010629.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000010629.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,67
sample_nocs/0000010629.PDF,noc_reason,What was the reason for the submission?,Manufacturer and Product Name Change,94
sample_nocs/0000010629.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,47
sample_nocs/0000010629.PDF,dossier_id,What is the Dossier Id?,9427-R0798-76,90
sample_nocs/0000010629.PDF,submission_no,What is the Submission Number?,077775,98
sample_nocs/0000010629.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010629.PDF,product_name,What is the Product name?,RATIO-DESIPRAMINE,96
sample_nocs/0000010629.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","01948776 (TAB,ORL, 10mg)",88
sample_nocs/0000010629.PDF,species,What is the species?,NA,NA
sample_nocs/0000010629.PDF,noc_date,What is the date of the document?,JUN 0 6 2002,42
sample_nocs/0000010629.PDF,medicinal_ingredients,What are the medicinal ingredients?,Desipramine Hydrochloride,99
sample_nocs/0000010680.PDF,canadian_reference_product,What is the Canadian Reference Product?,Diflucan-150,96
sample_nocs/0000010680.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010680.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000010680.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000010680.PDF,dossier_id,What is the Dossier Id?,9427-G0452-223,80
sample_nocs/0000010680.PDF,submission_no,What is the Submission Number?,069123,98
sample_nocs/0000010680.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010680.PDF,product_name,What is the Product name?,GEN-FLUCONAZOLE Capsule,87
sample_nocs/0000010680.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02245697 - 150 mg,52.999996185302734
sample_nocs/0000010680.PDF,species,What is the species?,NA,NA
sample_nocs/0000010680.PDF,noc_date,What is the date of the document?,JUN 0 5 2002,36
sample_nocs/0000010680.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluconazole,98
sample_nocs/0000010688.PDF,canadian_reference_product,What is the Canadian Reference Product?,Gallium ciTRATE Ga 67 InJECTION,9
sample_nocs/0000010688.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,58.999996185302734
sample_nocs/0000010688.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000010688.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,50
sample_nocs/0000010688.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000010688.PDF,submission_no,What is the Submission Number?,076008,99
sample_nocs/0000010688.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010688.PDF,product_name,What is the Product name?,GALLIUM CITRATE Ga 67 INJECTION,54.000003814697266
sample_nocs/0000010688.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",N/A,95
sample_nocs/0000010688.PDF,species,What is the species?,NA,NA
sample_nocs/0000010688.PDF,noc_date,What is the date of the document?,FEV. 15 2002,88
sample_nocs/0000010688.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gallium 67,96
sample_nocs/0000010780.PDF,canadian_reference_product,What is the Canadian Reference Product?,REFLUDAN,98
sample_nocs/0000010780.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010780.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,95
sample_nocs/0000010780.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,46
sample_nocs/0000010780.PDF,dossier_id,What is the Dossier Id?,BGTD,51
sample_nocs/0000010780.PDF,submission_no,What is the Submission Number?,076158,98
sample_nocs/0000010780.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010780.PDF,product_name,What is the Product name?,REFLUDAN,98
sample_nocs/0000010780.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02240996 (PWSO,IV, 50mg/Vial)",76
sample_nocs/0000010780.PDF,species,What is the species?,NA,NA
sample_nocs/0000010780.PDF,noc_date,What is the date of the document?,fep 27 2002,33
sample_nocs/0000010780.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lepirudin,99
sample_nocs/0000010844.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000010844.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,73
sample_nocs/0000010844.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,95
sample_nocs/0000010844.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",26
sample_nocs/0000010844.PDF,dossier_id,What is the Dossier Id?,9427-M1125-30,95
sample_nocs/0000010844.PDF,submission_no,What is the Submission Number?,080418,98
sample_nocs/0000010844.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000010844.PDF,product_name,What is the Product name?,METHOTREXATE SODIUM INJECTION USP,64
sample_nocs/0000010844.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02182955 (SOL,IAR,IM,INT,IV, 25mg/mL)",41
sample_nocs/0000010844.PDF,species,What is the species?,NA,NA
sample_nocs/0000010844.PDF,noc_date,What is the date of the document?,OCT 24 2002,88
sample_nocs/0000010844.PDF,medicinal_ingredients,What are the medicinal ingredients?,Methotrexate as Methotrexate Sodium,94
sample_nocs/0000010982.PDF,canadian_reference_product,What is the Canadian Reference Product?,Rituxan,77
sample_nocs/0000010982.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000010982.PDF,noc_reason,What was the reason for the submission?,"New Indication for use in the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy",83
sample_nocs/0000010982.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Julia Hill,98
sample_nocs/0000010982.PDF,dossier_id,What is the Dossier Id?,071940,87
sample_nocs/0000010982.PDF,submission_no,What is the Submission Number?,071940,99
sample_nocs/0000010982.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,96
sample_nocs/0000010982.PDF,product_name,What is the Product name?,Rituxan®,60.000003814697266
sample_nocs/0000010982.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",N/A,94
sample_nocs/0000010982.PDF,species,What is the species?,NA,NA
sample_nocs/0000010982.PDF,noc_date,What is the date of the document?,6 NOV 2002,89
sample_nocs/0000010982.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rituximab,76
sample_nocs/0000011071.PDF,canadian_reference_product,What is the Canadian Reference Product?,tylosin 10 PREMIX,39
sample_nocs/0000011071.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000011071.PDF,noc_reason,What was the reason for the submission?,New zero-day withdrawal time when fed to swine at 110 mg tylosin per kg of complete feed,58.999996185302734
sample_nocs/0000011071.PDF,approving_dg,What is the name of the Director General that signed this NOC?,D.C. Kirkpatrick,56
sample_nocs/0000011071.PDF,dossier_id,What is the Dossier Id?,9460-B0264-28,97
sample_nocs/0000011071.PDF,submission_no,What is the Submission Number?,2000074S,73
sample_nocs/0000011071.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000011071.PDF,product_name,What is the Product name?,tylosin 10 PREMIX,46
sample_nocs/0000011071.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00713481,98
sample_nocs/0000011071.PDF,species,What is the species?,"Beef cattle, Swine",91
sample_nocs/0000011071.PDF,noc_date,What is the date of the document?,JUN 25 2002,58
sample_nocs/0000011071.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tylosin (as tylosin phosphate) 22 g/kg,63
sample_nocs/0000011131.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000011131.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000011131.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,96
sample_nocs/0000011131.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",25
sample_nocs/0000011131.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011131.PDF,submission_no,What is the Submission Number?,083279,98
sample_nocs/0000011131.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Wyeth Canada,95
sample_nocs/0000011131.PDF,product_name,What is the Product name?,AMICAR,97
sample_nocs/0000011131.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02169746 (LIQ,IV, 250mg/mL)",62
sample_nocs/0000011131.PDF,species,What is the species?,NA,NA
sample_nocs/0000011131.PDF,noc_date,What is the date of the document?,APR 14 2003,87
sample_nocs/0000011131.PDF,medicinal_ingredients,What are the medicinal ingredients?,E Aminocaproic Acid,97
sample_nocs/0000011175.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Clozaril, Sandoz Canada Inc.",39
sample_nocs/0000011175.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000011175.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000011175.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,47
sample_nocs/0000011175.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011175.PDF,submission_no,What is the Submission Number?,067185,98
sample_nocs/0000011175.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Genpharm Inc.,55
sample_nocs/0000011175.PDF,product_name,What is the Product name?,GEN-CLOZAPINE,79
sample_nocs/0000011175.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02247243 TAB, ORAL, 25mg",93
sample_nocs/0000011175.PDF,species,What is the species?,NA,NA
sample_nocs/0000011175.PDF,noc_date,What is the date of the document?,FEY 19 2003,83
sample_nocs/0000011175.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clozapine,98
sample_nocs/0000011177.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000011177.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000011177.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000011177.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",22
sample_nocs/0000011177.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011177.PDF,submission_no,What is the Submission Number?,071366,99
sample_nocs/0000011177.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Serono Canada Inc.,89
sample_nocs/0000011177.PDF,product_name,What is the Product name?,CETROTIDE,98
sample_nocs/0000011177.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02247766, SC, PWSO, 0.25 mg/vial",89
sample_nocs/0000011177.PDF,species,What is the species?,NA,NA
sample_nocs/0000011177.PDF,noc_date,What is the date of the document?,AUG 13 2003,22
sample_nocs/0000011177.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cetrorelix Acetate,93
sample_nocs/0000011258.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000011258.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000011258.PDF,noc_reason,What was the reason for the submission?,New Indication Allergic Rhinitis,92
sample_nocs/0000011258.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",28
sample_nocs/0000011258.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011258.PDF,submission_no,What is the Submission Number?,075470,99
sample_nocs/0000011258.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Schering Canada Inc.,69
sample_nocs/0000011258.PDF,product_name,What is the Product name?,AERIUS,95
sample_nocs/0000011258.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, ORL, TAB, 5mg",90
sample_nocs/0000011258.PDF,species,What is the species?,NA,NA
sample_nocs/0000011258.PDF,noc_date,What is the date of the document?,APR APR 2003,82
sample_nocs/0000011258.PDF,medicinal_ingredients,What are the medicinal ingredients?,Desloratadine,96
sample_nocs/0000011274.PDF,canadian_reference_product,What is the Canadian Reference Product?,ARTHROTEC 50,67
sample_nocs/0000011274.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,61
sample_nocs/0000011274.PDF,noc_reason,What was the reason for the submission?,Manufacturer Name Change,97
sample_nocs/0000011274.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000011274.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011274.PDF,submission_no,What is the Submission Number?,086536,98
sample_nocs/0000011274.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc,95
sample_nocs/0000011274.PDF,product_name,What is the Product name?,ARTHROTEC 50 ARTHROTEC 75,69
sample_nocs/0000011274.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","01917056 (ORL, TAB, 50mg Diclofenac Sodium / 200mcg",42
sample_nocs/0000011274.PDF,species,What is the species?,NA,NA
sample_nocs/0000011274.PDF,noc_date,What is the date of the document?,SEP 15 2003,99
sample_nocs/0000011274.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diclofenac Sodium / Misoprostol,94
sample_nocs/0000011286.PDF,canadian_reference_product,What is the Canadian Reference Product?,Canaural (Ear Drops),93
sample_nocs/0000011286.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000011286.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000011286.PDF,approving_dg,What is the name of the Director General that signed this NOC?,D.C. Kirkpatrick,49
sample_nocs/0000011286.PDF,dossier_id,What is the Dossier Id?,9460-L1099/1-501,95
sample_nocs/0000011286.PDF,submission_no,What is the Submission Number?,2002124G,97
sample_nocs/0000011286.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000011286.PDF,product_name,What is the Product name?,Canaural (Ear Drops),96
sample_nocs/0000011286.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00727709,98
sample_nocs/0000011286.PDF,species,What is the species?,"Dogs, Cats",95
sample_nocs/0000011286.PDF,noc_date,What is the date of the document?,AUG 26 2003,96
sample_nocs/0000011286.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Diethanolamine fusidate 5 mg/g Framycetin sulphate 5 mg/g Nystatin 100,000 IU/g Prednisolone 2.5 mg/g",38
sample_nocs/0000011293.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lovenox,Lovenox HP",34
sample_nocs/0000011293.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,63
sample_nocs/0000011293.PDF,noc_reason,What was the reason for the submission?,Revisions to the Product Monograph including reduced dosage regimen for patients with severe renal impairment,92
sample_nocs/0000011293.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000011293.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011293.PDF,submission_no,What is the Submission Number?,075409,99
sample_nocs/0000011293.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Aventis Pharma Inc.,64
sample_nocs/0000011293.PDF,product_name,What is the Product name?,"Lovenox, Lovenox HP",78
sample_nocs/0000011293.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Liq, SC 100 mg/ml",87
sample_nocs/0000011293.PDF,species,What is the species?,NA,NA
sample_nocs/0000011293.PDF,noc_date,What is the date of the document?,28 Apr 2003,19
sample_nocs/0000011293.PDF,medicinal_ingredients,What are the medicinal ingredients?,Enoxaparin Sodium,93
sample_nocs/0000011378.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Gamimune® N, 5% and Gamimune® N, 10%",80
sample_nocs/0000011378.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,44
sample_nocs/0000011378.PDF,noc_reason,What was the reason for the submission?,new sterile filling facility,96
sample_nocs/0000011378.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Julia Hill,99
sample_nocs/0000011378.PDF,dossier_id,What is the Dossier Id?,081287,78
sample_nocs/0000011378.PDF,submission_no,What is the Submission Number?,081287,98
sample_nocs/0000011378.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Corporation,99
sample_nocs/0000011378.PDF,product_name,What is the Product name?,"Gamimune® N, 5% and Gamimune® N, 10%",81
sample_nocs/0000011378.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 5 gm/100mL",77
sample_nocs/0000011378.PDF,species,What is the species?,NA,NA
sample_nocs/0000011378.PDF,noc_date,What is the date of the document?,25 SEP 2003,98
sample_nocs/0000011378.PDF,medicinal_ingredients,What are the medicinal ingredients?,immune globulin intravenous (human),96
sample_nocs/0000011455.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Mobicox, Boehringer Ingelheim (Canada) Ltd, Canada",54.000003814697266
sample_nocs/0000011455.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000011455.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000011455.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",25
sample_nocs/0000011455.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011455.PDF,submission_no,What is the Submission Number?,080840,98
sample_nocs/0000011455.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc.,61
sample_nocs/0000011455.PDF,product_name,What is the Product name?,pms-meLOXICAM,35
sample_nocs/0000011455.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02248267 ORL, TAB, 7.5mg",94
sample_nocs/0000011455.PDF,species,What is the species?,NA,NA
sample_nocs/0000011455.PDF,noc_date,What is the date of the document?,Nov. 6 2003,63
sample_nocs/0000011455.PDF,medicinal_ingredients,What are the medicinal ingredients?,meloxicam,90
sample_nocs/0000011580.PDF,canadian_reference_product,What is the Canadian Reference Product?,NIX CREME RINSE,95
sample_nocs/0000011580.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,72
sample_nocs/0000011580.PDF,noc_reason,What was the reason for the submission?,Manufacture Name Change,51
sample_nocs/0000011580.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",27.000001907348633
sample_nocs/0000011580.PDF,dossier_id,What is the Dossier Id?,9427-J1043-21,58
sample_nocs/0000011580.PDF,submission_no,What is the Submission Number?,083888,98
sample_nocs/0000011580.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Insight Pharmaceuticals Corporation,89
sample_nocs/0000011580.PDF,product_name,What is the Product name?,NIX CREME RINSE,97
sample_nocs/0000011580.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00771368 (CRM,TOP, 1%)",66
sample_nocs/0000011580.PDF,species,What is the species?,NA,NA
sample_nocs/0000011580.PDF,noc_date,What is the date of the document?,AVR 302003,84
sample_nocs/0000011580.PDF,medicinal_ingredients,What are the medicinal ingredients?,Permethrin,98
sample_nocs/0000011673.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZOCOR Merck Frosst Canada & Co. Canada,27.000001907348633
sample_nocs/0000011673.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000011673.PDF,noc_reason,What was the reason for the submission?,Administrative ANDS for Cress Referenced Submission,88
sample_nocs/0000011673.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Robert G. Peterson, M.D. PhD, MPH",24
sample_nocs/0000011673.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011673.PDF,submission_no,What is the Submission Number?,083808,98
sample_nocs/0000011673.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Prempharm Inc.,58
sample_nocs/0000011673.PDF,product_name,What is the Product name?,SIMVASTATIN,98
sample_nocs/0000011673.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02247531 (TAB,ORL, 5mg)",74
sample_nocs/0000011673.PDF,species,What is the species?,NA,NA
sample_nocs/0000011673.PDF,noc_date,What is the date of the document?,AVR 30 2003,74
sample_nocs/0000011673.PDF,medicinal_ingredients,What are the medicinal ingredients?,SIMVASTATIN,99
sample_nocs/0000011775.PDF,canadian_reference_product,What is the Canadian Reference Product?,REVITALENS OCUTEC MULTI-PURPOSE SOLUTION,95
sample_nocs/0000011775.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,61
sample_nocs/0000011775.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000011775.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000011775.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000011775.PDF,submission_no,What is the Submission Number?,148299,98
sample_nocs/0000011775.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AMO Canada Company,85
sample_nocs/0000011775.PDF,product_name,What is the Product name?,REVITALENS OCUTEC MULTI-PURPOSE SOLUTION,94
sample_nocs/0000011775.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02405784, Disinfectant, Solution, 0.00016 %/W/W / 0.0003 %/W/W",57
sample_nocs/0000011775.PDF,species,What is the species?,NA,NA
sample_nocs/0000011775.PDF,noc_date,What is the date of the document?,MAY 9 2013,55
sample_nocs/0000011775.PDF,medicinal_ingredients,What are the medicinal ingredients?,Alexidine Dihydrochloride / Polyquaternium 1,82
sample_nocs/0000011852.PDF,canadian_reference_product,What is the Canadian Reference Product?,Metacam Oral Suspension (DIN 02237715),63
sample_nocs/0000011852.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000011852.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two companies,80
sample_nocs/0000011852.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,86
sample_nocs/0000011852.PDF,dossier_id,What is the Dossier Id?,OF15-21-P23931-100164003,67
sample_nocs/0000011852.PDF,submission_no,What is the Submission Number?,164003,98
sample_nocs/0000011852.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000011852.PDF,product_name,What is the Product name?,M-Eloxyn,94
sample_nocs/0000011852.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02406403, Oral, Suspension, 1.5 mg/mL",74
sample_nocs/0000011852.PDF,species,What is the species?,Dogs,99
sample_nocs/0000011852.PDF,noc_date,What is the date of the document?,MAY 22 2013,99
sample_nocs/0000011852.PDF,medicinal_ingredients,What are the medicinal ingredients?,Meloxicam,96
sample_nocs/0000011899.PDF,canadian_reference_product,What is the Canadian Reference Product?,YAZ PLUS,95
sample_nocs/0000011899.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000011899.PDF,noc_reason,What was the reason for the submission?,Change in synthesis of drug substance.,58.999996185302734
sample_nocs/0000011899.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000011899.PDF,dossier_id,What is the Dossier Id?,Certified Product Information Document,82
sample_nocs/0000011899.PDF,submission_no,What is the Submission Number?,159406,98
sample_nocs/0000011899.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Inc.,50
sample_nocs/0000011899.PDF,product_name,What is the Product name?,YAZ PLUS,96
sample_nocs/0000011899.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 3.0 mg, 0.02 mg, 0.451 mg and 0.451 mg",84
sample_nocs/0000011899.PDF,species,What is the species?,NA,NA
sample_nocs/0000011899.PDF,noc_date,What is the date of the document?,JUN 0 7 2013,58.999996185302734
sample_nocs/0000011899.PDF,medicinal_ingredients,What are the medicinal ingredients?,"drospirenone, ethinyl estradiol, levomefolate calcium, and levomefolate calcium",79
sample_nocs/0000012116.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pariet, Janssen-Ortho Inc., Canada",44
sample_nocs/0000012116.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,73
sample_nocs/0000012116.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000012116.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000012116.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012116.PDF,submission_no,What is the Submission Number?,147842,98
sample_nocs/0000012116.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,90
sample_nocs/0000012116.PDF,product_name,What is the Product name?,Mylan-Rabeprazole,97
sample_nocs/0000012116.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02408392, Oral, Tablet (delayed-release), 10 mg",51
sample_nocs/0000012116.PDF,species,What is the species?,NA,NA
sample_nocs/0000012116.PDF,noc_date,What is the date of the document?,JUL 5 2013,86
sample_nocs/0000012116.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rabeprazole Sodium,93
sample_nocs/0000012118.PDF,canadian_reference_product,What is the Canadian Reference Product?,Metacam 20 mg/mL Solution for Injection,45
sample_nocs/0000012118.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000012118.PDF,noc_reason,What was the reason for the submission?,Additional claim,99
sample_nocs/0000012118.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,98
sample_nocs/0000012118.PDF,dossier_id,What is the Dossier Id?,OF15-21-B1716-114-156673,68
sample_nocs/0000012118.PDF,submission_no,What is the Submission Number?,156673,98
sample_nocs/0000012118.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000012118.PDF,product_name,What is the Product name?,Metacam 20 mg/mL Solution for Injection,77
sample_nocs/0000012118.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02330059, Subcutaneous, Intravenous, Solution, 20mg/mL",74
sample_nocs/0000012118.PDF,species,What is the species?,Cattle,99
sample_nocs/0000012118.PDF,noc_date,What is the date of the document?,JUL 102013,83
sample_nocs/0000012118.PDF,medicinal_ingredients,What are the medicinal ingredients?,Meloxicam,95
sample_nocs/0000012215.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cordarone, Wyeth Ayerst Canada Inc., Canada",31
sample_nocs/0000012215.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,81
sample_nocs/0000012215.PDF,noc_reason,What was the reason for the submission?,Administrative,54.000003814697266
sample_nocs/0000012215.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000012215.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012215.PDF,submission_no,What is the Submission Number?,165851,97
sample_nocs/0000012215.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,65
sample_nocs/0000012215.PDF,product_name,What is the Product name?,NTP-AMIODARONE,78
sample_nocs/0000012215.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02361280 (oral, tablet, 200 mg)",49
sample_nocs/0000012215.PDF,species,What is the species?,NA,NA
sample_nocs/0000012215.PDF,noc_date,What is the date of the document?,JUL 19 2013,86
sample_nocs/0000012215.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amiodarone Hydrochloride,97
sample_nocs/0000012419.PDF,canadian_reference_product,What is the Canadian Reference Product?,ILEVRO,96
sample_nocs/0000012419.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,57
sample_nocs/0000012419.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000012419.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000012419.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012419.PDF,submission_no,What is the Submission Number?,158863,97
sample_nocs/0000012419.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alcon Canada Incorporated,95
sample_nocs/0000012419.PDF,product_name,What is the Product name?,ILEVRO,98
sample_nocs/0000012419.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02411393, Ophthalmic, Suspension, 0.3% / W/V",85
sample_nocs/0000012419.PDF,species,What is the species?,NA,NA
sample_nocs/0000012419.PDF,noc_date,What is the date of the document?,AUG 22 2013,41
sample_nocs/0000012419.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nepafenac,98
sample_nocs/0000012432.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Atacand, AstraZeneca Canada Inc., Canada",29
sample_nocs/0000012432.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,77
sample_nocs/0000012432.PDF,noc_reason,What was the reason for the submission?,Administrative additional product name / Administratif nom du produit additionnel,39
sample_nocs/0000012432.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000012432.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012432.PDF,submission_no,What is the Submission Number?,166986,97
sample_nocs/0000012432.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ranbaxy Pharmaceuticals Canada Inc.,88
sample_nocs/0000012432.PDF,product_name,What is the Product name?,Candesartan,85
sample_nocs/0000012432.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02410478 (oral, tablet, 4 mg)",65
sample_nocs/0000012432.PDF,species,What is the species?,NA,NA
sample_nocs/0000012432.PDF,noc_date,What is the date of the document?,AUG 21 2013,72
sample_nocs/0000012432.PDF,medicinal_ingredients,What are the medicinal ingredients?,Candesartan Cilexetil,93
sample_nocs/0000012539.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Losec, Astra Pharma Inc., Canada",57
sample_nocs/0000012539.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,81
sample_nocs/0000012539.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,15.000000953674316
sample_nocs/0000012539.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,81
sample_nocs/0000012539.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012539.PDF,submission_no,What is the Submission Number?,167451,97
sample_nocs/0000012539.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sivem Pharmaceuticals ULC,88
sample_nocs/0000012539.PDF,product_name,What is the Product name?,OMEPRAZOLE-20,55
sample_nocs/0000012539.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02411857,58
sample_nocs/0000012539.PDF,species,What is the species?,NA,NA
sample_nocs/0000012539.PDF,noc_date,What is the date of the document?,SEP 11 2013,55
sample_nocs/0000012539.PDF,medicinal_ingredients,What are the medicinal ingredients?,Omeprazole,95
sample_nocs/0000012760.PDF,canadian_reference_product,What is the Canadian Reference Product?,BOTOX,67
sample_nocs/0000012760.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,37
sample_nocs/0000012760.PDF,noc_reason,What was the reason for the submission?,"New indication for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are Intolerant of antichollnergic medication.",43
sample_nocs/0000012760.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,73
sample_nocs/0000012760.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012760.PDF,submission_no,What is the Submission Number?,154908,99
sample_nocs/0000012760.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Allergan Inc,98
sample_nocs/0000012760.PDF,product_name,What is the Product name?,BOTOX,49
sample_nocs/0000012760.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","NA, IM, PWSO, 50 Units/vial, 100 Units/vial, 200 Units/vial",91
sample_nocs/0000012760.PDF,species,What is the species?,NA,NA
sample_nocs/0000012760.PDF,noc_date,What is the date of the document?,OCT 10 2013,88
sample_nocs/0000012760.PDF,medicinal_ingredients,What are the medicinal ingredients?,OnabotulinumtoxinA,35
sample_nocs/0000012766.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Xalacom, Pfizer Canada Inc., Canada",39
sample_nocs/0000012766.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,67
sample_nocs/0000012766.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000012766.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,90
sample_nocs/0000012766.PDF,dossier_id,What is the Dossier Id?,e162151,64
sample_nocs/0000012766.PDF,submission_no,What is the Submission Number?,162151,98
sample_nocs/0000012766.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,84
sample_nocs/0000012766.PDF,product_name,What is the Product name?,Apo-Latanoprost-Timop,94
sample_nocs/0000012766.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02414155, Ophthalmic, Solution, 50 g/mL / 5 mg/mL",19
sample_nocs/0000012766.PDF,species,What is the species?,NA,NA
sample_nocs/0000012766.PDF,noc_date,What is the date of the document?,OCT 10 2013,39
sample_nocs/0000012766.PDF,medicinal_ingredients,What are the medicinal ingredients?,Latanoprost Timolol(supplied as timolol maleate 6.83 mg/mL),40
sample_nocs/0000012910.PDF,canadian_reference_product,What is the Canadian Reference Product?,Carbamazepine CR,71
sample_nocs/0000012910.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000012910.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,13
sample_nocs/0000012910.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000012910.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000012910.PDF,submission_no,What is the Submission Number?,168228,98
sample_nocs/0000012910.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000012910.PDF,product_name,What is the Product name?,Carbamazepine CR,83
sample_nocs/0000012910.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02413590 (oral, extended-release tablet, 200 mg)",58
sample_nocs/0000012910.PDF,species,What is the species?,NA,NA
sample_nocs/0000012910.PDF,noc_date,What is the date of the document?,OCT 31 2013,78
sample_nocs/0000012910.PDF,medicinal_ingredients,What are the medicinal ingredients?,Carbamazepine,94
sample_nocs/0000013027.PDF,canadian_reference_product,What is the Canadian Reference Product?,TEVA-FROVATRIPTAN,92
sample_nocs/0000013027.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000013027.PDF,noc_reason,What was the reason for the submission?,Administrative additional product name / Administratif nom du produit additionnel,37
sample_nocs/0000013027.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000013027.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000013027.PDF,submission_no,What is the Submission Number?,168806,97
sample_nocs/0000013027.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Endo Pharmaceuticals Inc.,78
sample_nocs/0000013027.PDF,product_name,What is the Product name?,TEVA-FROVATRIPTAN,97
sample_nocs/0000013027.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02415844 (oral, tablet, 2.5 mg)",38
sample_nocs/0000013027.PDF,species,What is the species?,NA,NA
sample_nocs/0000013027.PDF,noc_date,What is the date of the document?,NOV 21 2013,85
sample_nocs/0000013027.PDF,medicinal_ingredients,What are the medicinal ingredients?,Frovatriptan supplied as Frovatriptan Succinate,93
sample_nocs/0000013042.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Aerius, Schering Canada Inc., Canada",46
sample_nocs/0000013042.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,72
sample_nocs/0000013042.PDF,noc_reason,What was the reason for the submission?,Administrative additional product name / Administratif nom du produit additionnel,37
sample_nocs/0000013042.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000013042.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000013042.PDF,submission_no,What is the Submission Number?,169400,99
sample_nocs/0000013042.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,94
sample_nocs/0000013042.PDF,product_name,What is the Product name?,ALLERGY CONTROL DESLORATADINE,90
sample_nocs/0000013042.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02415771 (oral, tablet, 5 mg)",54.000003814697266
sample_nocs/0000013042.PDF,species,What is the species?,NA,NA
sample_nocs/0000013042.PDF,noc_date,What is the date of the document?,NOV 26 2013,83
sample_nocs/0000013042.PDF,medicinal_ingredients,What are the medicinal ingredients?,Desloratadine,95
sample_nocs/0000013637.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000013637.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,43
sample_nocs/0000013637.PDF,noc_reason,What was the reason for the submission?,Update format of Product Monograph / mise a jour le format de Monographie de Product,29
sample_nocs/0000013637.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr Robert Cushman,79
sample_nocs/0000013637.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000013637.PDF,submission_no,What is the Submission Number?,171120,99
sample_nocs/0000013637.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GlaxoSmithKline Inc,98
sample_nocs/0000013637.PDF,product_name,What is the Product name?,Typherix,98
sample_nocs/0000013637.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, PWSO, Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi",39
sample_nocs/0000013637.PDF,species,What is the species?,Salmonella,60.000003814697266
sample_nocs/0000013637.PDF,noc_date,What is the date of the document?,FEB 11 2014,66
sample_nocs/0000013637.PDF,medicinal_ingredients,What are the medicinal ingredients?,Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi,88
sample_nocs/0000013710.PDF,canadian_reference_product,What is the Canadian Reference Product?,Zeniquin,87
sample_nocs/0000013710.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000013710.PDF,noc_reason,What was the reason for the submission?,Administrative Transfer of Drug Identification Number (DIN) Holder,93
sample_nocs/0000013710.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,97
sample_nocs/0000013710.PDF,dossier_id,What is the Dossier Id?,OF15-21-Z01501-182169096,63
sample_nocs/0000013710.PDF,submission_no,What is the Submission Number?,169096,98
sample_nocs/0000013710.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000013710.PDF,product_name,What is the Product name?,Zeniquin,75
sample_nocs/0000013710.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02241413, Oral, Tablets, 100 mg/tab",84
sample_nocs/0000013710.PDF,species,What is the species?,Dogs,99
sample_nocs/0000013710.PDF,noc_date,What is the date of the document?,FEB 13 2014,81
sample_nocs/0000013710.PDF,medicinal_ingredients,What are the medicinal ingredients?,Marbofloxacin,97
sample_nocs/0000013767.PDF,canadian_reference_product,What is the Canadian Reference Product?,Ketaset,82
sample_nocs/0000013767.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000013767.PDF,noc_reason,What was the reason for the submission?,Administrative Transfer of Drug Identification Number (DIN) Holder,93
sample_nocs/0000013767.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,98
sample_nocs/0000013767.PDF,dossier_id,What is the Dossier Id?,OF15-21-Z01501-151167719,46
sample_nocs/0000013767.PDF,submission_no,What is the Submission Number?,167719,98
sample_nocs/0000013767.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000013767.PDF,product_name,What is the Product name?,Ketaset,65
sample_nocs/0000013767.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02173239, Intramuscular, Solution, 100 mg/mL",76
sample_nocs/0000013767.PDF,species,What is the species?,Cats,99
sample_nocs/0000013767.PDF,noc_date,What is the date of the document?,FEB 24 2014,85
sample_nocs/0000013767.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ketamine (as ketamine hydrochloride),83
sample_nocs/0000013925.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Xalatan, Pfizer Canada Inc., Canada",31
sample_nocs/0000013925.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,49
sample_nocs/0000013925.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000013925.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000013925.PDF,dossier_id,What is the Dossier Id?,p161370,93
sample_nocs/0000013925.PDF,submission_no,What is the Submission Number?,161370,98
sample_nocs/0000013925.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mint Pharmaceuticals Inc.,96
sample_nocs/0000013925.PDF,product_name,What is the Product name?,Mint-Latanoprost,96
sample_nocs/0000013925.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02421127, Ophthalmic, Solution, 50 mcg/mL",74
sample_nocs/0000013925.PDF,species,What is the species?,NA,NA
sample_nocs/0000013925.PDF,noc_date,What is the date of the document?,MAR 7 2014,97
sample_nocs/0000013925.PDF,medicinal_ingredients,What are the medicinal ingredients?,Latanoprost,94
sample_nocs/0000013938.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cipro, Bayer Inc., Canada",48
sample_nocs/0000013938.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,57
sample_nocs/0000013938.PDF,noc_reason,What was the reason for the submission?,Extension of the shelf life,99
sample_nocs/0000013938.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000013938.PDF,dossier_id,What is the Dossier Id?,p142130,98
sample_nocs/0000013938.PDF,submission_no,What is the Submission Number?,167571,97
sample_nocs/0000013938.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,79
sample_nocs/0000013938.PDF,product_name,What is the Product name?,Auro-Ciprofloxacin,93
sample_nocs/0000013938.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 250 mg",86
sample_nocs/0000013938.PDF,species,What is the species?,NA,NA
sample_nocs/0000013938.PDF,noc_date,What is the date of the document?,MAR 10 2014,79
sample_nocs/0000013938.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin (Supplied as Ciprofloxacin Hydrochloride),64
sample_nocs/0000013953.PDF,canadian_reference_product,What is the Canadian Reference Product?,Aureomycin 220 g,26
sample_nocs/0000013953.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000013953.PDF,noc_reason,What was the reason for the submission?,Administrative Transfer of Drug Identification Number (DIN) Holder,91
sample_nocs/0000013953.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,98
sample_nocs/0000013953.PDF,dossier_id,What is the Dossier Id?,171152,44
sample_nocs/0000013953.PDF,submission_no,What is the Submission Number?,171152,97
sample_nocs/0000013953.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000013953.PDF,product_name,What is the Product name?,Aureomycin® 220 G,31
sample_nocs/0000013953.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02242693, Oral, Drug Premix, 220 g/kg",79
sample_nocs/0000013953.PDF,species,What is the species?,"Chickens, turkeys, lambs, swine, cattle, mink",96
sample_nocs/0000013953.PDF,noc_date,What is the date of the document?,MAR 14 2014,46
sample_nocs/0000013953.PDF,medicinal_ingredients,What are the medicinal ingredients?,Chlortetracycline hydrochloride (as chlortetracycline calcium complex),85
sample_nocs/0000014072.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Seroquel XR, AstraZeneca Canada Inc., Canada",70
sample_nocs/0000014072.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000014072.PDF,noc_reason,What was the reason for the submission?,Additional Drug Product manufacturing site,75
sample_nocs/0000014072.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000014072.PDF,dossier_id,What is the Dossier Id?,e121486,95
sample_nocs/0000014072.PDF,submission_no,What is the Submission Number?,167141,99
sample_nocs/0000014072.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,61
sample_nocs/0000014072.PDF,product_name,What is the Product name?,Teva-Quetiapine XR,91
sample_nocs/0000014072.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet (extended-release) 50 mg",54.000003814697266
sample_nocs/0000014072.PDF,species,What is the species?,NA,NA
sample_nocs/0000014072.PDF,noc_date,What is the date of the document?,MAR 25 2014,96
sample_nocs/0000014072.PDF,medicinal_ingredients,What are the medicinal ingredients?,Quetiapine (supplied as quetiapine fumarate),58.999996185302734
sample_nocs/0000014178.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Vfend, Pfizer Canada Inc., Canada",49
sample_nocs/0000014178.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,72
sample_nocs/0000014178.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000014178.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,94
sample_nocs/0000014178.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000014178.PDF,submission_no,What is the Submission Number?,147630,99
sample_nocs/0000014178.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,teva  Canada Limited,12
sample_nocs/0000014178.PDF,product_name,What is the Product name?,Teva-Voriconazole,92
sample_nocs/0000014178.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02396866, Oral, Tablet, 50 mg",92
sample_nocs/0000014178.PDF,species,What is the species?,NA,NA
sample_nocs/0000014178.PDF,noc_date,What is the date of the document?,MAR 31 2014,96
sample_nocs/0000014178.PDF,medicinal_ingredients,What are the medicinal ingredients?,Voriconazole,98
sample_nocs/0000014379.PDF,canadian_reference_product,What is the Canadian Reference Product?,Prochymal,93
sample_nocs/0000014379.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,58
sample_nocs/0000014379.PDF,noc_reason,What was the reason for the submission?,Administrative Manufacturer name change,89
sample_nocs/0000014379.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,85
sample_nocs/0000014379.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000014379.PDF,submission_no,What is the Submission Number?,172934,98
sample_nocs/0000014379.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mesoblast International Sull,8
sample_nocs/0000014379.PDF,product_name,What is the Product name?,Prochymal,99
sample_nocs/0000014379.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02386380, IV, SOL, 100 X 106 hMSCs / 15 mL",49
sample_nocs/0000014379.PDF,species,What is the species?,NA,NA
sample_nocs/0000014379.PDF,noc_date,What is the date of the document?,MAY 02 2014,85
sample_nocs/0000014379.PDF,medicinal_ingredients,What are the medicinal ingredients?,remestemcel-L,52
sample_nocs/0000014768.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Primacor Injection, Sanofi Synthelabo Canada Inc.",31
sample_nocs/0000014768.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000014768.PDF,noc_reason,What was the reason for the submission?,Administrative: merger buyout / Administratif:fusion rachat,34
sample_nocs/0000014768.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000014768.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000014768.PDF,submission_no,What is the Submission Number?,174323,98
sample_nocs/0000014768.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mylan Pharmaceuticals ULC,87
sample_nocs/0000014768.PDF,product_name,What is the Product name?,Milrinone Lactate Injection,51
sample_nocs/0000014768.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02383519,68
sample_nocs/0000014768.PDF,species,What is the species?,NA,NA
sample_nocs/0000014768.PDF,noc_date,What is the date of the document?,JUN 24 2014,80
sample_nocs/0000014768.PDF,medicinal_ingredients,What are the medicinal ingredients?,Milrinone supplied as Milrinone Lactate,94
sample_nocs/0000014781.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Actonel, Procter & Gamble Pharmaceuticals Canada Inc., Canada",9
sample_nocs/0000014781.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,79
sample_nocs/0000014781.PDF,noc_reason,What was the reason for the submission?,Administrative Change in film coating of the drug product.,71
sample_nocs/0000014781.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000014781.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000014781.PDF,submission_no,What is the Submission Number?,175592,98
sample_nocs/0000014781.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sivem Pharmaceuticals ULC,88
sample_nocs/0000014781.PDF,product_name,What is the Product name?,Risedronate,49
sample_nocs/0000014781.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, (oral, tablet, 35 mg)",73
sample_nocs/0000014781.PDF,species,What is the species?,NA,NA
sample_nocs/0000014781.PDF,noc_date,What is the date of the document?,JUN 2 6 2014,57
sample_nocs/0000014781.PDF,medicinal_ingredients,What are the medicinal ingredients?,Risedronate sodium supplied as risedronate sodium hemi-pentahydrate,83
sample_nocs/0000014925.PDF,canadian_reference_product,What is the Canadian Reference Product?,Isathal Eye Gel,92
sample_nocs/0000014925.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000014925.PDF,noc_reason,What was the reason for the submission?,Administrative Licensing agreement between two companies,96
sample_nocs/0000014925.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,91
sample_nocs/0000014925.PDF,dossier_id,What is the Dossier Id?,OF15-21-D2797(1-101175389,20
sample_nocs/0000014925.PDF,submission_no,What is the Submission Number?,175389,98
sample_nocs/0000014925.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000014925.PDF,product_name,What is the Product name?,Isathal Eye Gel,87
sample_nocs/0000014925.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02427869, Ophthalmic, Gel, 10 mg/g",86
sample_nocs/0000014925.PDF,species,What is the species?,Dogs,99
sample_nocs/0000014925.PDF,noc_date,What is the date of the document?,JUL 5 2014,79
sample_nocs/0000014925.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fusidic acid,98
sample_nocs/0000015487.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Celexa, Lundbeck Canada Inc.",50
sample_nocs/0000015487.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,60.000003814697266
sample_nocs/0000015487.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,27.000001907348633
sample_nocs/0000015487.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000015487.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000015487.PDF,submission_no,What is the Submission Number?,177200,99
sample_nocs/0000015487.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000015487.PDF,product_name,What is the Product name?,CITALOPRAM,71
sample_nocs/0000015487.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02430517 (oral, tablet, 10 mg)",79
sample_nocs/0000015487.PDF,species,What is the species?,NA,NA
sample_nocs/0000015487.PDF,noc_date,What is the date of the document?,SEP 9 2014,56
sample_nocs/0000015487.PDF,medicinal_ingredients,What are the medicinal ingredients?,Citalopram supplied as Citalopram Hydrobromide,95
sample_nocs/0000015615.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Neurontin, Pfizer Canada Inc., Canada",30.000001907348633
sample_nocs/0000015615.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,51
sample_nocs/0000015615.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,23
sample_nocs/0000015615.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000015615.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000015615.PDF,submission_no,What is the Submission Number?,177298,97
sample_nocs/0000015615.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,65
sample_nocs/0000015615.PDF,product_name,What is the Product name?,Gabapentin,58
sample_nocs/0000015615.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02431289 (oral, tablet, 600 mg)",55
sample_nocs/0000015615.PDF,species,What is the species?,NA,NA
sample_nocs/0000015615.PDF,noc_date,What is the date of the document?,SEP 17 2014,93
sample_nocs/0000015615.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gabapentin,97
sample_nocs/0000015657.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Glucophage, Aventis Pharma Inc., Canada",52.999996185302734
sample_nocs/0000015657.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,49
sample_nocs/0000015657.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000015657.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Robert G. Peterson,44
sample_nocs/0000015657.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000015657.PDF,submission_no,What is the Submission Number?,084174,98
sample_nocs/0000015657.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Cobalt Pharmaceuticals Inc.,97
sample_nocs/0000015657.PDF,product_name,What is the Product name?,Co-Metformin,98
sample_nocs/0000015657.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02257726, ORL, TAB, 500MG",94
sample_nocs/0000015657.PDF,species,What is the species?,NA,NA
sample_nocs/0000015657.PDF,noc_date,What is the date of the document?,AUG 24 2004,34
sample_nocs/0000015657.PDF,medicinal_ingredients,What are the medicinal ingredients?,Metformin Hydrochloride,98
sample_nocs/0000015661.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Micotil (Elanco Animal Health, DIN 00857602)",76
sample_nocs/0000015661.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000015661.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000015661.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Daniel Chaput,87
sample_nocs/0000015661.PDF,dossier_id,What is the Dossier Id?,OF15-21-M2324-2-104-149591,22
sample_nocs/0000015661.PDF,submission_no,What is the Submission Number?,149591,98
sample_nocs/0000015661.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000015661.PDF,product_name,What is the Product name?,HYMATIL,99
sample_nocs/0000015661.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02431912, Subcutanous, Solution, 300 mg/mL",72
sample_nocs/0000015661.PDF,species,What is the species?,"Cattle, Sheep",67
sample_nocs/0000015661.PDF,noc_date,What is the date of the document?,SEP 29 2014,86
sample_nocs/0000015661.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tilmicosin,94
sample_nocs/0000015962.PDF,canadian_reference_product,What is the Canadian Reference Product?,Nuwiq,88
sample_nocs/0000015962.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000015962.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000015962.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Robert Cushman,70
sample_nocs/0000015962.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000015962.PDF,submission_no,What is the Submission Number?,169551,97
sample_nocs/0000015962.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Octapharma Pharmazeutika Produktionsges.m.b.H,55
sample_nocs/0000015962.PDF,product_name,What is the Product name?,Nuwiq,98
sample_nocs/0000015962.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02432951, IV, PWSO, 250 IU/vial",38
sample_nocs/0000015962.PDF,species,What is the species?,NA,NA
sample_nocs/0000015962.PDF,noc_date,What is the date of the document?,"October 23, 2014",75
sample_nocs/0000015962.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Antihemophilic Factor (Recombinant, B-domain deleted) / Facteur antihémophilique (recombinant et dépourvu du domaine B)",13
sample_nocs/0000016167.PDF,canadian_reference_product,What is the Canadian Reference Product?,SEPTRA INJECTION,98
sample_nocs/0000016167.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,74
sample_nocs/0000016167.PDF,noc_reason,What was the reason for the submission?,Administrative manufacturer name change / Administrative change of nom du fabricant,39
sample_nocs/0000016167.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000016167.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000016167.PDF,submission_no,What is the Submission Number?,178910,98
sample_nocs/0000016167.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Aspri Pharma Canada Inc.,85
sample_nocs/0000016167.PDF,product_name,What is the Product name?,SEPTRA INJECTION,98
sample_nocs/0000016167.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00550086,72
sample_nocs/0000016167.PDF,species,What is the species?,NA,NA
sample_nocs/0000016167.PDF,noc_date,What is the date of the document?,NOV 21 2014,84
sample_nocs/0000016167.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Sulfamethoxazole, Trimethoprim",78
sample_nocs/0000016222.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Micardis Plus, Boehringer Ingelheim (Canada) Ltd., Canada",51
sample_nocs/0000016222.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,64
sample_nocs/0000016222.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,23
sample_nocs/0000016222.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000016222.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000016222.PDF,submission_no,What is the Submission Number?,179134,99
sample_nocs/0000016222.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Vanc Pharmaceuticals Inc.,81
sample_nocs/0000016222.PDF,product_name,What is the Product name?,VAN-TELMISARTAN-HCTZ,87
sample_nocs/0000016222.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02434067,82
sample_nocs/0000016222.PDF,species,What is the species?,NA,NA
sample_nocs/0000016222.PDF,noc_date,What is the date of the document?,NOV 28 2014,88
sample_nocs/0000016222.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Telmisartan, Hydrochlorothiazide",81
sample_nocs/0000016470.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Atacand, AstraZeneca Canada Inc., Canada",51
sample_nocs/0000016470.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,70
sample_nocs/0000016470.PDF,noc_reason,What was the reason for the submission?,New indication,89
sample_nocs/0000016470.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000016470.PDF,dossier_id,What is the Dossier Id?,p136945,98
sample_nocs/0000016470.PDF,submission_no,What is the Submission Number?,180251,98
sample_nocs/0000016470.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ACTavis  Pharma Company,64
sample_nocs/0000016470.PDF,product_name,What is the Product name?,ACT Candesartan,96
sample_nocs/0000016470.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 4 mg",84
sample_nocs/0000016470.PDF,species,What is the species?,NA,NA
sample_nocs/0000016470.PDF,noc_date,What is the date of the document?,DEC 30 2014,63
sample_nocs/0000016470.PDF,medicinal_ingredients,What are the medicinal ingredients?,Candesartan Cilexetil,95
sample_nocs/0000016825.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000016825.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,41
sample_nocs/0000016825.PDF,noc_reason,What was the reason for the submission?,Product monograph update / Mise a jour de la monographie de produit,47
sample_nocs/0000016825.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000016825.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000016825.PDF,submission_no,What is the Submission Number?,172636,98
sample_nocs/0000016825.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,63
sample_nocs/0000016825.PDF,product_name,What is the Product name?,STELARA,97
sample_nocs/0000016825.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 45 mg/0.5mL",84
sample_nocs/0000016825.PDF,species,What is the species?,NA,NA
sample_nocs/0000016825.PDF,noc_date,What is the date of the document?,FEB 19 2015,93
sample_nocs/0000016825.PDF,medicinal_ingredients,What are the medicinal ingredients?,ustekinumab,95
sample_nocs/0000016957.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Vancocin, Iroko International LP, Canada",81
sample_nocs/0000016957.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,73
sample_nocs/0000016957.PDF,noc_reason,What was the reason for the submission?,Administrative manufacturer name change / Administrative change of nom du fabricant,29
sample_nocs/0000016957.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000016957.PDF,dossier_id,What is the Dossier Id?,p144773,96
sample_nocs/0000016957.PDF,submission_no,What is the Submission Number?,181576,98
sample_nocs/0000016957.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd,96
sample_nocs/0000016957.PDF,product_name,What is the Product name?,"VANCOMYCIN HYDROCHLORIDE CAPSULES, USP",58
sample_nocs/0000016957.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02377470 (oral, capsule, 125 mg)",48
sample_nocs/0000016957.PDF,species,What is the species?,NA,NA
sample_nocs/0000016957.PDF,noc_date,What is the date of the document?,MAR 05 2015,97
sample_nocs/0000016957.PDF,medicinal_ingredients,What are the medicinal ingredients?,Vancomycin supplied as Vancomycin Hydrochloride,93
sample_nocs/0000016958.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Vancomycin Hydrochloride for InJECTION, USP",20
sample_nocs/0000016958.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000016958.PDF,noc_reason,What was the reason for the submission?,change of nom of fabricant,24
sample_nocs/0000016958.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000016958.PDF,dossier_id,What is the Dossier Id?,p144773,96
sample_nocs/0000016958.PDF,submission_no,What is the Submission Number?,181577,98
sample_nocs/0000016958.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd,95
sample_nocs/0000016958.PDF,product_name,What is the Product name?,"VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP",52
sample_nocs/0000016958.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02139375,90
sample_nocs/0000016958.PDF,species,What is the species?,NA,NA
sample_nocs/0000016958.PDF,noc_date,What is the date of the document?,MAR 05 2015,97
sample_nocs/0000016958.PDF,medicinal_ingredients,What are the medicinal ingredients?,Vancomycin supplied as Vancomycin Hydrochloride,93
sample_nocs/0000017295.PDF,canadian_reference_product,What is the Canadian Reference Product?,"INTRALIPID 10%, INTRALIPID 20%, INTRALIPID 30%",56
sample_nocs/0000017295.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,68
sample_nocs/0000017295.PDF,noc_reason,What was the reason for the submission?,Administrative transfer of drug identification Number(s) / selected Administrative transfer of identification numérique de(s) drogue(s),38
sample_nocs/0000017295.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,92
sample_nocs/0000017295.PDF,dossier_id,What is the Dossier Id?,p122902,97
sample_nocs/0000017295.PDF,submission_no,What is the Submission Number?,182668,98
sample_nocs/0000017295.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd,92
sample_nocs/0000017295.PDF,product_name,What is the Product name?,"INTRALIPID 10%, INTRALIPID 20%, INTRALIPID 30%",87
sample_nocs/0000017295.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02065681,76
sample_nocs/0000017295.PDF,species,What is the species?,NA,NA
sample_nocs/0000017295.PDF,noc_date,What is the date of the document?,APR 17 2015,92
sample_nocs/0000017295.PDF,medicinal_ingredients,What are the medicinal ingredients?,Soybean Oil,99
sample_nocs/0000017556.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Hycamtin, GlaxoSmithKline Inc., Canada",71
sample_nocs/0000017556.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,73
sample_nocs/0000017556.PDF,noc_reason,What was the reason for the submission?,Administrative manufacturer name change / Administrative change of nom du fabricant,32
sample_nocs/0000017556.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000017556.PDF,dossier_id,What is the Dossier Id?,p123979,96
sample_nocs/0000017556.PDF,submission_no,What is the Submission Number?,183703,98
sample_nocs/0000017556.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd.,55
sample_nocs/0000017556.PDF,product_name,What is the Product name?,TOPOTECAN FOR INJECTION,97
sample_nocs/0000017556.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",o2346656,41
sample_nocs/0000017556.PDF,species,What is the species?,NA,NA
sample_nocs/0000017556.PDF,noc_date,What is the date of the document?,MAY 19 2015,98
sample_nocs/0000017556.PDF,medicinal_ingredients,What are the medicinal ingredients?,Topotecan supplied as Topotecan Hydrochloride,96
sample_nocs/0000018088.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Prevacid, Takeda Pharmaceuticals America Inc., Canada",65
sample_nocs/0000018088.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000018088.PDF,noc_reason,What was the reason for the submission?,"Administrative update to the Product Monograph, new indication / Administratif Mise a jour de la monographie du produit, nouvelle indication",11
sample_nocs/0000018088.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,94
sample_nocs/0000018088.PDF,dossier_id,What is the Dossier Id?,e162597,61
sample_nocs/0000018088.PDF,submission_no,What is the Submission Number?,184946,98
sample_nocs/0000018088.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ranbaxy Pharmaceuticals Canada Inc,92
sample_nocs/0000018088.PDF,product_name,What is the Product name?,RAN-LANSOPRAZOLE,70
sample_nocs/0000018088.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, (oral, delayed-release capsule, 15 mg)",78
sample_nocs/0000018088.PDF,species,What is the species?,NA,NA
sample_nocs/0000018088.PDF,noc_date,What is the date of the document?,JUL 27 2015,94
sample_nocs/0000018088.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lansoprazole,98
sample_nocs/0000018137.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Vasotec, Merck Frosst Canada Ltd, Canada",73
sample_nocs/0000018137.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000018137.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,24
sample_nocs/0000018137.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000018137.PDF,dossier_id,What is the Dossier Id?,p185281,97
sample_nocs/0000018137.PDF,submission_no,What is the Submission Number?,185281,98
sample_nocs/0000018137.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sivem Pharmaceuticals ULC,90
sample_nocs/0000018137.PDF,product_name,What is the Product name?,ENALAPRIL,58
sample_nocs/0000018137.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02442957 (oral, tablet, 2 mg)",66
sample_nocs/0000018137.PDF,species,What is the species?,NA,NA
sample_nocs/0000018137.PDF,noc_date,What is the date of the document?,JUL 31 2015,84
sample_nocs/0000018137.PDF,medicinal_ingredients,What are the medicinal ingredients?,Enalapril Sodium,89
sample_nocs/0000018276.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEMURON,84
sample_nocs/0000018276.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,74
sample_nocs/0000018276.PDF,noc_reason,What was the reason for the submission?,"Revision of the wording, font, and layout of the outer carton label and inner vial labels",63
sample_nocs/0000018276.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,95
sample_nocs/0000018276.PDF,dossier_id,What is the Dossier Id?,e131761,94
sample_nocs/0000018276.PDF,submission_no,What is the Submission Number?,185046,98
sample_nocs/0000018276.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,51
sample_nocs/0000018276.PDF,product_name,What is the Product name?,ZEMURON,97
sample_nocs/0000018276.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution for Injection, 10 mg/mL",82
sample_nocs/0000018276.PDF,species,What is the species?,NA,NA
sample_nocs/0000018276.PDF,noc_date,What is the date of the document?,AUG 1 0 2015,34
sample_nocs/0000018276.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rocuronium Bromide,94
sample_nocs/0000018414.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Topamax, Janssen-Cilag Ltd., UK",52.999996185302734
sample_nocs/0000018414.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000018414.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,13
sample_nocs/0000018414.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,90
sample_nocs/0000018414.PDF,dossier_id,What is the Dossier Id?,p186085,97
sample_nocs/0000018414.PDF,submission_no,What is the Submission Number?,186085,98
sample_nocs/0000018414.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Vanc Pharmaceuticals Inc.,87
sample_nocs/0000018414.PDF,product_name,What is the Product name?,VAN-TOPIRAMATE,64
sample_nocs/0000018414.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02444283 (oral, tablet, 25 mg)",40
sample_nocs/0000018414.PDF,species,What is the species?,NA,NA
sample_nocs/0000018414.PDF,noc_date,What is the date of the document?,AUG 28 2015,98
sample_nocs/0000018414.PDF,medicinal_ingredients,What are the medicinal ingredients?,Topiramate,97
sample_nocs/0000018697.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Adcirca, Eli Lilly Canada Inc., Canada",51
sample_nocs/0000018697.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000018697.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000018697.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,90
sample_nocs/0000018697.PDF,dossier_id,What is the Dossier Id?,e154167,96
sample_nocs/0000018697.PDF,submission_no,What is the Submission Number?,167295,97
sample_nocs/0000018697.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Incorporated,94
sample_nocs/0000018697.PDF,product_name,What is the Product name?,Apo-Tadalafil PAH,97
sample_nocs/0000018697.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02421933, Oral, Tablet, 20 mg",77
sample_nocs/0000018697.PDF,species,What is the species?,NA,NA
sample_nocs/0000018697.PDF,noc_date,What is the date of the document?,OCT 14 2015,82
sample_nocs/0000018697.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tadalafil,99
sample_nocs/0000018720.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Valtrex, GlaxoSmithKline Inc., Canada",49
sample_nocs/0000018720.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000018720.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,11
sample_nocs/0000018720.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000018720.PDF,dossier_id,What is the Dossier Id?,p186214,98
sample_nocs/0000018720.PDF,submission_no,What is the Submission Number?,186214,99
sample_nocs/0000018720.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000018720.PDF,product_name,What is the Product name?,BIO-VALACYCLOVIR,90
sample_nocs/0000018720.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02444860 (oral, tablet, 500 mg)",41
sample_nocs/0000018720.PDF,species,What is the species?,NA,NA
sample_nocs/0000018720.PDF,noc_date,What is the date of the document?,OCT 14 2015,90
sample_nocs/0000018720.PDF,medicinal_ingredients,What are the medicinal ingredients?,Valacyclovir supplied as Valacyclovir Hydrochloride,95
sample_nocs/0000018858.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Tygacil, Pfizer Canada Inc., Canada",34
sample_nocs/0000018858.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000018858.PDF,noc_reason,What was the reason for the submission?,Revisions to product monograph,91
sample_nocs/0000018858.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,88
sample_nocs/0000018858.PDF,dossier_id,What is the Dossier Id?,e158755,86
sample_nocs/0000018858.PDF,submission_no,What is the Submission Number?,187986,96
sample_nocs/0000018858.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,85
sample_nocs/0000018858.PDF,product_name,What is the Product name?,Tigecycline,88
sample_nocs/0000018858.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 50 mg / vial",81
sample_nocs/0000018858.PDF,species,What is the species?,NA,NA
sample_nocs/0000018858.PDF,noc_date,What is the date of the document?,NOV 04 2015,89
sample_nocs/0000018858.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tigecycline,87
sample_nocs/0000019186.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Eloxatin, Sanofi-aventis Canada Inc.",23
sample_nocs/0000019186.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,76
sample_nocs/0000019186.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000019186.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,91
sample_nocs/0000019186.PDF,dossier_id,What is the Dossier Id?,e165864,61
sample_nocs/0000019186.PDF,submission_no,What is the Submission Number?,165864,97
sample_nocs/0000019186.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,91
sample_nocs/0000019186.PDF,product_name,What is the Product name?,Oxaliplatin Injection,93
sample_nocs/0000019186.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02436957, Intravenous, Solution, 5 mg / mL",40
sample_nocs/0000019186.PDF,species,What is the species?,NA,NA
sample_nocs/0000019186.PDF,noc_date,What is the date of the document?,DEC 16 2015,91
sample_nocs/0000019186.PDF,medicinal_ingredients,What are the medicinal ingredients?,Oxaliplatin,88
sample_nocs/0000019330.PDF,canadian_reference_product,What is the Canadian Reference Product?,ADACEL POLIO,76
sample_nocs/0000019330.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,25
sample_nocs/0000019330.PDF,noc_reason,What was the reason for the submission?,Changes to the manufacturing facility / modification a l'emplacement de fabrication,51
sample_nocs/0000019330.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000019330.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000019330.PDF,submission_no,What is the Submission Number?,182878,98
sample_nocs/0000019330.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi Pasteur Limited,96
sample_nocs/0000019330.PDF,product_name,What is the Product name?,ADACEL POLIO,97
sample_nocs/0000019330.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, SUS, 0.5mL dose;",48
sample_nocs/0000019330.PDF,species,What is the species?,NA,NA
sample_nocs/0000019330.PDF,noc_date,What is the date of the document?,DEC 18 2015,93
sample_nocs/0000019330.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, diphtheria toxoid, tetanus toxoid, inactivated poliomye",52
sample_nocs/0000019531.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Paxil, GlaxoSmithKline Inc., Canada",50
sample_nocs/0000019531.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000019531.PDF,noc_reason,What was the reason for the submission?,Administrative: merger buyout / Administrative fusion,14
sample_nocs/0000019531.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,89
sample_nocs/0000019531.PDF,dossier_id,What is the Dossier Id?,e161898,94
sample_nocs/0000019531.PDF,submission_no,What is the Submission Number?,190520,100
sample_nocs/0000019531.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Marcan Pharmaceuticals Inc,98
sample_nocs/0000019531.PDF,product_name,What is the Product name?,IPG-PAROXETINE,76
sample_nocs/0000019531.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02410834(oral, tablet, 10 mg)",57
sample_nocs/0000019531.PDF,species,What is the species?,NA,NA
sample_nocs/0000019531.PDF,noc_date,What is the date of the document?,JAN 19 2016,81
sample_nocs/0000019531.PDF,medicinal_ingredients,What are the medicinal ingredients?,Paroxetine supplied as Paroxetine Hydrochloride Hemihydrate,92
sample_nocs/0000019694.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Plavix, Sanofi-Aventis Canada Inc., Canada",51
sample_nocs/0000019694.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000019694.PDF,noc_reason,What was the reason for the submission?,Updates to the product monograph and labels,94
sample_nocs/0000019694.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,67
sample_nocs/0000019694.PDF,dossier_id,What is the Dossier Id?,e123869,97
sample_nocs/0000019694.PDF,submission_no,What is the Submission Number?,190886,98
sample_nocs/0000019694.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,35
sample_nocs/0000019694.PDF,product_name,What is the Product name?,pms-clopidogrel,93
sample_nocs/0000019694.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 75 mg",69
sample_nocs/0000019694.PDF,species,What is the species?,NA,NA
sample_nocs/0000019694.PDF,noc_date,What is the date of the document?,FEB 11 2016,61
sample_nocs/0000019694.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel Bisulfate,94
sample_nocs/0000019841.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Nexium, AstraZeneca Canada Inc., Canada",46
sample_nocs/0000019841.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000019841.PDF,noc_reason,What was the reason for the submission?,To propose an alternate mode of administration,87
sample_nocs/0000019841.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,95
sample_nocs/0000019841.PDF,dossier_id,What is the Dossier Id?,e136222,93
sample_nocs/0000019841.PDF,submission_no,What is the Submission Number?,178874,98
sample_nocs/0000019841.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc.,34
sample_nocs/0000019841.PDF,product_name,What is the Product name?,pms-esomeprazole DR,61
sample_nocs/0000019841.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Delayed-Release Capsule, 20 mg",87
sample_nocs/0000019841.PDF,species,What is the species?,NA,NA
sample_nocs/0000019841.PDF,noc_date,What is the date of the document?,FEB 25 2016,92
sample_nocs/0000019841.PDF,medicinal_ingredients,What are the medicinal ingredients?,Esomeprazole Magnesium Dihydrate,96
sample_nocs/0000019843.PDF,canadian_reference_product,What is the Canadian Reference Product?,Zyprexa Zydis,32
sample_nocs/0000019843.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000019843.PDF,noc_reason,What was the reason for the submission?,Change in manufacturing site for the drug product,55
sample_nocs/0000019843.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,96
sample_nocs/0000019843.PDF,dossier_id,What is the Dossier Id?,e133596,97
sample_nocs/0000019843.PDF,submission_no,What is the Submission Number?,180937,98
sample_nocs/0000019843.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,75
sample_nocs/0000019843.PDF,product_name,What is the Product name?,Teva-Olanzapine ODT,94
sample_nocs/0000019843.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet (Orally Disintegrating) 5 mg",50
sample_nocs/0000019843.PDF,species,What is the species?,NA,NA
sample_nocs/0000019843.PDF,noc_date,What is the date of the document?,FEB 25 2016,91
sample_nocs/0000019843.PDF,medicinal_ingredients,What are the medicinal ingredients?,Olanzapine,92
sample_nocs/0000020292.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000020292.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,36
sample_nocs/0000020292.PDF,noc_reason,What was the reason for the submission?,Update to Product Monograph,94
sample_nocs/0000020292.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,100
sample_nocs/0000020292.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000020292.PDF,submission_no,What is the Submission Number?,193104,98
sample_nocs/0000020292.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Baxter Corporation,99
sample_nocs/0000020292.PDF,product_name,What is the Product name?,Artiss,98
sample_nocs/0000020292.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, TOP, KIT, Sealer Protein (Human): 96-125 mg/mL;",63
sample_nocs/0000020292.PDF,species,What is the species?,NA,NA
sample_nocs/0000020292.PDF,noc_date,What is the date of the document?,APR 18 2016,92
sample_nocs/0000020292.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Sealer Protein (Human), Aprotinin (synthetic), Thrombin (Human), Calcium Chloride / Colle protéinée (Humaine), Aprotinine (synthétique), Chloride de Calcium.",23
sample_nocs/0000020458.PDF,canadian_reference_product,What is the Canadian Reference Product?,nivolumab,43
sample_nocs/0000020458.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000020458.PDF,noc_reason,What was the reason for the submission?,nature prometteuse of données cliniques,30.000001907348633
sample_nocs/0000020458.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000020458.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000020458.PDF,submission_no,What is the Submission Number?,NA,NA
sample_nocs/0000020458.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000020458.PDF,product_name,What is the Product name?,OPDIVOMD,60.000003814697266
sample_nocs/0000020458.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000020458.PDF,species,What is the species?,NA,NA
sample_nocs/0000020458.PDF,noc_date,What is the date of the document?,29 avril 2016,72
sample_nocs/0000020458.PDF,medicinal_ingredients,What are the medicinal ingredients?,"nivolumab, nivolumab",57
sample_nocs/0000020501.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cymbalta, Eli Lilly Canada Inc.",47
sample_nocs/0000020501.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000020501.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000020501.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,95
sample_nocs/0000020501.PDF,dossier_id,What is the Dossier Id?,e161910,66
sample_nocs/0000020501.PDF,submission_no,What is the Submission Number?,161910,98
sample_nocs/0000020501.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ranbaxy Pharmaceuticals Canada Inc.,86
sample_nocs/0000020501.PDF,product_name,What is the Product name?,RAN-Duloxetine,94
sample_nocs/0000020501.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02438259, Oral, Capsule (delayed-release), 30 mg",49
sample_nocs/0000020501.PDF,species,What is the species?,NA,NA
sample_nocs/0000020501.PDF,noc_date,What is the date of the document?,MAY 02 2016,99
sample_nocs/0000020501.PDF,medicinal_ingredients,What are the medicinal ingredients?,Duloxetine(supplied as duloxetine hydrochloride),52.999996185302734
sample_nocs/0000020683.PDF,canadian_reference_product,What is the Canadian Reference Product?,INFLECTRA,96
sample_nocs/0000020683.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000020683.PDF,noc_reason,What was the reason for the submission?,New Indications:,58
sample_nocs/0000020683.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000020683.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000020683.PDF,submission_no,What is the Submission Number?,184564,98
sample_nocs/0000020683.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,CELLTRION HEALTHCARE Co. Ltd.,83
sample_nocs/0000020683.PDF,product_name,What is the Product name?,INFLECTRA,95
sample_nocs/0000020683.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000020683.PDF,species,What is the species?,NA,NA
sample_nocs/0000020683.PDF,noc_date,What is the date of the document?,"June 10, 2016",79
sample_nocs/0000020683.PDF,medicinal_ingredients,What are the medicinal ingredients?,Infliximab,78
sample_nocs/0000020721.PDF,canadian_reference_product,What is the Canadian Reference Product?,CORTIMENT,99
sample_nocs/0000020721.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000020721.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle citée en rubrique,30.000001907348633
sample_nocs/0000020721.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000020721.PDF,dossier_id,What is the Dossier Id?,e177637,91
sample_nocs/0000020721.PDF,submission_no,What is the Submission Number?,183534,97
sample_nocs/0000020721.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ferring Inc,55
sample_nocs/0000020721.PDF,product_name,What is the Product name?,CORTIMENT,99
sample_nocs/0000020721.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02455889, Oral, Delayed and Extended Release Tablet, 9 mg",60.000003814697266
sample_nocs/0000020721.PDF,species,What is the species?,NA,NA
sample_nocs/0000020721.PDF,noc_date,What is the date of the document?,JUN 20 2016,56
sample_nocs/0000020721.PDF,medicinal_ingredients,What are the medicinal ingredients?,Budesonide,99
sample_nocs/0000020803.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Plavix, Sanofi-aventis Canada Inc., Canada",45
sample_nocs/0000020803.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000020803.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,15.000000953674316
sample_nocs/0000020803.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000020803.PDF,dossier_id,What is the Dossier Id?,p186476,82
sample_nocs/0000020803.PDF,submission_no,What is the Submission Number?,186476,96
sample_nocs/0000020803.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Biomed Pharma,75
sample_nocs/0000020803.PDF,product_name,What is the Product name?,BIO-CLOPIDOGREL,88
sample_nocs/0000020803.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02444895 (oral, tablet, 75 mg)",51
sample_nocs/0000020803.PDF,species,What is the species?,NA,NA
sample_nocs/0000020803.PDF,noc_date,What is the date of the document?,JUL 18 2016,92
sample_nocs/0000020803.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel supplied as Clopidogrel Bisulfate,94
sample_nocs/0000020948.PDF,canadian_reference_product,What is the Canadian Reference Product?,Tussionex,98
sample_nocs/0000020948.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000020948.PDF,noc_reason,What was the reason for the submission?,"Changes to the hydrocodone bitartrate drug substance manufacturing process and manufacturing, release testing, and packaging stability testing sites.",85
sample_nocs/0000020948.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000020948.PDF,dossier_id,What is the Dossier Id?,e104725,96
sample_nocs/0000020948.PDF,submission_no,What is the Submission Number?,191087,99
sample_nocs/0000020948.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,41
sample_nocs/0000020948.PDF,product_name,What is the Product name?,Tussionex,99
sample_nocs/0000020948.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Suspension, 5 mg/10 mg per 5 mL",77
sample_nocs/0000020948.PDF,species,What is the species?,NA,NA
sample_nocs/0000020948.PDF,noc_date,What is the date of the document?,AUG 23 2016,79
sample_nocs/0000020948.PDF,medicinal_ingredients,What are the medicinal ingredients?,Hydrocodone Bitartrate/Phenyltoloxamine Citrate,86
sample_nocs/0000020962.PDF,canadian_reference_product,What is the Canadian Reference Product?,IMOVAX POLIO,80
sample_nocs/0000020962.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000020962.PDF,noc_reason,What was the reason for the submission?,Changes to the manufacturing facility / modification a l'emplacement de fabrication,54.000003814697266
sample_nocs/0000020962.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000020962.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000020962.PDF,submission_no,What is the Submission Number?,196112,99
sample_nocs/0000020962.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi Pasteur Limited,97
sample_nocs/0000020962.PDF,product_name,What is the Product name?,IMOVAX POLIO,96
sample_nocs/0000020962.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SUS, 0.5ml dose",58
sample_nocs/0000020962.PDF,species,What is the species?,NA,NA
sample_nocs/0000020962.PDF,noc_date,What is the date of the document?,AUG 19 2016,89
sample_nocs/0000020962.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Inactivated poliomyelitis vaccine type 1 (Mahoney), inactivated poliomyelitis vaccine type 2 (M,E,F,1). inactivated poliomyelitis vaccine type 3 (Saukett)",32
sample_nocs/0000020971.PDF,canadian_reference_product,What is the Canadian Reference Product?,"AVELOX, Bayer Inc.",79
sample_nocs/0000020971.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000020971.PDF,noc_reason,What was the reason for the submission?,Administrative,76
sample_nocs/0000020971.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000020971.PDF,dossier_id,What is the Dossier Id?,p190659,96
sample_nocs/0000020971.PDF,submission_no,What is the Submission Number?,196677,99
sample_nocs/0000020971.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Laboratoire Riva Inc.,66
sample_nocs/0000020971.PDF,product_name,What is the Product name?,RIVA-MOXIFLOXACIN,91
sample_nocs/0000020971.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02450976,48
sample_nocs/0000020971.PDF,species,What is the species?,NA,NA
sample_nocs/0000020971.PDF,noc_date,What is the date of the document?,AUG 18 2016,97
sample_nocs/0000020971.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Moxifloxacin, supplied as Moxifloxacin Hydrochloride",85
sample_nocs/0000021060.PDF,canadian_reference_product,What is the Canadian Reference Product?,BENLYSTA,74
sample_nocs/0000021060.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021060.PDF,noc_reason,What was the reason for the submission?,Product Monograph update / Mise a jour de la monographie de produit,55
sample_nocs/0000021060.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000021060.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000021060.PDF,submission_no,What is the Submission Number?,193395,99
sample_nocs/0000021060.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GlaxoSmithKline Inc.,97
sample_nocs/0000021060.PDF,product_name,What is the Product name?,BENLYSTA,98
sample_nocs/0000021060.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, LPWSO, 120mg/vial",90
sample_nocs/0000021060.PDF,species,What is the species?,NA,NA
sample_nocs/0000021060.PDF,noc_date,What is the date of the document?,SEP 08 2016,52
sample_nocs/0000021060.PDF,medicinal_ingredients,What are the medicinal ingredients?,Belimumab,96
sample_nocs/0000021118.PDF,canadian_reference_product,What is the Canadian Reference Product?,"NIGHTTIME COLD, COUGH & FLU",85
sample_nocs/0000021118.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021118.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000021118.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Bruce Randall,99
sample_nocs/0000021118.PDF,dossier_id,What is the Dossier Id?,E163055,98
sample_nocs/0000021118.PDF,submission_no,What is the Submission Number?,192563,99
sample_nocs/0000021118.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,74
sample_nocs/0000021118.PDF,product_name,What is the Product name?,"NIGHTTIME COLD, COUGH & FLU",94
sample_nocs/0000021118.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02457946, Oral, Liquid Gel Capsule, 200 mg Ibuprofen/25 mg",28
sample_nocs/0000021118.PDF,species,What is the species?,NA,NA
sample_nocs/0000021118.PDF,noc_date,What is the date of the document?,SEP 23 2016,97
sample_nocs/0000021118.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Ibuprofen, Diphenhydramine hydrochloride",86
sample_nocs/0000021172.PDF,canadian_reference_product,What is the Canadian Reference Product?,Risperidone,0
sample_nocs/0000021172.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000021172.PDF,noc_reason,What was the reason for the submission?,Change to the drug product manufacturing process.,61
sample_nocs/0000021172.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021172.PDF,dossier_id,What is the Dossier Id?,e125852,96
sample_nocs/0000021172.PDF,submission_no,What is the Submission Number?,192878,99
sample_nocs/0000021172.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,58.999996185302734
sample_nocs/0000021172.PDF,product_name,What is the Product name?,Risperidai CONSTA,7
sample_nocs/0000021172.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intramuscular, Kit, Powder for Suspension (Sustained- Release)",28
sample_nocs/0000021172.PDF,species,What is the species?,NA,NA
sample_nocs/0000021172.PDF,noc_date,What is the date of the document?,OCT 11 2016,73
sample_nocs/0000021172.PDF,medicinal_ingredients,What are the medicinal ingredients?,Risperidone,98
sample_nocs/0000021257.PDF,canadian_reference_product,What is the Canadian Reference Product?,NEXIUM 24HR,95
sample_nocs/0000021257.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021257.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000021257.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Bruce Randall,99
sample_nocs/0000021257.PDF,dossier_id,What is the Dossier Id?,E167884,96
sample_nocs/0000021257.PDF,submission_no,What is the Submission Number?,175512,98
sample_nocs/0000021257.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Consumer Healthcare,38
sample_nocs/0000021257.PDF,product_name,What is the Product name?,NEXIUM 24HR,96
sample_nocs/0000021257.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02444712, Oral, Capsule (Delayed-release), 20mg",47
sample_nocs/0000021257.PDF,species,What is the species?,NA,NA
sample_nocs/0000021257.PDF,noc_date,What is the date of the document?,AUG 4 2016,65
sample_nocs/0000021257.PDF,medicinal_ingredients,What are the medicinal ingredients?,Esomeprazole,94
sample_nocs/0000021331.PDF,canadian_reference_product,What is the Canadian Reference Product?,PMS-CHOLESTYRAMINE,82
sample_nocs/0000021331.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000021331.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif -accord de licence entre deux sociétés,7
sample_nocs/0000021331.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,93
sample_nocs/0000021331.PDF,dossier_id,What is the Dossier Id?,197876,95
sample_nocs/0000021331.PDF,submission_no,What is the Submission Number?,197876,99
sample_nocs/0000021331.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,68
sample_nocs/0000021331.PDF,product_name,What is the Product name?,PMS-CHOLESTYRAMINE,96
sample_nocs/0000021331.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02458365 (oral, powder for suspension, 4g/5g)",56
sample_nocs/0000021331.PDF,species,What is the species?,NA,NA
sample_nocs/0000021331.PDF,noc_date,What is the date of the document?,OCT 28 2016,91
sample_nocs/0000021331.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cholestyramine Resin,96
sample_nocs/0000021438.PDF,canadian_reference_product,What is the Canadian Reference Product?,CYTOVENE,98
sample_nocs/0000021438.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000021438.PDF,noc_reason,What was the reason for the submission?,Addition of new drug product manufacturing and QC testing site,93
sample_nocs/0000021438.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021438.PDF,dossier_id,What is the Dossier Id?,p126661,98
sample_nocs/0000021438.PDF,submission_no,What is the Submission Number?,194642,99
sample_nocs/0000021438.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,99
sample_nocs/0000021438.PDF,product_name,What is the Product name?,CYTOVENE,98
sample_nocs/0000021438.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 500 mg/vial",89
sample_nocs/0000021438.PDF,species,What is the species?,NA,NA
sample_nocs/0000021438.PDF,noc_date,What is the date of the document?,DEC 02 2016,95
sample_nocs/0000021438.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ganciclovir (supplied as Ganciclovir Sodium),79
sample_nocs/0000021446.PDF,canadian_reference_product,What is the Canadian Reference Product?,TRAMADOL/ ACETAMINOPHEN,36
sample_nocs/0000021446.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000021446.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,16
sample_nocs/0000021446.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021446.PDF,dossier_id,What is the Dossier Id?,p176992,97
sample_nocs/0000021446.PDF,submission_no,What is the Submission Number?,199104,99
sample_nocs/0000021446.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sivem Pharmaceuticals ULC,92
sample_nocs/0000021446.PDF,product_name,What is the Product name?,TRAMADOL / ACETAMINOPHEN,88
sample_nocs/0000021446.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02429969,71
sample_nocs/0000021446.PDF,species,What is the species?,NA,NA
sample_nocs/0000021446.PDF,noc_date,What is the date of the document?,NOV 29 2016,89
sample_nocs/0000021446.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Acetaminophen, Tramadol Hydrochloride",89
sample_nocs/0000021452.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000021452.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000021452.PDF,noc_reason,What was the reason for the submission?,Administrative,96
sample_nocs/0000021452.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021452.PDF,dossier_id,What is the Dossier Id?,e129280,95
sample_nocs/0000021452.PDF,submission_no,What is the Submission Number?,199396,99
sample_nocs/0000021452.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,58
sample_nocs/0000021452.PDF,product_name,What is the Product name?,ASA DAILY LOW DOSE,96
sample_nocs/0000021452.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02394790 (oral, chewable tablet, 81mg)",73
sample_nocs/0000021452.PDF,species,What is the species?,NA,NA
sample_nocs/0000021452.PDF,noc_date,What is the date of the document?,DEC 1 2016,80
sample_nocs/0000021452.PDF,medicinal_ingredients,What are the medicinal ingredients?,Acetylsalicylic Acid,92
sample_nocs/0000021468.PDF,canadian_reference_product,What is the Canadian Reference Product?,STELARA,96
sample_nocs/0000021468.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021468.PDF,noc_reason,What was the reason for the submission?,New Indication,42
sample_nocs/0000021468.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000021468.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000021468.PDF,submission_no,What is the Submission Number?,190732,99
sample_nocs/0000021468.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,68
sample_nocs/0000021468.PDF,product_name,What is the Product name?,STELARA,99
sample_nocs/0000021468.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02459671 IV, SOL, 5 mg/mL",81
sample_nocs/0000021468.PDF,species,What is the species?,NA,NA
sample_nocs/0000021468.PDF,noc_date,What is the date of the document?,DEC 2 2016,94
sample_nocs/0000021468.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ustekinumab,78
sample_nocs/0000021517.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Aureomycin 220 G (Zoetis Canada Inc., DIN 02242693)",68
sample_nocs/0000021517.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021517.PDF,noc_reason,What was the reason for the submission?,Removal of growth promotion claim,83
sample_nocs/0000021517.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,91
sample_nocs/0000021517.PDF,dossier_id,What is the Dossier Id?,v187515,95
sample_nocs/0000021517.PDF,submission_no,What is the Submission Number?,191572,98
sample_nocs/0000021517.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bio Agri Mix Limited Partnership,95
sample_nocs/0000021517.PDF,product_name,What is the Product name?,CHLOR 100,96
sample_nocs/0000021517.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00698210, Oral, Medicated Premix, 220 g/kg",56
sample_nocs/0000021517.PDF,species,What is the species?,"Swine, Cattle, Turkey, Lambs",92
sample_nocs/0000021517.PDF,noc_date,What is the date of the document?,DEC 20 2016,72
sample_nocs/0000021517.PDF,medicinal_ingredients,What are the medicinal ingredients?,Chlortetracycline (as chlortetracycline hydrochloride),85
sample_nocs/0000021529.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Levofloxacin in 5% Dextrose Injection, Hospira Healthcare Corporation, Canada",34
sample_nocs/0000021529.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000021529.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000021529.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021529.PDF,dossier_id,What is the Dossier Id?,p190858,93
sample_nocs/0000021529.PDF,submission_no,What is the Submission Number?,190858,98
sample_nocs/0000021529.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,73
sample_nocs/0000021529.PDF,product_name,What is the Product name?,Levofloxacin in 5% Dextrose Injection,92
sample_nocs/0000021529.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02460122, Intravenous, Solution, 5 mg/mL",66
sample_nocs/0000021529.PDF,species,What is the species?,NA,NA
sample_nocs/0000021529.PDF,noc_date,What is the date of the document?,DEC 22 2016,90
sample_nocs/0000021529.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levofloxacin,91
sample_nocs/0000021897.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000021897.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000021897.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph/ Mise a jour de la monographie de produit,23
sample_nocs/0000021897.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000021897.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000021897.PDF,submission_no,What is the Submission Number?,193785,99
sample_nocs/0000021897.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,98
sample_nocs/0000021897.PDF,product_name,What is the Product name?,KADCYLA,89
sample_nocs/0000021897.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, PWSO, 20 mg/mL",82
sample_nocs/0000021897.PDF,species,What is the species?,NA,NA
sample_nocs/0000021897.PDF,noc_date,What is the date of the document?,MAR 10 2017,81
sample_nocs/0000021897.PDF,medicinal_ingredients,What are the medicinal ingredients?,Trastuzumab emtansine,97
sample_nocs/0000021958.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEVTERA,96
sample_nocs/0000021958.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000021958.PDF,noc_reason,What was the reason for the submission?,To increase the drug product's shelf life specifications for two individual and total degradation products,80
sample_nocs/0000021958.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021958.PDF,dossier_id,What is the Dossier Id?,e174396,97
sample_nocs/0000021958.PDF,submission_no,What is the Submission Number?,196769,99
sample_nocs/0000021958.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Basilea Pharmaceutica International AG,98
sample_nocs/0000021958.PDF,product_name,What is the Product name?,ZEVTERA,97
sample_nocs/0000021958.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 500 mg/vial",88
sample_nocs/0000021958.PDF,species,What is the species?,NA,NA
sample_nocs/0000021958.PDF,noc_date,What is the date of the document?,FEB 07 2017,93
sample_nocs/0000021958.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ceftobiprole (supplied as ceftobiprole medocaril sodium),50
sample_nocs/0000021991.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Andriol, Organon Canada Ltd., Canada",65
sample_nocs/0000021991.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000021991.PDF,noc_reason,What was the reason for the submission?,Revisions to the labels,98
sample_nocs/0000021991.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000021991.PDF,dossier_id,What is the Dossier Id?,e156618,96
sample_nocs/0000021991.PDF,submission_no,What is the Submission Number?,202290,99
sample_nocs/0000021991.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Taro Pharmaceuticals Inc.,93
sample_nocs/0000021991.PDF,product_name,What is the Product name?,Taro-Testosterone,97
sample_nocs/0000021991.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule, 40 mg",73
sample_nocs/0000021991.PDF,species,What is the species?,NA,NA
sample_nocs/0000021991.PDF,noc_date,What is the date of the document?,MAR 14 2017,95
sample_nocs/0000021991.PDF,medicinal_ingredients,What are the medicinal ingredients?,Testosterone Undecanoate,99
sample_nocs/0000022040.PDF,canadian_reference_product,What is the Canadian Reference Product?,Methotrexate,76
sample_nocs/0000022040.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000022040.PDF,noc_reason,What was the reason for the submission?,To remove information pertaining to the injection formulation from the Product Monograph,49
sample_nocs/0000022040.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022040.PDF,dossier_id,What is the Dossier Id?,E133862,98
sample_nocs/0000022040.PDF,submission_no,What is the Submission Number?,200730,99
sample_nocs/0000022040.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,83
sample_nocs/0000022040.PDF,product_name,What is the Product name?,Methotrexate,46
sample_nocs/0000022040.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 2.5 mg",88
sample_nocs/0000022040.PDF,species,What is the species?,NA,NA
sample_nocs/0000022040.PDF,noc_date,What is the date of the document?,MAR 06 2017,65
sample_nocs/0000022040.PDF,medicinal_ingredients,What are the medicinal ingredients?,Methotrexate (supplied as methotrexate disodium),58
sample_nocs/0000022055.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000022055.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000022055.PDF,noc_reason,What was the reason for the submission?,Administrative: Transfer of Drug Identification Numbers / Administratif: Transfert d'identification numérique des drogues,26
sample_nocs/0000022055.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022055.PDF,dossier_id,What is the Dossier Id?,e125722,90
sample_nocs/0000022055.PDF,submission_no,What is the Submission Number?,202905,99
sample_nocs/0000022055.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,82
sample_nocs/0000022055.PDF,product_name,What is the Product name?,CILOXAN,92
sample_nocs/0000022055.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",01945270,66
sample_nocs/0000022055.PDF,species,What is the species?,NA,NA
sample_nocs/0000022055.PDF,noc_date,What is the date of the document?,APR 03 2017,94
sample_nocs/0000022055.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin Hydrochloride,95
sample_nocs/0000022185.PDF,canadian_reference_product,What is the Canadian Reference Product?,DIPROSONE,45
sample_nocs/0000022185.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000022185.PDF,noc_reason,What was the reason for the submission?,Change in the drug product manufacturing and testing site.,73
sample_nocs/0000022185.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022185.PDF,dossier_id,What is the Dossier Id?,E144901,97
sample_nocs/0000022185.PDF,submission_no,What is the Submission Number?,198311,99
sample_nocs/0000022185.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,54.000003814697266
sample_nocs/0000022185.PDF,product_name,What is the Product name?,DIPROSONE,97
sample_nocs/0000022185.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Topical, Cream, 0.05%",93
sample_nocs/0000022185.PDF,species,What is the species?,NA,NA
sample_nocs/0000022185.PDF,noc_date,What is the date of the document?,MAY 03 2017,99
sample_nocs/0000022185.PDF,medicinal_ingredients,What are the medicinal ingredients?,Betamethasone dipropionate,97
sample_nocs/0000022200.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Prograf, Astellas Pharma Canada Inc., Canada",41
sample_nocs/0000022200.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000022200.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,16
sample_nocs/0000022200.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022200.PDF,dossier_id,What is the Dossier Id?,199887,68
sample_nocs/0000022200.PDF,submission_no,What is the Submission Number?,199889,99
sample_nocs/0000022200.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000022200.PDF,product_name,What is the Product name?,JAMP-TACROLIMUS,78
sample_nocs/0000022200.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02460238,52
sample_nocs/0000022200.PDF,species,What is the species?,NA,NA
sample_nocs/0000022200.PDF,noc_date,What is the date of the document?,APR 11 2017,79
sample_nocs/0000022200.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tacrolimus,98
sample_nocs/0000022217.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Didrocal, Procter and Gamble Pharmaceuticals Canada, Inc., Canada",9
sample_nocs/0000022217.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000022217.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph regarding Osteonecrosis of the Jaw (ONJ) in response to an Advisement Letter.,58.999996185302734
sample_nocs/0000022217.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022217.PDF,dossier_id,What is the Dossier Id?,P124075,98
sample_nocs/0000022217.PDF,submission_no,What is the Submission Number?,201597,99
sample_nocs/0000022217.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ACTavis  Pharma Company,60.000003814697266
sample_nocs/0000022217.PDF,product_name,What is the Product name?,ACT ETIDROCAL,83
sample_nocs/0000022217.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 400 mg / 1250 mg",76
sample_nocs/0000022217.PDF,species,What is the species?,NA,NA
sample_nocs/0000022217.PDF,noc_date,What is the date of the document?,APR 12 2017,86
sample_nocs/0000022217.PDF,medicinal_ingredients,What are the medicinal ingredients?,Etidronate disodium / Calcium carbonate,97
sample_nocs/0000022331.PDF,canadian_reference_product,What is the Canadian Reference Product?,INTRALIPID 10% INTRALIPID 20%,39
sample_nocs/0000022331.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000022331.PDF,noc_reason,What was the reason for the submission?,To add a Patient Medication Information Section to the Product Monograph and Package Insert.,39
sample_nocs/0000022331.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022331.PDF,dossier_id,What is the Dossier Id?,e122902,96
sample_nocs/0000022331.PDF,submission_no,What is the Submission Number?,203141,99
sample_nocs/0000022331.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd.,58.999996185302734
sample_nocs/0000022331.PDF,product_name,What is the Product name?,INTRALIPID 10% INTRALIPID 20% INTRALIPID 30%,77
sample_nocs/0000022331.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Emulsion, 10% / W/V",85
sample_nocs/0000022331.PDF,species,What is the species?,NA,NA
sample_nocs/0000022331.PDF,noc_date,What is the date of the document?,MAY 12 2017,98
sample_nocs/0000022331.PDF,medicinal_ingredients,What are the medicinal ingredients?,Soybean Oil,99
sample_nocs/0000022420.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000022420.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000022420.PDF,noc_reason,What was the reason for the submission?,Manufacturing Changes,98
sample_nocs/0000022420.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,91
sample_nocs/0000022420.PDF,dossier_id,What is the Dossier Id?,v175167,95
sample_nocs/0000022420.PDF,submission_no,What is the Submission Number?,201435,99
sample_nocs/0000022420.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Intervet Canada Corp.,96
sample_nocs/0000022420.PDF,product_name,What is the Product name?,SALIX,97
sample_nocs/0000022420.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00116238, Intravenous, Intramuscular, Solution, 50 mg/mL",82
sample_nocs/0000022420.PDF,species,What is the species?,"Dogs, Cats, Horses, Cattle",96
sample_nocs/0000022420.PDF,noc_date,What is the date of the document?,MAY 26 2017,99
sample_nocs/0000022420.PDF,medicinal_ingredients,What are the medicinal ingredients?,Furosemide,99
sample_nocs/0000022454.PDF,canadian_reference_product,What is the Canadian Reference Product?,MOVANTIK,94
sample_nocs/0000022454.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000022454.PDF,noc_reason,What was the reason for the submission?,Additional alternate manufacturing and testing site for the drug substance,98
sample_nocs/0000022454.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kimby N. Barton,84
sample_nocs/0000022454.PDF,dossier_id,What is the Dossier Id?,e158636,96
sample_nocs/0000022454.PDF,submission_no,What is the Submission Number?,201180,99
sample_nocs/0000022454.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AstraZeneca Canada Inc.,70
sample_nocs/0000022454.PDF,product_name,What is the Product name?,MOVANTIK,99
sample_nocs/0000022454.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 12.5 mg",88
sample_nocs/0000022454.PDF,species,What is the species?,NA,NA
sample_nocs/0000022454.PDF,noc_date,What is the date of the document?,JUN 20 2017,86
sample_nocs/0000022454.PDF,medicinal_ingredients,What are the medicinal ingredients?,Naloxegol (supplied as naloxegol oxalate),58.999996185302734
sample_nocs/0000022491.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Maxalt Smelt, Merck Sharp & Dohme BV, The Netherlands",63
sample_nocs/0000022491.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000022491.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,15.000000953674316
sample_nocs/0000022491.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000022491.PDF,dossier_id,What is the Dossier Id?,e153424,92
sample_nocs/0000022491.PDF,submission_no,What is the Submission Number?,205473,98
sample_nocs/0000022491.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000022491.PDF,product_name,What is the Product name?,JAMP-RIZATRIPTAN ODT,83
sample_nocs/0000022491.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02465086 (oral, orally disintegrating tablet, 5mg)",52
sample_nocs/0000022491.PDF,species,What is the species?,NA,NA
sample_nocs/0000022491.PDF,noc_date,What is the date of the document?,JUN 16 2017,89
sample_nocs/0000022491.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Rizatriptan, supplied as Rizatriptan Benzoate",90
sample_nocs/0000022523.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lipidil EZ, Fournier Pharma Inc., Canada",62
sample_nocs/0000022523.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000022523.PDF,noc_reason,What was the reason for the submission?,abrégée de drogue nouvelle,34
sample_nocs/0000022523.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kimby N. Barton,82
sample_nocs/0000022523.PDF,dossier_id,What is the Dossier Id?,186636,46
sample_nocs/0000022523.PDF,submission_no,What is the Submission Number?,186636,95
sample_nocs/0000022523.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mint Pharmaceuticals Inc.,97
sample_nocs/0000022523.PDF,product_name,What is the Product name?,Mint-Fenofibrate E,95
sample_nocs/0000022523.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02465167, Oral, Tablet, 145 mg",81
sample_nocs/0000022523.PDF,species,What is the species?,NA,NA
sample_nocs/0000022523.PDF,noc_date,What is the date of the document?,JUN 21 2017,73
sample_nocs/0000022523.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fenofibrate,95
sample_nocs/0000022559.PDF,canadian_reference_product,What is the Canadian Reference Product?,Docetaxel Injection USP,97
sample_nocs/0000022559.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000022559.PDF,noc_reason,What was the reason for the submission?,Alternate drug substance manufacturing site,98
sample_nocs/0000022559.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kimby N. Barton,82
sample_nocs/0000022559.PDF,dossier_id,What is the Dossier Id?,e116151,98
sample_nocs/0000022559.PDF,submission_no,What is the Submission Number?,201500,99
sample_nocs/0000022559.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,89
sample_nocs/0000022559.PDF,product_name,What is the Product name?,Docetaxel Injection USP,98
sample_nocs/0000022559.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, 10 mg/mL",52.999996185302734
sample_nocs/0000022559.PDF,species,What is the species?,NA,NA
sample_nocs/0000022559.PDF,noc_date,What is the date of the document?,JUL 10 2017,83
sample_nocs/0000022559.PDF,medicinal_ingredients,What are the medicinal ingredients?,Docetaxel,99
sample_nocs/0000022718.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Atripla, Bristol-Myers Squibb & Gilead Sciences, LLC., Canada",55
sample_nocs/0000022718.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000022718.PDF,noc_reason,What was the reason for the submission?,Change in the drug substance supplier,80
sample_nocs/0000022718.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,70
sample_nocs/0000022718.PDF,dossier_id,What is the Dossier Id?,e151693,91
sample_nocs/0000022718.PDF,submission_no,What is the Submission Number?,198372,99
sample_nocs/0000022718.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,62
sample_nocs/0000022718.PDF,product_name,What is the Product name?,Teva-Efavirenz/Emtricitabine/Tenofovir,70
sample_nocs/0000022718.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 600 mg/ 200 mg/ 300 mg",32
sample_nocs/0000022718.PDF,species,What is the species?,NA,NA
sample_nocs/0000022718.PDF,noc_date,What is the date of the document?,JUL 26 2017,85
sample_nocs/0000022718.PDF,medicinal_ingredients,What are the medicinal ingredients?,Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,79
sample_nocs/0000022724.PDF,canadian_reference_product,What is the Canadian Reference Product?,DUAVIVE,83
sample_nocs/0000022724.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000022724.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph reflecting the results of a drug-drug interaction (DDI) study.,72
sample_nocs/0000022724.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,66
sample_nocs/0000022724.PDF,dossier_id,What is the Dossier Id?,E157762,97
sample_nocs/0000022724.PDF,submission_no,What is the Submission Number?,199318,99
sample_nocs/0000022724.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,84
sample_nocs/0000022724.PDF,product_name,What is the Product name?,DUAVIVE,88
sample_nocs/0000022724.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 0.45 mg and 20 mg",84
sample_nocs/0000022724.PDF,species,What is the species?,NA,NA
sample_nocs/0000022724.PDF,noc_date,What is the date of the document?,JUL 20 2017,71
sample_nocs/0000022724.PDF,medicinal_ingredients,What are the medicinal ingredients?,Conjugated estrogens and bazedoxifene (suppled as bazedoxifene acetate),66
sample_nocs/0000022849.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Taxol, Bristol-Myers Squibb Canada",31
sample_nocs/0000022849.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000022849.PDF,noc_reason,What was the reason for the submission?,Administrative,64
sample_nocs/0000022849.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,72
sample_nocs/0000022849.PDF,dossier_id,What is the Dossier Id?,e120541,94
sample_nocs/0000022849.PDF,submission_no,What is the Submission Number?,207276,97
sample_nocs/0000022849.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,85
sample_nocs/0000022849.PDF,product_name,What is the Product name?,PACLITAXEL FOR INJECTION,89
sample_nocs/0000022849.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02296624 (intravenous, solution, 6 mg/mL)",37
sample_nocs/0000022849.PDF,species,What is the species?,NA,NA
sample_nocs/0000022849.PDF,noc_date,What is the date of the document?,AUG 11 2017,58
sample_nocs/0000022849.PDF,medicinal_ingredients,What are the medicinal ingredients?,Paclitaxel,92
sample_nocs/0000022980.PDF,canadian_reference_product,What is the Canadian Reference Product?,LMD 10% IN 0.9% SODIUM CHLORIDE,75
sample_nocs/0000022980.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000022980.PDF,noc_reason,What was the reason for the submission?,Administrative,54.000003814697266
sample_nocs/0000022980.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,83
sample_nocs/0000022980.PDF,dossier_id,What is the Dossier Id?,e113071,95
sample_nocs/0000022980.PDF,submission_no,What is the Submission Number?,208703,98
sample_nocs/0000022980.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,88
sample_nocs/0000022980.PDF,product_name,What is the Product name?,LMD 10% IN 0.9% SODIUM CHLORIDE,85
sample_nocs/0000022980.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",00224227,92
sample_nocs/0000022980.PDF,species,What is the species?,NA,NA
sample_nocs/0000022980.PDF,noc_date,What is the date of the document?,SEP 20 2017,87
sample_nocs/0000022980.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Dextran, Sodium Chloride",91
sample_nocs/0000023031.PDF,canadian_reference_product,What is the Canadian Reference Product?,CETROTIDE,68
sample_nocs/0000023031.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000023031.PDF,noc_reason,What was the reason for the submission?,Update the Product Monograph and Package Insert to remove references to the discontinued 3 mg strength formulation.,71
sample_nocs/0000023031.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000023031.PDF,dossier_id,What is the Dossier Id?,E126924,98
sample_nocs/0000023031.PDF,submission_no,What is the Submission Number?,208150,100
sample_nocs/0000023031.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,EMD Serono,57
sample_nocs/0000023031.PDF,product_name,What is the Product name?,CETROTIDE,96
sample_nocs/0000023031.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Subcutaneous, Powder for Solution, 0.25 mg/vial",80
sample_nocs/0000023031.PDF,species,What is the species?,NA,NA
sample_nocs/0000023031.PDF,noc_date,What is the date of the document?,SEP 27 2017,98
sample_nocs/0000023031.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cetrorelix (supplied as cetrorelix acetate),68
sample_nocs/0000023035.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cipralex, Lundbeck Canada Inc.",34
sample_nocs/0000023035.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000023035.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,17
sample_nocs/0000023035.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,72
sample_nocs/0000023035.PDF,dossier_id,What is the Dossier Id?,e176931,91
sample_nocs/0000023035.PDF,submission_no,What is the Submission Number?,208547,98
sample_nocs/0000023035.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jamp Pharma Corporation,98
sample_nocs/0000023035.PDF,product_name,What is the Product name?,JAMP-ESCITALOPRAM,77
sample_nocs/0000023035.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02429780 (oral, tablet, 10mg)",79
sample_nocs/0000023035.PDF,species,What is the species?,NA,NA
sample_nocs/0000023035.PDF,noc_date,What is the date of the document?,SEP 2 2017,46
sample_nocs/0000023035.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Escitalopram, supplied as Escitalopram Oxalate",91
sample_nocs/0000023077.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Diclectin, Duchesnay Inc., Canada",48
sample_nocs/0000023077.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000023077.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000023077.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,70
sample_nocs/0000023077.PDF,dossier_id,What is the Dossier Id?,p108249,98
sample_nocs/0000023077.PDF,submission_no,What is the Submission Number?,108249,99
sample_nocs/0000023077.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,68
sample_nocs/0000023077.PDF,product_name,What is the Product name?,Teva-Doxylamine/Pyridoxine DR,88
sample_nocs/0000023077.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02304503, Oral, Tablet (delayed-release), 10 mg/10 mg",33
sample_nocs/0000023077.PDF,species,What is the species?,NA,NA
sample_nocs/0000023077.PDF,noc_date,What is the date of the document?,OCT 05 2017,90
sample_nocs/0000023077.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxylamine Succinate / Pyridoxine Hydrochloride,86
sample_nocs/0000023095.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZYKADIA,72
sample_nocs/0000023095.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,92
sample_nocs/0000023095.PDF,noc_reason,What was the reason for the submission?,"Final report for study CLDK378X2101 as per the commitment in the Letter of Undertaking (LOU) dated March 20, 2015.",46
sample_nocs/0000023095.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000023095.PDF,dossier_id,What is the Dossier Id?,E162920,98
sample_nocs/0000023095.PDF,submission_no,What is the Submission Number?,201361,98
sample_nocs/0000023095.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,85
sample_nocs/0000023095.PDF,product_name,What is the Product name?,ZYKADIA,80
sample_nocs/0000023095.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule, 150 mg",85
sample_nocs/0000023095.PDF,species,What is the species?,NA,NA
sample_nocs/0000023095.PDF,noc_date,What is the date of the document?,OCT 20 2017,68
sample_nocs/0000023095.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ceritinib,98
sample_nocs/0000023265.PDF,canadian_reference_product,What is the Canadian Reference Product?,ACTEMRA,58.999996185302734
sample_nocs/0000023265.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000023265.PDF,noc_reason,What was the reason for the submission?,New Indication / Nouvelle indication,30.000001907348633
sample_nocs/0000023265.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,100
sample_nocs/0000023265.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000023265.PDF,submission_no,What is the Submission Number?,204251,99
sample_nocs/0000023265.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffman-La Roche Limited,99
sample_nocs/0000023265.PDF,product_name,What is the Product name?,ACTEMRA,96
sample_nocs/0000023265.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 162 mg/0.9mL",83
sample_nocs/0000023265.PDF,species,What is the species?,NA,NA
sample_nocs/0000023265.PDF,noc_date,What is the date of the document?,NOV 14 2017,83
sample_nocs/0000023265.PDF,medicinal_ingredients,What are the medicinal ingredients?,tocilizumab,96
sample_nocs/0000023307.PDF,canadian_reference_product,What is the Canadian Reference Product?,APO-NORTRIPTYLINE,67
sample_nocs/0000023307.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000023307.PDF,noc_reason,What was the reason for the submission?,Change in specifications,99
sample_nocs/0000023307.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000023307.PDF,dossier_id,What is the Dossier Id?,e133219,96
sample_nocs/0000023307.PDF,submission_no,What is the Submission Number?,205519,99
sample_nocs/0000023307.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,81
sample_nocs/0000023307.PDF,product_name,What is the Product name?,APO-NORTRIPTYLINE,92
sample_nocs/0000023307.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule, 10 mg",85
sample_nocs/0000023307.PDF,species,What is the species?,NA,NA
sample_nocs/0000023307.PDF,noc_date,What is the date of the document?,NOV 28 2017,82
sample_nocs/0000023307.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nortriptyline hydrochloride,98
sample_nocs/0000023379.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Manerix, Hoffmann-La Roche Limited",55
sample_nocs/0000023379.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000023379.PDF,noc_reason,What was the reason for the submission?,Labelling Assessment and Administrative Transfer of Drug Identification Number (DIN),89
sample_nocs/0000023379.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,67
sample_nocs/0000023379.PDF,dossier_id,What is the Dossier Id?,e125499,96
sample_nocs/0000023379.PDF,submission_no,What is the Submission Number?,210015,99
sample_nocs/0000023379.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Inc,55
sample_nocs/0000023379.PDF,product_name,What is the Product name?,Moclobemide,99
sample_nocs/0000023379.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02232148, Oral, Tablet, 100 mg",91
sample_nocs/0000023379.PDF,species,What is the species?,NA,NA
sample_nocs/0000023379.PDF,noc_date,What is the date of the document?,NOV 14 2017,88
sample_nocs/0000023379.PDF,medicinal_ingredients,What are the medicinal ingredients?,Moclobemide,99
sample_nocs/0000023380.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Norvasc, Pfizer Canada Inc.",34
sample_nocs/0000023380.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000023380.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,11
sample_nocs/0000023380.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,74
sample_nocs/0000023380.PDF,dossier_id,What is the Dossier Id?,e208443,94
sample_nocs/0000023380.PDF,submission_no,What is the Submission Number?,210071,99
sample_nocs/0000023380.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,45
sample_nocs/0000023380.PDF,product_name,What is the Product name?,PHARMA-AMLODIPINE,95
sample_nocs/0000023380.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02469022 (oral, tablet, 2.5 mg)",77
sample_nocs/0000023380.PDF,species,What is the species?,NA,NA
sample_nocs/0000023380.PDF,noc_date,What is the date of the document?,NOV 15 2017,90
sample_nocs/0000023380.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Amlodipine, supplied as Amlodipine Besylate",92
sample_nocs/0000023544.PDF,canadian_reference_product,What is the Canadian Reference Product?,TOVIAZ,95
sample_nocs/0000023544.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000023544.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph based on a Pediatric Pharmacokinetic Study,52
sample_nocs/0000023544.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000023544.PDF,dossier_id,What is the Dossier Id?,E142326,98
sample_nocs/0000023544.PDF,submission_no,What is the Submission Number?,202700,99
sample_nocs/0000023544.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,81
sample_nocs/0000023544.PDF,product_name,What is the Product name?,TOVIAZ,98
sample_nocs/0000023544.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablets (Extended-Release) 4 mg",71
sample_nocs/0000023544.PDF,species,What is the species?,NA,NA
sample_nocs/0000023544.PDF,noc_date,What is the date of the document?,DEC 15 2017,92
sample_nocs/0000023544.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fesoterodine fumarate,97
sample_nocs/0000023568.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Effexor XR, Wyeth Canada",56
sample_nocs/0000023568.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000023568.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre two companies,14
sample_nocs/0000023568.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,75
sample_nocs/0000023568.PDF,dossier_id,What is the Dossier Id?,p211793,64
sample_nocs/0000023568.PDF,submission_no,What is the Submission Number?,211793,93
sample_nocs/0000023568.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc,50
sample_nocs/0000023568.PDF,product_name,What is the Product name?,M-VENLAFAXINE XR,78
sample_nocs/0000023568.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02471280,54.000003814697266
sample_nocs/0000023568.PDF,species,What is the species?,NA,NA
sample_nocs/0000023568.PDF,noc_date,What is the date of the document?,DEC 28 2017,88
sample_nocs/0000023568.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Venlafaxine, supplied as Venlafaxine Hydrochloride",83
sample_nocs/0000024567.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000024567.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000024567.PDF,noc_reason,What was the reason for the submission?,Administrative,56
sample_nocs/0000024567.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,67
sample_nocs/0000024567.PDF,dossier_id,What is the Dossier Id?,e186494,87
sample_nocs/0000024567.PDF,submission_no,What is the Submission Number?,214192,99
sample_nocs/0000024567.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Shire Pharma Canada ULC,96
sample_nocs/0000024567.PDF,product_name,What is the Product name?,ONIVYDE,99
sample_nocs/0000024567.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02467135,52.999996185302734
sample_nocs/0000024567.PDF,species,What is the species?,NA,NA
sample_nocs/0000024567.PDF,noc_date,What is the date of the document?,APR 10 2018,67
sample_nocs/0000024567.PDF,medicinal_ingredients,What are the medicinal ingredients?,Irinotecan Hydrochloride supplied as Irinotecan Sucrose Octasulfate,73
sample_nocs/0000024923.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Coated Aspirin Daily Low Dose 81 mg, Bayer Inc., Canada",48
sample_nocs/0000024923.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000024923.PDF,noc_reason,What was the reason for the submission?,Alternate manufacturing site for the finished product,98
sample_nocs/0000024923.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000024923.PDF,dossier_id,What is the Dossier Id?,e120247,96
sample_nocs/0000024923.PDF,submission_no,What is the Submission Number?,205004,99
sample_nocs/0000024923.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,75
sample_nocs/0000024923.PDF,product_name,What is the Product name?,Entrophen,97
sample_nocs/0000024923.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet (Delayed-Release) 81 mg",42
sample_nocs/0000024923.PDF,species,What is the species?,NA,NA
sample_nocs/0000024923.PDF,noc_date,What is the date of the document?,MAY 15 2018,99
sample_nocs/0000024923.PDF,medicinal_ingredients,What are the medicinal ingredients?,Acetylsalicylic Acid,93
sample_nocs/0000025039.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ACTos, Takeda Canada Inc., Canada",19
sample_nocs/0000025039.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000025039.PDF,noc_reason,What was the reason for the submission?,Revisions to the product monograph,93
sample_nocs/0000025039.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000025039.PDF,dossier_id,What is the Dossier Id?,e122069,97
sample_nocs/0000025039.PDF,submission_no,What is the Submission Number?,215901,98
sample_nocs/0000025039.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ACTavis  Pharma Company,39
sample_nocs/0000025039.PDF,product_name,What is the Product name?,ACT PIOGLITAZONE,79
sample_nocs/0000025039.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 15 mg",87
sample_nocs/0000025039.PDF,species,What is the species?,NA,NA
sample_nocs/0000025039.PDF,noc_date,What is the date of the document?,MAY 29 2018,99
sample_nocs/0000025039.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pioglitazone hydrochloride,98
sample_nocs/0000025061.PDF,canadian_reference_product,What is the Canadian Reference Product?,"olmetec Plus, merck canadian Inc.",4
sample_nocs/0000025061.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000025061.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000025061.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000025061.PDF,dossier_id,What is the Dossier Id?,e208976,71
sample_nocs/0000025061.PDF,submission_no,What is the Submission Number?,208976,98
sample_nocs/0000025061.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,73
sample_nocs/0000025061.PDF,product_name,What is the Product name?,Auro-Olmesartan HCTZ,92
sample_nocs/0000025061.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02476487, Oral, Tablet, 20 mg/12.5 mg",84
sample_nocs/0000025061.PDF,species,What is the species?,NA,NA
sample_nocs/0000025061.PDF,noc_date,What is the date of the document?,MAY 31 2018,98
sample_nocs/0000025061.PDF,medicinal_ingredients,What are the medicinal ingredients?,Olmesartan Medoxomil and Hydrochlorothiazide,92
sample_nocs/0000025140.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Coversyl, Servier Canada Inc., Canada",41
sample_nocs/0000025140.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000025140.PDF,noc_reason,What was the reason for the submission?,Licensing agreement between two companies and revisions to the labels,98
sample_nocs/0000025140.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000025140.PDF,dossier_id,What is the Dossier Id?,e215532,80
sample_nocs/0000025140.PDF,submission_no,What is the Submission Number?,215532,98
sample_nocs/0000025140.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mint Pharmaceuticals Inc.,86
sample_nocs/0000025140.PDF,product_name,What is the Product name?,Mint-Perindopril,98
sample_nocs/0000025140.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02476762, Oral, Tablet, 2 mg",89
sample_nocs/0000025140.PDF,species,What is the species?,NA,NA
sample_nocs/0000025140.PDF,noc_date,What is the date of the document?,JUN 4 2018,27.000001907348633
sample_nocs/0000025140.PDF,medicinal_ingredients,What are the medicinal ingredients?,Perindopril Erbumine,96
sample_nocs/0000025347.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Sublinox, Meda Valeant Pharma Canada Inc., Canada",55
sample_nocs/0000025347.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000025347.PDF,noc_reason,What was the reason for the submission?,Revised labels,99
sample_nocs/0000025347.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,69
sample_nocs/0000025347.PDF,dossier_id,What is the Dossier Id?,E174228,99
sample_nocs/0000025347.PDF,submission_no,What is the Submission Number?,213240,99
sample_nocs/0000025347.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,70
sample_nocs/0000025347.PDF,product_name,What is the Product name?,PMS-ZOLPIDEM ODT,96
sample_nocs/0000025347.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Sublingual, Tablet (orally disintegrating), 5 mg",72
sample_nocs/0000025347.PDF,species,What is the species?,NA,NA
sample_nocs/0000025347.PDF,noc_date,What is the date of the document?,MAR 15 2018,97
sample_nocs/0000025347.PDF,medicinal_ingredients,What are the medicinal ingredients?,Zolpidem Tartrate,85
sample_nocs/0000025502.PDF,canadian_reference_product,What is the Canadian Reference Product?,DALACIN C FLAVOURED GRANULES,93
sample_nocs/0000025502.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000025502.PDF,noc_reason,What was the reason for the submission?,Updates to the action and clinical pharmacology and microbiology sections of the pm.,50
sample_nocs/0000025502.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000025502.PDF,dossier_id,What is the Dossier Id?,e131745,96
sample_nocs/0000025502.PDF,submission_no,What is the Submission Number?,210068,99
sample_nocs/0000025502.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada Inc.,78
sample_nocs/0000025502.PDF,product_name,What is the Product name?,DALACIN C FLAVOURED GRANULES,96
sample_nocs/0000025502.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Powder for solution, 75 mg / 5 mL",61
sample_nocs/0000025502.PDF,species,What is the species?,NA,NA
sample_nocs/0000025502.PDF,noc_date,What is the date of the document?,JUN 25 2018,83
sample_nocs/0000025502.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clindamycin Palmitate Hydrochloride,97
sample_nocs/0000025529.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Kivexa, GlaxoSmithKline Shire Canada",49
sample_nocs/0000025529.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000025529.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph,97
sample_nocs/0000025529.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000025529.PDF,dossier_id,What is the Dossier Id?,e149894,95
sample_nocs/0000025529.PDF,submission_no,What is the Submission Number?,216323,98
sample_nocs/0000025529.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,77
sample_nocs/0000025529.PDF,product_name,What is the Product name?,Apo-Abacavir-Lamivudine,94
sample_nocs/0000025529.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 600 mg/300 mg",54.000003814697266
sample_nocs/0000025529.PDF,species,What is the species?,NA,NA
sample_nocs/0000025529.PDF,noc_date,What is the date of the document?,JUN 29 2018,90
sample_nocs/0000025529.PDF,medicinal_ingredients,What are the medicinal ingredients?,Abacavir Sulfate/Lamivudine,94
sample_nocs/0000025598.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000025598.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000025598.PDF,noc_reason,What was the reason for the submission?,New manufacturing area and manufacturing scale-up / nouvel emplacement de fabrication et nouvelle échelle de fabrication,40
sample_nocs/0000025598.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,100
sample_nocs/0000025598.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000025598.PDF,submission_no,What is the Submission Number?,211896,98
sample_nocs/0000025598.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,56
sample_nocs/0000025598.PDF,product_name,What is the Product name?,Lantus,98
sample_nocs/0000025598.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A SC, SOL, 100 Unit/mL (10 mL vial)",73
sample_nocs/0000025598.PDF,species,What is the species?,NA,NA
sample_nocs/0000025598.PDF,noc_date,What is the date of the document?,JUL 162018,88
sample_nocs/0000025598.PDF,medicinal_ingredients,What are the medicinal ingredients?,insulin glargine,97
sample_nocs/0000025755.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Micardis, Boehringer Ingelheim (Canada) Ltd",85
sample_nocs/0000025755.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000025755.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,20
sample_nocs/0000025755.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000025755.PDF,dossier_id,What is the Dossier Id?,e155671,85
sample_nocs/0000025755.PDF,submission_no,What is the Submission Number?,217251,98
sample_nocs/0000025755.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alembic Pharmaceuticals Limited,47
sample_nocs/0000025755.PDF,product_name,What is the Product name?,ALEMBIC-TELMISARTAN,79
sample_nocs/0000025755.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02428245 (oral, tablet, 40 mg)",64
sample_nocs/0000025755.PDF,species,What is the species?,NA,NA
sample_nocs/0000025755.PDF,noc_date,What is the date of the document?,JUL 23 2018,92
sample_nocs/0000025755.PDF,medicinal_ingredients,What are the medicinal ingredients?,Telmisartan,97
sample_nocs/0000025864.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000025864.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000025864.PDF,noc_reason,What was the reason for the submission?,New presentation / nouvelle présentation,44
sample_nocs/0000025864.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000025864.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000025864.PDF,submission_no,What is the Submission Number?,214191,98
sample_nocs/0000025864.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Eli Lilly Canada Inc.,62
sample_nocs/0000025864.PDF,product_name,What is the Product name?,LARTRUVO,98
sample_nocs/0000025864.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02480271, IV, SOL, 190mg/19mL",90
sample_nocs/0000025864.PDF,species,What is the species?,NA,NA
sample_nocs/0000025864.PDF,noc_date,What is the date of the document?,AUG 22 2018,97
sample_nocs/0000025864.PDF,medicinal_ingredients,What are the medicinal ingredients?,olaratumab,54.000003814697266
sample_nocs/0000026082.PDF,canadian_reference_product,What is the Canadian Reference Product?,XERMELO,97
sample_nocs/0000026082.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000026082.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle citée en rubrique,18
sample_nocs/0000026082.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000026082.PDF,dossier_id,What is the Dossier Id?,E208730,98
sample_nocs/0000026082.PDF,submission_no,What is the Submission Number?,208730,98
sample_nocs/0000026082.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ipsen Biopharmaceuticals Canada Inc.,49
sample_nocs/0000026082.PDF,product_name,What is the Product name?,XERMELO,98
sample_nocs/0000026082.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02481553, Oral, Tablet, 250 mg",56
sample_nocs/0000026082.PDF,species,What is the species?,NA,NA
sample_nocs/0000026082.PDF,noc_date,What is the date of the document?,OCT 12 2018,58.999996185302734
sample_nocs/0000026082.PDF,medicinal_ingredients,What are the medicinal ingredients?,Telotristat ethyl (supplied as telotristat etiprate),84
sample_nocs/0000026126.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Diflucan, Pfizer Canada Inc., Canada",45
sample_nocs/0000026126.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000026126.PDF,noc_reason,What was the reason for the submission?,Updates to product monograph,94
sample_nocs/0000026126.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000026126.PDF,dossier_id,What is the Dossier Id?,p100422,96
sample_nocs/0000026126.PDF,submission_no,What is the Submission Number?,219109,99
sample_nocs/0000026126.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Incorporated,90
sample_nocs/0000026126.PDF,product_name,What is the Product name?,FLUCONAZOLE INJECTION and FLUCONAZOLE INJECTION SDZ,71
sample_nocs/0000026126.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, 2 mg / mL",55
sample_nocs/0000026126.PDF,species,What is the species?,NA,NA
sample_nocs/0000026126.PDF,noc_date,What is the date of the document?,OCT 9 2018,91
sample_nocs/0000026126.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluconazole,97
sample_nocs/0000026333.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000026333.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000026333.PDF,noc_reason,What was the reason for the submission?,new presentation / nouvelle presentation,83
sample_nocs/0000026333.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000026333.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000026333.PDF,submission_no,What is the Submission Number?,212299,98
sample_nocs/0000026333.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,98
sample_nocs/0000026333.PDF,product_name,What is the Product name?,Actemra,92
sample_nocs/0000026333.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02483327, SC, SOL, 162 mg / 0.9 mL (autoinjector)",62
sample_nocs/0000026333.PDF,species,What is the species?,NA,NA
sample_nocs/0000026333.PDF,noc_date,What is the date of the document?,NOV 28 2018,86
sample_nocs/0000026333.PDF,medicinal_ingredients,What are the medicinal ingredients?,tocilizumab,97
sample_nocs/0000026538.PDF,canadian_reference_product,What is the Canadian Reference Product?,Ruby-Fill,94
sample_nocs/0000026538.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000026538.PDF,noc_reason,What was the reason for the submission?,An alternative source of Strontium (Sr-82) chloride,61
sample_nocs/0000026538.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000026538.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000026538.PDF,submission_no,What is the Submission Number?,215950,98
sample_nocs/0000026538.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jubilant Draximage Inc.,96
sample_nocs/0000026538.PDF,product_name,What is the Product name?,Ruby-Fill,99
sample_nocs/0000026538.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A IV, SOL, 3.7 GBq",92
sample_nocs/0000026538.PDF,species,What is the species?,NA,NA
sample_nocs/0000026538.PDF,noc_date,What is the date of the document?,DEC 21 2018,87
sample_nocs/0000026538.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rubidium Rb-82 Generator,98
sample_nocs/0000026626.PDF,canadian_reference_product,What is the Canadian Reference Product?,APTIOM,84
sample_nocs/0000026626.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000026626.PDF,noc_reason,What was the reason for the submission?,Addition of new labels with increased size,98
sample_nocs/0000026626.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000026626.PDF,dossier_id,What is the Dossier Id?,e128891,97
sample_nocs/0000026626.PDF,submission_no,What is the Submission Number?,222182,98
sample_nocs/0000026626.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sunovion Pharmaceuticals Canada Inc.,80
sample_nocs/0000026626.PDF,product_name,What is the Product name?,APTIOM,90
sample_nocs/0000026626.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 200 mg",90
sample_nocs/0000026626.PDF,species,What is the species?,NA,NA
sample_nocs/0000026626.PDF,noc_date,What is the date of the document?,JAN 24 2019,86
sample_nocs/0000026626.PDF,medicinal_ingredients,What are the medicinal ingredients?,Eslicarbazepine Acetate,87
sample_nocs/0000026695.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cipro I.V. Mini Bags, Bayer Inc., Canada",47
sample_nocs/0000026695.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000026695.PDF,noc_reason,What was the reason for the submission?,To updated the Product Monograph with new Safety Information,79
sample_nocs/0000026695.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000026695.PDF,dossier_id,What is the Dossier Id?,e128847,96
sample_nocs/0000026695.PDF,submission_no,What is the Submission Number?,221068,98
sample_nocs/0000026695.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,83
sample_nocs/0000026695.PDF,product_name,What is the Product name?,"CIPROFLOXACIN INTRAVENOUS INFUSION, BP",66
sample_nocs/0000026695.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, 2 mg/ml",85
sample_nocs/0000026695.PDF,species,What is the species?,NA,NA
sample_nocs/0000026695.PDF,noc_date,What is the date of the document?,JAN 22 2019,82
sample_nocs/0000026695.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin,82
sample_nocs/0000026698.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Duragesic, Janssen-Ortho Inc., Canada",48
sample_nocs/0000026698.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000026698.PDF,noc_reason,What was the reason for the submission?,Administrative,63
sample_nocs/0000026698.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000026698.PDF,dossier_id,What is the Dossier Id?,e163054,93
sample_nocs/0000026698.PDF,submission_no,What is the Submission Number?,221785,98
sample_nocs/0000026698.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Ranbaxy Pharmaceuticals Canada Inc.,88
sample_nocs/0000026698.PDF,product_name,What is the Product name?,RAN-FENTANYL MATRIX PATCH,80
sample_nocs/0000026698.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A (transdermal, patch, 12 mcg/hour)",52
sample_nocs/0000026698.PDF,species,What is the species?,NA,NA
sample_nocs/0000026698.PDF,noc_date,What is the date of the document?,NOV 28 2018,86
sample_nocs/0000026698.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fentanyl,88
sample_nocs/0000026768.PDF,canadian_reference_product,What is the Canadian Reference Product?,OvuGel,78
sample_nocs/0000026768.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000026768.PDF,noc_reason,What was the reason for the submission?,Administrative Change in Product Ownership,99
sample_nocs/0000026768.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,90
sample_nocs/0000026768.PDF,dossier_id,What is the Dossier Id?,v161303,81
sample_nocs/0000026768.PDF,submission_no,What is the Submission Number?,223856,98
sample_nocs/0000026768.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Vétoquinol N.-A. Inc.,54.000003814697266
sample_nocs/0000026768.PDF,product_name,What is the Product name?,OvuGel,82
sample_nocs/0000026768.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02424150, Intravaginal, Gel, 100 g/mL",47
sample_nocs/0000026768.PDF,species,What is the species?,Sows,98
sample_nocs/0000026768.PDF,noc_date,What is the date of the document?,JAN 25 2019,67
sample_nocs/0000026768.PDF,medicinal_ingredients,What are the medicinal ingredients?,Triptorelin (as triptorelin acetate),63
sample_nocs/0000026898.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000026898.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,42
sample_nocs/0000026898.PDF,noc_reason,What was the reason for the submission?,New indication,48
sample_nocs/0000026898.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Catherine Parker,99
sample_nocs/0000026898.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000026898.PDF,submission_no,What is the Submission Number?,202488,98
sample_nocs/0000026898.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Endo Ventures Ltd.,55
sample_nocs/0000026898.PDF,product_name,What is the Product name?,XIAFLEX,99
sample_nocs/0000026898.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IL, PWSO, 0.9 mg/vial",85
sample_nocs/0000026898.PDF,species,What is the species?,NA,NA
sample_nocs/0000026898.PDF,noc_date,What is the date of the document?,JAN 2 2018,27.000001907348633
sample_nocs/0000026898.PDF,medicinal_ingredients,What are the medicinal ingredients?,collagenase clostridium histolyticum,97
sample_nocs/0000027048.PDF,canadian_reference_product,What is the Canadian Reference Product?,SANDOZ FINGOLIMOD,49
sample_nocs/0000027048.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000027048.PDF,noc_reason,What was the reason for the submission?,New Product Labels and Product Monograph,57
sample_nocs/0000027048.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,60.000003814697266
sample_nocs/0000027048.PDF,dossier_id,What is the Dossier Id?,p219836,78
sample_nocs/0000027048.PDF,submission_no,What is the Submission Number?,219836,97
sample_nocs/0000027048.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,74
sample_nocs/0000027048.PDF,product_name,What is the Product name?,SANDOZ FINGOLIMOD,76
sample_nocs/0000027048.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02482606, Oral, Capsule, 0.5 mg",79
sample_nocs/0000027048.PDF,species,What is the species?,NA,NA
sample_nocs/0000027048.PDF,noc_date,What is the date of the document?,MAR 11 2019,90
sample_nocs/0000027048.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fingolimod (supplied as fingolimod hydrochloride),68
sample_nocs/0000027060.PDF,canadian_reference_product,What is the Canadian Reference Product?,BAR-HYDROmorphone HCI,87
sample_nocs/0000027060.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000027060.PDF,noc_reason,What was the reason for the submission?,Administrative Licensing Agreement Between Two Companies,98
sample_nocs/0000027060.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marion Law,100
sample_nocs/0000027060.PDF,dossier_id,What is the Dossier Id?,e198972,34
sample_nocs/0000027060.PDF,submission_no,What is the Submission Number?,198972,98
sample_nocs/0000027060.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bard Pharmaceuticals (1990) Inc.,93
sample_nocs/0000027060.PDF,product_name,What is the Product name?,BAR-HYDROmorphone HCI,89
sample_nocs/0000027060.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02460777, Oral, Extended-Release Capsule, 3 mg",84
sample_nocs/0000027060.PDF,species,What is the species?,NA,NA
sample_nocs/0000027060.PDF,noc_date,What is the date of the document?,JAN 2 0 2017,21
sample_nocs/0000027060.PDF,medicinal_ingredients,What are the medicinal ingredients?,Hydromorphone hydrochloride,87
sample_nocs/0000027271.PDF,canadian_reference_product,What is the Canadian Reference Product?,CELEBREX,85
sample_nocs/0000027271.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000027271.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph,86
sample_nocs/0000027271.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000027271.PDF,dossier_id,What is the Dossier Id?,E139670,98
sample_nocs/0000027271.PDF,submission_no,What is the Submission Number?,206954,98
sample_nocs/0000027271.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada ULC,94
sample_nocs/0000027271.PDF,product_name,What is the Product name?,CELEBREX,92
sample_nocs/0000027271.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsules, 100 mg",87
sample_nocs/0000027271.PDF,species,What is the species?,NA,NA
sample_nocs/0000027271.PDF,noc_date,What is the date of the document?,APR 02 2019,92
sample_nocs/0000027271.PDF,medicinal_ingredients,What are the medicinal ingredients?,celecoxib,93
sample_nocs/0000027344.PDF,canadian_reference_product,What is the Canadian Reference Product?,Prevnar 13,96
sample_nocs/0000027344.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000027344.PDF,noc_reason,What was the reason for the submission?,Extension of an indication,67
sample_nocs/0000027344.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000027344.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000027344.PDF,submission_no,What is the Submission Number?,216208,100
sample_nocs/0000027344.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada ULC,94
sample_nocs/0000027344.PDF,product_name,What is the Product name?,Prevnar 13,97
sample_nocs/0000027344.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",NA,NA
sample_nocs/0000027344.PDF,species,What is the species?,Streptococcus pneumoniae,58
sample_nocs/0000027344.PDF,noc_date,What is the date of the document?,APR 15 2019,87
sample_nocs/0000027344.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Pneumococcal polysaccharide serotype 1*, Pneumococcal polysaccharide serotype 3*, Pneumococcal polysaccharide serotype 4*, Pneumococcal polysacc",19
sample_nocs/0000027374.PDF,canadian_reference_product,What is the Canadian Reference Product?,"SINGULAIR MERCK SHARP & DOHME CORP., USA",75
sample_nocs/0000027374.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000027374.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,64
sample_nocs/0000027374.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000027374.PDF,dossier_id,What is the Dossier Id?,226311,89
sample_nocs/0000027374.PDF,submission_no,What is the Submission Number?,226311,98
sample_nocs/0000027374.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc,50
sample_nocs/0000027374.PDF,product_name,What is the Product name?,M-MONTELUKAST,93
sample_nocs/0000027374.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02488167 (oral, tablet chewable, 4 mg)",50
sample_nocs/0000027374.PDF,species,What is the species?,NA,NA
sample_nocs/0000027374.PDF,noc_date,What is the date of the document?,MAY 03 2019,99
sample_nocs/0000027374.PDF,medicinal_ingredients,What are the medicinal ingredients?,Montelukast supplied as Montelukast Sodium,91
sample_nocs/0000027488.PDF,canadian_reference_product,What is the Canadian Reference Product?,Component TE-S Implants with Tylan,93
sample_nocs/0000027488.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000027488.PDF,noc_reason,What was the reason for the submission?,"Change to Prescription Status, Labelling updates",98
sample_nocs/0000027488.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,84
sample_nocs/0000027488.PDF,dossier_id,What is the Dossier Id?,v159519,97
sample_nocs/0000027488.PDF,submission_no,What is the Submission Number?,209224,98
sample_nocs/0000027488.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Elanco, Division Eli Lilly Canada Inc.",64
sample_nocs/0000027488.PDF,product_name,What is the Product name?,Component TE-S Implants with Tylan,97
sample_nocs/0000027488.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02245745,58.999996185302734
sample_nocs/0000027488.PDF,species,What is the species?,Feedlot steers,99
sample_nocs/0000027488.PDF,noc_date,What is the date of the document?,JAN 08 2018,85
sample_nocs/0000027488.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Trenbolone Acetate, Estradiol, Tylosin Tartrate",92
sample_nocs/0000027656.PDF,canadian_reference_product,What is the Canadian Reference Product?,Norfloxacin,94
sample_nocs/0000027656.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000027656.PDF,noc_reason,What was the reason for the submission?,Labelling Assessment and Administrative - Transfer of Drug Identification Number (DIN),84
sample_nocs/0000027656.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,69
sample_nocs/0000027656.PDF,dossier_id,What is the Dossier Id?,e183162,95
sample_nocs/0000027656.PDF,submission_no,What is the Submission Number?,212191,98
sample_nocs/0000027656.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Inc,54.000003814697266
sample_nocs/0000027656.PDF,product_name,What is the Product name?,Norfloxacin,97
sample_nocs/0000027656.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02229524, Oral, Tablet, 400 mg",76
sample_nocs/0000027656.PDF,species,What is the species?,NA,NA
sample_nocs/0000027656.PDF,noc_date,What is the date of the document?,FEB 08 2018,95
sample_nocs/0000027656.PDF,medicinal_ingredients,What are the medicinal ingredients?,Norfloxacin,98
sample_nocs/0000027672.PDF,canadian_reference_product,What is the Canadian Reference Product?,Component TE-100 Implants with Tylan,85
sample_nocs/0000027672.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000027672.PDF,noc_reason,What was the reason for the submission?,Administrative Merger/Buyout,97
sample_nocs/0000027672.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,89
sample_nocs/0000027672.PDF,dossier_id,What is the Dossier Id?,v154547,96
sample_nocs/0000027672.PDF,submission_no,What is the Submission Number?,213181,98
sample_nocs/0000027672.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Elanco Canada Limited,94
sample_nocs/0000027672.PDF,product_name,What is the Product name?,Component TE-100 Implants with Tylan,97
sample_nocs/0000027672.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02366916,56
sample_nocs/0000027672.PDF,species,What is the species?,Feedlot steers and heifers,98
sample_nocs/0000027672.PDF,noc_date,What is the date of the document?,FEB 14 2018,91
sample_nocs/0000027672.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Trenbolone Acetate, Estradiol, Tylosin Tartrate",92
sample_nocs/0000027883.PDF,canadian_reference_product,What is the Canadian Reference Product?,Comfortis,98
sample_nocs/0000027883.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000027883.PDF,noc_reason,What was the reason for the submission?,Administrative Merger/Buyout,98
sample_nocs/0000027883.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,85
sample_nocs/0000027883.PDF,dossier_id,What is the Dossier Id?,v148503,94
sample_nocs/0000027883.PDF,submission_no,What is the Submission Number?,214620,100
sample_nocs/0000027883.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Elanco Canada Limited,94
sample_nocs/0000027883.PDF,product_name,What is the Product name?,Comfortis,98
sample_nocs/0000027883.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02332493, Oral, Chewable Tablet, 140 mg/tab",64
sample_nocs/0000027883.PDF,species,What is the species?,"Dogs, Cats",88
sample_nocs/0000027883.PDF,noc_date,What is the date of the document?,MAR 22 2018,43
sample_nocs/0000027883.PDF,medicinal_ingredients,What are the medicinal ingredients?,Spinosad,99
sample_nocs/0000028101.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Micardis, Boehringer Ingelheim (Canada) Ltd., Canada",41
sample_nocs/0000028101.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000028101.PDF,noc_reason,What was the reason for the submission?,Administrative,49
sample_nocs/0000028101.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000028101.PDF,dossier_id,What is the Dossier Id?,e223649,75
sample_nocs/0000028101.PDF,submission_no,What is the Submission Number?,226749,98
sample_nocs/0000028101.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,MINT Pharmaceuticals Inc.,92
sample_nocs/0000028101.PDF,product_name,What is the Product name?,MINT-TELMISARTAN,96
sample_nocs/0000028101.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A (oral, tablet, 40 mg)",82
sample_nocs/0000028101.PDF,species,What is the species?,NA,NA
sample_nocs/0000028101.PDF,noc_date,What is the date of the document?,MAY 13 2019,99
sample_nocs/0000028101.PDF,medicinal_ingredients,What are the medicinal ingredients?,Telmisartan,96
sample_nocs/0000028152.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Nexium, AstraZeneca Canada Inc.",42
sample_nocs/0000028152.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,70
sample_nocs/0000028152.PDF,noc_reason,What was the reason for the submission?,Administrative licensing agreement between two companies / Administratif-accord de licence entre deux sociétés,30.000001907348633
sample_nocs/0000028152.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Barbara J. Sabourin,93
sample_nocs/0000028152.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000028152.PDF,submission_no,What is the Submission Number?,177202,98
sample_nocs/0000028152.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,60.000003814697266
sample_nocs/0000028152.PDF,product_name,What is the Product name?,ESOMEPRAZOLE,71
sample_nocs/0000028152.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02431173,58
sample_nocs/0000028152.PDF,species,What is the species?,NA,NA
sample_nocs/0000028152.PDF,noc_date,What is the date of the document?,SEP 18 2014,90
sample_nocs/0000028152.PDF,medicinal_ingredients,What are the medicinal ingredients?,Esomeprazole supplied as Esomeprazole Magnesium,94
sample_nocs/0000028736.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZOMETA® Concentrate,35
sample_nocs/0000028736.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000028736.PDF,noc_reason,What was the reason for the submission?,Revisions to the Product Monograph,95
sample_nocs/0000028736.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000028736.PDF,dossier_id,What is the Dossier Id?,e171179,94
sample_nocs/0000028736.PDF,submission_no,What is the Submission Number?,228711,98
sample_nocs/0000028736.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,MDA Inc.,49
sample_nocs/0000028736.PDF,product_name,What is the Product name?,ZOLEDRONIC ACID FOR INJECTION,79
sample_nocs/0000028736.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, 4 mg / 5 mL",71
sample_nocs/0000028736.PDF,species,What is the species?,NA,NA
sample_nocs/0000028736.PDF,noc_date,What is the date of the document?,JUL 9 2019,92
sample_nocs/0000028736.PDF,medicinal_ingredients,What are the medicinal ingredients?,Zoledronic Acid (Supplied as Zoledronic Acid Monohydrate),17
sample_nocs/0000028791.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cymbalta, Eli Lilly Canada Inc.",43
sample_nocs/0000028791.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000028791.PDF,noc_reason,What was the reason for the submission?,New labelling documents AND Licensing Agreement Between Two Companies,85
sample_nocs/0000028791.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000028791.PDF,dossier_id,What is the Dossier Id?,p227544,97
sample_nocs/0000028791.PDF,submission_no,What is the Submission Number?,228333,99
sample_nocs/0000028791.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,52
sample_nocs/0000028791.PDF,product_name,What is the Product name?,DULOXETINE,50
sample_nocs/0000028791.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02490889, Oral, Capsule (delayed-release), 30 mg",56
sample_nocs/0000028791.PDF,species,What is the species?,NA,NA
sample_nocs/0000028791.PDF,noc_date,What is the date of the document?,JUL 25 2019,91
sample_nocs/0000028791.PDF,medicinal_ingredients,What are the medicinal ingredients?,Duloxetine(supplied as duloxetine hydrochloride),47
sample_nocs/0000029014.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lotensin, Novartis Pharmaceuticals Canada Inc., Canada",48
sample_nocs/0000029014.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000029014.PDF,noc_reason,What was the reason for the submission?,Addition of a drug substance manufacturer,97
sample_nocs/0000029014.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000029014.PDF,dossier_id,What is the Dossier Id?,e115011,98
sample_nocs/0000029014.PDF,submission_no,What is the Submission Number?,224301,100
sample_nocs/0000029014.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,50
sample_nocs/0000029014.PDF,product_name,What is the Product name?,BENAZEPRIL,66
sample_nocs/0000029014.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 5 mg",87
sample_nocs/0000029014.PDF,species,What is the species?,NA,NA
sample_nocs/0000029014.PDF,noc_date,What is the date of the document?,AUG 16 2019,96
sample_nocs/0000029014.PDF,medicinal_ingredients,What are the medicinal ingredients?,Benazepril Hydrochloride,95
sample_nocs/0000029045.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pantoloc,soLVAY PHARMA INC., Canada / ALTANA PHARMA AG,GERMANY,Canada",0
sample_nocs/0000029045.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000029045.PDF,noc_reason,What was the reason for the submission?,Change in manufacturing process,96
sample_nocs/0000029045.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000029045.PDF,dossier_id,What is the Dossier Id?,e115391,96
sample_nocs/0000029045.PDF,submission_no,What is the Submission Number?,224689,98
sample_nocs/0000029045.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,54.000003814697266
sample_nocs/0000029045.PDF,product_name,What is the Product name?,TEVA-PANTOPRAZOLE,93
sample_nocs/0000029045.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet (Delayed-Release) 20 mg",77
sample_nocs/0000029045.PDF,species,What is the species?,NA,NA
sample_nocs/0000029045.PDF,noc_date,What is the date of the document?,AUG 08 2019,97
sample_nocs/0000029045.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pantoprazole (as pantoprazole sodium sesquihydrate),45
sample_nocs/0000029387.PDF,canadian_reference_product,What is the Canadian Reference Product?,Sodium lodide I-123 Oral Solution,68
sample_nocs/0000029387.PDF,directorate,What is the directorate that approved the submission?,Biologics and Genetic Therapies Directorate,35
sample_nocs/0000029387.PDF,noc_reason,What was the reason for the submission?,Administrative transfer of drug identification Number (DIN); Labelling updates / Administratif transfert d'identification numérique de drogue (DIN); Mise à jour desétiquettes,3
sample_nocs/0000029387.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",39
sample_nocs/0000029387.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000029387.PDF,submission_no,What is the Submission Number?,229358,98
sample_nocs/0000029387.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"BWXT ITG Canada, Inc.",73
sample_nocs/0000029387.PDF,product_name,What is the Product name?,Sodium lodide I-123 Oral Solution,91
sample_nocs/0000029387.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, ORL, SOL, 74 MBq/0.08mL",79
sample_nocs/0000029387.PDF,species,What is the species?,NA,NA
sample_nocs/0000029387.PDF,noc_date,What is the date of the document?,SEP 192019,93
sample_nocs/0000029387.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium lodide I-123,93
sample_nocs/0000029793.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZYTRAM XL,74
sample_nocs/0000029793.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000029793.PDF,noc_reason,What was the reason for the submission?,"Increase the amount of drug product coating for the 150 mg, 200 mg, 300 mg and 400 mg tablet strengths.",34
sample_nocs/0000029793.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. N. Patrick Stewart,67
sample_nocs/0000029793.PDF,dossier_id,What is the Dossier Id?,e131292,96
sample_nocs/0000029793.PDF,submission_no,What is the Submission Number?,226362,98
sample_nocs/0000029793.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Purdue Pharma,99
sample_nocs/0000029793.PDF,product_name,What is the Product name?,ZYTRAM XL,90
sample_nocs/0000029793.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet (extended-release), 75 mg",46
sample_nocs/0000029793.PDF,species,What is the species?,NA,NA
sample_nocs/0000029793.PDF,noc_date,What is the date of the document?,DEC 13 2019,90
sample_nocs/0000029793.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tramadol Hydrochloride,98
sample_nocs/0000029825.PDF,canadian_reference_product,What is the Canadian Reference Product?,SATIVEX,96
sample_nocs/0000029825.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,93
sample_nocs/0000029825.PDF,noc_reason,What was the reason for the submission?,To remove the cancer pain indication and neuropathic pain indication approved under the NOC/c policy,70
sample_nocs/0000029825.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,66
sample_nocs/0000029825.PDF,dossier_id,What is the Dossier Id?,e137419,94
sample_nocs/0000029825.PDF,submission_no,What is the Submission Number?,207694,98
sample_nocs/0000029825.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GW Pharma Limited,95
sample_nocs/0000029825.PDF,product_name,What is the Product name?,SATIVEX,94
sample_nocs/0000029825.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Buccal, Spray, 27 mg / 25 mg",77
sample_nocs/0000029825.PDF,species,What is the species?,NA,NA
sample_nocs/0000029825.PDF,noc_date,What is the date of the document?,DEC 12 2019,93
sample_nocs/0000029825.PDF,medicinal_ingredients,What are the medicinal ingredients?,delta-9-tetrahydrocannabinol / cannabidiol,94
sample_nocs/0000029852.PDF,canadian_reference_product,What is the Canadian Reference Product?,Revolution Zoetis Canada Inc.,91
sample_nocs/0000029852.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000029852.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle citée en rubrique,22
sample_nocs/0000029852.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,83
sample_nocs/0000029852.PDF,dossier_id,What is the Dossier Id?,v209006,61
sample_nocs/0000029852.PDF,submission_no,What is the Submission Number?,222846,97
sample_nocs/0000029852.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Virbac Animal Health Inc.,56
sample_nocs/0000029852.PDF,product_name,What is the Product name?,EVICTO,89
sample_nocs/0000029852.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02495260, Topical, Solution, 15 mg/0.25 mL (dog, cat)",51
sample_nocs/0000029852.PDF,species,What is the species?,"Dogs, Cats",78
sample_nocs/0000029852.PDF,noc_date,What is the date of the document?,JAN 02 2020,69
sample_nocs/0000029852.PDF,medicinal_ingredients,What are the medicinal ingredients?,Selamectin,98
sample_nocs/0000029949.PDF,canadian_reference_product,What is the Canadian Reference Product?,TEVA-BETAMETHASONE/CALCIPOTRIOL,37
sample_nocs/0000029949.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,78
sample_nocs/0000029949.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000029949.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,71
sample_nocs/0000029949.PDF,dossier_id,What is the Dossier Id?,E165693,97
sample_nocs/0000029949.PDF,submission_no,What is the Submission Number?,165693,98
sample_nocs/0000029949.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,65
sample_nocs/0000029949.PDF,product_name,What is the Product name?,TEVA-BETAMETHASONE/CALCIPOTRIOL,81
sample_nocs/0000029949.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02427419,50
sample_nocs/0000029949.PDF,species,What is the species?,NA,NA
sample_nocs/0000029949.PDF,noc_date,What is the date of the document?,JAN 28 2020,86
sample_nocs/0000029949.PDF,medicinal_ingredients,What are the medicinal ingredients?,betamethasone(supplied as betamethasone dipropionate)/calcipotriol,29
sample_nocs/0000029965.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Mestinon, Valeant Pharmaceuticals North America LLC, USA",79
sample_nocs/0000029965.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000029965.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,25
sample_nocs/0000029965.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,67
sample_nocs/0000029965.PDF,dossier_id,What is the Dossier Id?,e217959,81
sample_nocs/0000029965.PDF,submission_no,What is the Submission Number?,235263,98
sample_nocs/0000029965.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Laboratoire Riva Inc.,85
sample_nocs/0000029965.PDF,product_name,What is the Product name?,RIVA-PYRIDOSTIGMINE,92
sample_nocs/0000029965.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02495643, oral, tablet, 60 mg",72
sample_nocs/0000029965.PDF,species,What is the species?,NA,NA
sample_nocs/0000029965.PDF,noc_date,What is the date of the document?,JAN 31 2020,57
sample_nocs/0000029965.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pyridostigmine Bromide,95
sample_nocs/0000029995.PDF,canadian_reference_product,What is the Canadian Reference Product?,HYDREA,52.999996185302734
sample_nocs/0000029995.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000029995.PDF,noc_reason,What was the reason for the submission?,Update to the product monograph,94
sample_nocs/0000029995.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000029995.PDF,dossier_id,What is the Dossier Id?,E118964,97
sample_nocs/0000029995.PDF,submission_no,What is the Submission Number?,226144,99
sample_nocs/0000029995.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bristol-Myers Squibb Canada,66
sample_nocs/0000029995.PDF,product_name,What is the Product name?,HYDREA,82
sample_nocs/0000029995.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule, 500 mg",84
sample_nocs/0000029995.PDF,species,What is the species?,NA,NA
sample_nocs/0000029995.PDF,noc_date,What is the date of the document?,FEB 10 2020,93
sample_nocs/0000029995.PDF,medicinal_ingredients,What are the medicinal ingredients?,Hydroxyurea,98
sample_nocs/0000030060.PDF,canadian_reference_product,What is the Canadian Reference Product?,REACTINE,57
sample_nocs/0000030060.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,71
sample_nocs/0000030060.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000030060.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,66
sample_nocs/0000030060.PDF,dossier_id,What is the Dossier Id?,227027,46
sample_nocs/0000030060.PDF,submission_no,What is the Submission Number?,227027,96
sample_nocs/0000030060.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,76
sample_nocs/0000030060.PDF,product_name,What is the Product name?,NAT-CETIRIZINE,86
sample_nocs/0000030060.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02496461, Oral, Tablet, 10 mg (non-prescription)",84
sample_nocs/0000030060.PDF,species,What is the species?,NA,NA
sample_nocs/0000030060.PDF,noc_date,What is the date of the document?,FEB 21 2020,88
sample_nocs/0000030060.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cetirizine Hydrochloride,93
sample_nocs/0000030177.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000030177.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000030177.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,19
sample_nocs/0000030177.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000030177.PDF,dossier_id,What is the Dossier Id?,e155181,95
sample_nocs/0000030177.PDF,submission_no,What is the Submission Number?,235993,98
sample_nocs/0000030177.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Chiesi Canada Corp.,95
sample_nocs/0000030177.PDF,product_name,What is the Product name?,FERRIPROX,95
sample_nocs/0000030177.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02436531, oral, tablet, 500 mg",93
sample_nocs/0000030177.PDF,species,What is the species?,NA,NA
sample_nocs/0000030177.PDF,noc_date,What is the date of the document?,MAR 12 2020,97
sample_nocs/0000030177.PDF,medicinal_ingredients,What are the medicinal ingredients?,Deferiprone,96
sample_nocs/0000030187.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000030187.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000030187.PDF,noc_reason,What was the reason for the submission?,New manufacturing process / Nouveau procédé de fabrication,50
sample_nocs/0000030187.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",37
sample_nocs/0000030187.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000030187.PDF,submission_no,What is the Submission Number?,230268,98
sample_nocs/0000030187.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc,95
sample_nocs/0000030187.PDF,product_name,What is the Product name?,Kymriah,96
sample_nocs/0000030187.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SUS, 2.0x106 to 6.0x108 CAR positive viable T cells/ lymphocytes T CAR-positifs viables",46
sample_nocs/0000030187.PDF,species,What is the species?,T CAR-positifs viables,44
sample_nocs/0000030187.PDF,noc_date,What is the date of the document?,MAR 13 2020,96
sample_nocs/0000030187.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tisagenlecleucel,93
sample_nocs/0000030234.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Anafranil, AA Pharma Inc., Canada (25 mg)",52.999996185302734
sample_nocs/0000030234.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,81
sample_nocs/0000030234.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000030234.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,66
sample_nocs/0000030234.PDF,dossier_id,What is the Dossier Id?,e212895,56
sample_nocs/0000030234.PDF,submission_no,What is the Submission Number?,212895,97
sample_nocs/0000030234.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Taro Pharmaceuticals Inc.,91
sample_nocs/0000030234.PDF,product_name,What is the Product name?,TARO-CLOMIPRAMINE,93
sample_nocs/0000030234.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02497506, Oral, Capsule, 25 mg",69
sample_nocs/0000030234.PDF,species,What is the species?,NA,NA
sample_nocs/0000030234.PDF,noc_date,What is the date of the document?,MAR 24 2020,96
sample_nocs/0000030234.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clomipramine hydrochloride,95
sample_nocs/0000030320.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pharmorubicin PFS, Pfizer Canada Inc., Canada",50
sample_nocs/0000030320.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,82
sample_nocs/0000030320.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,24
sample_nocs/0000030320.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,66
sample_nocs/0000030320.PDF,dossier_id,What is the Dossier Id?,e149286,88
sample_nocs/0000030320.PDF,submission_no,What is the Submission Number?,238025,98
sample_nocs/0000030320.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Strides Pharma Canada Inc.,42
sample_nocs/0000030320.PDF,product_name,What is the Product name?,EPIRUBICIN HYDROCHLORIDE INJECTION,51
sample_nocs/0000030320.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02413221, intravenous, solution, 2 mg/mL",54.000003814697266
sample_nocs/0000030320.PDF,species,What is the species?,NA,NA
sample_nocs/0000030320.PDF,noc_date,What is the date of the document?,"May 19, 2020",85
sample_nocs/0000030320.PDF,medicinal_ingredients,What are the medicinal ingredients?,Epirubicin Hydrochloride,91
sample_nocs/0000030345.PDF,canadian_reference_product,What is the Canadian Reference Product?,Paracillin SP,97
sample_nocs/0000030345.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000030345.PDF,noc_reason,What was the reason for the submission?,Addition of drug substance supplier,98
sample_nocs/0000030345.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,93
sample_nocs/0000030345.PDF,dossier_id,What is the Dossier Id?,v196113,96
sample_nocs/0000030345.PDF,submission_no,What is the Submission Number?,238187,99
sample_nocs/0000030345.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Intervet Canada Corp.,97
sample_nocs/0000030345.PDF,product_name,What is the Product name?,Paracillin SP,98
sample_nocs/0000030345.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02281376, Oral, Powder for solution, 800 mg/g",90
sample_nocs/0000030345.PDF,species,What is the species?,"Poultry: Chicken, Swine",45
sample_nocs/0000030345.PDF,noc_date,What is the date of the document?,"May 26, 2020",65
sample_nocs/0000030345.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin trihydrate,99
sample_nocs/0000030388.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000030388.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000030388.PDF,noc_reason,What was the reason for the submission?,Ceci is pour vous aviser que la présentation de drogue nouvelle citée en rubrique est conforme aux exigences des C.08.002 and des Regulations.,0
sample_nocs/0000030388.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,93
sample_nocs/0000030388.PDF,dossier_id,What is the Dossier Id?,v209003,96
sample_nocs/0000030388.PDF,submission_no,What is the Submission Number?,226414,98
sample_nocs/0000030388.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Virbac Animal Health Inc.,50
sample_nocs/0000030388.PDF,product_name,What is the Product name?,Eradia,100
sample_nocs/0000030388.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02499819, Oral, Suspension, 125 mg/mL",62
sample_nocs/0000030388.PDF,species,What is the species?,Dogs,99
sample_nocs/0000030388.PDF,noc_date,What is the date of the document?,"June 3, 2020",50
sample_nocs/0000030388.PDF,medicinal_ingredients,What are the medicinal ingredients?,Metronidazole,98
sample_nocs/0000030416.PDF,canadian_reference_product,What is the Canadian Reference Product?,TUKYSA,89
sample_nocs/0000030416.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000030416.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle,19
sample_nocs/0000030416.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000030416.PDF,dossier_id,What is the Dossier Id?,E205780,98
sample_nocs/0000030416.PDF,submission_no,What is the Submission Number?,235295,98
sample_nocs/0000030416.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Seattle Genetics Inc.,92
sample_nocs/0000030416.PDF,product_name,What is the Product name?,TUKYSA,91
sample_nocs/0000030416.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02499827, Oral, Tablet, 50 mg",92
sample_nocs/0000030416.PDF,species,What is the species?,NA,NA
sample_nocs/0000030416.PDF,noc_date,What is the date of the document?,"June 5, 2020",75
sample_nocs/0000030416.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tucatinib,98
sample_nocs/0000030464.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Pataday, Alcon Canada Inc., Canada",36
sample_nocs/0000030464.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000030464.PDF,noc_reason,What was the reason for the submission?,Administrative,62
sample_nocs/0000030464.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000030464.PDF,dossier_id,What is the Dossier Id?,e150554,61
sample_nocs/0000030464.PDF,submission_no,What is the Submission Number?,239276,98
sample_nocs/0000030464.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,78
sample_nocs/0000030464.PDF,product_name,What is the Product name?,ACT OLOPATADINE 0.2%,54.000003814697266
sample_nocs/0000030464.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02404095, ophthalmic, solution, 0.2% w/v",73
sample_nocs/0000030464.PDF,species,What is the species?,NA,NA
sample_nocs/0000030464.PDF,noc_date,What is the date of the document?,"June 15, 2020",76
sample_nocs/0000030464.PDF,medicinal_ingredients,What are the medicinal ingredients?,Olopatadine supplied as Olopatadine Hydrochloride,86
sample_nocs/0000030492.PDF,canadian_reference_product,What is the Canadian Reference Product?,Component TE-H Implants with Tylan,50
sample_nocs/0000030492.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000030492.PDF,noc_reason,What was the reason for the submission?,Addition of a new drug product manufacturing and testing site,92
sample_nocs/0000030492.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. Mary Jane Ireland,93
sample_nocs/0000030492.PDF,dossier_id,What is the Dossier Id?,v159534,97
sample_nocs/0000030492.PDF,submission_no,What is the Submission Number?,227003,98
sample_nocs/0000030492.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Elanco Canada Limited,93
sample_nocs/0000030492.PDF,product_name,What is the Product name?,Component TE-H Implants with Tylan,97
sample_nocs/0000030492.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02245665,80
sample_nocs/0000030492.PDF,species,What is the species?,Feedlot heifers,98
sample_nocs/0000030492.PDF,noc_date,What is the date of the document?,"June 17, 2020",73
sample_nocs/0000030492.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Trenbolone Acetate, Estradiol, Tylosin Tartrate",93
sample_nocs/0000030759.PDF,canadian_reference_product,What is the Canadian Reference Product?,Dupixent,56
sample_nocs/0000030759.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,34
sample_nocs/0000030759.PDF,noc_reason,What was the reason for the submission?,New Indication,51
sample_nocs/0000030759.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",37
sample_nocs/0000030759.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000030759.PDF,submission_no,What is the Submission Number?,231268,98
sample_nocs/0000030759.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,71
sample_nocs/0000030759.PDF,product_name,What is the Product name?,Dupixent,88
sample_nocs/0000030759.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A SC, SOL, 150 mg/mL",84
sample_nocs/0000030759.PDF,species,What is the species?,NA,NA
sample_nocs/0000030759.PDF,noc_date,What is the date of the document?,"August 12, 2020",81
sample_nocs/0000030759.PDF,medicinal_ingredients,What are the medicinal ingredients?,dupilumab,51
sample_nocs/0000030942.PDF,canadian_reference_product,What is the Canadian Reference Product?,PMS-METHOTREXATE,97
sample_nocs/0000030942.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000030942.PDF,noc_reason,What was the reason for the submission?,"Changes to box label, foil and package insert.",58.999996185302734
sample_nocs/0000030942.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,60.000003814697266
sample_nocs/0000030942.PDF,dossier_id,What is the Dossier Id?,E133862,98
sample_nocs/0000030942.PDF,submission_no,What is the Submission Number?,236541,99
sample_nocs/0000030942.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,48
sample_nocs/0000030942.PDF,product_name,What is the Product name?,PMS-METHOTREXATE,97
sample_nocs/0000030942.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 2.5 mg",89
sample_nocs/0000030942.PDF,species,What is the species?,NA,NA
sample_nocs/0000030942.PDF,noc_date,What is the date of the document?,"April 20, 2020",72
sample_nocs/0000030942.PDF,medicinal_ingredients,What are the medicinal ingredients?,Methotrexate sodium,98
sample_nocs/0000030960.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Tazocin, Wyeth Canada",42
sample_nocs/0000030960.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,80
sample_nocs/0000030960.PDF,noc_reason,What was the reason for the submission?,Update to labels,99
sample_nocs/0000030960.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000030960.PDF,dossier_id,What is the Dossier Id?,e134897,96
sample_nocs/0000030960.PDF,submission_no,What is the Submission Number?,236789,98
sample_nocs/0000030960.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,80
sample_nocs/0000030960.PDF,product_name,What is the Product name?,PIPERACILLIN AND TAZOBACTAM FOR INJECTION,84
sample_nocs/0000030960.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Powder for Solution, 4 g/vial / 0.5 g/vial",29
sample_nocs/0000030960.PDF,species,What is the species?,NA,NA
sample_nocs/0000030960.PDF,noc_date,What is the date of the document?,"April 30, 2020",70
sample_nocs/0000030960.PDF,medicinal_ingredients,What are the medicinal ingredients?,Piperacillin (supplied as piperacillin sodium) Tazobactam (supplied as tazobactam sodium),35
sample_nocs/0000030967.PDF,canadian_reference_product,What is the Canadian Reference Product?,FORADIL,89
sample_nocs/0000030967.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000030967.PDF,noc_reason,What was the reason for the submission?,Change of the leaflet to outsert format,97
sample_nocs/0000030967.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,60.000003814697266
sample_nocs/0000030967.PDF,dossier_id,What is the Dossier Id?,e137506,95
sample_nocs/0000030967.PDF,submission_no,What is the Submission Number?,236909,98
sample_nocs/0000030967.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,85
sample_nocs/0000030967.PDF,product_name,What is the Product name?,FORADIL,94
sample_nocs/0000030967.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Inhalation, Capsule, 12 mcg",84
sample_nocs/0000030967.PDF,species,What is the species?,NA,NA
sample_nocs/0000030967.PDF,noc_date,What is the date of the document?,"May 12, 2020",87
sample_nocs/0000030967.PDF,medicinal_ingredients,What are the medicinal ingredients?,Formoterol fumarate,91
sample_nocs/0000031044.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PROSCAR, Merck Frosst Canada Ltd., Canada",34
sample_nocs/0000031044.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,92
sample_nocs/0000031044.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,92
sample_nocs/0000031044.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000031044.PDF,dossier_id,What is the Dossier Id?,E127055,98
sample_nocs/0000031044.PDF,submission_no,What is the Submission Number?,238997,98
sample_nocs/0000031044.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,80
sample_nocs/0000031044.PDF,product_name,What is the Product name?,TEVA-FINASTERIDE,93
sample_nocs/0000031044.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 5 mg",83
sample_nocs/0000031044.PDF,species,What is the species?,NA,NA
sample_nocs/0000031044.PDF,noc_date,What is the date of the document?,"September 1, 2020",87
sample_nocs/0000031044.PDF,medicinal_ingredients,What are the medicinal ingredients?,finasteride,97
sample_nocs/0000031046.PDF,canadian_reference_product,What is the Canadian Reference Product?,JULUCA,94
sample_nocs/0000031046.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000031046.PDF,noc_reason,What was the reason for the submission?,To change the labelling from an Outer Carton to an Extended Content Label (ECL) with affixed patient insert/leaflet.,45
sample_nocs/0000031046.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000031046.PDF,dossier_id,What is the Dossier Id?,E201196,98
sample_nocs/0000031046.PDF,submission_no,What is the Submission Number?,239817,99
sample_nocs/0000031046.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ViiV Healthcare ULC,97
sample_nocs/0000031046.PDF,product_name,What is the Product name?,JULUCA,92
sample_nocs/0000031046.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 50 MG / 25 MG",83
sample_nocs/0000031046.PDF,species,What is the species?,NA,NA
sample_nocs/0000031046.PDF,noc_date,What is the date of the document?,"August 24, 2020",81
sample_nocs/0000031046.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dolutegravir (supplied as dolutegravir sodium) / Rilpivirine (supplied as rilpivirine hydrochloride),41
sample_nocs/0000031114.PDF,canadian_reference_product,What is the Canadian Reference Product?,"FOSAMAX, Merck Frosst Canada Ltd., Canada",68
sample_nocs/0000031114.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,85
sample_nocs/0000031114.PDF,noc_reason,What was the reason for the submission?,Updating Labelling and the Product Monograph,97
sample_nocs/0000031114.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,61
sample_nocs/0000031114.PDF,dossier_id,What is the Dossier Id?,e159078,95
sample_nocs/0000031114.PDF,submission_no,What is the Submission Number?,239200,99
sample_nocs/0000031114.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mint Pharmaceuticals Inc.,89
sample_nocs/0000031114.PDF,product_name,What is the Product name?,MINT-ALENDRONATE,81
sample_nocs/0000031114.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 5 mg",89
sample_nocs/0000031114.PDF,species,What is the species?,NA,NA
sample_nocs/0000031114.PDF,noc_date,What is the date of the document?,"September 11, 2020",90
sample_nocs/0000031114.PDF,medicinal_ingredients,What are the medicinal ingredients?,Alendronic Acid supplied as Alendronate Sodium,89
sample_nocs/0000031142.PDF,canadian_reference_product,What is the Canadian Reference Product?,FluLaval Tetra,99
sample_nocs/0000031142.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,22
sample_nocs/0000031142.PDF,noc_reason,What was the reason for the submission?,Annual update strain changes / Mise a jour annuelle changements de souches virales,35
sample_nocs/0000031142.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",39
sample_nocs/0000031142.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000031142.PDF,submission_no,What is the Submission Number?,241231,98
sample_nocs/0000031142.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,ID Biomedical Corporation of Quebec,47
sample_nocs/0000031142.PDF,product_name,What is the Product name?,FluLaval Tetra,99
sample_nocs/0000031142.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A IM, SUS, 15 g/strain/0.5 mL / 15 g/souche/0.5 mL",19
sample_nocs/0000031142.PDF,species,What is the species?,NA,NA
sample_nocs/0000031142.PDF,noc_date,What is the date of the document?,"September 11, 2020",86
sample_nocs/0000031142.PDF,medicinal_ingredients,What are the medicinal ingredients?,Haemagglutinin strain A (H1N1) / hémagglutinine souche A (H1N1) Haemagglutinin strain B (Victoria) / hémagglutinine souche A (H,16
sample_nocs/0000031212.PDF,canadian_reference_product,What is the Canadian Reference Product?,Adacel,62
sample_nocs/0000031212.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,40
sample_nocs/0000031212.PDF,noc_reason,What was the reason for the submission?,Vaccination during pregnancy for passive immunization against pertussis disease in young infants.,65
sample_nocs/0000031212.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",38
sample_nocs/0000031212.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000031212.PDF,submission_no,What is the Submission Number?,220103,98
sample_nocs/0000031212.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi Pasteur Limited,96
sample_nocs/0000031212.PDF,product_name,What is the Product name?,Adacel,96
sample_nocs/0000031212.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, SUS, 5Lf / 0.5mL Tetanus Toxoid,",51
sample_nocs/0000031212.PDF,species,What is the species?,Tetanus Toxoid,67
sample_nocs/0000031212.PDF,noc_date,What is the date of the document?,"September 25, 2020",89
sample_nocs/0000031212.PDF,medicinal_ingredients,What are the medicinal ingredients?,"(Pertussis Toxoid, Filamentous Haemagglutinin, Pertactin, Fimbriae Types 2 and 3)",39
sample_nocs/0000031287.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEPOSIA,96
sample_nocs/0000031287.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,79
sample_nocs/0000031287.PDF,noc_reason,What was the reason for the submission?,complies with the requirements of sections drogue nouvelle citée en rubrique,33
sample_nocs/0000031287.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000031287.PDF,dossier_id,What is the Dossier Id?,E216035,98
sample_nocs/0000031287.PDF,submission_no,What is the Submission Number?,232761,98
sample_nocs/0000031287.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Celgene Inc.,96
sample_nocs/0000031287.PDF,product_name,What is the Product name?,ZEPOSIA,99
sample_nocs/0000031287.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02506009, Oral, Capsule (Kit), 0.23 mg / 0.46 mg",58.999996185302734
sample_nocs/0000031287.PDF,species,What is the species?,NA,NA
sample_nocs/0000031287.PDF,noc_date,What is the date of the document?,"October 2, 2020",80
sample_nocs/0000031287.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ozanimod (Supplied as Ozanimod hydrochloride),82
sample_nocs/0000031494.PDF,canadian_reference_product,What is the Canadian Reference Product?,MAVIRET,97
sample_nocs/0000031494.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000031494.PDF,noc_reason,What was the reason for the submission?,To shorten treatment duration in treatment-nave patients with compensated cirrhosis and HCV genotype 3 infection from 12 weeks to 8 weeks.,36
sample_nocs/0000031494.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,69
sample_nocs/0000031494.PDF,dossier_id,What is the Dossier Id?,E195768,98
sample_nocs/0000031494.PDF,submission_no,What is the Submission Number?,234362,99
sample_nocs/0000031494.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AbbVie Corporation,94
sample_nocs/0000031494.PDF,product_name,What is the Product name?,MAVIRET,84
sample_nocs/0000031494.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 40mg / 100mg",69
sample_nocs/0000031494.PDF,species,What is the species?,NA,NA
sample_nocs/0000031494.PDF,noc_date,What is the date of the document?,"October 30, 2020",57
sample_nocs/0000031494.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pibrentasvir / Glecaprevir,94
sample_nocs/0000031499.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Amiodarone Hydrochloride for injection, Sandoz Canada",82
sample_nocs/0000031499.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000031499.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000031499.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000031499.PDF,dossier_id,What is the Dossier Id?,235195,71
sample_nocs/0000031499.PDF,submission_no,What is the Submission Number?,235195,99
sample_nocs/0000031499.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000031499.PDF,product_name,What is the Product name?,Amiodarone Hydrochloride for injection,65
sample_nocs/0000031499.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02423227, Intravenous, Solution, 50 mg / mL",38
sample_nocs/0000031499.PDF,species,What is the species?,NA,NA
sample_nocs/0000031499.PDF,noc_date,What is the date of the document?,"November 9, 2020",73
sample_nocs/0000031499.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amiodarone hydrochloride,70
sample_nocs/0000031564.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000031564.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000031564.PDF,noc_reason,What was the reason for the submission?,Administrative Change in Product Ownership,94
sample_nocs/0000031564.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",39
sample_nocs/0000031564.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000031564.PDF,submission_no,What is the Submission Number?,242584,98
sample_nocs/0000031564.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Emergent Travel Health Inc.,51
sample_nocs/0000031564.PDF,product_name,What is the Product name?,VIVOTIF,99
sample_nocs/0000031564.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00885975, ORL, ECC, 2-10 X 109 CFU",91
sample_nocs/0000031564.PDF,species,What is the species?,NA,NA
sample_nocs/0000031564.PDF,noc_date,What is the date of the document?,"November 13, 2020",81
sample_nocs/0000031564.PDF,medicinal_ingredients,What are the medicinal ingredients?,Typhoid vaccine live oral attenuated TY21A / Vaccin antityphodique vivant oral atténué TY21A,55
sample_nocs/0000031581.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Vfend, Pfizer Canada, Inc., Canada",71
sample_nocs/0000031581.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,94
sample_nocs/0000031581.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,89
sample_nocs/0000031581.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Scott Appleton, PhD",52
sample_nocs/0000031581.PDF,dossier_id,What is the Dossier Id?,E185905,98
sample_nocs/0000031581.PDF,submission_no,What is the Submission Number?,244145,98
sample_nocs/0000031581.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,74
sample_nocs/0000031581.PDF,product_name,What is the Product name?,AURO-VORICONAZOLE,82
sample_nocs/0000031581.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 50mg",91
sample_nocs/0000031581.PDF,species,What is the species?,NA,NA
sample_nocs/0000031581.PDF,noc_date,What is the date of the document?,"November 6, 2020",74
sample_nocs/0000031581.PDF,medicinal_ingredients,What are the medicinal ingredients?,Voriconazole,97
sample_nocs/0000031634.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CLAVULIN, GlaxoSmithKline Inc., Canada",36
sample_nocs/0000031634.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,81
sample_nocs/0000031634.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000031634.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000031634.PDF,dossier_id,What is the Dossier Id?,233779,62
sample_nocs/0000031634.PDF,submission_no,What is the Submission Number?,233779,98
sample_nocs/0000031634.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,85
sample_nocs/0000031634.PDF,product_name,What is the Product name?,JAMP AMOXI CLAV,93
sample_nocs/0000031634.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02508249, Oral, Tablet, 250 mg/125 mg",38
sample_nocs/0000031634.PDF,species,What is the species?,NA,NA
sample_nocs/0000031634.PDF,noc_date,What is the date of the document?,"November 20, 2020",72
sample_nocs/0000031634.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin (as Amoxicillin Trihydrate) Clavulanic Acid (as Clavulanate Potassium),65
sample_nocs/0000031709.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000031709.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000031709.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,18
sample_nocs/0000031709.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,69
sample_nocs/0000031709.PDF,dossier_id,What is the Dossier Id?,e149943,89
sample_nocs/0000031709.PDF,submission_no,What is the Submission Number?,245239,98
sample_nocs/0000031709.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Glenwood GmbH Pharmazeutische Erzeugnisse,47
sample_nocs/0000031709.PDF,product_name,What is the Product name?,PERSANTINE,98
sample_nocs/0000031709.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00637734, intravenous, solution, 5 mg/mL",48
sample_nocs/0000031709.PDF,species,What is the species?,NA,NA
sample_nocs/0000031709.PDF,noc_date,What is the date of the document?,"November 30, 2020",72
sample_nocs/0000031709.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dipyridamole,98
sample_nocs/0000031732.PDF,canadian_reference_product,What is the Canadian Reference Product?,oZANEX,19
sample_nocs/0000031732.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000031732.PDF,noc_reason,What was the reason for the submission?,Addition of drug substance manufacturing sites,98
sample_nocs/0000031732.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000031732.PDF,dossier_id,What is the Dossier Id?,e192925,92
sample_nocs/0000031732.PDF,submission_no,What is the Submission Number?,237870,98
sample_nocs/0000031732.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Ferrer Internacional, S.A.",52
sample_nocs/0000031732.PDF,product_name,What is the Product name?,OZANEX,69
sample_nocs/0000031732.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Topical, Cream, 1% w/w",91
sample_nocs/0000031732.PDF,species,What is the species?,NA,NA
sample_nocs/0000031732.PDF,noc_date,What is the date of the document?,"December 10, 2020",82
sample_nocs/0000031732.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ozenoxacin,79
sample_nocs/0000031733.PDF,canadian_reference_product,What is the Canadian Reference Product?,STRIBILD,85
sample_nocs/0000031733.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000031733.PDF,noc_reason,What was the reason for the submission?,"To update the Contraindication and Consumer Information sections of the Product Monograph with the drug-drug interaction with lomitapide (JUXTAPID), as per Advisement Letter dated April 17, 2020.",34
sample_nocs/0000031733.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000031733.PDF,dossier_id,What is the Dossier Id?,e149436,96
sample_nocs/0000031733.PDF,submission_no,What is the Submission Number?,238174,98
sample_nocs/0000031733.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Gilead Sciences Canada Inc.,88
sample_nocs/0000031733.PDF,product_name,What is the Product name?,STRIBILD,86
sample_nocs/0000031733.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 150 mg / 150 mg / 200 mg / 300 mg",79
sample_nocs/0000031733.PDF,species,What is the species?,NA,NA
sample_nocs/0000031733.PDF,noc_date,What is the date of the document?,"December 4, 2020",88
sample_nocs/0000031733.PDF,medicinal_ingredients,What are the medicinal ingredients?,Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate,88
sample_nocs/0000031746.PDF,canadian_reference_product,What is the Canadian Reference Product?,"TWYNSTA, Boehringer Ingelheim (Canada) Ltd./Ltee, Canada",42
sample_nocs/0000031746.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000031746.PDF,noc_reason,What was the reason for the submission?,Relaxation of acceptance criterion for a test in the drug product specifications,95
sample_nocs/0000031746.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,67
sample_nocs/0000031746.PDF,dossier_id,What is the Dossier Id?,e172953,89
sample_nocs/0000031746.PDF,submission_no,What is the Submission Number?,241017,98
sample_nocs/0000031746.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Inc,47
sample_nocs/0000031746.PDF,product_name,What is the Product name?,AA-TELMISARTAN-AMLODIPINE,90
sample_nocs/0000031746.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 40 mg/ 5 mg",82
sample_nocs/0000031746.PDF,species,What is the species?,NA,NA
sample_nocs/0000031746.PDF,noc_date,What is the date of the document?,"December 7, 2020",88
sample_nocs/0000031746.PDF,medicinal_ingredients,What are the medicinal ingredients?,Telmisartan / Amlodipine (as Amlodipine Besylate),82
sample_nocs/0000031851.PDF,canadian_reference_product,What is the Canadian Reference Product?,Zyprexa and Zyprexa Intramuscular,32
sample_nocs/0000031851.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000031851.PDF,noc_reason,What was the reason for the submission?,Updated labelling materials,98
sample_nocs/0000031851.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000031851.PDF,dossier_id,What is the Dossier Id?,e162307,97
sample_nocs/0000031851.PDF,submission_no,What is the Submission Number?,242469,98
sample_nocs/0000031851.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Incorporated,92
sample_nocs/0000031851.PDF,product_name,What is the Product name?,SANDOZ OLANZAPINE; OLANZAPINE FOR INJECTION,65
sample_nocs/0000031851.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 2.5 mg",88
sample_nocs/0000031851.PDF,species,What is the species?,NA,NA
sample_nocs/0000031851.PDF,noc_date,What is the date of the document?,"December 16, 2020",82
sample_nocs/0000031851.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Olanzapine, Olanzapine (supplied as olanzapine tartrate)",42
sample_nocs/0000032270.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Technescan PYP, Mallinckrodt Canada ULC, Canada",62
sample_nocs/0000032270.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000032270.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000032270.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000032270.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000032270.PDF,submission_no,What is the Submission Number?,242036,98
sample_nocs/0000032270.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Isologic Innovative Radiopharmaceuticals Ltd,83
sample_nocs/0000032270.PDF,product_name,What is the Product name?,Kit for the Preparation of Technetium (99mTc) Pyrophosphate Injection / Trousse for the préparation of pyrophosphate de technétium (99mTc) injectable,10
sample_nocs/0000032270.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02513870 IV, PWSO, 12 mg/vial",84
sample_nocs/0000032270.PDF,species,What is the species?,NA,NA
sample_nocs/0000032270.PDF,noc_date,What is the date of the document?,"March 19, 2021",95
sample_nocs/0000032270.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium pyrophosphate / pyrophosphate de sodium,34
sample_nocs/0000032722.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ESBRIET, Roche Registration GmbH, Germany",60.000003814697266
sample_nocs/0000032722.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000032722.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000032722.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000032722.PDF,dossier_id,What is the Dossier Id?,e235384,93
sample_nocs/0000032722.PDF,submission_no,What is the Submission Number?,243865,98
sample_nocs/0000032722.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,68
sample_nocs/0000032722.PDF,product_name,What is the Product name?,JAMP PIRFENIDONE,93
sample_nocs/0000032722.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02514702, Oral, Tablet, 267 mg",85
sample_nocs/0000032722.PDF,species,What is the species?,NA,NA
sample_nocs/0000032722.PDF,noc_date,What is the date of the document?,"May 18, 2021",94
sample_nocs/0000032722.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pirfenidone,92
sample_nocs/0000032950.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PLAVIX, Sanofi-Aventis Canada Inc., Canada",67
sample_nocs/0000032950.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000032950.PDF,noc_reason,What was the reason for the submission?,Updates to labelling materials,98
sample_nocs/0000032950.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000032950.PDF,dossier_id,What is the Dossier Id?,e157025,93
sample_nocs/0000032950.PDF,submission_no,What is the Submission Number?,247816,97
sample_nocs/0000032950.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,24
sample_nocs/0000032950.PDF,product_name,What is the Product name?,AURO-CLOPIDOGREL,76
sample_nocs/0000032950.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 75 mg",73
sample_nocs/0000032950.PDF,species,What is the species?,NA,NA
sample_nocs/0000032950.PDF,noc_date,What is the date of the document?,"May 5, 2021",83
sample_nocs/0000032950.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel (supplied as Clopidogrel Bisulfate),49
sample_nocs/0000032995.PDF,canadian_reference_product,What is the Canadian Reference Product?,SANDOSTATIN / SANDOSTATIN LAR,76
sample_nocs/0000032995.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000032995.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,94
sample_nocs/0000032995.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000032995.PDF,dossier_id,What is the Dossier Id?,e130761,95
sample_nocs/0000032995.PDF,submission_no,What is the Submission Number?,247160,98
sample_nocs/0000032995.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,82
sample_nocs/0000032995.PDF,product_name,What is the Product name?,SANDOSTATIN / SANDOSTATIN LAR,84
sample_nocs/0000032995.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Subcutaneous, Intravenous, Solution, 50 mcg/mL",73
sample_nocs/0000032995.PDF,species,What is the species?,NA,NA
sample_nocs/0000032995.PDF,noc_date,What is the date of the document?,"April 22, 2021",87
sample_nocs/0000032995.PDF,medicinal_ingredients,What are the medicinal ingredients?,Octreotide (supplied as octreotide acetate),60.000003814697266
sample_nocs/0000033029.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000033029.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000033029.PDF,noc_reason,What was the reason for the submission?,Additional manufacturing site / site de fabrication additionnel,61
sample_nocs/0000033029.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",40
sample_nocs/0000033029.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000033029.PDF,submission_no,What is the Submission Number?,247709,98
sample_nocs/0000033029.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,92
sample_nocs/0000033029.PDF,product_name,What is the Product name?,Lucentis,98
sample_nocs/0000033029.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IVL, SOL, 10 mg / mL",68
sample_nocs/0000033029.PDF,species,What is the species?,NA,NA
sample_nocs/0000033029.PDF,noc_date,What is the date of the document?,"April 14, 2021",89
sample_nocs/0000033029.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ranibizumab,99
sample_nocs/0000033045.PDF,canadian_reference_product,What is the Canadian Reference Product?,Indivior UK Limited,52.999996185302734
sample_nocs/0000033045.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000033045.PDF,noc_reason,What was the reason for the submission?,Update to the outer carton and pouch labels,98
sample_nocs/0000033045.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000033045.PDF,dossier_id,What is the Dossier Id?,e195538,89
sample_nocs/0000033045.PDF,submission_no,What is the Submission Number?,247489,98
sample_nocs/0000033045.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Indivior UK Limited,93
sample_nocs/0000033045.PDF,product_name,What is the Product name?,SUBLOCADE,95
sample_nocs/0000033045.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",ml,69
sample_nocs/0000033045.PDF,species,What is the species?,NA,NA
sample_nocs/0000033045.PDF,noc_date,What is the date of the document?,"April 13, 2021",89
sample_nocs/0000033045.PDF,medicinal_ingredients,What are the medicinal ingredients?,Buprenorphine,94
sample_nocs/0000033063.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Tiazac, Crystaal Corporation, Canada",29
sample_nocs/0000033063.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000033063.PDF,noc_reason,What was the reason for the submission?,Administrative,85
sample_nocs/0000033063.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000033063.PDF,dossier_id,What is the Dossier Id?,e165395,85
sample_nocs/0000033063.PDF,submission_no,What is the Submission Number?,249784,97
sample_nocs/0000033063.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000033063.PDF,product_name,What is the Product name?,DILTIAZEM TZ,80
sample_nocs/0000033063.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral, capsule (extended release), 120 mg",78
sample_nocs/0000033063.PDF,species,What is the species?,NA,NA
sample_nocs/0000033063.PDF,noc_date,What is the date of the document?,"April 8, 2021",84
sample_nocs/0000033063.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diltiazem Hydrochloride,84
sample_nocs/0000033126.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000033126.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,27.000001907348633
sample_nocs/0000033126.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,38
sample_nocs/0000033126.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",41
sample_nocs/0000033126.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000033126.PDF,submission_no,What is the Submission Number?,246916,98
sample_nocs/0000033126.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,92
sample_nocs/0000033126.PDF,product_name,What is the Product name?,AIMOVIG,97
sample_nocs/0000033126.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 70 mg/mL (prefilled syringe)",48
sample_nocs/0000033126.PDF,species,What is the species?,NA,NA
sample_nocs/0000033126.PDF,noc_date,What is the date of the document?,"March 23, 2021",93
sample_nocs/0000033126.PDF,medicinal_ingredients,What are the medicinal ingredients?,erenumab / érénumab,64
sample_nocs/0000033142.PDF,canadian_reference_product,What is the Canadian Reference Product?,ESTROGEL,63
sample_nocs/0000033142.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000033142.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,17
sample_nocs/0000033142.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000033142.PDF,dossier_id,What is the Dossier Id?,e135833,74
sample_nocs/0000033142.PDF,submission_no,What is the Submission Number?,249154,98
sample_nocs/0000033142.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Organon Canada Inc.,80
sample_nocs/0000033142.PDF,product_name,What is the Product name?,ESTROGEL,92
sample_nocs/0000033142.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02238704, transdermal, gel, 0.06%",62
sample_nocs/0000033142.PDF,species,What is the species?,NA,NA
sample_nocs/0000033142.PDF,noc_date,What is the date of the document?,"March 22, 2021",90
sample_nocs/0000033142.PDF,medicinal_ingredients,What are the medicinal ingredients?,Estradiol supplied as Estradiol Hemihydrate,78
sample_nocs/0000033254.PDF,canadian_reference_product,What is the Canadian Reference Product?,CAELYX,88
sample_nocs/0000033254.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,83
sample_nocs/0000033254.PDF,noc_reason,What was the reason for the submission?,Addition of drug substance manufacturing site.,85
sample_nocs/0000033254.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000033254.PDF,dossier_id,What is the Dossier Id?,e142951,91
sample_nocs/0000033254.PDF,submission_no,What is the Submission Number?,247530,97
sample_nocs/0000033254.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,58.999996185302734
sample_nocs/0000033254.PDF,product_name,What is the Product name?,CAELYX,96
sample_nocs/0000033254.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Suspension, 2 mg/mL",82
sample_nocs/0000033254.PDF,species,What is the species?,NA,NA
sample_nocs/0000033254.PDF,noc_date,What is the date of the document?,"July 6, 2021",73
sample_nocs/0000033254.PDF,medicinal_ingredients,What are the medicinal ingredients?,Doxorubicin Hydrochloride,96
sample_nocs/0000033279.PDF,canadian_reference_product,What is the Canadian Reference Product?,TISSUEBLUE,97
sample_nocs/0000033279.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000033279.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle citée en rubrique,26
sample_nocs/0000033279.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,69
sample_nocs/0000033279.PDF,dossier_id,What is the Dossier Id?,e225686,86
sample_nocs/0000033279.PDF,submission_no,What is the Submission Number?,232449,98
sample_nocs/0000033279.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Dutch Ophthalmic Research Center International BV,97
sample_nocs/0000033279.PDF,product_name,What is the Product name?,TISSUEBLUE,99
sample_nocs/0000033279.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02510995, Intravitreal, Solution, 0.25 mg/ml",85
sample_nocs/0000033279.PDF,species,What is the species?,NA,NA
sample_nocs/0000033279.PDF,noc_date,What is the date of the document?,"January 15, 2021",82
sample_nocs/0000033279.PDF,medicinal_ingredients,What are the medicinal ingredients?,Brilliant Blue G,95
sample_nocs/0000033312.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ATACAND PLUS, ASTRAZENECA CANADA INC., Canada",54.000003814697266
sample_nocs/0000033312.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000033312.PDF,noc_reason,What was the reason for the submission?,Alternate manufacturing site for the active pharmaceutical ingredient (candesartan cilexetil),61
sample_nocs/0000033312.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000033312.PDF,dossier_id,What is the Dossier Id?,e119036,97
sample_nocs/0000033312.PDF,submission_no,What is the Submission Number?,241745,98
sample_nocs/0000033312.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,78
sample_nocs/0000033312.PDF,product_name,What is the Product name?,SANDOZ CANDESARTAN PLUS,78
sample_nocs/0000033312.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 16 mg / 12.5 mg",77
sample_nocs/0000033312.PDF,species,What is the species?,NA,NA
sample_nocs/0000033312.PDF,noc_date,What is the date of the document?,"February 9, 2021",93
sample_nocs/0000033312.PDF,medicinal_ingredients,What are the medicinal ingredients?,Candesartan cilexetil / hydrochlorothiazide,70
sample_nocs/0000033377.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Diflucan, Pfizer Canada, Inc., Canada",70
sample_nocs/0000033377.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,94
sample_nocs/0000033377.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,97
sample_nocs/0000033377.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Scott Appleton, PhD",52.999996185302734
sample_nocs/0000033377.PDF,dossier_id,What is the Dossier Id?,E116647,97
sample_nocs/0000033377.PDF,submission_no,What is the Submission Number?,244369,98
sample_nocs/0000033377.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,78
sample_nocs/0000033377.PDF,product_name,What is the Product name?,ACT FLUCONAZOLE,95
sample_nocs/0000033377.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 50mg",89
sample_nocs/0000033377.PDF,species,What is the species?,NA,NA
sample_nocs/0000033377.PDF,noc_date,What is the date of the document?,"February 17, 2021",93
sample_nocs/0000033377.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluconazole,97
sample_nocs/0000033449.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zytiga, Janssen Inc., Canada",40
sample_nocs/0000033449.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,93
sample_nocs/0000033449.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,89
sample_nocs/0000033449.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000033449.PDF,dossier_id,What is the Dossier Id?,e207120,96
sample_nocs/0000033449.PDF,submission_no,What is the Submission Number?,250541,99
sample_nocs/0000033449.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,86
sample_nocs/0000033449.PDF,product_name,What is the Product name?,APO-ABIRATERONE FILM COATED TABLETS,86
sample_nocs/0000033449.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 250mg",88
sample_nocs/0000033449.PDF,species,What is the species?,NA,NA
sample_nocs/0000033449.PDF,noc_date,What is the date of the document?,"April 8, 2021",85
sample_nocs/0000033449.PDF,medicinal_ingredients,What are the medicinal ingredients?,Abiraterone Acetate,92
sample_nocs/0000033619.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000033619.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,33
sample_nocs/0000033619.PDF,noc_reason,What was the reason for the submission?,Product Monograph update / Mise a jour de la monographie de produit,48
sample_nocs/0000033619.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",40
sample_nocs/0000033619.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000033619.PDF,submission_no,What is the Submission Number?,250276,98
sample_nocs/0000033619.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novo Nordisk Canada Inc.,67
sample_nocs/0000033619.PDF,product_name,What is the Product name?,Tresiba,98
sample_nocs/0000033619.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 100 U/mL (Penfill)",65
sample_nocs/0000033619.PDF,species,What is the species?,NA,NA
sample_nocs/0000033619.PDF,noc_date,What is the date of the document?,"July 23, 2021",82
sample_nocs/0000033619.PDF,medicinal_ingredients,What are the medicinal ingredients?,insulin degludec,98
sample_nocs/0000033710.PDF,canadian_reference_product,What is the Canadian Reference Product?,VITAMIN A ACID,98
sample_nocs/0000033710.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000033710.PDF,noc_reason,What was the reason for the submission?,Administrative: Change in Product Ownership,41
sample_nocs/0000033710.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000033710.PDF,dossier_id,What is the Dossier Id?,E137526,98
sample_nocs/0000033710.PDF,submission_no,What is the Submission Number?,238421,98
sample_nocs/0000033710.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Bausch Health, Canada Inc.",80
sample_nocs/0000033710.PDF,product_name,What is the Product name?,VITAMIN A ACID,99
sample_nocs/0000033710.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","01926462, Topical, Gel, 0.01%",91
sample_nocs/0000033710.PDF,species,What is the species?,NA,NA
sample_nocs/0000033710.PDF,noc_date,What is the date of the document?,"September 30, 2020",76
sample_nocs/0000033710.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tretinoin,96
sample_nocs/0000033941.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Revlimid, Celgene Inc., Canada",66
sample_nocs/0000033941.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,93
sample_nocs/0000033941.PDF,noc_reason,What was the reason for the submission?,Addition of New Indication and addition of previously approved strength,89
sample_nocs/0000033941.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000033941.PDF,dossier_id,What is the Dossier Id?,e203536,94
sample_nocs/0000033941.PDF,submission_no,What is the Submission Number?,230928,99
sample_nocs/0000033941.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Dr. Reddy's Laboratories Ltd.,73
sample_nocs/0000033941.PDF,product_name,What is the Product name?,REDDY-LENALIDOMIDE,88
sample_nocs/0000033941.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02484714, Oral, Capsule, 2.5 mg",85
sample_nocs/0000033941.PDF,species,What is the species?,NA,NA
sample_nocs/0000033941.PDF,noc_date,What is the date of the document?,"September 1, 2021",89
sample_nocs/0000033941.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lenalidomide,93
sample_nocs/0000033990.PDF,canadian_reference_product,What is the Canadian Reference Product?,BIPHENTIN,82
sample_nocs/0000033990.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000033990.PDF,noc_reason,What was the reason for the submission?,Safety updates to the product monograph and to convert the product monograph to 2020 format,51
sample_nocs/0000033990.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,62
sample_nocs/0000033990.PDF,dossier_id,What is the Dossier Id?,e123442,95
sample_nocs/0000033990.PDF,submission_no,What is the Submission Number?,249146,98
sample_nocs/0000033990.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Elvium Life Sciences,63
sample_nocs/0000033990.PDF,product_name,What is the Product name?,BIPHENTIN,89
sample_nocs/0000033990.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Capsule (extended-release) 10 mg",52.999996185302734
sample_nocs/0000033990.PDF,species,What is the species?,NA,NA
sample_nocs/0000033990.PDF,noc_date,What is the date of the document?,"September 2, 2021",92
sample_nocs/0000033990.PDF,medicinal_ingredients,What are the medicinal ingredients?,methylphenidate hydrochloride,84
sample_nocs/0000034318.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Comprimé, 400 mg",90
sample_nocs/0000034318.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000034318.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,61
sample_nocs/0000034318.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,64
sample_nocs/0000034318.PDF,dossier_id,What is the Dossier Id?,e248884,69
sample_nocs/0000034318.PDF,submission_no,What is the Submission Number?,248884,96
sample_nocs/0000034318.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,65
sample_nocs/0000034318.PDF,product_name,What is the Product name?,IMATINIB,66
sample_nocs/0000034318.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02521202, Oral, Tablet, 100 mg / 02521202, Orale, Dosage Comprimé, 100 mg",16
sample_nocs/0000034318.PDF,species,What is the species?,NA,NA
sample_nocs/0000034318.PDF,noc_date,What is the date of the document?,"October 13, 2021",81
sample_nocs/0000034318.PDF,medicinal_ingredients,What are the medicinal ingredients?,Imatinib (as Imatinib Mesylate) / Imatinib (comme Mésylate d'imatinib),69
sample_nocs/0000034377.PDF,canadian_reference_product,What is the Canadian Reference Product?,OZEMPIC,47
sample_nocs/0000034377.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,38
sample_nocs/0000034377.PDF,noc_reason,What was the reason for the submission?,Modifications to the Drug Product manufacturing process / Modifications au process of fabrication of the produit médicamenteux,13
sample_nocs/0000034377.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",41
sample_nocs/0000034377.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000034377.PDF,submission_no,What is the Submission Number?,252312,99
sample_nocs/0000034377.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novo Nordisk Canada Inc.,69
sample_nocs/0000034377.PDF,product_name,What is the Product name?,OZEMPIC,84
sample_nocs/0000034377.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 1.34 mg/mL",73
sample_nocs/0000034377.PDF,species,What is the species?,NA,NA
sample_nocs/0000034377.PDF,noc_date,What is the date of the document?,"October 19, 2021",84
sample_nocs/0000034377.PDF,medicinal_ingredients,What are the medicinal ingredients?,Semaglutide injection,96
sample_nocs/0000034436.PDF,canadian_reference_product,What is the Canadian Reference Product?,"VOLIBRIS, GlaxoSmithKline Inc., Canada",49
sample_nocs/0000034436.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000034436.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000034436.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,67
sample_nocs/0000034436.PDF,dossier_id,What is the Dossier Id?,e249136,65
sample_nocs/0000034436.PDF,submission_no,What is the Submission Number?,249136,97
sample_nocs/0000034436.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,49
sample_nocs/0000034436.PDF,product_name,What is the Product name?,JAMP AMBRISENTAN,82
sample_nocs/0000034436.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02521938, Oral / Orale, Tablet / Comprimé, 5 mg",69
sample_nocs/0000034436.PDF,species,What is the species?,NA,NA
sample_nocs/0000034436.PDF,noc_date,What is the date of the document?,"October 29, 2021",79
sample_nocs/0000034436.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ambrisentan,98
sample_nocs/0000034452.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000034452.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000034452.PDF,noc_reason,What was the reason for the submission?,New drug product manufacturing site/ nouveau site of fabrication for the product médicamenteux,22
sample_nocs/0000034452.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",42
sample_nocs/0000034452.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000034452.PDF,submission_no,What is the Submission Number?,251117,99
sample_nocs/0000034452.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,99
sample_nocs/0000034452.PDF,product_name,What is the Product name?,HERCEPTIN,52.999996185302734
sample_nocs/0000034452.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, PWSO, 440 mg/vial",90
sample_nocs/0000034452.PDF,species,What is the species?,NA,NA
sample_nocs/0000034452.PDF,noc_date,What is the date of the document?,"November 1, 2021",76
sample_nocs/0000034452.PDF,medicinal_ingredients,What are the medicinal ingredients?,trastuzumab,98
sample_nocs/0000034458.PDF,canadian_reference_product,What is the Canadian Reference Product?,Pediapharm Naproxen Suspension,78
sample_nocs/0000034458.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000034458.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph to reflect safety concerns during pregnancy as per Advisement Letter and serious skin reactions,92
sample_nocs/0000034458.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000034458.PDF,dossier_id,What is the Dossier Id?,e176234,95
sample_nocs/0000034458.PDF,submission_no,What is the Submission Number?,253528,99
sample_nocs/0000034458.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Medexus Pharmaceuticals Inc.,92
sample_nocs/0000034458.PDF,product_name,What is the Product name?,Pediapharm Naproxen Suspension,97
sample_nocs/0000034458.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Suspension, 25 mg / mL",60.000003814697266
sample_nocs/0000034458.PDF,species,What is the species?,NA,NA
sample_nocs/0000034458.PDF,noc_date,What is the date of the document?,"November 2, 2021",75
sample_nocs/0000034458.PDF,medicinal_ingredients,What are the medicinal ingredients?,Naproxen,97
sample_nocs/0000034546.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PAXIL, GlaxoSmithKline Inc., Canada",66
sample_nocs/0000034546.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000034546.PDF,noc_reason,What was the reason for the submission?,Update to labels / Mise a jour desétiquettes,58.999996185302734
sample_nocs/0000034546.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,60.000003814697266
sample_nocs/0000034546.PDF,dossier_id,What is the Dossier Id?,e137776,93
sample_nocs/0000034546.PDF,submission_no,What is the Submission Number?,253508,99
sample_nocs/0000034546.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,92
sample_nocs/0000034546.PDF,product_name,What is the Product name?,PMS-PAROXETINE,95
sample_nocs/0000034546.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 10 mg",80
sample_nocs/0000034546.PDF,species,What is the species?,NA,NA
sample_nocs/0000034546.PDF,noc_date,What is the date of the document?,"November 16, 2021",74
sample_nocs/0000034546.PDF,medicinal_ingredients,What are the medicinal ingredients?,Paroxetine(as paroxetine hydrochloride)/Paroxétine (sous forme de chlorhydrate de paroxétine),10
sample_nocs/0000034858.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000034858.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000034858.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,66
sample_nocs/0000034858.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000034858.PDF,dossier_id,What is the Dossier Id?,e138463,94
sample_nocs/0000034858.PDF,submission_no,What is the Submission Number?,259429,98
sample_nocs/0000034858.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Inc,49
sample_nocs/0000034858.PDF,product_name,What is the Product name?,FENOFIBRATE,78
sample_nocs/0000034858.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02225980, oral/orale, capsule, 100 mg",56
sample_nocs/0000034858.PDF,species,What is the species?,NA,NA
sample_nocs/0000034858.PDF,noc_date,What is the date of the document?,"January 5, 2022",82
sample_nocs/0000034858.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fenofibrate/Fénofibrate,72
sample_nocs/0000035006.PDF,canadian_reference_product,What is the Canadian Reference Product?,VITRAKVI,98
sample_nocs/0000035006.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,93
sample_nocs/0000035006.PDF,noc_reason,What was the reason for the submission?,To fulfill Commitment #1 of the Letter of Undertaking,45
sample_nocs/0000035006.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,61
sample_nocs/0000035006.PDF,dossier_id,What is the Dossier Id?,e213708,94
sample_nocs/0000035006.PDF,submission_no,What is the Submission Number?,251374,99
sample_nocs/0000035006.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bayer Inc.,54.000003814697266
sample_nocs/0000035006.PDF,product_name,What is the Product name?,VITRAKVI,99
sample_nocs/0000035006.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Solution, 20 mg/ml",74
sample_nocs/0000035006.PDF,species,What is the species?,NA,NA
sample_nocs/0000035006.PDF,noc_date,What is the date of the document?,"January 26, 2022",83
sample_nocs/0000035006.PDF,medicinal_ingredients,What are the medicinal ingredients?,Larotrectinib Sulfate / Sulfate de Larotrectinib,80
sample_nocs/0000035048.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Sensipar, Amgen Canada Inc., Canada",39
sample_nocs/0000035048.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,84
sample_nocs/0000035048.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,69
sample_nocs/0000035048.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000035048.PDF,dossier_id,What is the Dossier Id?,259251,83
sample_nocs/0000035048.PDF,submission_no,What is the Submission Number?,259251,97
sample_nocs/0000035048.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,38
sample_nocs/0000035048.PDF,product_name,What is the Product name?,CINACALCET,61
sample_nocs/0000035048.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02524880, oral / orale, tablet / comprimé, 30 mg",65
sample_nocs/0000035048.PDF,species,What is the species?,NA,NA
sample_nocs/0000035048.PDF,noc_date,What is the date of the document?,"February 2, 2022",90
sample_nocs/0000035048.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cinacalcet supplied as Cinacalcet Hydrochloride / Cinacalcet sous forme de chlorhydrate de cinacalcet,84
sample_nocs/0000035065.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Dexdomitor (DIN 02333929, Orion Corporation)",51
sample_nocs/0000035065.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000035065.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000035065.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,96
sample_nocs/0000035065.PDF,dossier_id,What is the Dossier Id?,v251674,92
sample_nocs/0000035065.PDF,submission_no,What is the Submission Number?,251674,98
sample_nocs/0000035065.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Dechra Veterinary Products Inc.,80
sample_nocs/0000035065.PDF,product_name,What is the Product name?,Dexmedesed,95
sample_nocs/0000035065.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02524945,62
sample_nocs/0000035065.PDF,species,What is the species?,"Dogs, Cats/ Chiens, Chats",46
sample_nocs/0000035065.PDF,noc_date,What is the date of the document?,"February 7, 2022 / 7 février 2022",39
sample_nocs/0000035065.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dexmedetomidine Hydrochloride/Chlorhydrate de dexmédétomidine,21
sample_nocs/0000035149.PDF,canadian_reference_product,What is the Canadian Reference Product?,Bromocriptine,55
sample_nocs/0000035149.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000035149.PDF,noc_reason,What was the reason for the submission?,To update the Product Monograph,51
sample_nocs/0000035149.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000035149.PDF,dossier_id,What is the Dossier Id?,e158025,96
sample_nocs/0000035149.PDF,submission_no,What is the Submission Number?,256286,97
sample_nocs/0000035149.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AA Pharma Inc.,48
sample_nocs/0000035149.PDF,product_name,What is the Product name?,BROMOCRIPTINE,49
sample_nocs/0000035149.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 2.5 mg",69
sample_nocs/0000035149.PDF,species,What is the species?,NA,NA
sample_nocs/0000035149.PDF,noc_date,What is the date of the document?,"February 16, 2022",90
sample_nocs/0000035149.PDF,medicinal_ingredients,What are the medicinal ingredients?,Bromocriptine(supplied as: bromocriptine mesylate)/ Bromocriptine (fourni comme: mésylate de bromocriptine),10
sample_nocs/0000035157.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Nucynta IR, Janssen Inc., Canada",47
sample_nocs/0000035157.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000035157.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph / Mise a jour de l'innocuité dans la monographie de produit,37
sample_nocs/0000035157.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,57
sample_nocs/0000035157.PDF,dossier_id,What is the Dossier Id?,e204031,95
sample_nocs/0000035157.PDF,submission_no,What is the Submission Number?,252954,98
sample_nocs/0000035157.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,83
sample_nocs/0000035157.PDF,product_name,What is the Product name?,APO-TAPENTADOL,94
sample_nocs/0000035157.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 50mg",88
sample_nocs/0000035157.PDF,species,What is the species?,NA,NA
sample_nocs/0000035157.PDF,noc_date,What is the date of the document?,"February 17, 2022",93
sample_nocs/0000035157.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tapentadol(supplied as Tapentadol Hydrochloride),46
sample_nocs/0000035188.PDF,canadian_reference_product,What is the Canadian Reference Product?,VYNDAQEL,94
sample_nocs/0000035188.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000035188.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph as per Advisement Letter,93
sample_nocs/0000035188.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000035188.PDF,dossier_id,What is the Dossier Id?,e148690,94
sample_nocs/0000035188.PDF,submission_no,What is the Submission Number?,255167,99
sample_nocs/0000035188.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada ULC,92
sample_nocs/0000035188.PDF,product_name,What is the Product name?,VYNDAQEL,97
sample_nocs/0000035188.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule, 20 mg",78
sample_nocs/0000035188.PDF,species,What is the species?,NA,NA
sample_nocs/0000035188.PDF,noc_date,What is the date of the document?,"February 23, 2022",93
sample_nocs/0000035188.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tafamidis meglumine,98
sample_nocs/0000035301.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZYMAR,86
sample_nocs/0000035301.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,88
sample_nocs/0000035301.PDF,noc_reason,What was the reason for the submission?,"To update the Product Monograph (PM) to the 2020 format, and to update the labels to meet Plain Language Labelling (PLL) requirements.",62
sample_nocs/0000035301.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000035301.PDF,dossier_id,What is the Dossier Id?,e109347,96
sample_nocs/0000035301.PDF,submission_no,What is the Submission Number?,257117,98
sample_nocs/0000035301.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Allergan Inc.,54.000003814697266
sample_nocs/0000035301.PDF,product_name,What is the Product name?,ZYMAR,94
sample_nocs/0000035301.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Ophthalmic/Ophtalmique, Solution, 0.3%",84
sample_nocs/0000035301.PDF,species,What is the species?,NA,NA
sample_nocs/0000035301.PDF,noc_date,What is the date of the document?,"March 11, 2022",82
sample_nocs/0000035301.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gatifloxacin / Gatifloxacine,88
sample_nocs/0000035369.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CYKLOKAPRON, Pfizer Canada Inc., Canada",40
sample_nocs/0000035369.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,87
sample_nocs/0000035369.PDF,noc_reason,What was the reason for the submission?,Updates to Labelling Material / Mises a jour du matériel d'étiquetage,65
sample_nocs/0000035369.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,58.999996185302734
sample_nocs/0000035369.PDF,dossier_id,What is the Dossier Id?,e185943,95
sample_nocs/0000035369.PDF,submission_no,What is the Submission Number?,250064,99
sample_nocs/0000035369.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,1,51
sample_nocs/0000035369.PDF,product_name,What is the Product name?,Tranexamic Acid Injection,98
sample_nocs/0000035369.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous, Solution, 100 mg/mL",25
sample_nocs/0000035369.PDF,species,What is the species?,NA,NA
sample_nocs/0000035369.PDF,noc_date,What is the date of the document?,"August 13, 2021",85
sample_nocs/0000035369.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tranexamic Acid,99
sample_nocs/0000035453.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Avalox, Bayer Schering Pharma AG, Germany",86
sample_nocs/0000035453.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000035453.PDF,noc_reason,What was the reason for the submission?,Addition of primary container closure system / Ajout du system de fermeture du conteneur primaire,54.000003814697266
sample_nocs/0000035453.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000035453.PDF,dossier_id,What is the Dossier Id?,e183969,96
sample_nocs/0000035453.PDF,submission_no,What is the Submission Number?,255995,98
sample_nocs/0000035453.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Generic Medical Partners Inc.,60.000003814697266
sample_nocs/0000035453.PDF,product_name,What is the Product name?,MED-MOXIFLOXACIN,90
sample_nocs/0000035453.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / orale, Tablet / comprimé, 400 mg",71
sample_nocs/0000035453.PDF,species,What is the species?,NA,NA
sample_nocs/0000035453.PDF,noc_date,What is the date of the document?,"March 25, 2022",91
sample_nocs/0000035453.PDF,medicinal_ingredients,What are the medicinal ingredients?,Moxifloxacin(supplied as moxifloxacin hydrochloride)/Moxifloxacine(sous forme de chlorhydrate de moxifloxacine),4
sample_nocs/0000035474.PDF,canadian_reference_product,What is the Canadian Reference Product?,FOSRENOL,93
sample_nocs/0000035474.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,89
sample_nocs/0000035474.PDF,noc_reason,What was the reason for the submission?,To update the Product Monograph,58
sample_nocs/0000035474.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,65
sample_nocs/0000035474.PDF,dossier_id,What is the Dossier Id?,e134345,95
sample_nocs/0000035474.PDF,submission_no,What is the Submission Number?,257792,98
sample_nocs/0000035474.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Takeda Canada Inc.,90
sample_nocs/0000035474.PDF,product_name,What is the Product name?,FOSRENOL,98
sample_nocs/0000035474.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet (chewable)/Comprimé (a mâcher), 250 mg",18
sample_nocs/0000035474.PDF,species,What is the species?,NA,NA
sample_nocs/0000035474.PDF,noc_date,What is the date of the document?,"March 25, 2022",90
sample_nocs/0000035474.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lanthanum(supplied as: lanthanum carbonate hydrate) / Lanthane,3
sample_nocs/0000035511.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ZESTORETIC, AstraZeneca Canada Inc., Canada",30.000001907348633
sample_nocs/0000035511.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,91
sample_nocs/0000035511.PDF,noc_reason,What was the reason for the submission?,Updating the Product Monograph / Mise a jour de la monographie de produit,41
sample_nocs/0000035511.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000035511.PDF,dossier_id,What is the Dossier Id?,e136346,96
sample_nocs/0000035511.PDF,submission_no,What is the Submission Number?,257491,98
sample_nocs/0000035511.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,54.000003814697266
sample_nocs/0000035511.PDF,product_name,What is the Product name?,SANDOZ LISINOPRIL HCT,69
sample_nocs/0000035511.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 10 mg / 12.5 mg",71
sample_nocs/0000035511.PDF,species,What is the species?,NA,NA
sample_nocs/0000035511.PDF,noc_date,What is the date of the document?,"March 30, 2022",79
sample_nocs/0000035511.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lisinopril (as Lisinopril Dihydrate) and Hydrochlorothiazide / Lisinopril (sous forme de lisinopril dihydraté) et hydrochlorothiazide,37
sample_nocs/0000035546.PDF,canadian_reference_product,What is the Canadian Reference Product?,"TraMACET, Janssen Inc., Canada",29
sample_nocs/0000035546.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,90
sample_nocs/0000035546.PDF,noc_reason,What was the reason for the submission?,Update to the product monograph as per advisement letter / Mise a jour of la monographie de produit,19
sample_nocs/0000035546.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,58
sample_nocs/0000035546.PDF,dossier_id,What is the Dossier Id?,e177304,95
sample_nocs/0000035546.PDF,submission_no,What is the Submission Number?,256359,98
sample_nocs/0000035546.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,80
sample_nocs/0000035546.PDF,product_name,What is the Product name?,AURO-TRAMADOL/ACETAMINOPHEN,63
sample_nocs/0000035546.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 37.5 mg tramadol",74
sample_nocs/0000035546.PDF,species,What is the species?,NA,NA
sample_nocs/0000035546.PDF,noc_date,What is the date of the document?,"March 31, 2022",90
sample_nocs/0000035546.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tramadol hydrochloride / Acetaminophen / chlorhydrate de tramadol / Acétaminophène,16
sample_nocs/0000035740.PDF,canadian_reference_product,What is the Canadian Reference Product?,Pfizer Canada ULC,55
sample_nocs/0000035740.PDF,directorate,What is the directorate that approved the submission?,Therapeutic Products Directorate,86
sample_nocs/0000035740.PDF,noc_reason,What was the reason for the submission?,Addition of Drug Product Manufacturing site,88
sample_nocs/0000035740.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,68
sample_nocs/0000035740.PDF,dossier_id,What is the Dossier Id?,e256440,96
sample_nocs/0000035740.PDF,submission_no,What is the Submission Number?,261288,98
sample_nocs/0000035740.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pfizer Canada ULC,94
sample_nocs/0000035740.PDF,product_name,What is the Product name?,PAXLOVID,97
sample_nocs/0000035740.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 100mg/150 mg",38
sample_nocs/0000035740.PDF,species,What is the species?,NA,NA
sample_nocs/0000035740.PDF,noc_date,What is the date of the document?,"April 14, 2022",88
sample_nocs/0000035740.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ritonavir / Nirmatrelvir,94
sample_nocs/0000035993.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Risperdal, Janssen-Ortho Inc., Canada",28
sample_nocs/0000035993.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,49
sample_nocs/0000035993.PDF,noc_reason,What was the reason for the submission?,Administrative,71
sample_nocs/0000035993.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Dr. J. Patrick Stewart,63
sample_nocs/0000035993.PDF,dossier_id,What is the Dossier Id?,e149092,84
sample_nocs/0000035993.PDF,submission_no,What is the Submission Number?,262912,97
sample_nocs/0000035993.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"May 5, 2022",49
sample_nocs/0000035993.PDF,product_name,What is the Product name?,MAR-RISPERIDONE,98
sample_nocs/0000035993.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 0.25 mg",84
sample_nocs/0000035993.PDF,species,What is the species?,NA,NA
sample_nocs/0000035993.PDF,noc_date,What is the date of the document?,"May 5, 2022",80
sample_nocs/0000035993.PDF,medicinal_ingredients,What are the medicinal ingredients?,Risperidone / Rispéridone,76
sample_nocs/0000036022.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Imitrex DF, GlaxoSmithKline Inc., Canada",58
sample_nocs/0000036022.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,31
sample_nocs/0000036022.PDF,noc_reason,What was the reason for the submission?,Update to product monograph to match CRP / Mise a jour de la monographie de produit pour correspondre au CRP,42
sample_nocs/0000036022.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Bruce Randall,99
sample_nocs/0000036022.PDF,dossier_id,What is the Dossier Id?,e130033,97
sample_nocs/0000036022.PDF,submission_no,What is the Submission Number?,259228,98
sample_nocs/0000036022.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000036022.PDF,product_name,What is the Product name?,PMS-SUMATRIPTAN,96
sample_nocs/0000036022.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / orale, Tablet / comprimé, 25 mg",78
sample_nocs/0000036022.PDF,species,What is the species?,NA,NA
sample_nocs/0000036022.PDF,noc_date,What is the date of the document?,"May 11, 2022",90
sample_nocs/0000036022.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sumatriptan (supplied as sumatriptan succinate) / Sumatriptan (sous forme de succinate de sumatriptan),44
sample_nocs/0000036055.PDF,canadian_reference_product,What is the Canadian Reference Product?,APO-VERAP,95
sample_nocs/0000036055.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,69
sample_nocs/0000036055.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph,97
sample_nocs/0000036055.PDF,approving_dg,What is the name of the Director General that signed this NOC?,M.A.R.C.,5
sample_nocs/0000036055.PDF,dossier_id,What is the Dossier Id?,e105800,95
sample_nocs/0000036055.PDF,submission_no,What is the Submission Number?,258995,98
sample_nocs/0000036055.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,82
sample_nocs/0000036055.PDF,product_name,What is the Product name?,APO-VERAP,97
sample_nocs/0000036055.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/ Orale, Tablet/ Comprimé, 80 mg",63
sample_nocs/0000036055.PDF,species,What is the species?,NA,NA
sample_nocs/0000036055.PDF,noc_date,What is the date of the document?,"May 13, 2022",86
sample_nocs/0000036055.PDF,medicinal_ingredients,What are the medicinal ingredients?,Verapamil hydrochloride / Chlorhydrate de vérapamil,70
sample_nocs/0000036072.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Aubagio, Genzyme Canada",43
sample_nocs/0000036072.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,45
sample_nocs/0000036072.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,94
sample_nocs/0000036072.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Bruce Randall,99
sample_nocs/0000036072.PDF,dossier_id,What is the Dossier Id?,e232901,91
sample_nocs/0000036072.PDF,submission_no,What is the Submission Number?,246943,98
sample_nocs/0000036072.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,46
sample_nocs/0000036072.PDF,product_name,What is the Product name?,pms-TERIFLUNOMIDE,72
sample_nocs/0000036072.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 14mg",87
sample_nocs/0000036072.PDF,species,What is the species?,NA,NA
sample_nocs/0000036072.PDF,noc_date,What is the date of the document?,"May 16, 2022",81
sample_nocs/0000036072.PDF,medicinal_ingredients,What are the medicinal ingredients?,Teriflunomide,95
sample_nocs/0000036255.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cymbalta, Eli Lilly Canada Inc.",30.000001907348633
sample_nocs/0000036255.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,52
sample_nocs/0000036255.PDF,noc_reason,What was the reason for the submission?,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise a jour de l'étiquetage (pour correspondre au concédant) AND / ET Update to product monograph / Mise a jour de la monographie de produit,2
sample_nocs/0000036255.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Bruce Randall,99
sample_nocs/0000036255.PDF,dossier_id,What is the Dossier Id?,e227544,94
sample_nocs/0000036255.PDF,submission_no,What is the Submission Number?,259738,98
sample_nocs/0000036255.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,50
sample_nocs/0000036255.PDF,product_name,What is the Product name?,DULOXETINE,50
sample_nocs/0000036255.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / orale, Capsule (delayed-release) / capsule",42
sample_nocs/0000036255.PDF,species,What is the species?,NA,NA
sample_nocs/0000036255.PDF,noc_date,What is the date of the document?,"May 27, 2022",92
sample_nocs/0000036255.PDF,medicinal_ingredients,What are the medicinal ingredients?,Duloxetine(supplied as duloxetine hydrochloride)/Duloxétine (sous forme de chlorhydrate de duloxétine),14
sample_nocs/0000036296.PDF,canadian_reference_product,What is the Canadian Reference Product?,ERLEADA,84
sample_nocs/0000036296.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,58.999996185302734
sample_nocs/0000036296.PDF,noc_reason,What was the reason for the submission?,To update the Product Monograph,56
sample_nocs/0000036296.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,96
sample_nocs/0000036296.PDF,dossier_id,What is the Dossier Id?,e198960,88
sample_nocs/0000036296.PDF,submission_no,What is the Submission Number?,252766,98
sample_nocs/0000036296.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,73
sample_nocs/0000036296.PDF,product_name,What is the Product name?,ERLEADA,92
sample_nocs/0000036296.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 60mg",81
sample_nocs/0000036296.PDF,species,What is the species?,NA,NA
sample_nocs/0000036296.PDF,noc_date,What is the date of the document?,"June 1, 2022",65
sample_nocs/0000036296.PDF,medicinal_ingredients,What are the medicinal ingredients?,Apalutamide,90
sample_nocs/0000036353.PDF,canadian_reference_product,What is the Canadian Reference Product?,TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR,96
sample_nocs/0000036353.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,69
sample_nocs/0000036353.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph as per Advisement Letter / Mise a jour of la monographie de produit comme la lettre d'annonce,19
sample_nocs/0000036353.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000036353.PDF,dossier_id,What is the Dossier Id?,e136763,95
sample_nocs/0000036353.PDF,submission_no,What is the Submission Number?,259791,98
sample_nocs/0000036353.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,94
sample_nocs/0000036353.PDF,product_name,What is the Product name?,TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR,97
sample_nocs/0000036353.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé",74
sample_nocs/0000036353.PDF,species,What is the species?,NA,NA
sample_nocs/0000036353.PDF,noc_date,What is the date of the document?,"June 7, 2022",77
sample_nocs/0000036353.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diclofenac Sodium / Diclofénac sodique,95
sample_nocs/0000036711.PDF,canadian_reference_product,What is the Canadian Reference Product?,Merck Canada Inc.,68
sample_nocs/0000036711.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,60.000003814697266
sample_nocs/0000036711.PDF,noc_reason,What was the reason for the submission?,drogue nouvelle citée en rubrique,18
sample_nocs/0000036711.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,99
sample_nocs/0000036711.PDF,dossier_id,What is the Dossier Id?,e243433,95
sample_nocs/0000036711.PDF,submission_no,What is the Submission Number?,254495,98
sample_nocs/0000036711.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,60.000003814697266
sample_nocs/0000036711.PDF,product_name,What is the Product name?,WELIREG,96
sample_nocs/0000036711.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02528908, Oral/Orale, Tablet/Comprimé, 40 mg",48
sample_nocs/0000036711.PDF,species,What is the species?,NA,NA
sample_nocs/0000036711.PDF,noc_date,What is the date of the document?,"July 11, 2022",77
sample_nocs/0000036711.PDF,medicinal_ingredients,What are the medicinal ingredients?,Belzutifan,99
sample_nocs/0000036792.PDF,canadian_reference_product,What is the Canadian Reference Product?,WELLBUTRIN SR,98
sample_nocs/0000036792.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,82
sample_nocs/0000036792.PDF,noc_reason,What was the reason for the submission?,Safety Update to the post-market ADR section of the Product Monograph (PM),57
sample_nocs/0000036792.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000036792.PDF,dossier_id,What is the Dossier Id?,e144609,95
sample_nocs/0000036792.PDF,submission_no,What is the Submission Number?,261888,99
sample_nocs/0000036792.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Bausch Health, Canada Inc.",77
sample_nocs/0000036792.PDF,product_name,What is the Product name?,WELLBUTRIN SR,98
sample_nocs/0000036792.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet (Extended-Release)/Comprimé",52
sample_nocs/0000036792.PDF,species,What is the species?,NA,NA
sample_nocs/0000036792.PDF,noc_date,What is the date of the document?,"July 18, 2022",88
sample_nocs/0000036792.PDF,medicinal_ingredients,What are the medicinal ingredients?,Bupropion Hydrochloride / Chlorhydrate de bupropion,62
sample_nocs/0000036894.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CERENIA (DIN 02299542, Zoetis Canada Inc.)",47
sample_nocs/0000036894.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000036894.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000036894.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Jennifer Geduld,98
sample_nocs/0000036894.PDF,dossier_id,What is the Dossier Id?,v218386,94
sample_nocs/0000036894.PDF,submission_no,What is the Submission Number?,257671,98
sample_nocs/0000036894.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Dechra Regulatory BV,95
sample_nocs/0000036894.PDF,product_name,What is the Product name?,Emavert,93
sample_nocs/0000036894.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02529564, Intravenous, Subcutaneous, Solution, 10 mg/mL",51
sample_nocs/0000036894.PDF,species,What is the species?,"Dogs, Cats / Chiens, Chats",84
sample_nocs/0000036894.PDF,noc_date,What is the date of the document?,"July 29, 2022 / 29 juillet 2022",44
sample_nocs/0000036894.PDF,medicinal_ingredients,What are the medicinal ingredients?,Maropitant / Maropitant,94
sample_nocs/0000037011.PDF,canadian_reference_product,What is the Canadian Reference Product?,OCTASA,50
sample_nocs/0000037011.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,58.999996185302734
sample_nocs/0000037011.PDF,noc_reason,What was the reason for the submission?,New strength and treatment regimen for moderate active ulcerative colitis (UC).,56
sample_nocs/0000037011.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000037011.PDF,dossier_id,What is the Dossier Id?,e169564,96
sample_nocs/0000037011.PDF,submission_no,What is the Submission Number?,255153,100
sample_nocs/0000037011.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"August 8, 2022",78
sample_nocs/0000037011.PDF,product_name,What is the Product name?,OCTASA,84
sample_nocs/0000037011.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02529610, Oral/Orale, Tablet (Delayed-Release)/Comprimé",21
sample_nocs/0000037011.PDF,species,What is the species?,NA,NA
sample_nocs/0000037011.PDF,noc_date,What is the date of the document?,"August 8, 2022",89
sample_nocs/0000037011.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mesalazine/Mésalazine,89
sample_nocs/0000037120.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Fosamax, Merck Frosst Canada Ltd., Canada",47
sample_nocs/0000037120.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,67
sample_nocs/0000037120.PDF,noc_reason,What was the reason for the submission?,Administrative,47
sample_nocs/0000037120.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,79
sample_nocs/0000037120.PDF,dossier_id,What is the Dossier Id?,e222662,64
sample_nocs/0000037120.PDF,submission_no,What is the Submission Number?,265965,96
sample_nocs/0000037120.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Angita Pharma Inc.,30.000001907348633
sample_nocs/0000037120.PDF,product_name,What is the Product name?,AG-ALENDRONATE,94
sample_nocs/0000037120.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 5 mg",83
sample_nocs/0000037120.PDF,species,What is the species?,NA,NA
sample_nocs/0000037120.PDF,noc_date,What is the date of the document?,"August 19, 2022",86
sample_nocs/0000037120.PDF,medicinal_ingredients,What are the medicinal ingredients?,Alendronic Acid supplied as Alendronate Sodium / Acide alendronique sous forme d'alendronate sodique,58.999996185302734
sample_nocs/0000037122.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ULTRAM, Janssen Inc., Canada",56
sample_nocs/0000037122.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,84
sample_nocs/0000037122.PDF,noc_reason,What was the reason for the submission?,Safety updates to the product monograph / Mise a jour de l'innocuité dans la monographie de produit,36
sample_nocs/0000037122.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Leslie Vrooman, M.Sc.",61
sample_nocs/0000037122.PDF,dossier_id,What is the Dossier Id?,e169077,94
sample_nocs/0000037122.PDF,submission_no,What is the Submission Number?,266565,97
sample_nocs/0000037122.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,77
sample_nocs/0000037122.PDF,product_name,What is the Product name?,APO-TRAMADOL,96
sample_nocs/0000037122.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 50 mg",79
sample_nocs/0000037122.PDF,species,What is the species?,NA,NA
sample_nocs/0000037122.PDF,noc_date,What is the date of the document?,"August 18, 2022",86
sample_nocs/0000037122.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tramadol hydrochloride / Chlorhydrate de tramadol,90
sample_nocs/0000037127.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lovenox, Lovenox HP",71
sample_nocs/0000037127.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000037127.PDF,noc_reason,What was the reason for the submission?,Additional drug substance manufacturing site / Site de fabrication additionnel for la substance médicamenteuse,24
sample_nocs/0000037127.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",40
sample_nocs/0000037127.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000037127.PDF,submission_no,What is the Submission Number?,260589,98
sample_nocs/0000037127.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Incorporated,93
sample_nocs/0000037127.PDF,product_name,What is the Product name?,"Inclunox, Inclunox HP",96
sample_nocs/0000037127.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A - SC, IV, SOL, 30 mg/0.3 mL",57
sample_nocs/0000037127.PDF,species,What is the species?,NA,NA
sample_nocs/0000037127.PDF,noc_date,What is the date of the document?,"August 18, 2022",93
sample_nocs/0000037127.PDF,medicinal_ingredients,What are the medicinal ingredients?,Enoxaparin sodium / énoxaparine sodique,84
sample_nocs/0000037218.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000037218.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,43
sample_nocs/0000037218.PDF,noc_reason,What was the reason for the submission?,Merger/Buy-out / Administratif: Fusion/rachat,16
sample_nocs/0000037218.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000037218.PDF,dossier_id,What is the Dossier Id?,e122158,95
sample_nocs/0000037218.PDF,submission_no,What is the Submission Number?,266495,97
sample_nocs/0000037218.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,AbbVie Corporation,72
sample_nocs/0000037218.PDF,product_name,What is the Product name?,ALPHAGAN P,98
sample_nocs/0000037218.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02248151,50
sample_nocs/0000037218.PDF,species,What is the species?,NA,NA
sample_nocs/0000037218.PDF,noc_date,What is the date of the document?,"August 29, 2022",79
sample_nocs/0000037218.PDF,medicinal_ingredients,What are the medicinal ingredients?,Brimonidine Tartrate / Tartrate de brimonidine,72
sample_nocs/0000037219.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Alertec, Shire Canada Inc., Canada",44
sample_nocs/0000037219.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,48
sample_nocs/0000037219.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,63
sample_nocs/0000037219.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000037219.PDF,dossier_id,What is the Dossier Id?,249329,77
sample_nocs/0000037219.PDF,submission_no,What is the Submission Number?,249329,97
sample_nocs/0000037219.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc,39
sample_nocs/0000037219.PDF,product_name,What is the Product name?,MODAFINIL,76
sample_nocs/0000037219.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02530244, oral / orale, tablet / comprimé, 100 mg",80
sample_nocs/0000037219.PDF,species,What is the species?,NA,NA
sample_nocs/0000037219.PDF,noc_date,What is the date of the document?,"August 30, 2022",71
sample_nocs/0000037219.PDF,medicinal_ingredients,What are the medicinal ingredients?,Modafinil,84
sample_nocs/0000037220.PDF,canadian_reference_product,What is the Canadian Reference Product?,"AFINITOR, Novartis Pharmaceuticals Canada Inc., Canada",43
sample_nocs/0000037220.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000037220.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000037220.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,98
sample_nocs/0000037220.PDF,dossier_id,What is the Dossier Id?,e203827,94
sample_nocs/0000037220.PDF,submission_no,What is the Submission Number?,251033,98
sample_nocs/0000037220.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,87
sample_nocs/0000037220.PDF,product_name,What is the Product name?,NAT-EVEROLIMUS,89
sample_nocs/0000037220.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02530090, Oral / Orale, Tablet / Comprimé, 2.5 mg",85
sample_nocs/0000037220.PDF,species,What is the species?,NA,NA
sample_nocs/0000037220.PDF,noc_date,What is the date of the document?,"August 29, 2022",81
sample_nocs/0000037220.PDF,medicinal_ingredients,What are the medicinal ingredients?,Everolimus / Évérolimus,87
sample_nocs/0000037382.PDF,canadian_reference_product,What is the Canadian Reference Product?,Keytruda,67
sample_nocs/0000037382.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,31
sample_nocs/0000037382.PDF,noc_reason,What was the reason for the submission?,Product Monograph update / Mise a jour de la monographie de produit,42
sample_nocs/0000037382.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Celia Lourenco, Ph.D.",41
sample_nocs/0000037382.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000037382.PDF,submission_no,What is the Submission Number?,263895,98
sample_nocs/0000037382.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Merck Canada Inc.,56
sample_nocs/0000037382.PDF,product_name,What is the Product name?,Keytruda,99
sample_nocs/0000037382.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 25 mg / mL",54.000003814697266
sample_nocs/0000037382.PDF,species,What is the species?,NA,NA
sample_nocs/0000037382.PDF,noc_date,What is the date of the document?,"September 14, 2022",93
sample_nocs/0000037382.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pembrolizumab,99
sample_nocs/0000037486.PDF,canadian_reference_product,What is the Canadian Reference Product?,ELIQUIS,51
sample_nocs/0000037486.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000037486.PDF,noc_reason,What was the reason for the submission?,Companies / Administratif: Accord de licence entre deux sociétés,49
sample_nocs/0000037486.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000037486.PDF,dossier_id,What is the Dossier Id?,e265050,68
sample_nocs/0000037486.PDF,submission_no,What is the Submission Number?,265050,97
sample_nocs/0000037486.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc.,50
sample_nocs/0000037486.PDF,product_name,What is the Product name?,M-APIXABAN,94
sample_nocs/0000037486.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02529009, oral / orale, tablet / comprimé, 2.5 mg",76
sample_nocs/0000037486.PDF,species,What is the species?,NA,NA
sample_nocs/0000037486.PDF,noc_date,What is the date of the document?,"September 20, 2022",83
sample_nocs/0000037486.PDF,medicinal_ingredients,What are the medicinal ingredients?,Apixaban,91
sample_nocs/0000037493.PDF,canadian_reference_product,What is the Canadian Reference Product?,APO-DICLO and APO-DICLO SR,97
sample_nocs/0000037493.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,68
sample_nocs/0000037493.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph as per Advisement Letter / Mise a jour of la monographie de produit,21
sample_nocs/0000037493.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000037493.PDF,dossier_id,What is the Dossier Id?,e124878,93
sample_nocs/0000037493.PDF,submission_no,What is the Submission Number?,260911,98
sample_nocs/0000037493.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,90
sample_nocs/0000037493.PDF,product_name,What is the Product name?,APO-DICLO and APO-DICLO SR,97
sample_nocs/0000037493.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé",75
sample_nocs/0000037493.PDF,species,What is the species?,NA,NA
sample_nocs/0000037493.PDF,noc_date,What is the date of the document?,"September 22, 2022",92
sample_nocs/0000037493.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diclofenac Sodium / Diclofénac sodique,95
sample_nocs/0000037656.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zoloft, Pfizer Canada Inc., Canada",4
sample_nocs/0000037656.PDF,directorate,What is the directorate that approved the submission?,Direction des médicaments pharmaceutiques,34
sample_nocs/0000037656.PDF,noc_reason,What was the reason for the submission?,Administrative,49
sample_nocs/0000037656.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000037656.PDF,dossier_id,What is the Dossier Id?,e139311,89
sample_nocs/0000037656.PDF,submission_no,What is the Submission Number?,267374,96
sample_nocs/0000037656.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,28
sample_nocs/0000037656.PDF,product_name,What is the Product name?,SERTRALINE,58
sample_nocs/0000037656.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, capsule, 25 mg",89
sample_nocs/0000037656.PDF,species,What is the species?,NA,NA
sample_nocs/0000037656.PDF,noc_date,What is the date of the document?,"October 4, 2022",80
sample_nocs/0000037656.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sertraline supplied as Sertraline Hydrochloride / Sertraline fournie sous forme de chlorhydrate de sertraline,40
sample_nocs/0000037791.PDF,canadian_reference_product,What is the Canadian Reference Product?,SPORANOX,97
sample_nocs/0000037791.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,56
sample_nocs/0000037791.PDF,noc_reason,What was the reason for the submission?,Updates to the Product Monograph (PM) with drug-drug interactions and PM conversion to the 2020 master template.,49
sample_nocs/0000037791.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000037791.PDF,dossier_id,What is the Dossier Id?,e136813,94
sample_nocs/0000037791.PDF,submission_no,What is the Submission Number?,264069,98
sample_nocs/0000037791.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,64
sample_nocs/0000037791.PDF,product_name,What is the Product name?,SPORANOX,96
sample_nocs/0000037791.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Capsule, 100 mg",85
sample_nocs/0000037791.PDF,species,What is the species?,NA,NA
sample_nocs/0000037791.PDF,noc_date,What is the date of the document?,"October 7, 2022",76
sample_nocs/0000037791.PDF,medicinal_ingredients,What are the medicinal ingredients?,Itraconazole,96
sample_nocs/0000037824.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PLAVIX, Sanofi-Synthelabo., Canada",49
sample_nocs/0000037824.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,39
sample_nocs/0000037824.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie du produit,36
sample_nocs/0000037824.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000037824.PDF,dossier_id,What is the Dossier Id?,e132233,96
sample_nocs/0000037824.PDF,submission_no,What is the Submission Number?,264359,97
sample_nocs/0000037824.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,93
sample_nocs/0000037824.PDF,product_name,What is the Product name?,ACT CLOPIDOGREL,85
sample_nocs/0000037824.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 75 mg",62
sample_nocs/0000037824.PDF,species,What is the species?,NA,NA
sample_nocs/0000037824.PDF,noc_date,What is the date of the document?,"October 20, 2022",64
sample_nocs/0000037824.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel (as Clopidogrel Bisulfate) / Clopidogrel (sous forme de bisulfate de clopidogrel),27.000001907348633
sample_nocs/0000037896.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000037896.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000037896.PDF,noc_reason,What was the reason for the submission?,Addition of an alternate pork liver flavour excipient supplier / Ajout du fournisseur alternatif d'excipients d'arôme de foie de porc,63
sample_nocs/0000037896.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,97
sample_nocs/0000037896.PDF,dossier_id,What is the Dossier Id?,v159938,96
sample_nocs/0000037896.PDF,submission_no,What is the Submission Number?,262863,98
sample_nocs/0000037896.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Intervet Canada Corp,97
sample_nocs/0000037896.PDF,product_name,What is the Product name?,BRAVECTO,85
sample_nocs/0000037896.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02425068, Oral, Chewable Tablet, 112.5 mg/tab",72
sample_nocs/0000037896.PDF,species,What is the species?,Dogs / Chiens,92
sample_nocs/0000037896.PDF,noc_date,What is the date of the document?,"October 26,2022 / 26 October 2022",24
sample_nocs/0000037896.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluralaner / Fluralaner,96
sample_nocs/0000038152.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ARIMIDEX, AstraZeneca UK Ltd., France",50
sample_nocs/0000038152.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,47
sample_nocs/0000038152.PDF,noc_reason,What was the reason for the submission?,Addition of manufacturing site of the drug substance / Ajout d'un site de fabrication of the drug substance / Remplacement d'un site of fabrication impliquant la production of the substance médicamenteuse,5
sample_nocs/0000038152.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000038152.PDF,dossier_id,What is the Dossier Id?,e124319,96
sample_nocs/0000038152.PDF,submission_no,What is the Submission Number?,263071,98
sample_nocs/0000038152.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,74
sample_nocs/0000038152.PDF,product_name,What is the Product name?,SANDOZ ANASTROZOLE,60.000003814697266
sample_nocs/0000038152.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 1 mg",60.000003814697266
sample_nocs/0000038152.PDF,species,What is the species?,NA,NA
sample_nocs/0000038152.PDF,noc_date,What is the date of the document?,"November 16, 2022",70
sample_nocs/0000038152.PDF,medicinal_ingredients,What are the medicinal ingredients?,Anastrozole / Anastrozole,72
sample_nocs/0000038201.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PLAVIX by Sanofi-Aventis Canada Inc., Canada",62
sample_nocs/0000038201.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,38
sample_nocs/0000038201.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,30.000001907348633
sample_nocs/0000038201.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000038201.PDF,dossier_id,What is the Dossier Id?,e157025,95
sample_nocs/0000038201.PDF,submission_no,What is the Submission Number?,264971,97
sample_nocs/0000038201.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,70
sample_nocs/0000038201.PDF,product_name,What is the Product name?,AURO-CLOPIDOGREL,70
sample_nocs/0000038201.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 75 mg",77
sample_nocs/0000038201.PDF,species,What is the species?,NA,NA
sample_nocs/0000038201.PDF,noc_date,What is the date of the document?,"November 17, 2022",78
sample_nocs/0000038201.PDF,medicinal_ingredients,What are the medicinal ingredients?,Clopidogrel(supplied as Clopidogrel Bisulfate)/(forme comme Bisulfate de clopidogrel),18
sample_nocs/0000038237.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ENABLEX, Novartis Pharmaceuticals Canada Inc., Canada",51
sample_nocs/0000038237.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000038237.PDF,noc_reason,What was the reason for the submission?,Update to Labels / Mise a jour desétiquettes,28
sample_nocs/0000038237.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000038237.PDF,dossier_id,What is the Dossier Id?,e170837,93
sample_nocs/0000038237.PDF,submission_no,What is the Submission Number?,265069,98
sample_nocs/0000038237.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,87
sample_nocs/0000038237.PDF,product_name,What is the Product name?,APO-DARIFENACIN,96
sample_nocs/0000038237.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé",58
sample_nocs/0000038237.PDF,species,What is the species?,NA,NA
sample_nocs/0000038237.PDF,noc_date,What is the date of the document?,"November 24, 2022",72
sample_nocs/0000038237.PDF,medicinal_ingredients,What are the medicinal ingredients?,Darifenacin (as darifenacin hydrobromide) / Darifénacine (forme comme bromhydrate de darifénacine),23
sample_nocs/0000038252.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Losec, AstraZeneca Canada Inc., Canada",56
sample_nocs/0000038252.PDF,directorate,What is the directorate that approved the submission?,Direction des médicaments pharmaceutiques,44
sample_nocs/0000038252.PDF,noc_reason,What was the reason for the submission?,Administrative: Mise a jour de l'étiquetage (pour correspondre au concédant),19
sample_nocs/0000038252.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,96
sample_nocs/0000038252.PDF,dossier_id,What is the Dossier Id?,e190063,94
sample_nocs/0000038252.PDF,submission_no,What is the Submission Number?,269353,96
sample_nocs/0000038252.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000038252.PDF,product_name,What is the Product name?,OMEPRAZOLE,61
sample_nocs/0000038252.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, capsule (delayed release) / capsule (to libération retardée), 20 mg",30.000001907348633
sample_nocs/0000038252.PDF,species,What is the species?,NA,NA
sample_nocs/0000038252.PDF,noc_date,What is the date of the document?,"November 22, 2022",77
sample_nocs/0000038252.PDF,medicinal_ingredients,What are the medicinal ingredients?,Omeprazole / Oméprazole,60.000003814697266
sample_nocs/0000038271.PDF,canadian_reference_product,What is the Canadian Reference Product?,"SENSIPAR, Amgen Canada Inc., Canada",62
sample_nocs/0000038271.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000038271.PDF,noc_reason,What was the reason for the submission?,Addition of a manufacturing site of the drug substance / Ajout d'un site de fabrication of the substance médicamenteuse,32
sample_nocs/0000038271.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000038271.PDF,dossier_id,What is the Dossier Id?,e205052,91
sample_nocs/0000038271.PDF,submission_no,What is the Submission Number?,255298,98
sample_nocs/0000038271.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,87
sample_nocs/0000038271.PDF,product_name,What is the Product name?,MAR-CINACALCET,95
sample_nocs/0000038271.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 30 mg",81
sample_nocs/0000038271.PDF,species,What is the species?,NA,NA
sample_nocs/0000038271.PDF,noc_date,What is the date of the document?,"November 25, 2022",70
sample_nocs/0000038271.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cinacalcet (supplied as Cinacalcet Hydrochloride) / Cinacalcet (sous forme de chlorhydrate de Cinacalcet),30.000001907348633
sample_nocs/0000038382.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Lipitor,Pfizer Canada Inc.",22
sample_nocs/0000038382.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,22
sample_nocs/0000038382.PDF,noc_reason,What was the reason for the submission?,Administrative: Accord de licence entre deux sociétés,20
sample_nocs/0000038382.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000038382.PDF,dossier_id,What is the Dossier Id?,e172769,83
sample_nocs/0000038382.PDF,submission_no,What is the Submission Number?,269424,96
sample_nocs/0000038382.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000038382.PDF,product_name,What is the Product name?,RIVA-ATORVASTATIN,89
sample_nocs/0000038382.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02422751, oral / orale, tablet / comprimé, 10 mg",76
sample_nocs/0000038382.PDF,species,What is the species?,NA,NA
sample_nocs/0000038382.PDF,noc_date,What is the date of the document?,"November 30, 2022",69
sample_nocs/0000038382.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Atorvastatin, Calcium / Atorvastatine sous forme d'atorvastatine calcique",23
sample_nocs/0000038414.PDF,canadian_reference_product,What is the Canadian Reference Product?,EVRYSDI,91
sample_nocs/0000038414.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,43
sample_nocs/0000038414.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph,76
sample_nocs/0000038414.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000038414.PDF,dossier_id,What is the Dossier Id?,e233002,91
sample_nocs/0000038414.PDF,submission_no,What is the Submission Number?,259796,98
sample_nocs/0000038414.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,99
sample_nocs/0000038414.PDF,product_name,What is the Product name?,EVRYSDI,92
sample_nocs/0000038414.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Powder for Solution/Poudre for solution,.75",32
sample_nocs/0000038414.PDF,species,What is the species?,NA,NA
sample_nocs/0000038414.PDF,noc_date,What is the date of the document?,"December 7, 2022",85
sample_nocs/0000038414.PDF,medicinal_ingredients,What are the medicinal ingredients?,Risdiplam / Risdiplam,96
sample_nocs/0000038681.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Arimidex, AstraZeneca Pharmaceuticals LP, USA",67
sample_nocs/0000038681.PDF,directorate,What is the directorate that approved the submission?,Direction des médicaments pharmaceutiques,20
sample_nocs/0000038681.PDF,noc_reason,What was the reason for the submission?,Companies / Administratif: Accord de licence entre deux sociétés,26
sample_nocs/0000038681.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000038681.PDF,dossier_id,What is the Dossier Id?,e269891,48
sample_nocs/0000038681.PDF,submission_no,What is the Submission Number?,269891,90
sample_nocs/0000038681.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Angita Pharma Inc.,52.999996185302734
sample_nocs/0000038681.PDF,product_name,What is the Product name?,AG-ANASTROZOLE,96
sample_nocs/0000038681.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02534118, oral / orale, tablet / comprimé, 1 mg",46
sample_nocs/0000038681.PDF,species,What is the species?,NA,NA
sample_nocs/0000038681.PDF,noc_date,What is the date of the document?,"January 3, 2023",81
sample_nocs/0000038681.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Anastrozole, 5.1.10",2
sample_nocs/0000038833.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CYKLOKAPRON, Pfizer Canada Inc., Canada",66
sample_nocs/0000038833.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,52.999996185302734
sample_nocs/0000038833.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,39
sample_nocs/0000038833.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,90
sample_nocs/0000038833.PDF,dossier_id,What is the Dossier Id?,e185943,92
sample_nocs/0000038833.PDF,submission_no,What is the Submission Number?,266686,97
sample_nocs/0000038833.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,80
sample_nocs/0000038833.PDF,product_name,What is the Product name?,Tranexamic Acid InJECTION,65
sample_nocs/0000038833.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous / Intraveineuse, Solution, 100 mg/mL",58
sample_nocs/0000038833.PDF,species,What is the species?,NA,NA
sample_nocs/0000038833.PDF,noc_date,What is the date of the document?,"January 16, 2023",74
sample_nocs/0000038833.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tranexamic Acid / Acide tranexamique,86
sample_nocs/0000039091.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Cymbalta, Eli Lilly Canada Inc.",28
sample_nocs/0000039091.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,25
sample_nocs/0000039091.PDF,noc_reason,What was the reason for the submission?,Supplement,65
sample_nocs/0000039091.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000039091.PDF,dossier_id,What is the Dossier Id?,e220439,80
sample_nocs/0000039091.PDF,submission_no,What is the Submission Number?,271223,98
sample_nocs/0000039091.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Altamed Pharma,90
sample_nocs/0000039091.PDF,product_name,What is the Product name?,DULOXETINE,52.999996185302734
sample_nocs/0000039091.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02481952, oral / orale, capsule (delayed release) / capsule (to libération retardée), 30 mg",27.000001907348633
sample_nocs/0000039091.PDF,species,What is the species?,NA,NA
sample_nocs/0000039091.PDF,noc_date,What is the date of the document?,"February 6, 2023",87
sample_nocs/0000039091.PDF,medicinal_ingredients,What are the medicinal ingredients?,Duloxetine supplied as Duloxetine Hydrochloride / Duloxétine sous forme de chlorhydrate de duloxétine,67
sample_nocs/0000039113.PDF,canadian_reference_product,What is the Canadian Reference Product?,PENTACEL,61
sample_nocs/0000039113.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,40
sample_nocs/0000039113.PDF,noc_reason,What was the reason for the submission?,Change in formulation / Changement  to the formulation,18
sample_nocs/0000039113.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Michael Rosu-Myles, Ph.D.",37
sample_nocs/0000039113.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000039113.PDF,submission_no,What is the Submission Number?,261020,98
sample_nocs/0000039113.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi Pasteur Limited,96
sample_nocs/0000039113.PDF,product_name,What is the Product name?,PENTACEL,98
sample_nocs/0000039113.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02534797, IM, SUS, 20 g / 0.5 mL",47
sample_nocs/0000039113.PDF,species,What is the species?,NA,NA
sample_nocs/0000039113.PDF,noc_date,What is the date of the document?,"February 9, 2023",92
sample_nocs/0000039113.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Pertussis toxoid / anatoxine coquelucheuse, filamentous haemagglutinin / hémagglutinine filamenteuse, pertactin / pertactine, fimbriae types 2 and",26
sample_nocs/0000039204.PDF,canadian_reference_product,What is the Canadian Reference Product?,"POMALYST, Celgene Inc., Canada",51
sample_nocs/0000039204.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000039204.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000039204.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000039204.PDF,dossier_id,What is the Dossier Id?,234814,81
sample_nocs/0000039204.PDF,submission_no,What is the Submission Number?,234814,98
sample_nocs/0000039204.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,83
sample_nocs/0000039204.PDF,product_name,What is the Product name?,REDDY-POMALIDOMIDE,77
sample_nocs/0000039204.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02504073, Oral / Orale, Capsule / Capsule, 1 mg",65
sample_nocs/0000039204.PDF,species,What is the species?,NA,NA
sample_nocs/0000039204.PDF,noc_date,What is the date of the document?,"February 20, 2023",91
sample_nocs/0000039204.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pomalidomide/Pomalidomide,56
sample_nocs/0000039234.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000039234.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,45
sample_nocs/0000039234.PDF,noc_reason,What was the reason for the submission?,A new drug product manufacturing site and a change in the drug product manufacturing process.,67
sample_nocs/0000039234.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000039234.PDF,dossier_id,What is the Dossier Id?,e117576,95
sample_nocs/0000039234.PDF,submission_no,What is the Submission Number?,264700,99
sample_nocs/0000039234.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Lantheus MI Canada Inc.,41
sample_nocs/0000039234.PDF,product_name,What is the Product name?,DEFINITY,98
sample_nocs/0000039234.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous/Intravenous Suspension, 150 mcl/ml",47
sample_nocs/0000039234.PDF,species,What is the species?,NA,NA
sample_nocs/0000039234.PDF,noc_date,What is the date of the document?,"February 17, 2023",94
sample_nocs/0000039234.PDF,medicinal_ingredients,What are the medicinal ingredients?,Perflutren / Perflutrène,95
sample_nocs/0000039240.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ADALAT XL, Bayer Inc., Canada",87
sample_nocs/0000039240.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000039240.PDF,noc_reason,What was the reason for the submission?,Update to labels to align with Plain Language Labelling Regulations / Mise a jour de l'étiquetage devant respecter les exigences de l'étiquetage en langage clair,33
sample_nocs/0000039240.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000039240.PDF,dossier_id,What is the Dossier Id?,e153082,93
sample_nocs/0000039240.PDF,submission_no,What is the Submission Number?,267700,99
sample_nocs/0000039240.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,86
sample_nocs/0000039240.PDF,product_name,What is the Product name?,PMS-NIFEDIPINE ER,94
sample_nocs/0000039240.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé",57
sample_nocs/0000039240.PDF,species,What is the species?,NA,NA
sample_nocs/0000039240.PDF,noc_date,What is the date of the document?,"February 22, 2023",96
sample_nocs/0000039240.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nifedipine / Nifédipine,82
sample_nocs/0000039388.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ZOCOR, Merck Canada Inc., Canada",23
sample_nocs/0000039388.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,79
sample_nocs/0000039388.PDF,noc_reason,What was the reason for the submission?,Administrative: Mise a jour de l'étiquetage (pour correspondre au concédant),13
sample_nocs/0000039388.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Laura Durno, MSc",67
sample_nocs/0000039388.PDF,dossier_id,What is the Dossier Id?,e144767,87
sample_nocs/0000039388.PDF,submission_no,What is the Submission Number?,272254,98
sample_nocs/0000039388.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,44
sample_nocs/0000039388.PDF,product_name,What is the Product name?,SIMVASTATIN,60.000003814697266
sample_nocs/0000039388.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 5 mg",87
sample_nocs/0000039388.PDF,species,What is the species?,NA,NA
sample_nocs/0000039388.PDF,noc_date,What is the date of the document?,"March 7, 2023",89
sample_nocs/0000039388.PDF,medicinal_ingredients,What are the medicinal ingredients?,Simvastatin / Simvastatine,88
sample_nocs/0000039431.PDF,canadian_reference_product,What is the Canadian Reference Product?,"TOVIAZ, Pfizer Canada Inc., Canada",80
sample_nocs/0000039431.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000039431.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000039431.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000039431.PDF,dossier_id,What is the Dossier Id?,259748,51
sample_nocs/0000039431.PDF,submission_no,What is the Submission Number?,259748,98
sample_nocs/0000039431.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,84
sample_nocs/0000039431.PDF,product_name,What is the Product name?,ACH-FESOTERODINE,83
sample_nocs/0000039431.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02535998, Oral / Orale, Tablet (Extended-Release)",61
sample_nocs/0000039431.PDF,species,What is the species?,NA,NA
sample_nocs/0000039431.PDF,noc_date,What is the date of the document?,"March 9, 2023",89
sample_nocs/0000039431.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fesoterodine Fumarate / Fumarate de fésotérodine,81
sample_nocs/0000039547.PDF,canadian_reference_product,What is the Canadian Reference Product?,"IMITREX, GlaxoSmithKline Inc., Canada",55
sample_nocs/0000039547.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,40
sample_nocs/0000039547.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,39
sample_nocs/0000039547.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000039547.PDF,dossier_id,What is the Dossier Id?,e106525,95
sample_nocs/0000039547.PDF,submission_no,What is the Submission Number?,269764,96
sample_nocs/0000039547.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,88
sample_nocs/0000039547.PDF,product_name,What is the Product name?,APO-SUMATRIPTAN,94
sample_nocs/0000039547.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Nasal / Nasale, Spray / Pulvérisation, 5 mg",73
sample_nocs/0000039547.PDF,species,What is the species?,NA,NA
sample_nocs/0000039547.PDF,noc_date,What is the date of the document?,"March 23, 2023",93
sample_nocs/0000039547.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sumatriptan (supplied as sumatriptan hemisulfate) / Sumatriptan (sous forme d'hémisulfate de sumatriptan),26
sample_nocs/0000039617.PDF,canadian_reference_product,What is the Canadian Reference Product?,XOFLUZA,97
sample_nocs/0000039617.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000039617.PDF,noc_reason,What was the reason for the submission?,Addition of a drug product manufacturer. Change in the drug product manufacturing process.,89
sample_nocs/0000039617.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000039617.PDF,dossier_id,What is the Dossier Id?,e222951,81
sample_nocs/0000039617.PDF,submission_no,What is the Submission Number?,267547,97
sample_nocs/0000039617.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Hoffmann-La Roche Limited,99
sample_nocs/0000039617.PDF,product_name,What is the Product name?,XOFLUZA,99
sample_nocs/0000039617.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 80 mg",80
sample_nocs/0000039617.PDF,species,What is the species?,NA,NA
sample_nocs/0000039617.PDF,noc_date,What is the date of the document?,"March 27, 2023",92
sample_nocs/0000039617.PDF,medicinal_ingredients,What are the medicinal ingredients?,Baloxavir Marboxil,98
sample_nocs/0000039929.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Gleevec, Novartis Pharmaceuticals Canada Inc.",26
sample_nocs/0000039929.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,72
sample_nocs/0000039929.PDF,noc_reason,What was the reason for the submission?,Administrative: Mise a jour de l'étiquetage (pour correspondre au concédant),16
sample_nocs/0000039929.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Laura Durno, MSc",65
sample_nocs/0000039929.PDF,dossier_id,What is the Dossier Id?,e241709,89
sample_nocs/0000039929.PDF,submission_no,What is the Submission Number?,274031,99
sample_nocs/0000039929.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,45
sample_nocs/0000039929.PDF,product_name,What is the Product name?,IMATINIB,63
sample_nocs/0000039929.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 100 mg",86
sample_nocs/0000039929.PDF,species,What is the species?,NA,NA
sample_nocs/0000039929.PDF,noc_date,What is the date of the document?,"April 28, 2023",86
sample_nocs/0000039929.PDF,medicinal_ingredients,What are the medicinal ingredients?,Imatinib supplied as Imatinib Mesylate / sous forme de mésylate d'imatinib,84
sample_nocs/0000040061.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Zoloft, Pfizer Canada Inc., Canada",30.000001907348633
sample_nocs/0000040061.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,84
sample_nocs/0000040061.PDF,noc_reason,What was the reason for the submission?,Safety updates to the product monograph / Mise a jour de l'innocuité dans la monographie de produit,33
sample_nocs/0000040061.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000040061.PDF,dossier_id,What is the Dossier Id?,e142626,93
sample_nocs/0000040061.PDF,submission_no,What is the Submission Number?,269955,97
sample_nocs/0000040061.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,teva  Canada Limited,14
sample_nocs/0000040061.PDF,product_name,What is the Product name?,TEVA-SERTRALINE,96
sample_nocs/0000040061.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule, 25 mg",81
sample_nocs/0000040061.PDF,species,What is the species?,NA,NA
sample_nocs/0000040061.PDF,noc_date,What is the date of the document?,"May 5, 2023",83
sample_nocs/0000040061.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sertraline HCL (sertraline as sertraline hydrochloride),58.999996185302734
sample_nocs/0000040126.PDF,canadian_reference_product,What is the Canadian Reference Product?,DIACETYLMORPHINE HYDROCHLORIDE,56
sample_nocs/0000040126.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,50
sample_nocs/0000040126.PDF,noc_reason,What was the reason for the submission?,Labelling update on the reconstitution of the product,96
sample_nocs/0000040126.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000040126.PDF,dossier_id,What is the Dossier Id?,e235155,97
sample_nocs/0000040126.PDF,submission_no,What is the Submission Number?,270525,99
sample_nocs/0000040126.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pharmascience Inc,50
sample_nocs/0000040126.PDF,product_name,What is the Product name?,DIACETYLMORPHINE HYDROCHLORIDE,62
sample_nocs/0000040126.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intramuscular, Intravenous/ Intramusculaire, Identification Numérique de(s) drogue(s) drogue(s) drogue(s) drogue(s), Voie(s), Forme, Intr",1
sample_nocs/0000040126.PDF,species,What is the species?,NA,NA
sample_nocs/0000040126.PDF,noc_date,What is the date of the document?,"May 12, 2023",91
sample_nocs/0000040126.PDF,medicinal_ingredients,What are the medicinal ingredients?,Diamorphine hydrochloride / Chlorhydrate de diamorphine,81
sample_nocs/0000040238.PDF,canadian_reference_product,What is the Canadian Reference Product?,APO-METOPROLOL (Type L),79
sample_nocs/0000040238.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,62
sample_nocs/0000040238.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,38
sample_nocs/0000040238.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000040238.PDF,dossier_id,What is the Dossier Id?,e131247,93
sample_nocs/0000040238.PDF,submission_no,What is the Submission Number?,270394,98
sample_nocs/0000040238.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,82
sample_nocs/0000040238.PDF,product_name,What is the Product name?,APO-METOPROLOL APO-METOPROLOL (Type L),81
sample_nocs/0000040238.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 25 mg",83
sample_nocs/0000040238.PDF,species,What is the species?,NA,NA
sample_nocs/0000040238.PDF,noc_date,What is the date of the document?,"May 25, 2023",95
sample_nocs/0000040238.PDF,medicinal_ingredients,What are the medicinal ingredients?,Metoprolol tartrate / Tartrate de métoprolol,82
sample_nocs/0000040456.PDF,canadian_reference_product,What is the Canadian Reference Product?,"SENSORCAINE, AstraZeneca Canada Inc., Canada",36
sample_nocs/0000040456.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000040456.PDF,noc_reason,What was the reason for the submission?,Update to Labels / Mise à jour desétiquettes,39
sample_nocs/0000040456.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000040456.PDF,dossier_id,What is the Dossier Id?,e180156,95
sample_nocs/0000040456.PDF,submission_no,What is the Submission Number?,271947,98
sample_nocs/0000040456.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,75
sample_nocs/0000040456.PDF,product_name,What is the Product name?,BUPIVACAINE INJECTION BP,79
sample_nocs/0000040456.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Block/Infiltration / Bloc/Infiltration, Epidural / Épidurale",62
sample_nocs/0000040456.PDF,species,What is the species?,NA,NA
sample_nocs/0000040456.PDF,noc_date,What is the date of the document?,"June 6, 2023",71
sample_nocs/0000040456.PDF,medicinal_ingredients,What are the medicinal ingredients?,Bupivacaine Hydrochloride / Chlorhydrate de bupivacane,44
sample_nocs/0000040475.PDF,canadian_reference_product,What is the Canadian Reference Product?,TOBRAMYCIN FOR INJECTION,86
sample_nocs/0000040475.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,52.999996185302734
sample_nocs/0000040475.PDF,noc_reason,What was the reason for the submission?,Change in specification for the drug substance,98
sample_nocs/0000040475.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000040475.PDF,dossier_id,What is the Dossier Id?,e119553,96
sample_nocs/0000040475.PDF,submission_no,What is the Submission Number?,267551,97
sample_nocs/0000040475.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Fresenius Kabi Canada Ltd.,65
sample_nocs/0000040475.PDF,product_name,What is the Product name?,TOBRAMYCIN FOR INJECTION,89
sample_nocs/0000040475.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous/Intravenous Powder for Solution/Poudre",70
sample_nocs/0000040475.PDF,species,What is the species?,NA,NA
sample_nocs/0000040475.PDF,noc_date,What is the date of the document?,"June 9, 2023",80
sample_nocs/0000040475.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tobramycin(supplied as Tobramycin Sulfate)/Tobramycine(sous forme de Sulfate de Tobramycine),10
sample_nocs/0000040572.PDF,canadian_reference_product,What is the Canadian Reference Product?,"HALAVEN, Eisai Limited, Canada",36
sample_nocs/0000040572.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000040572.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000040572.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000040572.PDF,dossier_id,What is the Dossier Id?,e263078,50
sample_nocs/0000040572.PDF,submission_no,What is the Submission Number?,263078,95
sample_nocs/0000040572.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Natco Pharma (Canada) Inc.,83
sample_nocs/0000040572.PDF,product_name,What is the Product name?,NAT-ERIBULIN,95
sample_nocs/0000040572.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02539136, Intravenous / Intraveineuse, Solution, 0.5 mg/mL",44
sample_nocs/0000040572.PDF,species,What is the species?,NA,NA
sample_nocs/0000040572.PDF,noc_date,What is the date of the document?,"June 27, 2023",77
sample_nocs/0000040572.PDF,medicinal_ingredients,What are the medicinal ingredients?,Eribulin Mesylate / Mésylate d'Éribuline,87
sample_nocs/0000040580.PDF,canadian_reference_product,What is the Canadian Reference Product?,AXID,49
sample_nocs/0000040580.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,34
sample_nocs/0000040580.PDF,noc_reason,What was the reason for the submission?,Addition of a test for an impurity NDMA,95
sample_nocs/0000040580.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,88
sample_nocs/0000040580.PDF,dossier_id,What is the Dossier Id?,e132614,94
sample_nocs/0000040580.PDF,submission_no,What is the Submission Number?,269696,97
sample_nocs/0000040580.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Pendopharm,52
sample_nocs/0000040580.PDF,product_name,What is the Product name?,AXID,72
sample_nocs/0000040580.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Capsule, 150 mg",83
sample_nocs/0000040580.PDF,species,What is the species?,NA,NA
sample_nocs/0000040580.PDF,noc_date,What is the date of the document?,"June 23, 2023",82
sample_nocs/0000040580.PDF,medicinal_ingredients,What are the medicinal ingredients?,Nizatidine,94
sample_nocs/0000040589.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000040589.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,44
sample_nocs/0000040589.PDF,noc_reason,What was the reason for the submission?,Updates to the Product Monograph / Mise a jour de la monographie de produit,38
sample_nocs/0000040589.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000040589.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000040589.PDF,submission_no,What is the Submission Number?,271667,98
sample_nocs/0000040589.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Biogen Canada Inc.,91
sample_nocs/0000040589.PDF,product_name,What is the Product name?,Plegridy,93
sample_nocs/0000040589.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, LIQ, 63 mcg / 0.5 mL",82
sample_nocs/0000040589.PDF,species,What is the species?,NA,NA
sample_nocs/0000040589.PDF,noc_date,What is the date of the document?,"June 26, 2023",82
sample_nocs/0000040589.PDF,medicinal_ingredients,What are the medicinal ingredients?,Peginterferon beta-1a,98
sample_nocs/0000040844.PDF,canadian_reference_product,What is the Canadian Reference Product?,"LYRICA, Pfizer Canada Inc., Canada",47
sample_nocs/0000040844.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,36
sample_nocs/0000040844.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,35
sample_nocs/0000040844.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000040844.PDF,dossier_id,What is the Dossier Id?,e158216,95
sample_nocs/0000040844.PDF,submission_no,What is the Submission Number?,272305,98
sample_nocs/0000040844.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,89
sample_nocs/0000040844.PDF,product_name,What is the Product name?,IPG-PREGABALIN,65
sample_nocs/0000040844.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule / Capsule, 25 mg",56
sample_nocs/0000040844.PDF,species,What is the species?,NA,NA
sample_nocs/0000040844.PDF,noc_date,What is the date of the document?,"July 20, 2023",70
sample_nocs/0000040844.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pregabalin / Prégabaline,84
sample_nocs/0000040966.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000040966.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,50
sample_nocs/0000040966.PDF,noc_reason,What was the reason for the submission?,Alternate drug product manufacturing site/ site of fabrication alternatif for the product médicamenteux,22
sample_nocs/0000040966.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000040966.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000040966.PDF,submission_no,What is the Submission Number?,272485,98
sample_nocs/0000040966.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alexion Pharma GMBH,93
sample_nocs/0000040966.PDF,product_name,What is the Product name?,Ultomiris,97
sample_nocs/0000040966.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 10mg/ml",91
sample_nocs/0000040966.PDF,species,What is the species?,NA,NA
sample_nocs/0000040966.PDF,noc_date,What is the date of the document?,"July 28, 2023",81
sample_nocs/0000040966.PDF,medicinal_ingredients,What are the medicinal ingredients?,ravulizumab,79
sample_nocs/0000041100.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000041100.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,45
sample_nocs/0000041100.PDF,noc_reason,What was the reason for the submission?,Addition of a new drug product manufacturing site / Ajout d'un nouveau site de fabrication for the product médicamenteux,19
sample_nocs/0000041100.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000041100.PDF,dossier_id,What is the Dossier Id?,q01245,16
sample_nocs/0000041100.PDF,submission_no,What is the Submission Number?,272284,98
sample_nocs/0000041100.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Alexion Pharma GmbH,92
sample_nocs/0000041100.PDF,product_name,What is the Product name?,Strensiq,96
sample_nocs/0000041100.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 18mg/0.45mL (40mg/mL)",69
sample_nocs/0000041100.PDF,species,What is the species?,NA,NA
sample_nocs/0000041100.PDF,noc_date,What is the date of the document?,"August 21, 2023",88
sample_nocs/0000041100.PDF,medicinal_ingredients,What are the medicinal ingredients?,Asfotase alfa,97
sample_nocs/0000041143.PDF,canadian_reference_product,What is the Canadian Reference Product?,"REVATIO, Pfizer Canada Inc., Canada",55
sample_nocs/0000041143.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000041143.PDF,noc_reason,What was the reason for the submission?,Update to Labels / Mise a jour desétiquettes,49
sample_nocs/0000041143.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000041143.PDF,dossier_id,What is the Dossier Id?,e182623,90
sample_nocs/0000041143.PDF,submission_no,What is the Submission Number?,273193,98
sample_nocs/0000041143.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,84
sample_nocs/0000041143.PDF,product_name,What is the Product name?,JAMP-SILDENAFIL R,93
sample_nocs/0000041143.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 20 mg",48
sample_nocs/0000041143.PDF,species,What is the species?,NA,NA
sample_nocs/0000041143.PDF,noc_date,What is the date of the document?,"August 28, 2023",82
sample_nocs/0000041143.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sildenafil (supplied as Sildenafil Citrate) / Sildénafil (fourni comme citrate de sildénafil),25
sample_nocs/0000041420.PDF,canadian_reference_product,What is the Canadian Reference Product?,"XIGDUO, AstraZeneca Canada Inc., Canada",55
sample_nocs/0000041420.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000041420.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,33
sample_nocs/0000041420.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000041420.PDF,dossier_id,What is the Dossier Id?,e265385,86
sample_nocs/0000041420.PDF,submission_no,What is the Submission Number?,275438,98
sample_nocs/0000041420.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,I,86
sample_nocs/0000041420.PDF,product_name,What is the Product name?,APO-DAPAGLIFLOZIN-METFORMIN,93
sample_nocs/0000041420.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 5 mg/850 mg",74
sample_nocs/0000041420.PDF,species,What is the species?,NA,NA
sample_nocs/0000041420.PDF,noc_date,What is the date of the document?,"September 21, 2023",96
sample_nocs/0000041420.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dapagliflozin / Metformin Hydrochloride / Dapagliflozine/Chlorhydrate de metformine,73
sample_nocs/0000041455.PDF,canadian_reference_product,What is the Canadian Reference Product?,"KEPPRA, UCB Canada Inc., Canada",71
sample_nocs/0000041455.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,81
sample_nocs/0000041455.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph / Mise a jour de l'innocuité dans la Monographie de Produit,33
sample_nocs/0000041455.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Sophie Gaudreault, PhD",51
sample_nocs/0000041455.PDF,dossier_id,What is the Dossier Id?,e230497,96
sample_nocs/0000041455.PDF,submission_no,What is the Submission Number?,275480,99
sample_nocs/0000041455.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,82
sample_nocs/0000041455.PDF,product_name,What is the Product name?,JAMP LEVETIRACETAM TABLETS,78
sample_nocs/0000041455.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 250 mg",83
sample_nocs/0000041455.PDF,species,What is the species?,NA,NA
sample_nocs/0000041455.PDF,noc_date,What is the date of the document?,"September 08, 2021",51
sample_nocs/0000041455.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levetiracetam / Lévétiracétam,79
sample_nocs/0000041779.PDF,canadian_reference_product,What is the Canadian Reference Product?,VIACORAM,99
sample_nocs/0000041779.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,57
sample_nocs/0000041779.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph Update to the Package Insert,93
sample_nocs/0000041779.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000041779.PDF,dossier_id,What is the Dossier Id?,e117334,94
sample_nocs/0000041779.PDF,submission_no,What is the Submission Number?,275866,99
sample_nocs/0000041779.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000041779.PDF,product_name,What is the Product name?,VIACORAM,99
sample_nocs/0000041779.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 3.5 mg / 2.5 mg",57
sample_nocs/0000041779.PDF,species,What is the species?,NA,NA
sample_nocs/0000041779.PDF,noc_date,What is the date of the document?,"October 25, 2023",83
sample_nocs/0000041779.PDF,medicinal_ingredients,What are the medicinal ingredients?,Perindopril arginine / Périndopril arginine Amlodipine (supplied as amlodipine besylate d'amlodipine),28
sample_nocs/0000041838.PDF,canadian_reference_product,What is the Canadian Reference Product?,"XARELTO, Bayer Inc., Canada",60.000003814697266
sample_nocs/0000041838.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,39
sample_nocs/0000041838.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph,97
sample_nocs/0000041838.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000041838.PDF,dossier_id,What is the Dossier Id?,E198316,98
sample_nocs/0000041838.PDF,submission_no,What is the Submission Number?,242215,98
sample_nocs/0000041838.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Taro Pharmaceuticals Inc.,62
sample_nocs/0000041838.PDF,product_name,What is the Product name?,TARO-RIVAROXABAN,89
sample_nocs/0000041838.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 10 mg",88
sample_nocs/0000041838.PDF,species,What is the species?,NA,NA
sample_nocs/0000041838.PDF,noc_date,What is the date of the document?,"November 1, 2023",67
sample_nocs/0000041838.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rivaroxaban,99
sample_nocs/0000041976.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000041976.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000041976.PDF,noc_reason,What was the reason for the submission?,Addition of a new drug product and drug substance manufacturing site. New manufacturing process. / Addition d'un nouveau site of fabrication for the substance médicamenteuse and the product médicamenteux. Nouveau process of fabrication.,1
sample_nocs/0000041976.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000041976.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000041976.PDF,submission_no,What is the Submission Number?,273937,98
sample_nocs/0000041976.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,86
sample_nocs/0000041976.PDF,product_name,What is the Product name?,Zolgensma,78
sample_nocs/0000041976.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 2.0 X 1013 vector genomes (vg)/mL",87
sample_nocs/0000041976.PDF,species,What is the species?,NA,NA
sample_nocs/0000041976.PDF,noc_date,What is the date of the document?,"November 10, 2023",74
sample_nocs/0000041976.PDF,medicinal_ingredients,What are the medicinal ingredients?,Onasemnogene abeparvovec / Onasemnogène abéparvovec,62
sample_nocs/0000042024.PDF,canadian_reference_product,What is the Canadian Reference Product?,"FORXIGA, AstraZeneca Canada Inc., Canada",49
sample_nocs/0000042024.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042024.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000042024.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000042024.PDF,dossier_id,What is the Dossier Id?,HC6-024-271312,98
sample_nocs/0000042024.PDF,submission_no,What is the Submission Number?,271312,98
sample_nocs/0000042024.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accel Pharma Inc.,85
sample_nocs/0000042024.PDF,product_name,What is the Product name?,ACCEL-DAPAGLIFLOZIN,97
sample_nocs/0000042024.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02543184, Oral / Orale, Tablet / Comprimé, 5 mg",70
sample_nocs/0000042024.PDF,species,What is the species?,NA,NA
sample_nocs/0000042024.PDF,noc_date,What is the date of the document?,"November 17, 2023",88
sample_nocs/0000042024.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dapagliflozin / Dapagliflozine,94
sample_nocs/0000042030.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000042030.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042030.PDF,noc_reason,What was the reason for the submission?,Labelling updates / Mise a jour desétiquettes,38
sample_nocs/0000042030.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000042030.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000042030.PDF,submission_no,What is the Submission Number?,276004,98
sample_nocs/0000042030.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Advanced Accelerator Applications USA Inc.,89
sample_nocs/0000042030.PDF,product_name,What is the Product name?,Lutathera,92
sample_nocs/0000042030.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 370 MBq/mL at calibration",75
sample_nocs/0000042030.PDF,species,What is the species?,NA,NA
sample_nocs/0000042030.PDF,noc_date,What is the date of the document?,"November 17, 2023",82
sample_nocs/0000042030.PDF,medicinal_ingredients,What are the medicinal ingredients?,lutetium (177Lu) oxodotreotide / lutécium (177Lu) oxodotréotide,45
sample_nocs/0000042076.PDF,canadian_reference_product,What is the Canadian Reference Product?,APO-IBUPROFEN,84
sample_nocs/0000042076.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,62
sample_nocs/0000042076.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph as per Advisement Letter,54.000003814697266
sample_nocs/0000042076.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000042076.PDF,dossier_id,What is the Dossier Id?,HC6-024-e102963,98
sample_nocs/0000042076.PDF,submission_no,What is the Submission Number?,274895,98
sample_nocs/0000042076.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,73
sample_nocs/0000042076.PDF,product_name,What is the Product name?,APO-IBUPROFEN,94
sample_nocs/0000042076.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 600 mg",56
sample_nocs/0000042076.PDF,species,What is the species?,NA,NA
sample_nocs/0000042076.PDF,noc_date,What is the date of the document?,"November 24, 2023",75
sample_nocs/0000042076.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ibuprofen / Ibuprofène,83
sample_nocs/0000042082.PDF,canadian_reference_product,What is the Canadian Reference Product?,AMIODARONE HYDROCHLORIDE FOR INJECTION,44
sample_nocs/0000042082.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042082.PDF,noc_reason,What was the reason for the submission?,Update to Labels / Mise a jour desétiquettes,51
sample_nocs/0000042082.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000042082.PDF,dossier_id,What is the Dossier Id?,HC6-024-e235195,98
sample_nocs/0000042082.PDF,submission_no,What is the Submission Number?,277332,98
sample_nocs/0000042082.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,77
sample_nocs/0000042082.PDF,product_name,What is the Product name?,AMIODARONE HYDROCHLORIDE FOR INJECTION,68
sample_nocs/0000042082.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous / Intraveineuse, Solution / Solution,",22
sample_nocs/0000042082.PDF,species,What is the species?,NA,NA
sample_nocs/0000042082.PDF,noc_date,What is the date of the document?,"November 24, 2023",76
sample_nocs/0000042082.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amiodarone Hydrochloride / Chlorhydrate d'amiodarone,88
sample_nocs/0000042116.PDF,canadian_reference_product,What is the Canadian Reference Product?,KALYDECO,98
sample_nocs/0000042116.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,62
sample_nocs/0000042116.PDF,noc_reason,What was the reason for the submission?,Expansion of indication,96
sample_nocs/0000042116.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,89
sample_nocs/0000042116.PDF,dossier_id,What is the Dossier Id?,HC6-024-A153673,36
sample_nocs/0000042116.PDF,submission_no,What is the Submission Number?,273575,98
sample_nocs/0000042116.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Vertex Pharmaceuticals (Canada) Incorporated,73
sample_nocs/0000042116.PDF,product_name,What is the Product name?,KALYDECO,97
sample_nocs/0000042116.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02543451, Oral/Orale, Granules, 13.4 mg / sachet",54.000003814697266
sample_nocs/0000042116.PDF,species,What is the species?,NA,NA
sample_nocs/0000042116.PDF,noc_date,What is the date of the document?,"November 28, 2023",78
sample_nocs/0000042116.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ivacaftor,97
sample_nocs/0000042254.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Keppra, UCB Canada Inc., Canada",31
sample_nocs/0000042254.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,63
sample_nocs/0000042254.PDF,noc_reason,What was the reason for the submission?,Administrative,56
sample_nocs/0000042254.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Tanya Ramsamy,49
sample_nocs/0000042254.PDF,dossier_id,What is the Dossier Id?,e139279,82
sample_nocs/0000042254.PDF,submission_no,What is the Submission Number?,281034,99
sample_nocs/0000042254.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanis Health Inc.,48
sample_nocs/0000042254.PDF,product_name,What is the Product name?,Levetiracetam,48
sample_nocs/0000042254.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 250 mg",88
sample_nocs/0000042254.PDF,species,What is the species?,NA,NA
sample_nocs/0000042254.PDF,noc_date,What is the date of the document?,"December 7, 2023",82
sample_nocs/0000042254.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levetiracetam / Lévétiracétam,68
sample_nocs/0000042353.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZEPOSIA,97
sample_nocs/0000042353.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,65
sample_nocs/0000042353.PDF,noc_reason,What was the reason for the submission?,To add new data on the use in patients with hepatic impairment and to propose dosing recommendations.,45
sample_nocs/0000042353.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000042353.PDF,dossier_id,What is the Dossier Id?,HC6-024-e216035,98
sample_nocs/0000042353.PDF,submission_no,What is the Submission Number?,269878,97
sample_nocs/0000042353.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bristol-Myers Squibb Canada,80
sample_nocs/0000042353.PDF,product_name,What is the Product name?,ZEPOSIA,98
sample_nocs/0000042353.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Capsule/Capsule(Kit/Trousse), 0.23 mg",34
sample_nocs/0000042353.PDF,species,What is the species?,NA,NA
sample_nocs/0000042353.PDF,noc_date,What is the date of the document?,"December 20, 2023",83
sample_nocs/0000042353.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ozanimod (supplied as Ozanimod Hydrochloride) / Ozanimod (sous forme Chlorhydrate d'ozanimod),38
sample_nocs/0000042379.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Avodart, GlaxoSmithKline Inc., Canada",38
sample_nocs/0000042379.PDF,directorate,What is the directorate that approved the submission?,Direction des médicaments pharmaceutiques,28
sample_nocs/0000042379.PDF,noc_reason,What was the reason for the submission?,Administrative,52.999996185302734
sample_nocs/0000042379.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000042379.PDF,dossier_id,What is the Dossier Id?,e222010,75
sample_nocs/0000042379.PDF,submission_no,What is the Submission Number?,281767,99
sample_nocs/0000042379.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,77
sample_nocs/0000042379.PDF,product_name,What is the Product name?,JAMP DUTASTERIDE,86
sample_nocs/0000042379.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, capsule, 0.5 mg",88
sample_nocs/0000042379.PDF,species,What is the species?,NA,NA
sample_nocs/0000042379.PDF,noc_date,What is the date of the document?,"January 2, 2024",87
sample_nocs/0000042379.PDF,medicinal_ingredients,What are the medicinal ingredients?,Dutasteride / Dutastéride,72
sample_nocs/0000042406.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CLARITIN ALLERGY, Bayer Inc., Canada",40
sample_nocs/0000042406.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042406.PDF,noc_reason,What was the reason for the submission?,Addition of private retailer label / Ajout de marques privées,64
sample_nocs/0000042406.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Natalie Page,97
sample_nocs/0000042406.PDF,dossier_id,What is the Dossier Id?,e143995,96
sample_nocs/0000042406.PDF,submission_no,What is the Submission Number?,277533,98
sample_nocs/0000042406.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Vita Health Products Inc.,84
sample_nocs/0000042406.PDF,product_name,What is the Product name?,24 HOUR ALLERGY REMEDY,97
sample_nocs/0000042406.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral, Tablet, 10 mg",87
sample_nocs/0000042406.PDF,species,What is the species?,NA,NA
sample_nocs/0000042406.PDF,noc_date,What is the date of the document?,2023-12-29,97
sample_nocs/0000042406.PDF,medicinal_ingredients,What are the medicinal ingredients?,Loratadine,99
sample_nocs/0000042440.PDF,canadian_reference_product,What is the Canadian Reference Product?,"AUBAGIO, Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc., Canada",28
sample_nocs/0000042440.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,87
sample_nocs/0000042440.PDF,noc_reason,What was the reason for the submission?,Updates to Product Monograph / Mise a jour de la monographie de produit,48
sample_nocs/0000042440.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Gaudreault,99
sample_nocs/0000042440.PDF,dossier_id,What is the Dossier Id?,HC6-024-e234182,32
sample_nocs/0000042440.PDF,submission_no,What is the Submission Number?,277441,98
sample_nocs/0000042440.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accord Healthcare Inc,51
sample_nocs/0000042440.PDF,product_name,What is the Product name?,ACH-TERIFLUNOMIDE,93
sample_nocs/0000042440.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 14 mg",67
sample_nocs/0000042440.PDF,species,What is the species?,NA,NA
sample_nocs/0000042440.PDF,noc_date,What is the date of the document?,"January 09, 2024",74
sample_nocs/0000042440.PDF,medicinal_ingredients,What are the medicinal ingredients?,Teriflunomide / Tériflunomide,79
sample_nocs/0000042631.PDF,canadian_reference_product,What is the Canadian Reference Product?,"TOPAMAX, Janssen-Ortho Inc., Canada",54.000003814697266
sample_nocs/0000042631.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,35
sample_nocs/0000042631.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,33
sample_nocs/0000042631.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000042631.PDF,dossier_id,What is the Dossier Id?,HC6-024-e109960,98
sample_nocs/0000042631.PDF,submission_no,What is the Submission Number?,278404,98
sample_nocs/0000042631.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Glenmark Pharmaceuticals Canada Inc.,88
sample_nocs/0000042631.PDF,product_name,What is the Product name?,GLN-TOPIRAMATE,97
sample_nocs/0000042631.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 25 mg",82
sample_nocs/0000042631.PDF,species,What is the species?,NA,NA
sample_nocs/0000042631.PDF,noc_date,What is the date of the document?,"January 24, 2024",83
sample_nocs/0000042631.PDF,medicinal_ingredients,What are the medicinal ingredients?,Topiramate / Topiramate,93
sample_nocs/0000042657.PDF,canadian_reference_product,What is the Canadian Reference Product?,REVOLUTION PLUS,99
sample_nocs/0000042657.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042657.PDF,noc_reason,What was the reason for the submission?,Additional claim / Indication supplémentaire,93
sample_nocs/0000042657.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,97
sample_nocs/0000042657.PDF,dossier_id,What is the Dossier Id?,v190913,96
sample_nocs/0000042657.PDF,submission_no,What is the Submission Number?,277223,98
sample_nocs/0000042657.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Zoetis Canada Inc.,75
sample_nocs/0000042657.PDF,product_name,What is the Product name?,REVOLUTION PLUS,99
sample_nocs/0000042657.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Topical, Solution, Sarolaner 10 mg/mL, Selamectin 60 mg/mL",74
sample_nocs/0000042657.PDF,species,What is the species?,Cats / Chats,81
sample_nocs/0000042657.PDF,noc_date,What is the date of the document?,"February 1, 2024 / 1 février 2024",56
sample_nocs/0000042657.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Sarolaner, Selamectin / Sarolaner, Selamectin",85
sample_nocs/0000042837.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000042837.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000042837.PDF,noc_reason,What was the reason for the submission?,Labelling update / Mise a jour de l'étiquetage,49
sample_nocs/0000042837.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Cynthia Colapinto, PhD",57
sample_nocs/0000042837.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000042837.PDF,submission_no,What is the Submission Number?,278877,99
sample_nocs/0000042837.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,"Advanced Accelerator Applications USA, Inc.",88
sample_nocs/0000042837.PDF,product_name,What is the Product name?,Locametz,100
sample_nocs/0000042837.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, PWSO, 25 mcg/vial / N/A, IV, PWSO, 25 mcg/fiole",80
sample_nocs/0000042837.PDF,species,What is the species?,NA,NA
sample_nocs/0000042837.PDF,noc_date,What is the date of the document?,"February 22, 2024",97
sample_nocs/0000042837.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gallium (68Ga) gozetotide / Gallium (68Ga) gozétotide,63
sample_nocs/0000043127.PDF,canadian_reference_product,What is the Canadian Reference Product?,EXELON,57
sample_nocs/0000043127.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,43
sample_nocs/0000043127.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,38
sample_nocs/0000043127.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000043127.PDF,dossier_id,What is the Dossier Id?,HC6-024-e170376,95
sample_nocs/0000043127.PDF,submission_no,What is the Submission Number?,281759,98
sample_nocs/0000043127.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,78
sample_nocs/0000043127.PDF,product_name,What is the Product name?,AURO-RIVASTIGMINE,67
sample_nocs/0000043127.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule / Capsule, 1.5 mg",75
sample_nocs/0000043127.PDF,species,What is the species?,NA,NA
sample_nocs/0000043127.PDF,noc_date,What is the date of the document?,"April 2, 2024",88
sample_nocs/0000043127.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rivastigmine(supplied as Rivastigmine Hydrogen Tartrate)/ Rivastigmine (sous forme de tartrate hydrogéné de rivastigmine),24
sample_nocs/0000043139.PDF,canadian_reference_product,What is the Canadian Reference Product?,"APO-AMOXI, Apotex Inc, Canada",64
sample_nocs/0000043139.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,69
sample_nocs/0000043139.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour of la monographie de produit,43
sample_nocs/0000043139.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,97
sample_nocs/0000043139.PDF,dossier_id,What is the Dossier Id?,HC6-024-e172363,97
sample_nocs/0000043139.PDF,submission_no,What is the Submission Number?,279783,97
sample_nocs/0000043139.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP PHARMA CORPORATION,84
sample_nocs/0000043139.PDF,product_name,What is the Product name?,JAMP-AMOXICILLIN,95
sample_nocs/0000043139.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule / Capsule, 250 mg",55
sample_nocs/0000043139.PDF,species,What is the species?,NA,NA
sample_nocs/0000043139.PDF,noc_date,What is the date of the document?,"March 28, 2024",92
sample_nocs/0000043139.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amoxicillin (supplied as amoxicillin trihydrate) / Amoxicilline (sous forme d'amoxicilline trihydratée),58
sample_nocs/0000043151.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ADEMPAS, Bayer Inc., Canada",70
sample_nocs/0000043151.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,37
sample_nocs/0000043151.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000043151.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000043151.PDF,dossier_id,What is the Dossier Id?,e250471,56
sample_nocs/0000043151.PDF,submission_no,What is the Submission Number?,250471,97
sample_nocs/0000043151.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,87
sample_nocs/0000043151.PDF,product_name,What is the Product name?,SANDOZ RIOCIGUAT,71
sample_nocs/0000043151.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02533545, Oral/Orale, Tablet/Comprimé, 0.5 mg",62
sample_nocs/0000043151.PDF,species,What is the species?,NA,NA
sample_nocs/0000043151.PDF,noc_date,What is the date of the document?,"April 3, 2024",86
sample_nocs/0000043151.PDF,medicinal_ingredients,What are the medicinal ingredients?,Riociguat,94
sample_nocs/0000043156.PDF,canadian_reference_product,What is the Canadian Reference Product?,"XALATAN, PFIZER CANADA INC, Canada",88
sample_nocs/0000043156.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,54.000003814697266
sample_nocs/0000043156.PDF,noc_reason,What was the reason for the submission?,Product Monograph reformatted to the Master Template/Remise en forme de la monographie de produit selon le modèle principal,66
sample_nocs/0000043156.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000043156.PDF,dossier_id,What is the Dossier Id?,HC6-024-e153872,97
sample_nocs/0000043156.PDF,submission_no,What is the Submission Number?,279919,98
sample_nocs/0000043156.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Taro Pharmaceuticals Inc.,92
sample_nocs/0000043156.PDF,product_name,What is the Product name?,TARO-LATANOPROST,90
sample_nocs/0000043156.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Ophthalmic/Ophtalmique, Solution, 50 mcg/mL",61
sample_nocs/0000043156.PDF,species,What is the species?,NA,NA
sample_nocs/0000043156.PDF,noc_date,What is the date of the document?,"April 4, 2024",88
sample_nocs/0000043156.PDF,medicinal_ingredients,What are the medicinal ingredients?,Latanoprost,92
sample_nocs/0000043214.PDF,canadian_reference_product,What is the Canadian Reference Product?,NEXIUM,54.000003814697266
sample_nocs/0000043214.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043214.PDF,noc_reason,What was the reason for the submission?,Update to Labels / Mise / jour des Étiquettes,60.000003814697266
sample_nocs/0000043214.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000043214.PDF,dossier_id,What is the Dossier Id?,HC6-024-e166790,92
sample_nocs/0000043214.PDF,submission_no,What is the Submission Number?,277582,98
sample_nocs/0000043214.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,71
sample_nocs/0000043214.PDF,product_name,What is the Product name?,TEVA-ESOMEPRAZOLE,93
sample_nocs/0000043214.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet (Delayed-Release)/Comprimé",57
sample_nocs/0000043214.PDF,species,What is the species?,NA,NA
sample_nocs/0000043214.PDF,noc_date,What is the date of the document?,"April 11, 2024",86
sample_nocs/0000043214.PDF,medicinal_ingredients,What are the medicinal ingredients?,Esomeprazole(supplied as Esomeprazole Magnesium Dihydrate)/Esoméprazole(sous forme Ésoméprazole magnésien dihydraté),11
sample_nocs/0000043303.PDF,canadian_reference_product,What is the Canadian Reference Product?,ZITHROMAX,38
sample_nocs/0000043303.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,39
sample_nocs/0000043303.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement Between Two Manufacturers / Administratif: Accord de licence entre deux fabricants,52.999996185302734
sample_nocs/0000043303.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000043303.PDF,dossier_id,What is the Dossier Id?,283128,78
sample_nocs/0000043303.PDF,submission_no,What is the Submission Number?,283128,98
sample_nocs/0000043303.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,/,41
sample_nocs/0000043303.PDF,product_name,What is the Product name?,CIPROFLOXACIN,75
sample_nocs/0000043303.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02547139, oral / orale, tablet / comprimé, 250 mg",88
sample_nocs/0000043303.PDF,species,What is the species?,NA,NA
sample_nocs/0000043303.PDF,noc_date,What is the date of the document?,"April 19, 2024",87
sample_nocs/0000043303.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride / Ciprofloxacine sous forme de chlorhydrate de ciprofloxacine,77
sample_nocs/0000043320.PDF,canadian_reference_product,What is the Canadian Reference Product?,OPSYNVI,68
sample_nocs/0000043320.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043320.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph Updates to the package insert,89
sample_nocs/0000043320.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000043320.PDF,dossier_id,What is the Dossier Id?,HC6-024-e227269,81
sample_nocs/0000043320.PDF,submission_no,What is the Submission Number?,281575,98
sample_nocs/0000043320.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Janssen Inc,80
sample_nocs/0000043320.PDF,product_name,What is the Product name?,OPSYNVI,80
sample_nocs/0000043320.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 10 mg / 40 mg",61
sample_nocs/0000043320.PDF,species,What is the species?,NA,NA
sample_nocs/0000043320.PDF,noc_date,What is the date of the document?,"April 26, 2024",84
sample_nocs/0000043320.PDF,medicinal_ingredients,What are the medicinal ingredients?,Macitentan Tadalafil,98
sample_nocs/0000043614.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Diflucan One, Pfizer Canada ULC, Canada",42
sample_nocs/0000043614.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043614.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000043614.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Stephen Norman,97
sample_nocs/0000043614.PDF,dossier_id,What is the Dossier Id?,e272462,77
sample_nocs/0000043614.PDF,submission_no,What is the Submission Number?,272462,98
sample_nocs/0000043614.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,89
sample_nocs/0000043614.PDF,product_name,What is the Product name?,JAMP FLUCONAZOLE 150 MG,92
sample_nocs/0000043614.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02547864, Oral, Capsule, 150 mg",68
sample_nocs/0000043614.PDF,species,What is the species?,NA,NA
sample_nocs/0000043614.PDF,noc_date,What is the date of the document?,"May 28, 2024",94
sample_nocs/0000043614.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fluconazole,98
sample_nocs/0000043659.PDF,canadian_reference_product,What is the Canadian Reference Product?,"VYVANSE, Takeda Canada Inc., Canada",58
sample_nocs/0000043659.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043659.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000043659.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000043659.PDF,dossier_id,What is the Dossier Id?,HC6-024-e257296,52
sample_nocs/0000043659.PDF,submission_no,What is the Submission Number?,265912,97
sample_nocs/0000043659.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,86
sample_nocs/0000043659.PDF,product_name,What is the Product name?,SANDOZ LISDEXAMFETAMINE CAPSULES,72
sample_nocs/0000043659.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02546248, Oral / Orale, Capsule / Capsule, 10 mg",49
sample_nocs/0000043659.PDF,species,What is the species?,NA,NA
sample_nocs/0000043659.PDF,noc_date,What is the date of the document?,"June 3, 2024",75
sample_nocs/0000043659.PDF,medicinal_ingredients,What are the medicinal ingredients?,Lisdexamfetamine Dimesylate / Dimésylate de lisdexamfétamine,73
sample_nocs/0000043821.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000043821.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,32
sample_nocs/0000043821.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,37
sample_nocs/0000043821.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,98
sample_nocs/0000043821.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000043821.PDF,submission_no,What is the Submission Number?,282933,99
sample_nocs/0000043821.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Gilead Sciences Canada Inc.,84
sample_nocs/0000043821.PDF,product_name,What is the Product name?,Tecartus,97
sample_nocs/0000043821.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SUS, 1 X 106 chimeric antigen receptor (CAR)-",61
sample_nocs/0000043821.PDF,species,What is the species?,NA,NA
sample_nocs/0000043821.PDF,noc_date,What is the date of the document?,"June 17, 2024",86
sample_nocs/0000043821.PDF,medicinal_ingredients,What are the medicinal ingredients?,brexucabtagene autoleucel / brexucabtagène autoleucel,73
sample_nocs/0000043843.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Maxalt Smelt, Merck Sharp & Dohme BV, Netherlands",88
sample_nocs/0000043843.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,42
sample_nocs/0000043843.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre two fabricants,18
sample_nocs/0000043843.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,95
sample_nocs/0000043843.PDF,dossier_id,What is the Dossier Id?,285994,83
sample_nocs/0000043843.PDF,submission_no,What is the Submission Number?,285994,98
sample_nocs/0000043843.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc.,48
sample_nocs/0000043843.PDF,product_name,What is the Product name?,M-RIZATRIPTAN ODT,91
sample_nocs/0000043843.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02548801, oral / orale, tablet (orally disintegrating) / comprimé (a désintégration orale), 5 mg",47
sample_nocs/0000043843.PDF,species,What is the species?,NA,NA
sample_nocs/0000043843.PDF,noc_date,What is the date of the document?,"June 20, 2024",74
sample_nocs/0000043843.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rizatriptan Benzoate / sous forme de benzoate de rizatriptan,86
sample_nocs/0000043854.PDF,canadian_reference_product,What is the Canadian Reference Product?,PROMETRIUM,47
sample_nocs/0000043854.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043854.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000043854.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,89
sample_nocs/0000043854.PDF,dossier_id,What is the Dossier Id?,HC6-024-e275519,97
sample_nocs/0000043854.PDF,submission_no,What is the Submission Number?,281421,99
sample_nocs/0000043854.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Accord Healthcare Inc.,52.999996185302734
sample_nocs/0000043854.PDF,product_name,What is the Product name?,ACH-PROGESTERONE,91
sample_nocs/0000043854.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02549158, Oral / Orale, Capsule / Capsule, 100 mg",55
sample_nocs/0000043854.PDF,species,What is the species?,NA,NA
sample_nocs/0000043854.PDF,noc_date,What is the date of the document?,"June 25, 2024",85
sample_nocs/0000043854.PDF,medicinal_ingredients,What are the medicinal ingredients?,Progesterone / Progestérone,58.999996185302734
sample_nocs/0000043959.PDF,canadian_reference_product,What is the Canadian Reference Product?,Argatroban,52
sample_nocs/0000043959.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043959.PDF,noc_reason,What was the reason for the submission?,Product Monograph reformatted to the Master Template / Reformatage of the monographie de produit vers le modèle principal,12
sample_nocs/0000043959.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000043959.PDF,dossier_id,What is the Dossier Id?,HC6-024-e127236,93
sample_nocs/0000043959.PDF,submission_no,What is the Submission Number?,282415,99
sample_nocs/0000043959.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,80
sample_nocs/0000043959.PDF,product_name,What is the Product name?,Argatroban,58
sample_nocs/0000043959.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02548968, Intravenous/Intraveineuse, Solution, 1 mg / mL",37
sample_nocs/0000043959.PDF,species,What is the species?,NA,NA
sample_nocs/0000043959.PDF,noc_date,What is the date of the document?,"July 5, 2024",76
sample_nocs/0000043959.PDF,medicinal_ingredients,What are the medicinal ingredients?,Argatroban,96
sample_nocs/0000043965.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Uloric, Takeda Canada Inc., Canada",39
sample_nocs/0000043965.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000043965.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre two fabricants,20
sample_nocs/0000043965.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000043965.PDF,dossier_id,What is the Dossier Id?,e286201,52
sample_nocs/0000043965.PDF,submission_no,What is the Submission Number?,286201,93
sample_nocs/0000043965.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc.,52.999996185302734
sample_nocs/0000043965.PDF,product_name,What is the Product name?,M-FEBUXOSTAT,95
sample_nocs/0000043965.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02549425, oral / orale, tablet / comprimé, 80 mg",63
sample_nocs/0000043965.PDF,species,What is the species?,NA,NA
sample_nocs/0000043965.PDF,noc_date,What is the date of the document?,"July 5, 2024",68
sample_nocs/0000043965.PDF,medicinal_ingredients,What are the medicinal ingredients?,Febuxostat supplied as Febuxostat Hemihydrate / Fébuxostat sous forme de hémihydrate de fébuxostat,43
sample_nocs/0000044195.PDF,canadian_reference_product,What is the Canadian Reference Product?,TABRECTA,82
sample_nocs/0000044195.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,55
sample_nocs/0000044195.PDF,noc_reason,What was the reason for the submission?,Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication or d'un fabricant impliquant la fabrication of the substance médicamenteuse,12
sample_nocs/0000044195.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,92
sample_nocs/0000044195.PDF,dossier_id,What is the Dossier Id?,HC6-024-e251588,97
sample_nocs/0000044195.PDF,submission_no,What is the Submission Number?,283876,98
sample_nocs/0000044195.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,85
sample_nocs/0000044195.PDF,product_name,What is the Product name?,TABRECTA,94
sample_nocs/0000044195.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 150 mg",75
sample_nocs/0000044195.PDF,species,What is the species?,NA,NA
sample_nocs/0000044195.PDF,noc_date,What is the date of the document?,"July 29, 2024",82
sample_nocs/0000044195.PDF,medicinal_ingredients,What are the medicinal ingredients?,Capmatinib (supplied as capmatinib hydrochloride / sous forme de chlorhydrate de capmatinib),55
sample_nocs/0000044412.PDF,canadian_reference_product,What is the Canadian Reference Product?,"IVOMEC (DIN 00630470, Merial Canada Inc.)",48
sample_nocs/0000044412.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000044412.PDF,noc_reason,What was the reason for the submission?,Administrative Additional Product Name / Administratif Nom complémentaire de produit,78
sample_nocs/0000044412.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,96
sample_nocs/0000044412.PDF,dossier_id,What is the Dossier Id?,v286927,92
sample_nocs/0000044412.PDF,submission_no,What is the Submission Number?,286927,98
sample_nocs/0000044412.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,BIMEDA-MTC ANIMAL HEALTH INC,95
sample_nocs/0000044412.PDF,product_name,What is the Product name?,SOLMECTIN INJECTION FOR CATTLE AND SWINE,91
sample_nocs/0000044412.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02551179, Subcutaneous, Solution, 10 mg/mL",62
sample_nocs/0000044412.PDF,species,What is the species?,"Catlle, Swine / Bovins, Porcs",92
sample_nocs/0000044412.PDF,noc_date,What is the date of the document?,"August 26, 2024 / 26 août 2024",47
sample_nocs/0000044412.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ivermectin / Ivermectin,93
sample_nocs/0000044440.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Apresoline, SteriMax Inc., Canada",36
sample_nocs/0000044440.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,50
sample_nocs/0000044440.PDF,noc_reason,What was the reason for the submission?,Administrative,58
sample_nocs/0000044440.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,98
sample_nocs/0000044440.PDF,dossier_id,What is the Dossier Id?,e269453,69
sample_nocs/0000044440.PDF,submission_no,What is the Submission Number?,288891,97
sample_nocs/0000044440.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Eugia Pharma Inc.,60.000003814697266
sample_nocs/0000044440.PDF,product_name,What is the Product name?,"Hydralazine Hydrochloride InJECTION, USP / Chlorhydrate d'hydralazine InJECTION, USP",6
sample_nocs/0000044440.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, intravenous / intraveineuse, solution, 20 mg/mL",77
sample_nocs/0000044440.PDF,species,What is the species?,NA,NA
sample_nocs/0000044440.PDF,noc_date,What is the date of the document?,"August 27, 2024",86
sample_nocs/0000044440.PDF,medicinal_ingredients,What are the medicinal ingredients?,Hydralazine Hydrochloride / Chlorhydrate d'hydralazine,75
sample_nocs/0000044452.PDF,canadian_reference_product,What is the Canadian Reference Product?,Neulasta (pegfilgrastim),46
sample_nocs/0000044452.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000044452.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000044452.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000044452.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000044452.PDF,submission_no,What is the Submission Number?,262990,98
sample_nocs/0000044452.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Lupin Pharma Canada Limited,94
sample_nocs/0000044452.PDF,product_name,What is the Product name?,Armlupeg,97
sample_nocs/0000044452.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02550857, SC, SOL, 6 mg / 0.6 mL (10mg/mL)",63
sample_nocs/0000044452.PDF,species,What is the species?,Pegfilgrastim,78
sample_nocs/0000044452.PDF,noc_date,What is the date of the document?,"August 16, 2024",87
sample_nocs/0000044452.PDF,medicinal_ingredients,What are the medicinal ingredients?,Pegfilgrastim,81
sample_nocs/0000044552.PDF,canadian_reference_product,What is the Canadian Reference Product?,"BRIVLERA, UCB Canada Inc., Canada",31
sample_nocs/0000044552.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,48
sample_nocs/0000044552.PDF,noc_reason,What was the reason for the submission?,Updates to the Product Monograph / Mise a jour de la monographie de produit,48
sample_nocs/0000044552.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,90
sample_nocs/0000044552.PDF,dossier_id,What is the Dossier Id?,HC6-024-e261716,97
sample_nocs/0000044552.PDF,submission_no,What is the Submission Number?,283462,98
sample_nocs/0000044552.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Auro Pharma Inc.,75
sample_nocs/0000044552.PDF,product_name,What is the Product name?,AURO-BRIVARACETAM,58
sample_nocs/0000044552.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 50 mg",79
sample_nocs/0000044552.PDF,species,What is the species?,NA,NA
sample_nocs/0000044552.PDF,noc_date,What is the date of the document?,"September 10, 2024",88
sample_nocs/0000044552.PDF,medicinal_ingredients,What are the medicinal ingredients?,Brivaracetam / Brivaracétam,87
sample_nocs/0000044578.PDF,canadian_reference_product,What is the Canadian Reference Product?,"NEURONTIN (Capsule), Parke-Davis, Division of Warner-Canada",25
sample_nocs/0000044578.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,48
sample_nocs/0000044578.PDF,noc_reason,What was the reason for the submission?,Administrative: Update to labelling (to match Licensor) / Administratif: Mise a jour de l'étiquetage (pour correspondre au concédant),15.000000953674316
sample_nocs/0000044578.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Tanya Ramsamy, Ph.D.",28
sample_nocs/0000044578.PDF,dossier_id,What is the Dossier Id?,e188501,94
sample_nocs/0000044578.PDF,submission_no,What is the Submission Number?,289479,98
sample_nocs/0000044578.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Laboratoire Riva Inc.,89
sample_nocs/0000044578.PDF,product_name,What is the Product name?,RIVA-GABAPENTIN,94
sample_nocs/0000044578.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, capsule, 100 mg",90
sample_nocs/0000044578.PDF,species,What is the species?,NA,NA
sample_nocs/0000044578.PDF,noc_date,What is the date of the document?,"September 09, 2024",77
sample_nocs/0000044578.PDF,medicinal_ingredients,What are the medicinal ingredients?,Gabapentin / Gabapentine,95
sample_nocs/0000044631.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000044631.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,27.000001907348633
sample_nocs/0000044631.PDF,noc_reason,What was the reason for the submission?,Update to antigen composition (Omicron KP.2 variant) / mise a jour de la composition antigénique (variant Omicron KP.2),30.000001907348633
sample_nocs/0000044631.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000044631.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000044631.PDF,submission_no,What is the Submission Number?,287904,99
sample_nocs/0000044631.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Moderna Biopharma Canada Corporation,98
sample_nocs/0000044631.PDF,product_name,What is the Product name?,Spikevax,90
sample_nocs/0000044631.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, DISP, 0.1 mg / mL",52
sample_nocs/0000044631.PDF,species,What is the species?,NA,NA
sample_nocs/0000044631.PDF,noc_date,What is the date of the document?,"September 17, 2024",92
sample_nocs/0000044631.PDF,medicinal_ingredients,What are the medicinal ingredients?,"mRNA encoding sARS-CoV-2 spike protein, 5'(m7G-5'-ppp-5'-Gm) cap, 100-nucleotide 3' poly(A) tail",38
sample_nocs/0000044714.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ARIMIDEX, AstraZeneca Pharmaceuticals LP, USA",46
sample_nocs/0000044714.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,46
sample_nocs/0000044714.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre two fabricants,25
sample_nocs/0000044714.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000044714.PDF,dossier_id,What is the Dossier Id?,e157878,81
sample_nocs/0000044714.PDF,submission_no,What is the Submission Number?,287372,99
sample_nocs/0000044714.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000044714.PDF,product_name,What is the Product name?,RIVA-ANASTROZOLE,92
sample_nocs/0000044714.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02392259, oral / orale, tablet / comprimé, 1 mg",65
sample_nocs/0000044714.PDF,species,What is the species?,NA,NA
sample_nocs/0000044714.PDF,noc_date,What is the date of the document?,"June 25, 2024",75
sample_nocs/0000044714.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Anastrozole, 5.1 mg",5
sample_nocs/0000044765.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000044765.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000044765.PDF,noc_reason,What was the reason for the submission?,Update to antigen composition (Omicron JN. 1 variant) / mise a jour of the composition antigénique (variant Omicron JN. 1),15.000000953674316
sample_nocs/0000044765.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000044765.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000044765.PDF,submission_no,What is the Submission Number?,288077,99
sample_nocs/0000044765.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novavax Inc.,93
sample_nocs/0000044765.PDF,product_name,What is the Product name?,Nuvaxovid,95
sample_nocs/0000044765.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, SUS, 5 mcg / 0.5 mL",78
sample_nocs/0000044765.PDF,species,What is the species?,NA,NA
sample_nocs/0000044765.PDF,noc_date,What is the date of the document?,"September 19, 2024",91
sample_nocs/0000044765.PDF,medicinal_ingredients,What are the medicinal ingredients?,SARS-CoV-2 recombinant spike protein / Protéine de spicule recombinante du SRAS-CoV-2,78
sample_nocs/0000044818.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000044818.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000044818.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,43
sample_nocs/0000044818.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000044818.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000044818.PDF,submission_no,What is the Submission Number?,286502,99
sample_nocs/0000044818.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Regeneron Canada Company,93
sample_nocs/0000044818.PDF,product_name,What is the Product name?,Libtayo,99
sample_nocs/0000044818.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 350 mg / 7mL",77
sample_nocs/0000044818.PDF,species,What is the species?,NA,NA
sample_nocs/0000044818.PDF,noc_date,What is the date of the document?,"September 25, 2024",93
sample_nocs/0000044818.PDF,medicinal_ingredients,What are the medicinal ingredients?,Cemiplimab / Cémiplimab,92
sample_nocs/0000044831.PDF,canadian_reference_product,What is the Canadian Reference Product?,TRILEPTAL,98
sample_nocs/0000044831.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,56
sample_nocs/0000044831.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph with new safety information,78
sample_nocs/0000044831.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,90
sample_nocs/0000044831.PDF,dossier_id,What is the Dossier Id?,HC6-024-e127448,97
sample_nocs/0000044831.PDF,submission_no,What is the Submission Number?,278353,98
sample_nocs/0000044831.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,83
sample_nocs/0000044831.PDF,product_name,What is the Product name?,TRILEPTAL,98
sample_nocs/0000044831.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Suspension, 60 mg/mL",27.000001907348633
sample_nocs/0000044831.PDF,species,What is the species?,NA,NA
sample_nocs/0000044831.PDF,noc_date,What is the date of the document?,"September 24, 2024",94
sample_nocs/0000044831.PDF,medicinal_ingredients,What are the medicinal ingredients?,Oxcarbazepine / Oxcarbazépine,69
sample_nocs/0000044891.PDF,canadian_reference_product,What is the Canadian Reference Product?,"FLORINEF, Paladin Labs Inc., Canada",49
sample_nocs/0000044891.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000044891.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000044891.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,91
sample_nocs/0000044891.PDF,dossier_id,What is the Dossier Id?,HC6-024-e267932,94
sample_nocs/0000044891.PDF,submission_no,What is the Submission Number?,267932,96
sample_nocs/0000044891.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,JAMP Pharma Corporation,79
sample_nocs/0000044891.PDF,product_name,What is the Product name?,JAMP FLUDROCORTISONE,89
sample_nocs/0000044891.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02552248, Oral / Orale, Tablet (Immediate Release)",58.999996185302734
sample_nocs/0000044891.PDF,species,What is the species?,NA,NA
sample_nocs/0000044891.PDF,noc_date,What is the date of the document?,"October 4, 2024",80
sample_nocs/0000044891.PDF,medicinal_ingredients,What are the medicinal ingredients?,Fludrocortisone Acetate / Acétate de fludrocortisone,82
sample_nocs/0000044895.PDF,canadian_reference_product,What is the Canadian Reference Product?,"Levaquin, Janssen-Ortho Inc., Canada",34
sample_nocs/0000044895.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,87
sample_nocs/0000044895.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph / Mise a jour de l'innocuité dans la Monographie de Produit,31
sample_nocs/0000044895.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Scott Appleton, PhD",52
sample_nocs/0000044895.PDF,dossier_id,What is the Dossier Id?,HC6-024-e126216,98
sample_nocs/0000044895.PDF,submission_no,What is the Submission Number?,285880,99
sample_nocs/0000044895.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,81
sample_nocs/0000044895.PDF,product_name,What is the Product name?,ACT LEVOFLOXACIN,87
sample_nocs/0000044895.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 250 mg",67
sample_nocs/0000044895.PDF,species,What is the species?,NA,NA
sample_nocs/0000044895.PDF,noc_date,What is the date of the document?,"October 4, 2024",80
sample_nocs/0000044895.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levofloxacin(supplied as levofloxacin hemihydrate)/Lévofloxacine(sous forme de hémihydrate de lévofloxacine),12
sample_nocs/0000045153.PDF,canadian_reference_product,What is the Canadian Reference Product?,PMS-NAPROXEN,93
sample_nocs/0000045153.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000045153.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph as per advisement letter / Mise a jour of la monographie de produit conformément to la lettre d'avis,10
sample_nocs/0000045153.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000045153.PDF,dossier_id,What is the Dossier Id?,HC6-024-e139182,98
sample_nocs/0000045153.PDF,submission_no,What is the Submission Number?,280628,99
sample_nocs/0000045153.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NA,NA
sample_nocs/0000045153.PDF,product_name,What is the Product name?,PMS-NAPROXEN,94
sample_nocs/0000045153.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Rectal / Rectale, Suppository / Suppositoire, 500 mg",66
sample_nocs/0000045153.PDF,species,What is the species?,NA,NA
sample_nocs/0000045153.PDF,noc_date,What is the date of the document?,"October 28, 2024",81
sample_nocs/0000045153.PDF,medicinal_ingredients,What are the medicinal ingredients?,Naproxen / Naproxène,91
sample_nocs/0000045296.PDF,canadian_reference_product,What is the Canadian Reference Product?,"FERRIPROX, Chiesi Canada Corp., Canada",55
sample_nocs/0000045296.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000045296.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000045296.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,93
sample_nocs/0000045296.PDF,dossier_id,What is the Dossier Id?,e283688,56
sample_nocs/0000045296.PDF,submission_no,What is the Submission Number?,283688,98
sample_nocs/0000045296.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Taro Pharmaceuticals Inc.,95
sample_nocs/0000045296.PDF,product_name,What is the Product name?,TARO-DEFERIPRONE,80
sample_nocs/0000045296.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02553112, Oral / Orale, Tablet / Comprimé, 1000 mg",35
sample_nocs/0000045296.PDF,species,What is the species?,NA,NA
sample_nocs/0000045296.PDF,noc_date,What is the date of the document?,"November 13, 2024",88
sample_nocs/0000045296.PDF,medicinal_ingredients,What are the medicinal ingredients?,Deferiprone / Défériprone,85
sample_nocs/0000045859.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000045859.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000045859.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph with new safety information,69
sample_nocs/0000045859.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Karen Reynolds,94
sample_nocs/0000045859.PDF,dossier_id,What is the Dossier Id?,e135426,81
sample_nocs/0000045859.PDF,submission_no,What is the Submission Number?,289933,98
sample_nocs/0000045859.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Jazz Pharmaceuticals Ireland Limited,99
sample_nocs/0000045859.PDF,product_name,What is the Product name?,XYREM,95
sample_nocs/0000045859.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale Solution, 500 mg / mL",29
sample_nocs/0000045859.PDF,species,What is the species?,NA,NA
sample_nocs/0000045859.PDF,noc_date,What is the date of the document?,"January 23, 2025",88
sample_nocs/0000045859.PDF,medicinal_ingredients,What are the medicinal ingredients?,Sodium Oxybate / Oxybate de sodium,68
sample_nocs/0000046087.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000046087.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,70
sample_nocs/0000046087.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph with new safety information,82
sample_nocs/0000046087.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,97
sample_nocs/0000046087.PDF,dossier_id,What is the Dossier Id?,e120166,96
sample_nocs/0000046087.PDF,submission_no,What is the Submission Number?,287053,98
sample_nocs/0000046087.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-Aventis Canada Inc,92
sample_nocs/0000046087.PDF,product_name,What is the Product name?,PLAQUENIL,99
sample_nocs/0000046087.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 200 mg",80
sample_nocs/0000046087.PDF,species,What is the species?,NA,NA
sample_nocs/0000046087.PDF,noc_date,What is the date of the document?,"February 21, 2025",95
sample_nocs/0000046087.PDF,medicinal_ingredients,What are the medicinal ingredients?,Hydroxychloroquine sulfate / Sulfate d'hydroxychloroquine,91
sample_nocs/0000046096.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CRESTOR, AstraZeneca Canada Inc., Canada",47
sample_nocs/0000046096.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,89
sample_nocs/0000046096.PDF,noc_reason,What was the reason for the submission?,Update to Product Monograph/ Mise a jour de la monographie de produit,31
sample_nocs/0000046096.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Scott Appleton, PhD",51
sample_nocs/0000046096.PDF,dossier_id,What is the Dossier Id?,e120841,96
sample_nocs/0000046096.PDF,submission_no,What is the Submission Number?,293827,98
sample_nocs/0000046096.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Apotex Inc.,82
sample_nocs/0000046096.PDF,product_name,What is the Product name?,APO-ROSUVASTATIN,94
sample_nocs/0000046096.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 5 mg",69
sample_nocs/0000046096.PDF,species,What is the species?,NA,NA
sample_nocs/0000046096.PDF,noc_date,What is the date of the document?,"February 20, 2025",92
sample_nocs/0000046096.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rosuvastatin(supplied as rosuvastatin calcium) / Rosuvastatine(sous forme de rosuvastatine calcique),31
sample_nocs/0000046098.PDF,canadian_reference_product,What is the Canadian Reference Product?,"MICARDIS PLUS, Boehringer Ingelheim (Canada) Ltd.,",35
sample_nocs/0000046098.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,87
sample_nocs/0000046098.PDF,noc_reason,What was the reason for the submission?,Safety updates to the Product Monograph / Mise a jour de l'innocuité dans la Monographie de Produit,28
sample_nocs/0000046098.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Scott Appleton, PhD",50
sample_nocs/0000046098.PDF,dossier_id,What is the Dossier Id?,e144088,96
sample_nocs/0000046098.PDF,submission_no,What is the Submission Number?,293550,98
sample_nocs/0000046098.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,84
sample_nocs/0000046098.PDF,product_name,What is the Product name?,SANDOZ TELMISARTAN HCT,77
sample_nocs/0000046098.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 80 mg / 12.5 mg",56
sample_nocs/0000046098.PDF,species,What is the species?,NA,NA
sample_nocs/0000046098.PDF,noc_date,What is the date of the document?,"February 20, 2025",92
sample_nocs/0000046098.PDF,medicinal_ingredients,What are the medicinal ingredients?,Telmisartan / Hydrochlorothiazide,80
sample_nocs/0000046102.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ASPIRIN 81MG, Bayer Inc, Canada",55
sample_nocs/0000046102.PDF,directorate,What is the directorate that approved the submission?,Health Products Directorate,28
sample_nocs/0000046102.PDF,noc_reason,What was the reason for the submission?,Update to Product Monograph (to align with CRP approved PM) / Mise a jour de la monographie de produit,16
sample_nocs/0000046102.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Stephen Norman,98
sample_nocs/0000046102.PDF,dossier_id,What is the Dossier Id?,e120247,96
sample_nocs/0000046102.PDF,submission_no,What is the Submission Number?,290185,100
sample_nocs/0000046102.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,PHENDOPHARM,17
sample_nocs/0000046102.PDF,product_name,What is the Product name?,Entopen,2
sample_nocs/0000046102.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","n/a, Oral, Tablet (Delayed-Release) 81 mg",25
sample_nocs/0000046102.PDF,species,What is the species?,NA,NA
sample_nocs/0000046102.PDF,noc_date,What is the date of the document?,"February 25, 2025",97
sample_nocs/0000046102.PDF,medicinal_ingredients,What are the medicinal ingredients?,Acetylsalicylic acid,93
sample_nocs/0000046151.PDF,canadian_reference_product,What is the Canadian Reference Product?,OLIMEL,41
sample_nocs/0000046151.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,81
sample_nocs/0000046151.PDF,noc_reason,What was the reason for the submission?,Change in the specification for the drug product / Changement apporté aux spécifications of the product médicamenteux,21
sample_nocs/0000046151.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Melissa Hunt,99
sample_nocs/0000046151.PDF,dossier_id,What is the Dossier Id?,e118900,94
sample_nocs/0000046151.PDF,submission_no,What is the Submission Number?,288541,99
sample_nocs/0000046151.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Baxter corporation,98
sample_nocs/0000046151.PDF,product_name,What is the Product name?,"OLIMEL 4.4%, OLIMEL 5.7%, OLIMEL 7.6%",70
sample_nocs/0000046151.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",14% w/v / 4% w/v,71
sample_nocs/0000046151.PDF,species,What is the species?,NA,NA
sample_nocs/0000046151.PDF,noc_date,What is the date of the document?,"March 4, 2025",91
sample_nocs/0000046151.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Amino Acids/Acides Aminés, Dextrose Lipids/Lipides",47
sample_nocs/0000046327.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000046327.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000046327.PDF,noc_reason,What was the reason for the submission?,complies with the requirements of sections drogue nouvelle citée en rubrique,16
sample_nocs/0000046327.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,96
sample_nocs/0000046327.PDF,dossier_id,What is the Dossier Id?,e255389,94
sample_nocs/0000046327.PDF,submission_no,What is the Submission Number?,271972,98
sample_nocs/0000046327.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Formative Pharma Inc.,48
sample_nocs/0000046327.PDF,product_name,What is the Product name?,XFUSOR,99
sample_nocs/0000046327.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02556472, Block/Infiltration / Bloc/Infiltration, Solution, 2 mg",56
sample_nocs/0000046327.PDF,species,What is the species?,NA,NA
sample_nocs/0000046327.PDF,noc_date,What is the date of the document?,"March 20, 2025",89
sample_nocs/0000046327.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ropivacaine Hydrochloride / Chlorhydrate de ropivacane,62
sample_nocs/0000046393.PDF,canadian_reference_product,What is the Canadian Reference Product?,"COVERSYL PLUS HD, Servier Canada Inc., Canada",48
sample_nocs/0000046393.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,34
sample_nocs/0000046393.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre two fabricants,23
sample_nocs/0000046393.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000046393.PDF,dossier_id,What is the Dossier Id?,e294456,39
sample_nocs/0000046393.PDF,submission_no,What is the Submission Number?,294456,96
sample_nocs/0000046393.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Angita Pharma Inc.,74
sample_nocs/0000046393.PDF,product_name,What is the Product name?,AG-PERINDOPRIL / INDAPAMIDE,91
sample_nocs/0000046393.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02447991, oral / orale, tablet / comprimé, 2 mg / 0.625 mg",74
sample_nocs/0000046393.PDF,species,What is the species?,NA,NA
sample_nocs/0000046393.PDF,noc_date,What is the date of the document?,"March 31, 2025",93
sample_nocs/0000046393.PDF,medicinal_ingredients,What are the medicinal ingredients?,Perindopril Erbumine / Périndopril erbumine Indapamide,66
sample_nocs/0000046444.PDF,canadian_reference_product,What is the Canadian Reference Product?,"NORVASC, Pfizer Canada Inc., Canada",49
sample_nocs/0000046444.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,36
sample_nocs/0000046444.PDF,noc_reason,What was the reason for the submission?,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre two fabricants,20
sample_nocs/0000046444.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000046444.PDF,dossier_id,What is the Dossier Id?,e284229,77
sample_nocs/0000046444.PDF,submission_no,What is the Submission Number?,295075,97
sample_nocs/0000046444.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,NB Pharma Inc,55
sample_nocs/0000046444.PDF,product_name,What is the Product name?,NB-AMLODIPINE,87
sample_nocs/0000046444.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02556707, oral / orale, tablet / comprimé, 2.5 mg",79
sample_nocs/0000046444.PDF,species,What is the species?,NA,NA
sample_nocs/0000046444.PDF,noc_date,What is the date of the document?,"April 2, 2025",87
sample_nocs/0000046444.PDF,medicinal_ingredients,What are the medicinal ingredients?,Amlodipine supplied as Amlodipine Besylate / Amlodipine sous forme de bésylate d'amlodipine,80
sample_nocs/0000046521.PDF,canadian_reference_product,What is the Canadian Reference Product?,"ARIMIDEX, AstraZeneca Canada Inc., Canada",54.000003814697266
sample_nocs/0000046521.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,87
sample_nocs/0000046521.PDF,noc_reason,What was the reason for the submission?,Update to Product Monograph / Mise a jour de la monographie de produit,58.999996185302734
sample_nocs/0000046521.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Gaudreault,60.000003814697266
sample_nocs/0000046521.PDF,dossier_id,What is the Dossier Id?,e140647,93
sample_nocs/0000046521.PDF,submission_no,What is the Submission Number?,294917,98
sample_nocs/0000046521.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Generic Medical Partners Inc.,49
sample_nocs/0000046521.PDF,product_name,What is the Product name?,MED-ANASTROZOLE,97
sample_nocs/0000046521.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 1 mg",55
sample_nocs/0000046521.PDF,species,What is the species?,NA,NA
sample_nocs/0000046521.PDF,noc_date,What is the date of the document?,"April 11, 2025",84
sample_nocs/0000046521.PDF,medicinal_ingredients,What are the medicinal ingredients?,Anastrozole,95
sample_nocs/0000046616.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CRESTOR, AstraZeneca Canada Inc., Canada",71
sample_nocs/0000046616.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000046616.PDF,noc_reason,What was the reason for the submission?,Update to Package Labels / Mise a jour de l'étiquetage,63
sample_nocs/0000046616.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,96
sample_nocs/0000046616.PDF,dossier_id,What is the Dossier Id?,e128061,94
sample_nocs/0000046616.PDF,submission_no,What is the Submission Number?,292241,98
sample_nocs/0000046616.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,52.999996185302734
sample_nocs/0000046616.PDF,product_name,What is the Product name?,TEVA-ROSUVASTATIN,91
sample_nocs/0000046616.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral/Orale, Tablet/Comprimé, 5 mg",66
sample_nocs/0000046616.PDF,species,What is the species?,NA,NA
sample_nocs/0000046616.PDF,noc_date,What is the date of the document?,"April 25, 2025",88
sample_nocs/0000046616.PDF,medicinal_ingredients,What are the medicinal ingredients?,Rosuvastatin Calcium / Rosuvastatine calcique,92
sample_nocs/0000046727.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000046727.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000046727.PDF,noc_reason,What was the reason for the submission?,complies with the requirements of sections drogue nouvelle citée en rubrique,12
sample_nocs/0000046727.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,93
sample_nocs/0000046727.PDF,dossier_id,What is the Dossier Id?,e271421,91
sample_nocs/0000046727.PDF,submission_no,What is the Submission Number?,284373,98
sample_nocs/0000046727.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Bristol-Myers Squibb Canada,87
sample_nocs/0000046727.PDF,product_name,What is the Product name?,AUGTYRO,98
sample_nocs/0000046727.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02557444, Oral / Orale, Capsule, 40 mg",76
sample_nocs/0000046727.PDF,species,What is the species?,NA,NA
sample_nocs/0000046727.PDF,noc_date,What is the date of the document?,"May 7, 2025",86
sample_nocs/0000046727.PDF,medicinal_ingredients,What are the medicinal ingredients?,Repotrectinib,98
sample_nocs/0000046957.PDF,canadian_reference_product,What is the Canadian Reference Product?,DECCOX 6%,86
sample_nocs/0000046957.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000046957.PDF,noc_reason,What was the reason for the submission?,Administrative - Change in Product Ownership / Administratif Changement de propriétaire du produit,37
sample_nocs/0000046957.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,96
sample_nocs/0000046957.PDF,dossier_id,What is the Dossier Id?,v170635,96
sample_nocs/0000046957.PDF,submission_no,What is the Submission Number?,296147,99
sample_nocs/0000046957.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Phibro Animal Health Corporation,87
sample_nocs/0000046957.PDF,product_name,What is the Product name?,DECCOX 6%,96
sample_nocs/0000046957.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","00867349, Oral, Drug premix, 60 g/kg",51
sample_nocs/0000046957.PDF,species,What is the species?,"Broiler chickens, Cattle, Sheep / Poulets a griller / griller, Bovins, Moutons",22
sample_nocs/0000046957.PDF,noc_date,What is the date of the document?,"June 2, 2025 / 2 juin 2025",47
sample_nocs/0000046957.PDF,medicinal_ingredients,What are the medicinal ingredients?,Decoquinate / Décoquinate,93
sample_nocs/0000047067.PDF,canadian_reference_product,What is the Canadian Reference Product?,"pdp-levETIRAcetam, PENDOPHARM, Division of Canadian Pharmascience Inc., Canada",11
sample_nocs/0000047067.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047067.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000047067.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,44
sample_nocs/0000047067.PDF,dossier_id,What is the Dossier Id?,e252284,48
sample_nocs/0000047067.PDF,submission_no,What is the Submission Number?,252284,98
sample_nocs/0000047067.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mint Pharmaceuticals Inc.,95
sample_nocs/0000047067.PDF,product_name,What is the Product name?,MINT-LEVETIRACETAM SOLUTION,86
sample_nocs/0000047067.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","02558416, Oral / Orale, Solution / Solution, 100 mg/mL",42
sample_nocs/0000047067.PDF,species,What is the species?,NA,NA
sample_nocs/0000047067.PDF,noc_date,What is the date of the document?,"June 17, 2025",75
sample_nocs/0000047067.PDF,medicinal_ingredients,What are the medicinal ingredients?,Levetiracetam / Lévétiracétam,76
sample_nocs/0000047231.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000047231.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,29
sample_nocs/0000047231.PDF,noc_reason,What was the reason for the submission?,Additional manufacturing site / Addition d'un site de fabrication,49
sample_nocs/0000047231.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000047231.PDF,dossier_id,What is the Dossier Id?,CPID,32
sample_nocs/0000047231.PDF,submission_no,What is the Submission Number?,289770,99
sample_nocs/0000047231.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,GlaxoSmithKline Inc.,88
sample_nocs/0000047231.PDF,product_name,What is the Product name?,Boostrix,99
sample_nocs/0000047231.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IM, SUS, 0.5 mL",64
sample_nocs/0000047231.PDF,species,What is the species?,Diphtheria toxoid,54.000003814697266
sample_nocs/0000047231.PDF,noc_date,What is the date of the document?,"July 2, 2025",85
sample_nocs/0000047231.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Diphtheria toxoid, tetanus toxoid, filamentous haemagglutinin, pertactin",39
sample_nocs/0000047240.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000047240.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,41
sample_nocs/0000047240.PDF,noc_reason,What was the reason for the submission?,Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux,35
sample_nocs/0000047240.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,94
sample_nocs/0000047240.PDF,dossier_id,What is the Dossier Id?,e126730,95
sample_nocs/0000047240.PDF,submission_no,What is the Submission Number?,292967,98
sample_nocs/0000047240.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Novartis Pharmaceuticals Canada Inc.,86
sample_nocs/0000047240.PDF,product_name,What is the Product name?,TOBREX,96
sample_nocs/0000047240.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Ophthalmic/Ophtalmique, Solution, 0.3% w/v",82
sample_nocs/0000047240.PDF,species,What is the species?,NA,NA
sample_nocs/0000047240.PDF,noc_date,What is the date of the document?,"July 4, 2025",80
sample_nocs/0000047240.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tobramycin / Tobramycine,86
sample_nocs/0000047310.PDF,canadian_reference_product,What is the Canadian Reference Product?,Aranesp,78
sample_nocs/0000047310.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047310.PDF,noc_reason,What was the reason for the submission?,drug substance manufacturing process change / change au processus de fabrication of the substance médicamenteuse,9
sample_nocs/0000047310.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000047310.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000047310.PDF,submission_no,What is the Submission Number?,293410,98
sample_nocs/0000047310.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Amgen Canada Inc.,85
sample_nocs/0000047310.PDF,product_name,What is the Product name?,Aranesp,98
sample_nocs/0000047310.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC/IV, SOL, 15 g/mL",48
sample_nocs/0000047310.PDF,species,What is the species?,NA,NA
sample_nocs/0000047310.PDF,noc_date,What is the date of the document?,"June 27, 2025",89
sample_nocs/0000047310.PDF,medicinal_ingredients,What are the medicinal ingredients?,darbepoetin alfa,95
sample_nocs/0000047341.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000047341.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,77
sample_nocs/0000047341.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph with new safety and efficacy information / Mise a jour of la monographie de produit with new information  relatifs a l'innocuité et l'efficacité,1
sample_nocs/0000047341.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000047341.PDF,dossier_id,What is the Dossier Id?,e233861,92
sample_nocs/0000047341.PDF,submission_no,What is the Submission Number?,289289,98
sample_nocs/0000047341.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Loxo Oncology Inc,48
sample_nocs/0000047341.PDF,product_name,What is the Product name?,RETEVMO,69
sample_nocs/0000047341.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Capsule, 40 mg",79
sample_nocs/0000047341.PDF,species,What is the species?,NA,NA
sample_nocs/0000047341.PDF,noc_date,What is the date of the document?,"July 22, 2025",82
sample_nocs/0000047341.PDF,medicinal_ingredients,What are the medicinal ingredients?,Selpercatinib,98
sample_nocs/0000047356.PDF,canadian_reference_product,What is the Canadian Reference Product?,cyl,7
sample_nocs/0000047356.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,33
sample_nocs/0000047356.PDF,noc_reason,What was the reason for the submission?,Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),15.000000953674316
sample_nocs/0000047356.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,96
sample_nocs/0000047356.PDF,dossier_id,What is the Dossier Id?,e220985,40
sample_nocs/0000047356.PDF,submission_no,What is the Submission Number?,296914,98
sample_nocs/0000047356.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Mantra Pharma Inc.,58
sample_nocs/0000047356.PDF,product_name,What is the Product name?,M-PERINDOPRIL ERBUMINE,93
sample_nocs/0000047356.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 2 mg",82
sample_nocs/0000047356.PDF,species,What is the species?,NA,NA
sample_nocs/0000047356.PDF,noc_date,What is the date of the document?,"July 22, 2025",78
sample_nocs/0000047356.PDF,medicinal_ingredients,What are the medicinal ingredients?,Perindopril Erbumine / Périndopril erbumine,58.999996185302734
sample_nocs/0000047372.PDF,canadian_reference_product,What is the Canadian Reference Product?,"CIPRO I.V. MINIBAGS, Bayer Inc., Canada",79
sample_nocs/0000047372.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,47
sample_nocs/0000047372.PDF,noc_reason,What was the reason for the submission?,Addition of a manufacturing site and/or manufacturer involving production of the drug substance intermediate / Ajout d'un site de fabrication or d'un fabricant impliquant la fabrication d'un produit intermédiaire,40
sample_nocs/0000047372.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000047372.PDF,dossier_id,What is the Dossier Id?,e150833,92
sample_nocs/0000047372.PDF,submission_no,What is the Submission Number?,293373,97
sample_nocs/0000047372.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,89
sample_nocs/0000047372.PDF,product_name,What is the Product name?,CIPROFLOXACIN INTRAVENOUS INFUSION BP,78
sample_nocs/0000047372.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous/Intravenous Solution, 2 mg / mL",42
sample_nocs/0000047372.PDF,species,What is the species?,NA,NA
sample_nocs/0000047372.PDF,noc_date,What is the date of the document?,"July 23, 2025",80
sample_nocs/0000047372.PDF,medicinal_ingredients,What are the medicinal ingredients?,Ciprofloxacin / Ciprofloxacine,77
sample_nocs/0000047416.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000047416.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047416.PDF,noc_reason,What was the reason for the submission?,Update to the Product Monograph / Mise a jour de la monographie de produit,45
sample_nocs/0000047416.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000047416.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000047416.PDF,submission_no,What is the Submission Number?,296139,99
sample_nocs/0000047416.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,EMD Serono,52.999996185302734
sample_nocs/0000047416.PDF,product_name,What is the Product name?,Bavencio,98
sample_nocs/0000047416.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, IV, SOL, 20 mg/mL",83
sample_nocs/0000047416.PDF,species,What is the species?,NA,NA
sample_nocs/0000047416.PDF,noc_date,What is the date of the document?,"July 28, 2025",84
sample_nocs/0000047416.PDF,medicinal_ingredients,What are the medicinal ingredients?,Avelumab / Avélumab,86
sample_nocs/0000047492.PDF,canadian_reference_product,What is the Canadian Reference Product?,"AVAPRO, Sanofi-aventis Canada Inc., Canada",30.000001907348633
sample_nocs/0000047492.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,49
sample_nocs/0000047492.PDF,noc_reason,What was the reason for the submission?,Addition of a drug product manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication or d'un fabricant impliquant la fabrication of the substance médicamenteuse,12
sample_nocs/0000047492.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,96
sample_nocs/0000047492.PDF,dossier_id,What is the Dossier Id?,e119041,95
sample_nocs/0000047492.PDF,submission_no,What is the Submission Number?,293764,98
sample_nocs/0000047492.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sandoz Canada Inc.,85
sample_nocs/0000047492.PDF,product_name,What is the Product name?,SANDOZ IRBESARTAN,61
sample_nocs/0000047492.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet / Comprimé, 75 mg",82
sample_nocs/0000047492.PDF,species,What is the species?,NA,NA
sample_nocs/0000047492.PDF,noc_date,What is the date of the document?,"August 8, 2025",89
sample_nocs/0000047492.PDF,medicinal_ingredients,What are the medicinal ingredients?,Irbesartan,95
sample_nocs/0000047584.PDF,canadian_reference_product,What is the Canadian Reference Product?,"DRAXXIN (DIN 02285452, Zoetis Canada Inc.)",46
sample_nocs/0000047584.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047584.PDF,noc_reason,What was the reason for the submission?,NA,NA
sample_nocs/0000047584.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,97
sample_nocs/0000047584.PDF,dossier_id,What is the Dossier Id?,v284183,52.999996185302734
sample_nocs/0000047584.PDF,submission_no,What is the Submission Number?,284183,99
sample_nocs/0000047584.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Parnell Technologies PTY Ltd,98
sample_nocs/0000047584.PDF,product_name,What is the Product name?,VACASAN,97
sample_nocs/0000047584.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?",02560348,58
sample_nocs/0000047584.PDF,species,What is the species?,Cattle,56
sample_nocs/0000047584.PDF,noc_date,What is the date of the document?,August 20 2025,75
sample_nocs/0000047584.PDF,medicinal_ingredients,What are the medicinal ingredients?,Tulathromycin / tulathromycine,90
sample_nocs/0000047618.PDF,canadian_reference_product,What is the Canadian Reference Product?,HALAVEN,54.000003814697266
sample_nocs/0000047618.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047618.PDF,noc_reason,What was the reason for the submission?,Update to package labels / Mise a jour de l'étiquetage,63
sample_nocs/0000047618.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000047618.PDF,dossier_id,What is the Dossier Id?,e141946,90
sample_nocs/0000047618.PDF,submission_no,What is the Submission Number?,297312,98
sample_nocs/0000047618.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Eisai Limited,87
sample_nocs/0000047618.PDF,product_name,What is the Product name?,HALAVEN,97
sample_nocs/0000047618.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intravenous / Intraveineuse, Solution, 0.5 mg/mL",84
sample_nocs/0000047618.PDF,species,What is the species?,NA,NA
sample_nocs/0000047618.PDF,noc_date,What is the date of the document?,"August 21, 2025",85
sample_nocs/0000047618.PDF,medicinal_ingredients,What are the medicinal ingredients?,Eribulin Mesylate / Mésylate d'Éribuline,86
sample_nocs/0000047673.PDF,canadian_reference_product,What is the Canadian Reference Product?,SYNOVEX CHOICE,94
sample_nocs/0000047673.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000047673.PDF,noc_reason,What was the reason for the submission?,Additional indication / Indication supplémentaire,93
sample_nocs/0000047673.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Marilena Bassi,96
sample_nocs/0000047673.PDF,dossier_id,What is the Dossier Id?,v167721,96
sample_nocs/0000047673.PDF,submission_no,What is the Submission Number?,292836,98
sample_nocs/0000047673.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Zoetis Canada Inc.,83
sample_nocs/0000047673.PDF,product_name,What is the Product name?,SYNOVEX CHOICE,93
sample_nocs/0000047673.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Subcutaneous, Implant, Trenbolone Acetate 100 mg/implant, Estradiol Benzoate 14 mg/implant",62
sample_nocs/0000047673.PDF,species,What is the species?,Cattle / Bovins,96
sample_nocs/0000047673.PDF,noc_date,What is the date of the document?,"August 28, 2025 / 28 août 2025",55
sample_nocs/0000047673.PDF,medicinal_ingredients,What are the medicinal ingredients?,"Trenbolone Acetate, Estradiol Benzoate / Acétate de trenbolone, Benzoate d'estradiol",62
sample_nocs/0000048112.PDF,canadian_reference_product,What is the Canadian Reference Product?,Pfizer Canada Inc.,29
sample_nocs/0000048112.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,41
sample_nocs/0000048112.PDF,noc_reason,What was the reason for the submission?,Change in the drug product manufacturing process / Changement apporté au procédé de fabrication du produit médicamenteux,38
sample_nocs/0000048112.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,96
sample_nocs/0000048112.PDF,dossier_id,What is the Dossier Id?,e183428,92
sample_nocs/0000048112.PDF,submission_no,What is the Submission Number?,295576,97
sample_nocs/0000048112.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,52.999996185302734
sample_nocs/0000048112.PDF,product_name,What is the Product name?,TEVA-DESVENLAFAXINE,89
sample_nocs/0000048112.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé",65
sample_nocs/0000048112.PDF,species,What is the species?,NA,NA
sample_nocs/0000048112.PDF,noc_date,What is the date of the document?,"October 10, 2025",63
sample_nocs/0000048112.PDF,medicinal_ingredients,What are the medicinal ingredients?,Desvenlafaxine(supplied as Desvenlafaxine Succinate) / Desvenlafaxine (sous forme de succinate de desvenlafaxine),21
sample_nocs/0000048154.PDF,canadian_reference_product,What is the Canadian Reference Product?,SOLIQUA,67
sample_nocs/0000048154.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,69
sample_nocs/0000048154.PDF,noc_reason,What was the reason for the submission?,Changes to the manufacturing process / Changements to process de fabrication,27.000001907348633
sample_nocs/0000048154.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,95
sample_nocs/0000048154.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000048154.PDF,submission_no,What is the Submission Number?,295842,98
sample_nocs/0000048154.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Sanofi-aventis Canada Inc.,88
sample_nocs/0000048154.PDF,product_name,What is the Product name?,SOLIQUA,97
sample_nocs/0000048154.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 100 unit / mL + 33 mcg / mL",50
sample_nocs/0000048154.PDF,species,What is the species?,NA,NA
sample_nocs/0000048154.PDF,noc_date,What is the date of the document?,"October 11, 2025",84
sample_nocs/0000048154.PDF,medicinal_ingredients,What are the medicinal ingredients?,Insulin Glargine / Insuline glargine Lixisenatide / Lixisénatide,79
sample_nocs/0000048211.PDF,canadian_reference_product,What is the Canadian Reference Product?,"PULMICORT NEBUAMP, AstraZeneca Canada Inc., Canada",43
sample_nocs/0000048211.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000048211.PDF,noc_reason,What was the reason for the submission?,Update to package labels / Mise à jour de l'étiquetage,50
sample_nocs/0000048211.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000048211.PDF,dossier_id,What is the Dossier Id?,e134887,92
sample_nocs/0000048211.PDF,submission_no,What is the Submission Number?,298127,98
sample_nocs/0000048211.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,50
sample_nocs/0000048211.PDF,product_name,What is the Product name?,TEVA-BUDESONIDE,86
sample_nocs/0000048211.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Inhalation/Inhalation, Suspension/Suspension",82
sample_nocs/0000048211.PDF,species,What is the species?,NA,NA
sample_nocs/0000048211.PDF,noc_date,What is the date of the document?,"October 16, 2025",66
sample_nocs/0000048211.PDF,medicinal_ingredients,What are the medicinal ingredients?,Budesonide,98
sample_nocs/0000048349.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000048349.PDF,directorate,What is the directorate that approved the submission?,NA,NA
sample_nocs/0000048349.PDF,noc_reason,What was the reason for the submission?,"New formulation, New presentations",31
sample_nocs/0000048349.PDF,approving_dg,What is the name of the Director General that signed this NOC?,NA,NA
sample_nocs/0000048349.PDF,dossier_id,What is the Dossier Id?,NA,NA
sample_nocs/0000048349.PDF,submission_no,What is the Submission Number?,288758,98
sample_nocs/0000048349.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Eli Lilly Canada Inc,58.999996185302734
sample_nocs/0000048349.PDF,product_name,What is the Product name?,Omvoh,73
sample_nocs/0000048349.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 100 mg/mL (pre-filled syringe)",42
sample_nocs/0000048349.PDF,species,What is the species?,NA,NA
sample_nocs/0000048349.PDF,noc_date,What is the date of the document?,"October 30, 2025",66
sample_nocs/0000048349.PDF,medicinal_ingredients,What are the medicinal ingredients?,Mirikizumab,98
sample_nocs/0000048613.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000048613.PDF,directorate,What is the directorate that approved the submission?,Biologic and Radiopharmaceutical Drugs Directorate,27.000001907348633
sample_nocs/0000048613.PDF,noc_reason,What was the reason for the submission?,Changes to the drug product manufacturing process / Changements au processus de fabrication du produit médicamenteux,13
sample_nocs/0000048613.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Sophie Sommerer,99
sample_nocs/0000048613.PDF,dossier_id,What is the Dossier Id?,009C1P,2
sample_nocs/0000048613.PDF,submission_no,What is the Submission Number?,295676,97
sample_nocs/0000048613.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,EMD Serono,54.000003814697266
sample_nocs/0000048613.PDF,product_name,What is the Product name?,Pergoveris,96
sample_nocs/0000048613.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, SC, SOL, 900 IU/1.44 mL",57
sample_nocs/0000048613.PDF,species,What is the species?,NA,NA
sample_nocs/0000048613.PDF,noc_date,What is the date of the document?,"December 2, 2025",84
sample_nocs/0000048613.PDF,medicinal_ingredients,What are the medicinal ingredients?,Follitropin alfa and lutropin alfa / Follitropine alfa et lutropine alfa,60.000003814697266
sample_nocs/0000048717.PDF,canadian_reference_product,What is the Canadian Reference Product?,NA,NA
sample_nocs/0000048717.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,63
sample_nocs/0000048717.PDF,noc_reason,What was the reason for the submission?,Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux,30.000001907348633
sample_nocs/0000048717.PDF,approving_dg,What is the name of the Director General that signed this NOC?,Kelly Robinson,95
sample_nocs/0000048717.PDF,dossier_id,What is the Dossier Id?,e062902,97
sample_nocs/0000048717.PDF,submission_no,What is the Submission Number?,295630,98
sample_nocs/0000048717.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Teva Canada Limited,86
sample_nocs/0000048717.PDF,product_name,What is the Product name?,Leucovorin calcium inJECTION,36
sample_nocs/0000048717.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, Intramuscular / Intramusculaire, Intravenous",30.000001907348633
sample_nocs/0000048717.PDF,species,What is the species?,NA,NA
sample_nocs/0000048717.PDF,noc_date,What is the date of the document?,"December 11, 2025",86
sample_nocs/0000048717.PDF,medicinal_ingredients,What are the medicinal ingredients?,Leucovorin calcium / Leucovorine calcique,88
sample_nocs/0000048870.PDF,canadian_reference_product,What is the Canadian Reference Product?,ELIQUIS,56
sample_nocs/0000048870.PDF,directorate,What is the directorate that approved the submission?,Pharmaceutical Drugs Directorate,81
sample_nocs/0000048870.PDF,noc_reason,What was the reason for the submission?,Administrative: Update to labelling (to match Licensor) / Administratif: Mise a jour de l'étiquetage (pour correspondre au concédant),21
sample_nocs/0000048870.PDF,approving_dg,What is the name of the Director General that signed this NOC?,"Laura Durno, MSc",69
sample_nocs/0000048870.PDF,dossier_id,What is the Dossier Id?,e260843,78
sample_nocs/0000048870.PDF,submission_no,What is the Submission Number?,301458,98
sample_nocs/0000048870.PDF,manufacturer_name,Who is the Sponsor/Manufacturer?,Laboratoire RIVA Inc.,65
sample_nocs/0000048870.PDF,product_name,What is the Product name?,RIVA APIXABAN,92
sample_nocs/0000048870.PDF,din_route_form_strength,"What is the Drug Identification Number, Route, Form and Strength?","N/A, oral / orale, tablet / comprimé, 2.5 mg",85
sample_nocs/0000048870.PDF,species,What is the species?,NA,NA
sample_nocs/0000048870.PDF,noc_date,What is the date of the document?,"December 23, 2025",88
sample_nocs/0000048870.PDF,medicinal_ingredients,What are the medicinal ingredients?,Apixaban,92
